Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

Information

  • Patent Grant
  • 8580782
  • Patent Number
    8,580,782
  • Date Filed
    Friday, April 20, 2007
    17 years ago
  • Date Issued
    Tuesday, November 12, 2013
    11 years ago
Abstract
In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or compositions.
Description
FIELD OF THE INVENTION

The present invention relates to pyrazolo[1,5-a]pyrimidine compounds useful as protein kinase inhibitors (such as for example, the inhibitors of the cyclin-dependent kinases, mitogen-activated protein kinase (MAPK/ERK), glycogen synthase kinase 3 (GSK3beta) and the like), pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases such as, for example, cancer, inflammation, arthritis, viral diseases, neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, and fungal diseases. This application claims benefit of priority from U.S. provisional patent applications, Ser. No. 60/408,027 filed Sep. 4, 2002, and Ser. No. 60/421,959 filed Oct. 29, 2002.


BACKGROUND OF THE INVENTION

Protein kinase inhibitors include kinases such as, for example, the inhibitors of the cyclin-dependent kinases (CDKs), mitogen activated protein kinase (MAPK/ERK), glycogen synthase kinase 3 (GSK3beta), and the like. Protein kinase inhibitors are described, for example, by M. Hale et al in WO02/22610 A1 and by Y. Mettey et al in J. Med. Chem., (2003) 46 222-236. The cyclin-dependent kinases are serine/threonine protein kinases, which are the driving force behind the cell cycle and cell proliferation. Individual CDK's, such as, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6 and CDK7, CDK8, CDK9 and the like, perform distinct roles in cell cycle progression and can be classified as either G1, S, or G2M phase enzymes. Uncontrolled proliferation is a hallmark of cancer cells, and misregulation of CDK function occurs with high frequency in many important solid tumors. CDK2 and CDK4 are of particular interest because their activities are frequently misregulated in a wide variety of human cancers. CDK2 activity is required for progression through G1 to the S phase of the cell cycle, and CDK2 is one of the key components of the G1 checkpoint. Checkpoints serve to maintain the proper sequence of cell cycle events and allow the cell to respond to insults or to proliferative signals, while the loss of proper checkpoint control in cancer cells contributes to tumorgenesis. The CDK2 pathway influences tumorgenesis at the level of tumor suppressor function (e.g. p52, RB, and p27) and oncogene activation (cyclin E). Many reports have demonstrated that both the coactivator, cyclin E, and the inhibitor, p27, of CDK2 are either over- or underexpressed, respectively, in breast, colon, nonsmall cell lung, gastric, prostate, bladder, non-Hodgkin's lymphoma, ovarian, and other cancers. Their altered expression has been shown to correlate with increased CDK2 activity levels and poor overall survival. This observation makes CDK2 and its regulatory pathways compelling targets for the development years, a number of adenosine 5′-triphosphate (ATP) competitive small organic molecules as well as peptides have been reported in the literature as CDK inhibitors for the potential treatment of cancers. U.S. Pat. No. 6,413,974, col. 1, line 23-col. 15, line 10 offers a good description of the various CDKs and their relationship to various types of cancer.


CDK inhibitors are known. For example, flavopiridol (Formula I) is a nonselective CDK inhibitor that is currently undergoing human clinical trials, A. M. Sanderowicz et al, J. Clin. Oncol. (1998) 16, 2986-2999.




embedded image


Other known inhibitors of the CDKs include, for example, olomoucine (J. Vesely et al, Eur. J. Biochem., (1994) 224, 771-786) and roscovitine (I. Meijer et al, Eur. J. Biochem., (1997) 243, 527-536). U.S. Pat. No. 6,107,305 describes certain pyrazolo[3,4-b]pyridine compounds as CDK inhibitors. An illustrative compound from the '305 patent has the Formula II:




embedded image


K. S. Kim et al, J. Med. Chem. 45 (2002) 3905-3927 and WO 02/10162 disclose certain aminothiazole compounds as CDK inhibitors.


Pyrazolopyrimidines are known. For Example, WO92/18504, WO02/50079, WO95/35298, WO02/40485, EP94304104.6, EP0628559 (equivalent to U.S. Pat. Nos. 5,602,136, 5,602,137 and 5,571,813), U.S. Pat. No. 6,383,790, Chem. Pharm. Bull., (1999) 47 928, J. Med. Chem., (1977) 20, 296, J. Med. Chem., (1976) 19 517 and Chem. Pharm. Bull., (1962) 10 620 disclose various pyrazolopyrimidines. Other publications of interest are: WO 03/101993 (published Dec. 11, 2003), WO 03/091256 (published Nov. 6, 2003), and DE 10223917 (published Dec. 11, 2003).


There is a need for new compounds, formulations, treatments and therapies to treat diseases and disorders associated with CDKs. It is, therefore, an object of this invention to provide compounds useful in the treatment or prevention or amelioration of such diseases and disorders.


SUMMARY OF THE INVENTION

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions comprising one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.


In one aspect, the present application discloses a compound, or pharmaceutically acceptable salts or solvates of said compound, said compound having the general structure shown in Formula III:




embedded image



wherein:


R is H, alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, cycloalkyl, cycloalkylalkyl, alkenylalkyl, alkynylalkyl, heterocyclyl, heterocyclylalkyl, heteroarylalkyl (including N-oxide of said heteroaryl), —(CHR5)n-aryl, —(CHR5)n-heteroaryl,




embedded image



wherein each of said alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, and heteroaryl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, heterocyclylalkyl, CF3, OCF3, CN, —OR5, —NR5R10, —C(R4R5)p—R9, —N(R5)Boc, —(CR4R5)pOR5, —C(O2)R5, —C(O)R5, —C(O)NR5R10, —SO3H, —SR10, —S(O2)R7, —S(O2)NR5R10, —N(R5)S(O2)R7, —N(R5)C(O)R7 and —N(R5)C(O)NR5R10;


R2 is selected from the group consisting of H, R9, alkyl, alkenyl, alkynyl, CF3, heterocyclyl, heterocyclylalkyl, halogen, haloalkyl, aryl, arylalkyl, heteroarylalkyl, alkynylalkyl, cycloalkyl, heteroaryl, alkyl substituted with 1-6 R9 groups which can be the same or different and are independently selected from the list of R9 shown below, aryl substituted with 1-3 aryl or heteroaryl groups which can be the same or different and are independently selected from phenyl, pyridyl, thiophenyl, furanyl and thiazolo groups, aryl fused with an aryl or heteroaryl group, heteroaryl substituted with 1-3 aryl or heteroaryl groups which can be the same or different and are independently selected from phenyl, pyridyl, thiophenyl, furanyl and thiazolo groups, heteroaryl fused with an aryl or heteroaryl group,




embedded image


wherein one or more of the aryl and/or one or more of the heteroaryl in the above-noted definitions for R2 can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, —CN, —OR5, —SR5, —S(O2)R6, —S(O2)NR5R6, —NR5R6, —C(O)NR5R6, CF3, alkyl, aryl and OCF3;


R3 is selected from the group consisting of H, halogen, —NR5R6, —OR6, —SR6, —C(O)N(R5R6), alkyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl,




embedded image



wherein each of said alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl for R3 and the heterocyclyl moieties whose structures are shown immediately above for R3 can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF3, CN, —OCF3, —(CR4R5)pOR5, —OR5, —NR5R6, —(CR4R5)pNR5R6, —C(O2)R5, —C(O)R5, —C(O)NR5R6, —SR6, —S(O2)R6, —S(O2)NR5R6, —N(R5)S(O2)R7, —N(R5)C(O)R7, —N(R5)C(R4R5)nN(R5R6) and —N(R5)C(O)NR5R6, with the proviso that no carbon adjacent to a nitrogen atom on a heterocyclyl ring carries a —OR5 moiety;


R4 is H, halo or alkyl;


R5 is H, alkyl, aryl, heteroaryl, arylalkyl or cycloalkyl;


R6 is selected from the group consisting of H, Boc, alkyl, alkenyl, aryl, arylalkyl, arylalkenyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl, wherein each of said alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, heterocyclylalkyl, CF3, OCF3, CN, —OR5, —NR5R10, —C(R4R5)p—R9, —N(R5)Boc, —(CR4R5)pOR5, —C(O2)R5, —C(O)R5, —C(O)NR5R10, —SO3H, —SR10, —S(O2)R7, —S(O2)NR5R10, —N(R5)S(O2)R7, —N(R5)C(O)R7 and —N(R5)C(O)NR5R10;


R10 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl, wherein each of said alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, heterocyclylalkyl, CF3, OCF3, CN, —OR5, —NR4R5, —C(R4R5)p—R9, —N(R5)Boc, —(CR4R5)pOR5, —C(O2)R5, —C(O)NR4R5, —C(O)R5, —SO3H, —SR5, —S(O2)R7, —S(O2)NR4R5, —N(R5)S(O2)R7, —N(R5)C(O)R7 and —N(R5)C(O)NR4R5;


or optionally (i) R5 and R10 in the moiety —NR5R10, or (ii) R5 and R6 in the moiety —NR5R6, may be joined together to form a cycloalkyl or heterocyclyl moiety, with each of said cycloalkyl or heterocyclyl moiety being unsubstituted or optionally independently being substituted with one or more R9 groups;


R7 is selected from the group consisting of alkyl, cycloalkyl, aryl, arylalkenyl, heteroaryl, arylalkyl, heteroarylalkyl, heteroarylalkenyl, and heterocyclyl, wherein each of said alkyl, cycloalkyl, heteroarylalkyl, aryl, heteroaryl and arylalkyl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF3, OCF3, CN, —OR5, —NR5R10, —CH2OR5, —C(O2)R5, —C(O)NR5R10, —C(O)R5, —SR10, —S(O2)R10, —S(O2)NR5R10, —N(R5)S(O2)R10, —N(R5)C(O)R10 and —N(R5)C(O)NR5R10;


R8 is selected from the group consisting of R6, —OR6, —C(O)NR5R10, —S(O2)NR5R10, —C(O)R7, —C(═N—CN)—NH2, —C(═NH)—NHR5, heterocyclyl, and —S(O2)R7;


R9 is selected from the group consisting of halogen, —CN, —NR5R10, —SCN, —NO2, —C(O)R5, —C(O2)R6, —C(O)NR5R10, —OR6, —SR6, —S(O2)R7, —S(O2)NR5R10, —N(R5)S(O2)R7, —N(R5)C(O)R7 and —N(R5)C(O)NR5R10;


m is 0 to 4;


n is 1 to 4; and


p is 1 to 4,


with the proviso that when R2 is phenyl, R3 is not alkyl, alkynyl or halogen, and that when R2 is aryl, R is not




embedded image



and with the further proviso that when R is arylalkyl, then any heteroaryl substituent on the aryl of said arylalkyl contains at least three heteroatoms.


The compounds of Formula III can be useful as protein kinase inhibitors and can be useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.







DETAILED DESCRIPTION

In one embodiment, the present invention discloses pyrazolo[1,5-a]pyrimidine compounds which are represented by structural Formula III, or a pharmaceutically acceptable salt or solvate thereof, wherein the various moieties are as described above.


In another embodiment, R is —(CHR5)n-aryl, —(CHR5)n-heteroaryl, —(CHR5)n-heteroaryl (with said heteroaryl being substituted with an additional, same or different, heteroaryl), —(CHR5)n-heterocyclyl (with said heterocyclyl being substituted with an additional, same or different, heterocyclyl), or




embedded image


In another embodiment, R2 is halogen, CF3, CN, lower alkyl, alkyl substituted with —OR6, alkynyl, aryl, heteroaryl or heterocyclyl.


In another embodiment, R3 is H, lower alkyl, aryl, heteroaryl, cycloalkyl, —NR5R6,




embedded image



wherein said alkyl, aryl, heteroaryl, cycloalkyl and the heterocyclyl structures shown immediately above for R3 are optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, CF3, OCF3, lower alkyl, CN, —C(O)R5, —S(O2)R5, —C(═NH)—NH2, —C(═CN)—NH2, hydroxyalkyl, alkoxycarbonyl, —SR5, and OR5, with the proviso that no carbon adjacent to a nitrogen atom on a heterocyclyl ring carries a —OR5 moiety.


In another embodiment, R4 is H or lower alkyl.


In another embodiment, R5 is H, lower alkyl or cycloalkyl.


In another embodiment, n is 1 to 2.


In an additional embodiment, R is —(CHR5)n-aryl, —(CHR5)n-heteroaryl.


In an additional embodiment, R2 is halogen, CF3, CN, lower alkyl, alkynyl, or alkyl substituted with —OR6.


In an additional embodiment, R2 is lower alkyl, alkynyl or Br.


In an additional embodiment, R3 is H, lower alkyl, aryl,




embedded image



wherein said alkyl, aryl and the heterocyclyl moieties shown immediately above for R3 are optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, CF3, lower alkyl, hydroxyalkyl, alkoxy, —S(O2)R5, and CN.


In an additional embodiment, R4 is H.


In an additional embodiment, R5 is H, ethyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.


In an additional embodiment, R8 is alkyl or hydroxyalkyl.


In an additional embodiment, n is 1.


In an additional embodiment, p is 1 or 2.


In another embodiment, R is H.


In another embodiment, R2 is halogen.


In another embodiment, R2 is thiophene, furan, pyridine, pyrazole, alkylthio or arylthio, wherein each of said alkyl and aryl of R2 can independently be unsubstituted or substituted as defined above.


In another embodiment, R2 is thiophene, furan, pyridine or pyrazole.


In another embodiment, R2 is an amide which can be unsubstituted or substituted as defined above.


In another embodiment, R2 is an urea, which may be unsubstituted or substituted as defined above.


In another embodiment, R2 is an alkenyl.


In another embodiment, R2 is an alkynyl.


In another embodiment, R3 is —NR5R6.


In another embodiment, R4 is H.


In another embodiment, R4 is unsubstituted lower alkyl.


In another embodiment, R4 is alkyl substituted with —OR6.


In another embodiment, R4 is halo.


In another embodiment, R4 is —F, —Cl or —Br.


In another embodiment, both R2 and R4 are halogen.


In another embodiment, both R2 and R4 are halo and R is H.


In another embodiment, R is H, R2 is halo and R3 is heteroaryl.


In another embodiment, R is H, R2 is halo and R3 is aryl.


In another embodiment, R is H, R2 is halo and R3 is heterocyclyl.


Another embodiment discloses the inventive compounds shown in Table 1, which exhibited CDK2 inhibitory activity of about 0.0001 μM to >about 5 μM. The assay methods are described later (from page 333 onwards).









TABLE 1









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image









embedded image











Another embodiment of the invention discloses the following compounds, which exhibited CDK2 inhibitory activity of about 0.0001 μM to about 0.5 μM:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


Another embodiment of the invention discloses the following compounds, which exhibited CDK2 inhibitory activity of about 0.0001 μM to about 0.1 μM:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


Still additionally disclosed are the following compounds:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image



or a pharmaceutically acceptable salt or solvate thereof.


As used above, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:


“Patient” includes both human and animals.


“Mammal” means humans and other mammalian animals.


“Alkyl” means an aliphatic hydrocarbon group which may be straight or branched and comprising about 1 to about 20 carbon atoms in the chain. Preferred alkyl groups contain about 1 to about 12 carbon atoms in the chain. More preferred alkyl groups contain about 1 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkyl chain. “Lower alkyl” means a group having about 1 to about 6 carbon atoms in the chain which may be straight or branched. “Alkyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl, aryl, cycloalkyl, cyano, hydroxy, alkoxy, alkylthio, amino, —NH(alkyl), —NH(cycloalkyl), —N(alkyl)2, carboxy and —C(O)O-alkyl. Non-limiting examples of suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl and t-butyl.


“Alkenyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 6 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkenyl chain. “Lower alkenyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched. “Alkenyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of halo, alkyl. aryl, cycloalkyl, cyano, alkoxy and —S(alkyl). Non-limiting examples of suitable alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl.


“Alkylene” means a difunctional group obtained by removal of a hydrogen atom from an alkyl group that is defined above. Non-limiting examples of alkylene include methylene, ethylene and propylene.


“Alkynyl” means an aliphatic hydrocarbon group containing at least one carbon-carbon triple bond and which may be straight or branched and comprising about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have about 2 to about 12 carbon atoms in the chain; and more preferably about 2 to about 4 carbon atoms in the chain. Branched means that one or more lower alkyl groups such as methyl, ethyl or propyl, are attached to a linear alkynyl chain. “Lower alkynyl” means about 2 to about 6 carbon atoms in the chain which may be straight or branched. Non-limiting examples of suitable alkynyl groups include ethynyl, propynyl, 2-butynyl and 3-methylbutynyl. “Alkynyl” may be unsubstituted or optionally substituted by one or more substituents which may be the same or different, each substituent being independently selected from the group consisting of alkyl, aryl and cycloalkyl.


“Aryl” means an aromatic monocyclic or multicyclic ring system comprising about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl and naphthyl.


“Heteroaryl” means an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the ring atoms is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Preferred heteroaryls contain about 5 to about 6 ring atoms. The “heteroaryl” can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein. The prefix aza, oxa or thia before the heteroaryl root name means that at least a nitrogen, oxygen or sulfur atom respectively, is present as a ring atom. A nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like. The term “heteroaryl” also refers to partially saturated heteroaryl moieties such as, for example, tetrahydroisoquinolyl, tetrahydroquinolyl and the like.


“Aralkyl” or “arylalkyl” means an aryl-alkyl- group in which the aryl and alkyl are as previously described. Preferred aralkyls comprise a lower alkyl group. Non-limiting examples of suitable aralkyl groups include benzyl, 2-phenethyl and naphthalenylmethyl. The bond to the parent moiety is through the alkyl.


“Alkylaryl” means an alkyl-aryl- group in which the alkyl and aryl are as previously described. Preferred alkylaryls comprise a lower alkyl group. Non-limiting example of a suitable alkylaryl group is tolyl. The bond to the parent moiety is through the aryl.


“Cycloalkyl” means a non-aromatic mono- or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms. Preferred cycloalkyl rings contain about 5 to about 7 ring atoms. The cycloalkyl can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkyls include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl and the like. Non-limiting examples of suitable multicyclic cycloalkyls include 1-decalinyl, norbornyl, adamantyl and the like.


“Cycloalkylalkyl” means a cycloalkyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkylalkyls include cyclohexylmethyl, adamantylmethyl and the like.


“Cycloalkenyl” means a non-aromatic mono or multicyclic ring system comprising about 3 to about 10 carbon atoms, preferably about 5 to about 10 carbon atoms which contains at least one carbon-carbon double bond. Preferred cycloalkenyl rings contain about 5 to about 7 ring atoms. The cycloalkenyl can be optionally substituted with one or more “ring system substituents” which may be the same or different, and are as defined above. Non-limiting examples of suitable monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, cyclohepta-1,3-dienyl, and the like. Non-limiting example of a suitable multicyclic cycloalkenyl is norbornylenyl.


“Cycloalkenylalkyl” means a cycloalkenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable cycloalkenylalkyls include cyclopentenylmethyl, cyclohexenylmethyl and the like.


“Halogen” means fluorine, chlorine, bromine, or iodine. Preferred are fluorine, chlorine and bromine.


“Ring system substituent” means a substituent attached to an aromatic or non-aromatic ring system which, for example, replaces an available hydrogen on the ring system. Ring system substituents may be the same or different, each being independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, alkylaryl, heteroaralkyl, heteroarylalkenyl, heteroarylalkynyl, alkylheteroaryl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkoxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylthio, arylthio, heteroarylthio, aralkylthio, heteroaralkylthio, cycloalkyl, heterocyclyl, —C(═N—CN)—NH2, —C(═NH)—NH2, —C(═NH)—NH(alkyl), Y1Y2N—, Y1Y2N-alkyl-, Y1Y2NC(O)—, Y1Y2NSO2— and —SO2NY1Y2, wherein Y1 and Y2 can be the same or different and are independently selected from the group consisting of hydrogen, alkyl, aryl, cycloalkyl, and aralkyl. “Ring system substituent” may also mean a single moiety which simultaneously replaces two available hydrogens on two adjacent carbon atoms (one H on each carbon) on a ring system. Examples of such moiety are methylene dioxy, ethylenedioxy, —C(CH3)2— and the like which form moieties such as, for example:




embedded image


“Heteroarylalkyl” means a heteroaryl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heteroaryls include 2-pyridinylmethyl, quinolinylmethyl and the like.


“Heterocyclyl” means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any —NH in a heterocyclyl ring may exist protected such as, for example, as an —N(Boc), —N(CBz), —N(Tos) group and the like; such protections are also considered part of this invention. The heterocyclyl can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, lactam, lactone, and the like. “Heterocyclyl” may also mean a single moiety (e.g., carbonyl) which simultaneously replaces two available hydrogens on the same carbon atom on a ring system. Example of such moiety is pyrrolidone:




embedded image


“Heterocyclylalkyl” means a heterocyclyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core. Non-limiting examples of suitable heterocyclylalkyls include piperidinylmethyl, piperazinylmethyl and the like.


“Heterocyclenyl” means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. The heterocyclenyl can be optionally substituted by one or more ring system substituents, wherein “ring system substituent” is as defined above. The nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable heterocyclenyl groups include 1,2,3,4-tetrahydropyridinyl, 1,2-dihydropyridinyl, 1,4-dihydropyridinyl, 1,2,3,6-tetrahydropyridinyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydrooxazolyl, dihydrooxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl, 7-oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like. “Heterocyclenyl” may also mean a single moiety (e.g., carbonyl) which simultaneously replaces two available hydrogens on the same carbon atom on a ring system. Example of such moiety is pyrrolidinone:




embedded image


“Heterocyclenylalkyl” means a heterocyclenyl moiety as defined above linked via an alkyl moiety (defined above) to a parent core.


It should be noted that in hetero-atom containing ring systems of this invention, there are no hydroxyl groups on carbon atoms adjacent to a N, O or S, as well as there are no N or S groups on carbon adjacent to another heteroatom. Thus, for example, in the ring:




embedded image



there is no —OH attached directly to carbons marked 2 and 5.


It should also be noted that tautomeric forms such as, for example, the moieties:




embedded image



are considered equivalent in certain embodiments of this invention.


“Alkynylalkyl” means an alkynyl-alkyl- group in which the alkynyl and alkyl are as previously described. Preferred alkynylalkyls contain a lower alkynyl and a lower alkyl group. The bond to the parent moiety is through the alkyl. Non-limiting examples of suitable alkynylalkyl groups include propargylmethyl.


“Heteroaralkyl” means a heteroaryl-alkyl- group in which the heteroaryl and alkyl are as previously described. Preferred heteroaralkyls contain a lower alkyl group. Non-limiting examples of suitable aralkyl groups include pyridylmethyl, and quinolin-3-ylmethyl. The bond to the parent moiety is through the alkyl.


“Hydroxyalkyl” means a HO-alkyl- group in which alkyl is as previously defined. Preferred hydroxyalkyls contain lower alkyl. Non-limiting examples of suitable hydroxyalkyl groups include hydroxymethyl and 2-hydroxyethyl.


“Acyl” means an H—C(O)—, alkyl-C(O)— or cycloalkyl-C(O)—, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.


“Aroyl” means an aryl-C(O)— group in which the aryl group is as previously described. The bond to the parent moiety is through the carbonyl. Non-limiting examples of suitable groups include benzoyl and 1-naphthoyl.


“Alkoxy” means an alkyl-O— group in which the alkyl group is as previously described. Non-limiting examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy. The bond to the parent moiety is through the ether oxygen.


“Aryloxy” means an aryl-O— group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen.


“Aralkyloxy” means an aralkyl-O— group in which the aralkyl group is as previously described. Non-limiting examples of suitable aralkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy. The bond to the parent moiety is through the ether oxygen.


“Alkylthio” means an alkyl-S— group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur.


“Arylthio” means an aryl-S— group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur.


“Aralkylthio” means an aralkyl-S— group in which the aralkyl group is as previously described. Non-limiting example of a suitable aralkylthio group is benzylthio. The bond to the parent moiety is through the sulfur.


“Alkoxycarbonyl” means an alkyl-O—CO— group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl.


“Aryloxycarbonyl” means an aryl-O—C(O)— group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl.


“Aralkoxycarbonyl” means an aralkyl-O—C(O)— group. Non-limiting example of a suitable aralkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl.


“Alkylsulfonyl” means an alkyl-S(O2)— group. Preferred groups are those in which the alkyl group is lower alkyl. The bond to the parent moiety is through the sulfonyl.


“Arylsulfonyl” means an aryl-S(O2)— group. The bond to the parent moiety is through the sulfonyl.


The term “substituted” means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By “stable compound” or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.


The term “optionally substituted” means optional substitution with the specified groups, radicals or moieties.


The term “purified”, “in purified form” or “in isolated and purified form” for a compound refers to the physical state of said compound after being isolated from a synthetic process or natural source or combination thereof. Thus, the term “purified”, “in purified form” or “in isolated and purified form” for a compound refers to the physical state of said compound after being obtained from a purification process or processes described herein or well known to the skilled artisan, in sufficient purity to be characterizable by standard analytical techniques described herein or well known to the skilled artisan.


It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.


When a functional group in a compound is termed “protected”, this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in organic Synthesis (1991), Wiley, New York.


When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in Formula III, its definition on each occurrence is independent of its definition at every other occurrence.


As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.


Prodrugs and solvates of the compounds of the invention are also contemplated herein. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press. The term “prodrug” means a compound (e.g., a drug precursor) that is transformed in vivo to yield a compound of Formula (III) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g., by metabolic or chemical processes), such as, for example, through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.


For example, if a compound of Formula (III) or a pharmaceutically acceptable salt, hydrate or solvate of the compound contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (C1-C8)alkyl, (C2-C12)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N—(C1-C2)alkylamino(C2-C3)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C1-C2)alkyl, N,N-di(C1-C2)alkylcarbamoyl-(C1-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl, and the like.


Similarly, if a compound of Formula (III) contains an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as, for example, (C1-C6)alkanoyloxymethyl, 1-((C1-C6)alkanoyloxy)ethyl, 1-methyl-1-((C1-C6)alkanoyloxy)ethyl, (C1-C6)alkoxycarbonyloxymethyl, N—(C1-C6)alkoxycarbonylaminomethyl, succinoyl, (C1-C6)alkanoyl, α-amino(C1-C4)alkanyl, arylacyl and α-aminoacyl, or α-aminoacyl-α-aminoacyl, where each α-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, —P(O)(O(C1-C6)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate), and the like.


If a compound of Formula (III) incorporates an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as, for example, R-carbonyl, RO-carbonyl, NRR′-carbonyl where R and R′ are each independently (C1-C10)alkyl, (C3-C7) cycloalkyl, benzyl, or R-carbonyl is a natural α-aminoacyl or natural α-aminoacyl, —C(OH)C(O)OY1 wherein Y1 is H, (C1-C6)alkyl or benzyl, —C(OY2)Y3 wherein Y2 is (C1-C4) alkyl and Y3 is (C1-C6)alkyl, carboxy(C1-C6)alkyl, amino(C1-C4)alkyl or mono-N— or di-N,N—(C1-C6)alkylaminoalkyl, —C(Y4)Y5 wherein Y4 is H or methyl and Y5 is mono-N— or di-N,N—(C1-C6)alkylamino morpholino, piperidin-1-yl or pyrrolidin-1-yl, and the like.


One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H2O.


One or more compounds of the invention may optionally be converted to a solvate. Preparation of solvates is generally known. Thus, for example, M. Caira et al, J. Pharmaceutical Sci., 93(3), 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water. Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS Pharm Sci Tech., 5(1), article 12 (2004); and A. L. Bingham et al, Chem. Commun., 603-604 (2001). A typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods. Analytical techniques such as, for example I. R. spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).


“Effective amount” or “therapeutically effective amount” is meant to describe an amount of compound or a composition of the present invention effective in inhibiting the above-noted diseases and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.


The compounds of Formula III can form salts which are also within the scope of this invention. Reference to a compound of Formula III herein is understood to include reference to salts thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula III contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula III may be formed, for example, by reacting a compound of Formula III with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.


Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al, Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1-19; P. Gould, International J. of Pharmaceutics (1986) 33 201-217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.


Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g. benzyl and phenethyl bromides), and others.


All such acid salts and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.


Pharmaceutically acceptable esters of the present compounds include the following groups: (1) carboxylic acid esters obtained by esterification of the hydroxy groups, in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl), alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted with, for example, halogen, C1-4alkyl, or C1-4alkoxy or amino); (2) sulfonate esters, such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); (4) phosphonate esters and (5) mono-, di- or triphosphate esters. The phosphate esters may be further esterified by, for example, a C1-20 alcohol or reactive derivative thereof, or by a 2,3-di(C6-24)acyl glycerol.


Compounds of Formula III, and salts, solvates, esters and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention.


The compounds of Formula (III) may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula (III) as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (III) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.


Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Also, some of the compounds of Formula (III) may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of chiral HPLC column.


It is also possible that the compounds of Formula (III) may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.


All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example, if a compound of Formula (III) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.) Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms “salt”, “solvate”, “ester”, “prodrug” and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.


The present invention also embraces isotopically-labelled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2H, 3H, 13C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively.


Certain isotopically-labelled compounds of Formula (III) (e.g., those labeled with 3H and 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Isotopically labelled compounds of Formula (III) can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an appropriate isotopically labelled reagent for a non-isotopically labelled reagent.


Polymorphic forms of the compounds of Formula III, and of the salts, solvates, esters and prodrugs of the compounds of Formula III, are intended to be included in the present invention.


The term “pharmaceutical composition” is also intended to encompass both the bulk composition and individual dosage units comprised of more than one (e.g., two) pharmaceutically active agents such as, for example, a compound of the present invention and an additional agent selected from the lists of the additional agents described herein, along with any pharmaceutically inactive excipients. The bulk composition and each individual dosage unit can contain fixed amounts of the afore-said “more than one pharmaceutically active agents”. The bulk composition is material that has not yet been formed into individual dosage units. An illustrative dosage unit is an oral dosage unit such as tablets, pills and the like. Similarly, the herein-described method of treating a patient by administering a pharmaceutical composition of the present invention is also intended to encompass the administration of the afore-said bulk composition and individual dosage units.


The compounds according to the invention have pharmacological properties; in particular, the compounds of Formula III can be inhibitors of protein kinases such as, for example, the inhibitors of the cyclin-dependent kinases, mitogen-activated protein kinase (MAPK/ERK), glycogen synthase kinase 3(GSK3beta) and the like. The cyclin dependent kinases (CDKs) include, for example, CDC2 (CDK1), CDK2, CDK4, CDK5, CDK6, CDK7 CDK8 and CDK9. The novel compounds of Formula III are expected to be useful in the therapy of proliferative diseases such as cancer, autoimmune diseases, viral diseases, fungal diseases, neurological/neurodegenerative disorders, arthritis, inflammation, anti-proliferative (e.g., ocular retinopathy), neuronal, alopecia and cardiovascular disease. Many of these diseases and disorders are listed in U.S. Pat. No. 6,413,974 cited earlier, the disclosure of which is incorporated herein.


More specifically, the compounds of Formula III can be useful in the treatment of a variety of cancers, including (but not limited to) the following: carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, non-small cell lung cancer, head and neck, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;


hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma, and Burkett's lymphoma;


hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia;


tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma;


tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma and schwannomas; and


other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.


Non-limiting examples of some specific diseases that can be treated using the compounds and/or pharmaceutical compositions comprising such compounds, and/or with combination anti-cancer agents include the following:


tumor of the bladder, breast (including BRCA-mutated breast cancer), colorectal, colon, kidney, liver, lung, small cell lung cancer, non-small cell lung cancer, head and neck, esophagus, bladder, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;


leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkins lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma, mantle cell lymphoma, myeloma and Burkett's lymphoma;


chronic lymphocytic leukemia (“CLL”),


acute and chronic myelogenous leukemia, myelodysplastic syndrome and promyelocytic leukemia;


fibrosarcoma, rhabdomyosarcoma;


head and neck, mantle cell lymphoma, myeloma;


astrocytoma, neuroblastoma, glioma, glioblastoma, malignant glial tumors, astrocytoma, hepatocellular carcinoma, gastrointestinal stromal tumors (“GIST”) and schwannomas;


melanoma, multiple myeloma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.


Due to the key role of CDKs in the regulation of cellular proliferation in general, inhibitors could act as reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal infections.


Compounds of Formula III may also be useful in the treatment of Alzheimer's disease, as suggested by the recent finding that CDK5 is involved in the phosphorylation of tau protein (J. Biochem, (1995) 117, 741-749).


Compounds of Formula III may induce or inhibit apoptosis. The apoptotic response is aberrant in a variety of human diseases. Compounds of Formula III, as modulators of apoptosis, will be useful in the treatment of cancer (including but not limited to those types mentioned hereinabove), viral infections (including but not limited to herpevirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus), prevention of AIDS development in HIV-infected individuals, autoimmune diseases (including but not limited to systemic lupus, erythematosus, autoimmune mediated glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and autoimmune diabetes mellitus), neurodegenerative disorders (including but not limited to Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration), myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial infarctions, stroke and reperfusion injury, arrhythmia, atherosclerosis, toxin-induced or alcohol related liver diseases, hematological diseases (including but not limited to chronic anemia and aplastic anemia), degenerative diseases of the musculoskeletal system (including but not limited to osteoporosis and arthritis) aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple sclerosis, kidney diseases and cancer pain.


Compounds of Formula III, as inhibitors of the CDKs, can modulate the level of cellular RNA and DNA synthesis. These agents would therefore be useful in the treatment of viral infections (including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr virus, Sindbis virus and adenovirus).


Compounds of Formula III may also be useful in the chemoprevention of cancer. Chemoprevention is defined as inhibiting the development of invasive cancer by either blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells that have already suffered an insult or inhibiting tumor relapse.


Compounds of Formula III may also be useful in inhibiting tumor angiogenesis and metastasis.


Compounds of Formula III may also act as inhibitors of other protein kinases, e.g., protein kinase C, her2, raf 1, MEK1, MAP kinase, EGF receptor, PDGF receptor, IGF receptor, PI3 kinase, wee1 kinase, Src, Abl and thus be effective in the treatment of diseases associated with other protein kinases.


Another aspect of this invention is a method of treating a mammal (e.g., human) having a disease or condition associated with the CDKs by administering a therapeutically effective amount of at least one compound of Formula III, or a pharmaceutically acceptable salt or solvate of said compound to the mammal.


A preferred dosage is about 0.001 to 500 mg/kg of body weight/day of the compound of Formula III. An especially preferred dosage is about 0.01 to 25 mg/kg of body weight/day of a compound of Formula III, or a pharmaceutically acceptable salt or solvate of said compound.


The compounds of this invention may also be useful in combination (administered together or sequentially) with one or more of anti-cancer treatments such as radiation therapy, and/or one or more anti-cancer agents selected from the group consisting of cytostatic agents, cytotoxic agents (such as for example, but not limited to, DNA interactive agents (such as cisplatin or doxorubicin)); taxanes (e.g. taxotere, TAXOL® (paclitaxel)); topoisomerase II inhibitors (such as etoposide); topoisomerase I inhibitors (such as irinotecan (or CPT-11), camptostar, or topotecan); tubulin interacting agents (such as paclitaxel, docetaxel or the epothilones); hormonal agents (such as tamoxifen); thymidilate synthase inhibitors (such as 5-fluorouracil); anti-metabolites (such as methoxtrexate); alkylating agents (such as temozolomide (TEMODAR™ from Schering-Plough Corporation, Kenilworth, N.J.), cyclophosphamide); Farnesyl protein transferase inhibitors (such as, SARASAR™ (4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl-]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, or SCH 66336 from Schering-Plough Corporation, Kenilworth, N.J.), tipifarnib (Zarnestra® or R115777 from Janssen Pharmaceuticals), L778,123 (a farnesyl protein transferase inhibitor from Merck & Company, Whitehouse Station, N.J.), BMS 214662 (a farnesyl protein transferase inhibitor from Bristol-Myers Squibb Pharmaceuticals, Princeton, N.J.); signal transduction inhibitors (such as, IRESSA® (gefitinib) (from Astra Zeneca Pharmaceuticals, England), TARCEVA® (erlotinib) (EGFR kinase inhibitors), antibodies to EGFR (e.g., C225), GLEEVEC™ (C-abl kinase inhibitor from Novartis Pharmaceuticals, East Hanover, N.J.); interferons such as, for example, INTRON A® (Intereron alfa-2b) (from Schering-Plough Corporation), PEGINTRON A® (Peginterferon alfa-2b) (from Schering-Plough Corporation); hormonal therapy combinations; aromatase combinations; ara-C, ADRIAMYCIN® (doxorubicin), CYTOXAN® (cyclophosphamide), and gemcitabine.


Other anti-cancer (also known as anti-neoplastic) agents include but are not limited to Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, oxaliplatin (ELOXATIN™ from Sanofi-Synthelabo Pharmaeuticals, France), Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, liposomal doxorubicin (e.g., Caelyx®, Myocet®, Doxil®), Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, AVASTIN® (bevacuzimab), HERCEPTIN® (trastuzumab), BEXXAR® (tositumomab), VELCADE® (bortezomib), ZEVALIN® (ibritumomab tiuxetan), TRISENOX® (arsenic trioxide), XELODA® (capecitabine), Vinorelbine, Porfimer, ERBITUX® (cetuximab), Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, C225 (or Cetuximab from Merck KGaA, Darmstadt, Germany), and CAMPATH® (alemtuzumab).


The compounds of this invention may specifically be useful in combination (administered together, concurrently or sequentially) with at least one compound selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, taxotere, Taxol®, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R11577®, L778,123®, BMS 214662®, Iressa®, Tarceva®, antibodies to EGFR, antibodies to IGFR (including, for example, those published in US 2005/0136063 published Jun. 23, 2005), KSP inhibitors (such as, for example, those published in WO 2006/098962 and WO 2006/098961; ispinesib, SB-743921 from Cytokinetics), centrosome associated protein E (“CENP-E”) inhibitors (e.g., GSK-923295), Gleevec®, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN™, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Avastin, herceptin, Bexxar, bortezomib (“Velcade”), Zevalin, Trisenox, Xeloda, Vinorelbine, Porfimer, Erbitux, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, C225®, satriplatin, Alimta® (pemetrexed), Mylotarg® (Gemtuzumab ozogamicin), Avastin® (bevacizumab), panitubimab, Sutent® (sunitinib), sorafenib, Sprycel® (dastinib), nilotinib, Tykerb® (lapatinib) and Campath. This may optionally be combined with radiation therapy.


The compounds of this invention may specifically be useful in combination (administered together, concurrently or sequentially) with temozolomide and/or radiation therapy.


If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically active agent or treatment within its dosage range. For example, the CDC2 inhibitor olomucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis (J. Cell Sci., (1995) 108, 2897. Compounds of Formula III may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of Formula III may be administered either prior to or after administration of the known anticancer or cytotoxic agent. For example, the cytotoxic activity of the cyclin-dependent kinase inhibitor flavopiridol is affected by the sequence of administration with anticancer agents. Cancer Research, (1997) 57, 3375. Such techniques are within the skills of persons skilled in the art as well as attending physicians.


Accordingly, in an aspect, this invention includes combinations comprising an amount of at least one compound of Formula III, or a pharmaceutically acceptable salt or solvate thereof, and an amount of one or more anti-cancer treatments and anti-cancer agents listed above wherein the amounts of the compounds/treatments result in desired therapeutic effect.


The pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological assays. The exemplified pharmacological assays which are described later have been carried out with the compounds according to the invention and their salts.


This invention is also directed to pharmaceutical compositions which comprise at least one compound of Formula III, or a pharmaceutically acceptable salt or solvate of said compound and at least one pharmaceutically acceptable carrier.


For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pa.


Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.


Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.


Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.


The compounds of the invention may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.


The compounds of this invention may also be delivered subcutaneously.


Preferably the compound is administered orally or intravenously.


Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.


The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 1 mg to about 100 mg, preferably from about 1 mg to about 50 mg, more preferably from about 1 mg to about 25 mg, according to the particular application.


The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.


The amount and frequency of administration of the compounds of the invention and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage regimen for oral administration can range from about 1 mg/day to about 500 mg/day, preferably 1 mg/day to 200 mg/day, in two to four divided doses.


Another aspect of this invention is a kit comprising a therapeutically effective amount of at least one compound of Formula III, or a pharmaceutically acceptable salt or solvate of said compound and a pharmaceutically acceptable carrier, vehicle or diluent.


Yet another aspect of this invention is a kit comprising an amount of at least one compound of Formula III, or a pharmaceutically acceptable salt or solvate of said compound and an amount of at least one anticancer therapy and/or anti-cancer agent listed above, wherein the amounts of the two or more ingredients result in desired therapeutic effect.


The invention disclosed herein is exemplified by the following preparations and examples which should not be construed to limit the scope of the disclosure. Alternative mechanistic pathways and analogous structures will be apparent to those skilled in the art.


Where NMR data are presented, 1H spectra were obtained on either a Varian VXR-200 (200 MHz, 1H), Varian Gemini-300 (300 MHz) or XL-400 (400 MHz) and are reported as ppm down field from Me4Si with number of protons, multiplicities, and coupling constants in Hertz indicated parenthetically. Where LC/MS data are presented, analyses was performed using an Applied Biosystems API-100 mass spectrometer and Shimadzu SCL-10A LC column: Altech platinum C18, 3 micron, 33 mm×7 mm ID; gradient flow: 0 min—10% CH3CN, 5 min—95% CH3CN, 7 min—95% CH3CN, 7.5 min—10% CH3CN, 9 min—stop. The retention time and observed parent ion are given.


The following solvents and reagents may be referred to by their abbreviations in parenthesis:

  • Thin layer chromatography: TLC
  • dichloromethane: CH2Cl2
  • ethyl acetate: AcOEt or EtOAc
  • methanol: MeOH
  • trifluoroacetate: TFA
  • triethylamine: Et3N or TEA
  • butoxycarbonyl: n-Boc or Boc
  • nuclear magnetic resonance spectroscopy: NMR
  • liquid chromatography mass spectrometry: LCMS
  • high resolution mass spectrometry: HRMS
  • milliliters: mL
  • millimoles: mmol
  • microliters: μl
  • grams: g
  • milligrams: mg
  • room temperature or rt (ambient): about 25° C.
  • dimethoxyethane: DME


EXAMPLES

In general, the compounds described in this invention can be prepared through the general routes described below in Scheme 1. Treatment of the




embedded image



starting nitrile with potassium t-butoxide and ethyl formate gives rise to the intermediate enol 2 which upon treatment with hydrazine gives the desired substituted 3-aminopyrazole. Condensation of compounds of type 3 with the appropriately functionalized keto ester of type 5 gives rise to the pyridones 6 as shown in Scheme 3. The keto esters used in this general route are either commercially available or can be made as illustrated in Scheme 2.




embedded image


The chlorides of type 9 can be prepared by treatment of the pyridones 8 with POCl3. When R2 is equal to H, substitution in this position is possible on the compounds of type 9 by electrophilic halogenation, acylation, and various other electrophilic aromatic substitutions.


Introduction of the N7-amino functionality can be accomplished through displacement of the chloride of compounds of type 9 by reaction with the appropriate amine as shown in Scheme 3.




embedded image


Condensation of compounds of type 7 with the appropriately functionalized malonate ester of type 11 gives rise to the pyridones 13 as shown in Scheme 4.


The chlorides of type 14 can be prepared by treatment of the pyridones 13 with POCl3. When R2 is H, substitution in this position is possible on compounds of type 9 by electrophilic halogenation, acylation, and various other electrophilic aromatic substitutions.


Incorporation of the N7-amino functionality can be accomplished through regioselective displacement of the chloride of compounds of type 14. Incorporation of the N5-amino functionality by addition of an appropriate amine at higher temperature.




embedded image


Alternatively, condensations of the aminopyrazoles of type 7 with an appropriately functionalize keto ester as prepared in Scheme 5, leads to compounds of type 13 as shown in Scheme 4.




embedded image


The chlorides of type 14 can be prepared by treatment of the pyridones 13 with POCl3. When R2 is equal to H, substitution in this position is possible on compounds of type 14 by electrophilic halogenation, acylation, and various other electrophilic aromatic substitutions.


Incorporation of the N7-amino functionality can be accomplished through displacement of the chloride of compounds of type 15.


Preparative Examples
Preparative Example 1



embedded image


A procedure in German patent DE 19834047 A1, p 19 was followed. To a solution of KOtBu (6.17 g, 0.055 mol) in anhydrous THF (40 mL) was added, dropwise, a solution of cyclopropylacetonitrile (2.0 g, 0.025 mol) and ethyl formate (4.07 g, 0.055 mol) in anhydrous THF (4 mL). A precipitate formed immediately. This mixture was stirred for 12 hr. It was concentrated under vacuum and the residue stirred with Et2O (50 mL). The resulting residue was decanted and washed with Et2O (2×50 mL) and Et2O removed from the residue under vacuum. The residue was dissolved in cold H2O (20 mL) and pH adjusted to 4-5 with 12 N HCl. The mixture was extracted with CH2Cl2 (2×50 mL). The organic layers were combined, dried over MgSO4 and concentrated under vacuum to give the aldehyde as a tan liquid.


Step B:




embedded image


The product from Preparative Example 1, Step A (2.12 g, 0.0195 mol), NH2NH2.H2O (1.95 g, 0.039 mol) and 1.8 g (0.029 mole) of glacial CH3CO2H (1.8 g, 0.029 mol) were dissolved in EtOH (10 mL). It was refluxed for 6 hr and concentrated under vacuum. The residue was slurried in CH2Cl2 (150 mL) and the pH adjusted to 9 with 1N NaOH. The organic layer washed with brine, dried over MgSO4 and concentrated under vacuum to give the product as a waxy orange solid.


Preparative Examples 2-4

By essentially the same procedure set forth in Preparative Example 1, only substituting the nitrile shown in Column 2 of Table 2, the compounds in Column 3 of Table 2 were prepared:











TABLE 2





Prep.




Ex.
Column 2
Column 3

















2


embedded image




embedded image







3


embedded image




embedded image







3.10


embedded image




embedded image











Preparative Example 4



embedded image


2-Carbomethoxycyclopentanone (6.6 ml, 0.05 mol) in THF (15 ml) was added dropwise to a vigorously stirred suspension of NaH (60% in mineral oil, 4 g, 0.1 mol) in THF (100 ml) at 0-10° C. When bubbling ceased, the reaction mixture was treated at the same temperature with ClCOOMe (7.8 ml, 0.1 mol) in THF (15 ml). The resulted off-white suspension was stirred for 30 minutes at room temperature and 30 minutes under reflux. The reaction was monitored by TLC for disappearance of starting material. The reaction mixture was quenched with water carefully and partitioned between ethyl acetate and saturated solution of ammonium chloride in a funnel. Shaken and separated, the organic layer was washed with brine and dried over anhydrous sodium sulfate. Solvents were removed, and the residue was purified by flash chromatography, eluted with 5% and then 10% ethyl acetate in hexane. 9.4 g colorless oil was obtained with 94% yield. 1H NMR (CDCl3) δ 3.90(s, 3H), 3.73(s, 3H), 2.65(m, 4H), 1.98(m, 2H).


Preparative Example 5



embedded image


To lithium diisopropylamide solution in THF (2.0 N, 0.04 mol) at −65° C., was added dropwise 2,2-dicarbomethoxycyclopentanone (4 g, 0.02 mol) in THF (60 ml). The resulted reaction mixture was stirred at the same temperature before adding methyl chloroformate (1.54 ml, 0.02 mol). Reaction mixture stirred for an hour and poured into saturated ammonium chloride solution with some ice. This solution was extracted three times with ether, and the combined ethereal layers were dried over sodium sulfate. Solvents were removed in vacuo, and the residue was purified by flash chromatography, eluted with 30% increased to 50% ethyl acetate in hexane. 2.3 g yellowish oil was obtained with 58% yield. 1H NMR (CDCl3) δ 3.77(s, 6H), 3.32(t, 1H), 3.60-3.10(m, 4H).


Preparative Example 6



embedded image


The reactions were done as outlined in (K. O. Olsen, J. Org. Chem., (1987) 52, 4531-4536). Thus, to a stirred solution of lithium diisopropylamide in THF at −65 to −70 C was added freshly distilled ethyl acetate, dropwise. The resulting solution was stirred for 30 min and the acid chloride was added as a solution in THF. The reaction mixture was stirred at −65 to −70° C. for 30 min and then terminated by the addition of 1 N HCl solution. The resulting two-phased mixture was allowed to warm to ambient temperature. The resulting mixture was diluted with EtOAc (100 mL) the organic layer was collected. The aqueous layer was extracted with EtOAc (100 mL). The organic layers were combined, washed with brine, dried (Na2SO4), and concentrated in vacuo to give the crude β-keto esters, which were used in the subsequent condensations.


Preparative Examples 7-19

By essentially the same procedure set forth in Preparative Example 6 only substituting the acid chlorides shown in Column 2 of Table 3, the β-keto esters shown in Column 3 of Table 3 were prepared:












TABLE 3





Prep.





Ex.
Column 2
Column 3
DATA


















7


embedded image




embedded image


LCMS: MH+ = 223





8


embedded image




embedded image


LCMS: MH+ = 253





9


embedded image




embedded image


LCMS: MH+ = 261





10


embedded image




embedded image


MH+ = 199





11


embedded image




embedded image








12


embedded image




embedded image








13


embedded image




embedded image


LCMS: MH+ = 271





14


embedded image




embedded image


Yield = quant MH+ = 249





15


embedded image




embedded image


Yield = quant MH+ = 237





16


embedded image




embedded image


Yield = quant MH+ = 262





17


embedded image




embedded image


Yield = 48 MH+ = 195





18


embedded image




embedded image


Yield = 99 MH+ = 199





19


embedded image




embedded image


Yield = 77% 1H NMR (CDCl3) δ 7.42 (t, 1H), 6.68 (d, 2H), 4.29 (q, 2H), 3.97 (d, 2H), 3.95 (s, 3H), 1.38 (t, 3H).









Preparative Example 20



embedded image


To a solution of the acid in THF was added Et3N, followed by isobutyl chloroformate at −20 to −30° C. After the mixture was stirred for 30 min at −20 to −30° C., triethylamine hydrochloride was filtered off under argon, and the filtrate was added to the LDA-EtOAc reaction mixture (prepared as outlined in Method A) at −65 to −70° C. After addition of 1 N HCl, followed by routine workup of the reaction mixture and evaporation of the solvents, the crude β-keto esters were isolated. The crude material was used in the subsequent condensations.


Preparative Examples 21-28

By essentially the same conditions set forth in Preparative Example 20 only substituting the carboxylic acid shown in Column 2 of Table 4, the compounds shown in Column 3 of Table 4 were prepared:












TABLE 4





Prep. Ex.
Column 2
Column 3
CMPD







21


embedded image




embedded image


Yield = 99% MH+ = 213





22


embedded image




embedded image


Yield = 70% MH+ = 275





23


embedded image




embedded image


Yield = quant MH+ = 213





24


embedded image




embedded image


Yield = quant MH+ = 211





25


embedded image




embedded image


Yield = 99 MH+ = 334





26


embedded image




embedded image


Yield = 99 MH+ = 334





27


embedded image




embedded image


Yield = 99 MH+ = 334





28


embedded image




embedded image


Yield = 77% 1H NMR (CDCl3) δ 4.21 (q, 2H), 3.95 (d, 2H), 3.93-3.79 (m, 4H), 3.52 (s, 2H), 2.65 (m, 1H), 1.25 (t, 3H), 1.23-1.2 (m, 2H).









Preparative Example 29



embedded image


A solution of 3-aminopyrazole (2.0 g, 24.07 mmol) and ethyl benzoylacetate (4.58 mL, 1.1 eq.) in AcOH (15 mL) was heated at reflux for 3 hours. The reaction mixture was cooled to room temperature and concentrated in vacuo. The resulting solid was diluted with EtOAc and filtered to give a white solid (2.04 g, 40% yield).


Preparative Examples 30-73

By essentially the same procedure set forth in Preparative Example 29 only substituting the aminopyrazole shown in Column 2 of Table 5 and the ester shown in Column 3 of Table 5, the compounds shown in Column 4 of Table 5 were prepared:













TABLE 5





Prep.






Ex.
Column 2
Column 3
Column 4
Column 5



















30


embedded image




embedded image




embedded image








31


embedded image




embedded image




embedded image








32


embedded image




embedded image




embedded image








33


embedded image




embedded image




embedded image








34


embedded image




embedded image




embedded image








35


embedded image




embedded image




embedded image








36


embedded image




embedded image




embedded image








37


embedded image




embedded image




embedded image








37.10


embedded image




embedded image




embedded image








38


embedded image




embedded image




embedded image








39


embedded image




embedded image




embedded image








40


embedded image




embedded image




embedded image








41


embedded image




embedded image




embedded image








42


embedded image




embedded image




embedded image








43


embedded image




embedded image




embedded image








44


embedded image




embedded image




embedded image








45


embedded image




embedded image




embedded image








46


embedded image




embedded image




embedded image








47


embedded image




embedded image




embedded image








48


embedded image




embedded image




embedded image








49


embedded image




embedded image




embedded image








50


embedded image




embedded image




embedded image








51


embedded image




embedded image




embedded image








52


embedded image




embedded image




embedded image








53


embedded image




embedded image




embedded image








54


embedded image




embedded image




embedded image








55


embedded image




embedded image




embedded image








56


embedded image




embedded image




embedded image








57


embedded image




embedded image




embedded image








58


embedded image




embedded image




embedded image


Yield = 68 MH+ = 152





59


embedded image




embedded image




embedded image


Yield = 46 MH+ = 268





60


embedded image




embedded image




embedded image


Yield = 63 MH+ = 255





61


embedded image




embedded image




embedded image


Yield = 80 MH+ = 280





62


embedded image




embedded image




embedded image


Yield = 72 MH+ = 214





63


embedded image




embedded image




embedded image


Yield = 51 MH+ = 218





64


embedded image




embedded image




embedded image


Yield = 82 MH+ = 218





65


embedded image




embedded image




embedded image


Yield = 39 MH+ = 232





66


embedded image




embedded image




embedded image


Yield = 30 MH+ = 230





67


embedded image




embedded image




embedded image


Yield = 80 MH+ = 353





68


embedded image




embedded image




embedded image


Yield = 49 MH+ = 353





69


embedded image




embedded image




embedded image


Yield = 42 MH+ = 353





70


embedded image




embedded image




embedded image








71


embedded image




embedded image




embedded image








72


embedded image




embedded image




embedded image








73


embedded image




embedded image




embedded image











Preparative Example 74



embedded image


Ethyl benzoylacetate (1.76 mL, 1.1 eq.) and 3-amino-4-cyanopyrazole (1.0 g, 9.25 mmol) in AcOH (5.0 mL) and H2O (10 mL) was heated at reflux 72 hours. The resulting solution was cooled to room temperature, concentrated in vacuo, and diluted with EtOAc. The resulting precipitate was filtered, washed with EtOAc, and dried in vacuo (0.47 g, 21% yield).


Preparative Example 75



embedded image


A procedure in U.S. Pat. No. 3,907,799 was followed. Sodium (2.3 g, 2 eq.) was added to EtOH (150 mL) portionwise. When the sodium was completely dissolved, 3-aminopyrazole (4.2 g, 0.05 mol) and diethyl malonate (8.7 g, 1.1 eq.) were added and the resulting solution heated to reflux for 3 hours. The resulting suspension was cooled to room temperature and filtered. The filter cake washed with EtOH (100 mL) and dissolved in water (250 mL). The resulting solution was cooled in an ice bath and the pH adjusted to 1-2 with concentrated HCl. The resulting suspension was filtered, washed with water (100 mL) and dried under vacuum to give a white solid (4.75 g, 63% yield).


Preparative Examples 76-78

By essentially the same procedure set forth in Preparative Example 75 only substituting the compound shown in Column 2 of Table 6, the compounds shown in Column 3 of Table 6 are prepared:











TABLE 6





Prep.




Ex.
Column 2
Column 3







76


embedded image




embedded image







77


embedded image




embedded image







78


embedded image




embedded image











Preparative Example 79



embedded image


A solution of the compound prepared in Preparative Example 29 (1.0 g, 4.73 mmol) in POCl3 (5 mL) and pyridine (0.25 mL) was stirred at room temperature 3 days. The resulting slurry was diluted with Et2O, filtered, and the solid residue washed with Et2O. The combined Et2O washings were cooled to 0° C. and treated with ice. When the vigorous reaction ceased, the resulting mixture was diluted with H2O, separated, and the aqueous layer extracted with Et2O. The combined organics were washed with H2O and saturated NaCl, dried over Na2SO4, filtered, and concentrated to give a pale yellow solid (0.86 g, 79% yield). LCMS: MH+=230.


Preparative Example 80-122

By essentially the same procedure set forth in Preparative Example 79, only substituting the compound shown in Column 2 of Table 7, the compounds shown in Column 3 of Table 7 were prepared:












TABLE 7





Prep.





Ex.
Column 2
Column 3
CMPD


















80


embedded image




embedded image


MS: MH+ = 248





81


embedded image




embedded image







82


embedded image




embedded image


MS: MH+ = 298





83


embedded image




embedded image


MS: MH+ = 196





84


embedded image




embedded image


MS: MH+ = 210





85


embedded image




embedded image







86


embedded image




embedded image


MS: MH+ = 272





87


embedded image




embedded image







87.10


embedded image




embedded image







88


embedded image




embedded image


MS: MH+ = 255





89


embedded image




embedded image







90


embedded image




embedded image


Yield = 65% MS: MH+ = 260





91


embedded image




embedded image


Yield = 35% MS: MH+ = 290





92


embedded image




embedded image


Yield = 32% MS: MH+ = 298





93


embedded image




embedded image


Yield = 45% MS: MH+ = 236





94


embedded image




embedded image


Yield = 100% LCMS: MH+ = 250





95


embedded image




embedded image


Yield = 88% MS: MH+ = 314





96


embedded image




embedded image


Yield = 43% MS: MH+ = 223





97


embedded image




embedded image


Yield = 30% MS: MH+ = 295





98


embedded image




embedded image


Yield = 98% MS: MH+ = 244





99


embedded image




embedded image







100


embedded image




embedded image







101


embedded image




embedded image







102


embedded image




embedded image







103


embedded image




embedded image







104


embedded image




embedded image







105


embedded image




embedded image







106


embedded image




embedded image







107


embedded image




embedded image


45% yield; MS: MH+ = 226





108


embedded image




embedded image


MS: MH+ = 308





109


embedded image




embedded image


Yield = quant MH+ = 286





110


embedded image




embedded image


Yield = 50 MH+ = 272





111


embedded image




embedded image


Yield = 85 MH+ = 299





112


embedded image




embedded image


Yield = 97 MH+ = 231





113


embedded image




embedded image


Yield = 45 MH+ = 236





114


embedded image




embedded image


Yield = quant. MH+ = 236





115


embedded image




embedded image


Yield = 57 MH+ = 250





116


embedded image




embedded image


Yield = 89 MH+ = 248





117


embedded image




embedded image


Yield = 96 MH+ = 371





118


embedded image




embedded image


Yield = 99 MH+ = 371





119


embedded image




embedded image


Yield = 50 MH+ = 371





120


embedded image




embedded image


Yield = 57% LCMS: MH+ = 224





121


embedded image




embedded image


Yield = 34% LCMS: MH+ = 226





122


embedded image




embedded image


Yield = 100% 1H NMR (CDCl3) δ 8.53 (d, 1H), 7.66 (t, 1H), 7.51 (s, 1H), 7.45 (d, 1H), 6.84 (d, 2H).









Preparative Example 123



embedded image


POCl3 (62 mL) was cooled to 5° C. under nitrogen and dimethylaniline (11.4 g, 2.8 eq.) and the compound prepared in Preparative Example 75 (4.75 g, 0.032 mol). The reaction mixture was warmed to 60° C. and stirred overnight. The reaction mixture was cooled to 30° C. and the POCl3 was distilled off under reduced pressure. The residue was dissolved in CH2Cl2 (300 mL) and poured onto ice. After stirring 15 minutes, the pH of the mixture was adjusted to 7-8 with solid NaHCO3. The layers were separated and the organic layer washed with H2O (3×200 mL), dried over MgSO4, filtered, and concentrated. The crude product was purified by flash chromatography using a 50:50 CH2Cl2:hexanes solution as eluent to elute the dimethyl aniline. The eluent was then changed to 75:25 CH2Cl2:hexanes to elute the desired product (4.58 g, 77% yield). MS: MH+=188.


Preparative Examples 124-126

By essentially the same procedure set forth in Preparative Example 123 only substituting the compound in Column 2 of Table 8, the compounds shown in Column 3 of Table 8 are prepared:











TABLE 8





Prep.




Ex.
Column 2
Column 3







124


embedded image




embedded image







125


embedded image




embedded image







126


embedded image




embedded image











Preparative Example 127



embedded image


A solution of the compound prepared in Preparative Example 79 (0.10 g, 0.435 mmol) in CH3CN (3 mL) was treated with NBS (0.085 g, 1.1 eq.). The reaction mixture was stirred at room temperature 1 hour and concentrated under reduced pressure. The crude product was purified by flash chromatography using a 20% EtOAc-in-hexanes solution as eluent (0.13 g, 100% yield). LCMS: MH+=308.


Preparative Examples 128-164

By essentially the same procedure set forth in Preparative Example 127 only substituting the compounds shown in Column 2 of Table 9, the compounds shown in Column 3 of Table 9 were prepared:












TABLE 9





Prep.





Ex.
Column 2
Column 3
CMPD







128


embedded image




embedded image


MS: MH+ = 326





129


embedded image




embedded image


MS: MH+ = 342





130


embedded image




embedded image


MS: MH+ = 376





131


embedded image




embedded image


MS: MH+ = 274





132


embedded image




embedded image


MS: MH+ = 288





133


embedded image




embedded image







134


embedded image




embedded image


Yield = 75% MS: MH+ = 338





135


embedded image




embedded image


Yield = 52% MS: MH+ = 368





136


embedded image




embedded image


Yield = 87% MS: MH+ = 376





137


embedded image




embedded image


Yield = 100% MS: MH+ = 316





138


embedded image




embedded image


Yield = 92% MS: MH+ = 330





139


embedded image




embedded image


Yield = 82% MS: MH+ = 395





140


embedded image




embedded image


Yield = 88% MS: MH+ = 308





141


embedded image




embedded image


Yield = 100% MS: MH+ = 322





142


embedded image




embedded image


MH+ = 266





143


embedded image




embedded image







144


embedded image




embedded image







145


embedded image




embedded image







146


embedded image




embedded image







147


embedded image




embedded image







148


embedded image




embedded image







149


embedded image




embedded image







150


embedded image




embedded image







151


embedded image




embedded image


LCMS: MH+ = 386





152


embedded image




embedded image


Yield = quant MH+ = 364





153


embedded image




embedded image


Yield = quant MH+ = 353





154


embedded image




embedded image


Yield = 95 MH+ = 378





155


embedded image




embedded image


Yield = 77 MH+ = 311





156


embedded image




embedded image


Yield = quant. MH+ = 314





157


embedded image




embedded image


Yield = 99 MH+ = 328





158


embedded image




embedded image


Yield = 98 MH+ = 326





159


embedded image




embedded image


Yield = 99 MH+ = 449





160


embedded image




embedded image


Yield = 95 MH+ = 449





161


embedded image




embedded image


Yield = 72 MH+ = 449





162


embedded image




embedded image


Yield = 98% LCMS: MH+ = 302





163


embedded image




embedded image


Yield = 95% LCMS: MH+ = 305





164


embedded image




embedded image


Yield = 50% 1H NMR (CDCl3) δ 8.36 (s, 1H), 7.72 (d, 1H), 7.20 (s, 1H), 6.82 (d, 1H), 3.99 (s, 3H), 3.90 (s, 3H);









Preparative Example 165



embedded image


A solution of the compound prepared in Preparative Example 80 (0.3 g, 1.2 mmol) in CH3CN (15 mL) was treated with NCS (0.18 g, 1.1 eq.) and the resulting solution heated to reflux 4 hours. Additional NCS (0.032 g, 0.2 eq.) added and the resulting solution was stirred at reflux overnight. The reaction mixture was cooled to room temperature, concentrated in vacuo and the residue purified by flash chromatography using a 20% EtOAc in hexanes solution as eluent (0.28 g, 83% yield). LCMS: MH+=282.


Preparative Example 166-167

By essentially the same procedure set forth in Preparative Example 165 only substituting the compound shown in Column 2 of Table 10, the compound shown in Column 3 of Table 10 was prepared:












TABLE 10





Prep. Ex.
Column 2
Column 3
CMPD







166


embedded image




embedded image


Yield = 82% LCMS: MH+ = 286





167


embedded image




embedded image











Preparative Example 167.10



embedded image


By essentially the same procedure set forth in Preparative Example 165 only substituting N-iodosuccinimide, the above compound was prepared.


Preparative Example 168



embedded image


To a solution of the compound from Preparative Example 79 (1.0 g, 4.35 mmol) in DMF (6 mL) was added POCl3 (1.24 mL, 3.05 eq.) and the resulting mixture was stirred at room temperature overnight. The reaction mixture was cooled to 0° C. and the excess POCl3 was quenched by the addition of ice. The resulting solution was neutralized with 1N NaOH, diluted with H2O, and extracted with CH2Cl2. The combined organics were dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash chromatography using a 5% MeOH in CH2Cl2 solution as eluent (0.95 g, 85% yield). LCMS: MH+=258.


Preparative Example 169



embedded image


By essentially the same procedure set forth in Preparative Example 168 only substituting the compound prepared in Preparative Example 80, the above compound was prepared (0.45 g, 40% yield).


Preparative Example 170



embedded image


To a solution of the product of Preparative Example 169 (0.25 g, 0.97 mmol) in THF was added NaBH4 (0.041 g, 1.1 eq.) and the resulting solution was stirred at room temperature overnight. The reaction mixture was quenched by the addition of H2O and extracted with CH2Cl2. The combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography using a 60:40 hexanes:EtOAc mix as eluent (0.17 g, 69% yield). MS: MH+=260.


Preparative Example 171



embedded image


A solution of the compound prepared in Preparative Example 170 (0.12 g, 0.462 mmol), dimethyl sulfate (0.088 mL, 2.0 eq), 50% NaOH (0.26 mL) and catalytic Bu4NBr in CH2Cl2 (4 mL) was stirred at room temperature overnight. The reaction mixture was diluted with H2O and extracted with CH2Cl2. The combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography using a 30% EtOAc-in-hexanes solution as eluent (0.062 g, 48% yield).


Preparative Example 172



embedded image


To a solution of PPh3 (4.07 g, 4.0 eq.) and CBr4 (2.57 g, 2.0 eq.) in CH2Cl2 (75 mL) at 0° C. was added the compound prepared in Preparative Example 168 (1.0 g, 3.88 mmol). The resulting solution was stirred at 0° C. for 1 hour and concentrated under reduced pressure. The residue was purified by flash chromatography using a 20% EtOAc in hexanes solution as eluent (1.07 g, 67% yield).


Preparative Example 173



embedded image


By essentially the same procedure set forth in Preparative Example 172 only substituting the compound prepared in Preparative Example 169 the above compound was prepared (0.5 g, 70% yield).


Preparative Example 174



embedded image


The compound prepared in Preparative Example 127 (3.08 g, 10.0 mmol), 2.0 M NH3 in 2-propanol (50 mL, 100.0 mmol), and 37% aqueous NH3 (10.0 mL) were stirred in a closed pressure vessel at 50° C. for 1 day. The solvent was evaporated and the crude product was purified by flash chromatography using 3:1 CH2Cl2:EtOAc as eluent. Pale yellow solid (2.30 g, 80%) was obtained. LCMS: M+=289.


Preparative Examples 175-180

By essentially the same procedure set forth in Preparative Example 174 only substituting the compound shown in Column 2 of Table 11, the compounds shown in Column 3 of Table 11 were prepared.











TABLE 11





Prep.




Ex.
Column 2
Column 3







175


embedded image




embedded image







176


embedded image




embedded image







177


embedded image




embedded image







178


embedded image




embedded image







179


embedded image




embedded image







180


embedded image




embedded image











Preparative Examples 181



embedded image


The compound prepared in Preparative Example 80 (0.3 g, 1.2 mmol), K2CO3 (0.33 g, 2 eq.), and 4-aminomethylpyridine (0.13 mL, 1.1 eq.) was heated to reflux overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with H2O and extracted with CH2Cl2. The combined organics were dried over Na2SO4, filtered and, concentrated. The crude product was purified by flash chromatography using a 5% (10% NH4OH in MeOH) solution in CH2Cl2 as eluent (0.051 g, 40% yield). LCMS: MH+=320.


Preparative Example 182



embedded image


By essentially the same procedure set forth in Preparative Example 181 only substituting the compound described in Preparative Example 92, the above compound was prepared. LCMS: MH+=370.


Preparative Example 183



embedded image


To a solution of the compound prepared in Preparative Example 123 (0.25 g, 1.3 mmol) in dioxane (5 mL) was added iPr2NEt (0.47 mL, 2.0 eq.) and 3-aminomethylpyridine (0.15 ml, 1.1 eq.). The resulting solution was stirred at room temperature 72 hours. The reaction mixture was diluted with H2O and extracted with EtOAc. The combined organics were washed with H2O and saturated NaCl, dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography using a 5% MeOH in CH2Cl2 solution as eluent (0.29 g, 83% yield). MS: MH+=260.


Preparative Examples 184-187

By essentially the same procedure set forth in Preparative Example 183 only substituting the compound shown in Column 2 of Table 12, the compounds shown in Column 3 of Table 12 are prepared.











TABLE 12





Prep.




Ex.
Column 2
Column 3

















184


embedded image




embedded image







184.1


embedded image




embedded image







185


embedded image




embedded image







186


embedded image




embedded image







187


embedded image




embedded image







187.1


embedded image




embedded image







187.11


embedded image




embedded image











Preparative Example 188 and Preparative Example 189



embedded image


To a solution of the compound prepared in Preparative Example 185 (1.18 g, 3.98 mmol) in THF (35 mL) at −78° C. was added LAH (4.78 mL, 1M in Et2O, 1.0 eq.) dropwise. The reaction mixture was stirred at −78° C. for 3 hours at which time additional LAH (2.0 mL, 1M in Et2O, 0.42 eq.) was added dropwise. The reaction mixture was stirred an additional 1.25 hours and quenched by the addition of saturated Na2SO4 (8.5 mL). The reaction mixture was diluted with EtOAC (23 mL), H2O (2 mL), and CH3OH (50 mL). The resulting slurry was filtered through a plug of Celite. The Celite washed with CH3OH and the filtrate dried with Na2SO4, filtered, and concentrated. The product was purified by flash chromatography using a CH2Cl2:CH3OH (93:7) solution as eluent to yield aldehyde as the first eluting product and alcohol as the second eluting product.


Preparative Example 188

(aldehyde): 0.4 g, 39% yield. MS: MH+=254.


Preparative Example 189

(alcohol): 0.25 g, 24% yield. MS: MH+=256.


Preparative Example 190



embedded image


To a solution of the compound prepared in Preparative Example 188 (0.075 g, 0.30 mmol) in THF (2.0 mL) at 0° C. was added CH3MgBr (0.3 mL, 3.0M solution in Et2O, 3.0 eq.) dropwise. The resulting solution was stirred at 0° C. an additional 1.5 hours, warmed to room temperature, and stirred overnight. Additional CH3MgBr (0.15 mL, 3.0M in Et2O, 1. eq.) was added and the resulting solution stirred an additional 1.5 hours. The reaction mixture was cooled to 0° C. and quenched by the addition of saturated NH4Cl. The resulting solution was diluted with CH2Cl2 and H2O and extracted with CH2Cl2. The combined organics were washed with saturated NaCl and dried over Na2SO4, filtered, and concentrated. The crude product was purified by flash chromatography using a CH2Cl2:CH3OH (90:10) solution as eluent (0.048 g, 60% yield). MS: MH+=270.


Preparative Example 191



embedded image


By essentially the same procedure set forth in Preparative Example 190 only substituting the compound prepared in Preparative Example 185 and using excess MeMgBr (5 eq.), the above compound was prepared.


Preparative Example 192



embedded image


The compound prepared in Preparative Example 181 (0.29 g, 0.91 mmol), BOC2O (0.22 g, 1.1 eq), and DMAP (0.13 g, 1.1 eq.) in dioxane (10 mL) was stirred at room temperature 3 days. Additional BOC2O (0.10 g, 0.5 eq.) was added and the reaction mixture was stirred 4 hours. The reaction mixture was concentrated in vacuo, diluted with saturated NaHCO3 (15 mL), and extracted with CH2Cl2 (2×100 mL). The combined organics were dried over Na2SO4, filtered, and concentrated under reduce pressure. The crude product was purified by flash chromatography using a 5% (10% NH4OH in MeOH) solution in CH2Cl2 as eluent (0.35 g, 91% yield). LCMS: MH+=420.


Preparative Example 193



embedded image


By essentially the same procedure set forth in Preparative Example 192 only substituting the compound prepared in Preparative Example 183, the above compound was prepared. MS: MH+=360.


Preparative Example 193.10



embedded image


By essentially the same procedure set forth in Preparative Example 192 only substituting the compound prepared in Preparative Example 184.1, the above compound was prepared. MS: MH+=454.


Preparative Example 194



embedded image


By essentially the same procedure set forth in Preparative Example 192 only substituting the above compound prepared in Preparative Example 187.11, the above compound was prepared (0.223 g, 88% yield). MS: MH+=528.


Preparative Example 195



embedded image


By essentially the same procedure set forth in Preparative Example 127 only substituting the compound prepared in Preparative Example 192, the above compound was prepared (0.38 g, 95% yield). LCMS: MH+=498.


Preparative Example 196



embedded image


By essentially the same procedure set forth in Preparative Example 195, only substituting the compound prepared in Preparative Example 193, the above compound was prepared (0.3 g, 83% yield). MS: MH+=438.


Preparative Example 197



embedded image


A solution of the compound prepared in Preparative Example 195 (0.15 g, 0.3 mmol), phenylboronic acid (0.073 g, 2.0 eq.), K3PO4 (0.19 g, 3.0 eq.), and Pd(PPh3)4 (0.017 g, 5 mol %) was heated at reflux in DME (16 mL) and H2O (4 mL) 7 hours. The resulting solution was cooled to room temperature, diluted with H2O (10 mL), and extracted with CH2Cl2 (3×50 mL). The combined organics were dried over Na2SO4, filtered, and concentrated. The crude product was purified by flash chromatography using a 2.5% (10% NH4OH in MeOH) in CH2Cl2 solution as eluent (0.16 g, 100% yield).


Preparative Example 198



embedded image


To a solution of 4-aminomethylpyridine (1.41 mL, 13.87 mmol) in CH2Cl2 (50 mL) was added BOC2O (3.3 g, 1.1 eq.) and TEA and the resulting solution was stirred a room temperature 2 hours. The reaction mixture was diluted with H2O (50 mL) and extracted with CH2Cl2. The combined organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using a 5% (10% NH4OH in MeOH) solution in CH2Cl2 as eluent to give a yellow solid (2.62 g, 91% yield). LCMS: MH+=209.


Preparative Example 199



embedded image


By essentially the same procedure set forth in Preparative Example 198 only substituting 3-aminomethylpyridine, the above compound was prepared as a yellow oil (2.66 g, 92% yield). LCMS: MH+=209.


Preparative Example 200



embedded image


To a solution of the compound prepared in Preparative Example 198 (0.20 g, 0.96 mmol) in CH2Cl2 (5 mL) at 0° C. was added MCPBA (0.17 g, 1.0 eq) and the resulting solution stirred at 0° C. 2 hours and stored at 4° C. overnight at which time the reaction mixture was warmed to room temperature and stirred 3 hours. The reaction mixture was diluted with H2O and extracted with CH2Cl2. The combined organics were dried over Na2SO4, filtered, and concentrated. The crude product was purified by flash chromatography using a 10% (10% NH4OH in MeOH) solution as eluent: LCMS: MH+=255.


Preparative Example 201



embedded image


A solution of oxone (58.6 g) in H2O (250 mL) was added dropwise to the compound prepared in Preparative Example 199 (27 g, 0.13 mol) and NaHCO3 (21.8 g, 2.0 eq.) in MeOH (200 mL) and H2O (250 mL). The resulting solution was stirred at room temperature overnight. The reaction mixture was diluted with CH2Cl2 (500 mL) and filtered. The layers were separated and the aqueous layer extracted with CH2Cl2. The combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a white solid (21.0 g, 72% yield). MS: MH+=255.


Preparative Example 202



embedded image


The compound prepared in Preparative Example 200 (0.29 g, 1.29 mmol) was stirred at room temperature in 4M HCl in dioxane (0.97 mL) 2 hours. The reaction mixture was concentrated in vacuo and used without further purification. LCMS: MH+=125.


Preparative Example 203



embedded image


By essentially the same procedure set forth in Preparative Example 202 only substituting the compound prepared in Preparative Example 201, the compound shown above was prepared. LCMS: MH+=125.


Preparative Example 204



embedded image


To 4-N-t-Butoxycarbonylaminopiperidine (0.8 g, 4.0 mmol) in CH2Cl2 (10 mL) at 0° C. was added TEA (1.40 mL, 2.5 eq.) and 3-trifluoromethyl benzoyl chloride (1.05 g, 1.25 eq.). The resulting solution was stirred 15 minutes and warmed to room temperature and stirred 3 hours. The reaction mixture was diluted with CH2Cl2 and washed with 5% Na2CO3 (2×100 mL). The organic layer was dried over Na2SO4, filtered and concentrated to yield a pale yellow solid (quantitative crude yield).


Preparative Example 205



embedded image


To a solution of the compound prepared in Preparative Example 204 (1.0 g, 2.76 mmol) in CH2Cl2 (15 mL) at 0° C. was added TFA (8 mL) and the resulting solution was stirred at 0° C. for 30 minutes and room temperature 1 hour. The reaction mixture was poured onto Na2CO3 (40 g) and H2O (400 mL) added and the resulting mixture was extracted with CH2Cl2. The combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography using a 20% (7N NH3 in MeOH) solution in CH2Cl2 as eluent (0.6 g, 82% yield).


Preparative Examples 206



embedded image



Step A:


To a solution of 6-chloronicotinamide (1 g, 6.39 mmol) in isoamyl alcohol (15 mL) at rt was added Na2CO3 (0.81 g, 7.67 mmol) followed by methoxyethylamine (0.67 mL, 7.67 mmol). The mixture was heat at 130° C. for 16 h, cooled to rt, and was filtered thru a medium glass-fritted filter. The resulting filtrate was concentrated under reduced pressure and the resultant solid was triturated with Et2O (2×10 mL). The crude solid was placed under high vacuum to afford 1.2 g (96%) of a light yellow solid. M+H=196.


Step B:


To a solution of amide (1.2 g, 6.12 mmol) from Preparative Example 206, Step A in THF (5 mL) at 0° C. was added a solution of BH3-THF (43 mL; 43 mmol) dropwise over 10 min. The resultant solution was warmed to rt and stirred for 14 h. The mixture was cooled to 0° C. and was sequentially treated with 6M HCl (35 mL), water (30 mL), and MeOH (150 mL). The mixture was stirred for 8 h and was concentrated under reduced pressure. The crude residue was triturated with MeOH, concentrated under reduced pressure, and placed under high vacuum to afford 1.6 g (82%) of a white solid as the dihydrochloride salt. M+H (free base)=182.0. This material was used crude in the coupling with 7-Cl adducts.


Preparative Examples 207-211

By essentially the same known procedure set forth in Preparative Example 206 only by utilizing the amines shown in Column 2 of Table 13 and the amines shown in Column 3 of Table 13 were prepared:












TABLE 13








CMPD



Column 2
Column 3
M + H (free


Prep. Ex.
(Amine)
(Amine)
base)







207


embedded image




embedded image


M + H = 138





208


embedded image




embedded image


M + H = 152





209


embedded image




embedded image


M + H = 178





210


embedded image




embedded image


M + H = 195





211


embedded image




embedded image


M + H = 207









Preparative Example 212



embedded image


The above compound was prepared accordingly to the methods described in WO 91/18904.


Preparative Example 213



embedded image


The above compound was prepared accordingly to the methods described in U.S. Pat. No. 6,180,627 B1.


Preparative Example 214



embedded image


The known amine was prepared as described in J. Med. Chem. (2001), 44, 4505-4508.


Preparative Example 215



embedded image


The known amine was prepared as described in J. Med. Chem. (1997), 40, 3726-3733.


Preparative Example 216



embedded image



Step A:


A solution of aldehyde (50 g, 0.41 mol) [WO 0232893] in MeOH (300 mL) was cooled to 0° C. and carefully treated with NaBH4 (20 g, 0.53 mol in 6 batches) over 20 minutes. The reaction was then allowed to warm to 20° C. and was stirred for 4 hours. The mixture was again cooled to 0° C., carefully quenched with saturated aqueous NH4Cl, and concentrated. Flash chromatography (5-10% 7N NH3-MeOH/CH2Cl2) provided the primary alcohol (31 g, 62%) as a light yellow solid.


Step B:


A slurry of alcohol (31 g, 0.25 mol) from Preparative Example 216, Step A in CH2Cl2 (500 mL) was cooled to 0° C. and slowly treated with SOCl2 (55 mL, 0.74 mol over 30 minutes). The reaction was then stirred overnight at 20° C. The material was concentrated, slurried in acetone, and then filtered. The resulting beige solid was dried overnight in vacuo (38.4 g, 52%, HCl salt).


Step C:


To a 15 mL pressure tube charged with a stir bar was added chloride (150 mg, 0.83 mmol) from Preparative Example 216, Step B followed by 7 M NH3/MeOH (10 mL). The resulting solution was stirred for 48 h at rt where upon the mixture was concentrated under reduced pressure to afford a light yellow solid (0.146 g, 83%). M+H (free base)=140.


Preparative Example 217



embedded image


The above compound was prepared accordingly to methods described in WO 00/26210.


Preparative Example 218



embedded image


The above compound was prepared accordingly to methods described in WO 99/10325.


Preparative Example 219



embedded image


The known amine dihydrochloride was prepared according to methods described in WO 02/64211.


Preparative Example 220



embedded image


The above compound was prepared according to methods described in WO 02/64211.


Preparative Example 221



embedded image


The known primary alcohol was prepared according to WO 00/37473 and was converted to the desired amine dihydrochloride in analogous fashion as Preparative Example 220 according to WO 02/064211.


Preparative Example 222



embedded image



Step A:


To a solution of aldehyde (WO 02/32893) (0.46 g, 2.07 mmol) in MeOH/THF (2 mL/2 mL) at 0° C. was added NaBH4 (94 mg, 2.48 mmol) in one portion. The resulting mixture was stirred for 12 h at rt and was diluted with sat. aq. NH4Cl (3 mL). The mixture was concentrated under reduced pressure and the resultant aqueous layer was extracted with CH2Cl2 (3×5 mL). The organic layers were combined, washed with brine (1×5 mL), dried (Na2SO4), and filtered. The organic layer was concentrated under reduced pressure to afford 417 mg (90% yield) of a white solid. M+H=225.


Step B:


The crude alcohol from Preparative Example 222, step A (0.4 g, 1.78 mmol) in CH2Cl2 (4 mL) was added SOCl2 (0.65 mL, 8.91 mmol) and the mixture was stirred for 2 h at rt. The mixture was concentrated under reduced pressure to afford 407 mg (94%) of a light yellow solid. M+H=243. The crude product was taken on without further purification.


Step C:


To a solution of crude chloride from Preparative Example 222, Step B (0.33 g, 1.36 mmol) in a pressure tube charged with 7M NH3/MeOH (35 mL) and the mixture was stirred for 72 h. The mixture was concentrated under reduced pressure to afford 257 mg (85%) of a yellow semisolid. M+H (free base)=224.


Preparative Example 223



embedded image


To a round bottom flask charged with amine hydrochloride (0.24 g, 1.1 mmol) from Preparative Example 222 and a stir bar was added 4N HCl/dioxane (10 mL). The resulting solution was stirred for 12 h at rt, concentrated under reduced pressure, and triturated with CH2Cl2 (3×5 mL). The crude product was filtered, washed with Et2O (2×5 mL), and dried under high vacuum to afford 0.19 g (91%) as the dihydrochloride salt. M+H (free base)=124.


Preparative Example 224



embedded image


Pd(PPh3)4 (0.404 gm, 0.35 mmol) was added to a degassed solution of 4-cyanobenzene boronic acid (1.029 g, 7 mmol) and 2-bromopyridine (1.11 g, 7 mmol) in 75 mL acetonitrile. 0.4 M sodium carbonate solution (35 mL) was added to the reaction mixture and the resulting solution was refluxed at 90° C. under Ar for 24 hours (progress of reaction was monitored by TLC). The reaction mixture was cooled and aqueous layer was separated. The organic layer containing the product and spent catalyst was mixed with silica gel (15 g) and concentrated to dryness. The 4-(2-pyridyl)-benzonitrile was isolated by column chromatography (0.850 g, 68%). LCMS: MH+=181; 1H NMR (CDCl3) δ 8.85 (d, 1H), 8.7 (dd, 1H), 7.9 (dd, 1H), 7.75 (d, 2H), 7.7 (d, 2H), 7.4 (dd, 1H).


Preparative Examples 225-228

By following essentially same procedure described in Preparative Example 224, only substituting the bromides in column 2 of Table 14, compounds in column 3 of Table 14 were prepared.












TABLE 14





Prep.





Ex.
Column 2
Column 3
Column 4







225


embedded image




embedded image


Yield = 70% LCMS: MH+ = 187





226


embedded image




embedded image


Yield = 60% LCMS: MH+ = 187





227


embedded image




embedded image


Yield = 70% LCMS: MH+ = 186





228


embedded image




embedded image


Yield = 70% LCMS: MH+ = 200









Preparative Example 229



embedded image


BH3-THF solution (1 M, 24 mL, 5 eq) was added slowly to a stirring solution of 4-(2-pyridyl)-benzonitrile (0.85 g, 4.72 mmol) in anhydrous THF (25 mL) under Ar, and the resulting solution was refluxed for about 12 hr. The solution was cooled to 0° C. using ice-water. Methanol (15 mL) was added drop-wise to the cold reaction mixture and stirred for 1 h to destroy excess BH3. Added HCl-methanol (1M, 10 mL) slowly to the reaction mixture and refluxed for 5 h. Concentrated the solution to dryness and the residue was dissolved in 25 mL water and extracted with ether to remove any un-reacted material. The aqueous solution was neutralized with solid potassium carbonate to pH 10-11. The free amine, thus formed was extracted with ether, dried over potassium carbonate (0.45 g, 50%). LCMS: MH+=185; 1H NMR (CDCl3) δ 8.85 (d, 1H), 8.7 (dd, 1H), 7.9 (dd, 1H), 7.75 (d, 2H), 7.7 (d, 2H), 7.4 (dd, 1H), 3.7 (t, 2H), 1.7 (t, 2H).


Preparative Examples 230-233

By following essentially the same procedure set forth in Preparative Example 229, compounds in column 3 of Table 15 were prepared.












TABLE 15





Prep.





Ex.
Column 2
Column 3
Column 4







230


embedded image




embedded image


Yield = 60% LCMS: MH+ = 191





231


embedded image




embedded image


Yield = 60% LCMS: MH+ = 191





232


embedded image




embedded image


Yield = 70% LCMS: MH+ = 190





233


embedded image




embedded image


Yield = 70% LCMS: MH+ = 204









Preparative Example 234



embedded image



Step A:


A mixture 4-fluorobenzonitrile (3 g, 25 mmol) and imidazolyl sodium (2.48 g, 27.5 mmol) in DMF (50 mL) was stirred at 80° C. under Ar for 12 h. Progress of reaction was monitored by TLC. The reaction mixture was concentrated in vacuo and the residue was diluted with 50 mL water and stirred. The aqueous mixture was extracted with EtOAc (2×50 mL). Combined EtOAc extracts was dried over anhydrous MgSO4, concentrated, and the 4-(1-imidazolyl)-benzonitrile was isolated by column chromatography (3.6 g, 78%). LCMS: MH+=170; 1H NMR (CDCl3) δ 8.0 (s, 1H), 7.5 (d, 2H), 7.4 (m, 3H), 7.3 (d, 1H)


Step B:


4-(1-imidazolyl)-benzonitrile (1 g, 5.92 mmol) was dissolved in anhydrous THF (10 mL) and added drop-wise to a stirring solution of LAH-THF (1 M in THF, 18 mL) at room temperature. The reaction mixture was refluxed under Ar for 2 h and the progress was monitored by TLC. The mixture was cooled to 0° C. and quenched by drop-wise addition of a saturated Na2SO4—H2O solution. The mixture was stirred for 1 h and filtered to remove lithium salts. The filtrate was dried over anhydrous MgSO4 and concentrated to obtain 4-(1-imidazolyl)-benzylamine (0.8 g, 80%). LCMS: MH+=174.


Preparative Example 235



embedded image


A mixture of 4-(5-oxazolyl)benzoic acid (1.0 g, 5.46 mmol) and Et3N (552 mg, 5.46 mmol) in 25 mL of THF was cooled to 0° C. and ClCOOi-Bu (745 mg, 5.46 mmol) was added dropwise. After the addition was over, the reaction mixture was stirred for additional 5 min and then aq NH4OH (0.63 mL of 28% solution, 10.46 mmol) was added. After overnight stirring, the solvent was evaporated, the residue was taken up in water and basified to pH 9. The precipitated solid was filtered, washed with water and dried over P2O5 in a vacuum desiccator to provide 500 mg (48%) of the 4-(5-oxazolyl)-benzamide: 1H NMR (DMSO-d6) δ 8.50 (s, 1H), 8.20-7.80 (m, 5H).


Preparative Example 236



embedded image


A suspension of 4-(5-oxazolyl)benzamide (500 mg, 2.657 mmol) in 10 mL of dry THF was cooled to 0° C. and 10 mL of 1 M BH3.THF (10.00 mmol) was added. The contents were refluxed overnight and the excess borane was destroyed by dropwise addition of methanol. The solvent was evaporated and the residue was treated with methanolic HCl to decompose the amine-borane complex. After evaporation of the methanol, the residue was taken in water, basified to pH 10 and the product was extracted in to DCM. The DCM layer was dried (K2CO3) and the solvent was removed to provide 150 mg (32%) of 4-(5-oxazolyl)benzylamine: 1H NMR (CDCl3) δ 7.90 (s, 1H), 7.60 (d, 2H), 7.40 (d, 2H), 7.30 (s, 1H), 3.90 (s, 2H).


Preparative Examples 237-239

By essentially the same procedures set forth above, the compounds in Column 2 of Table 16 were reduced using the method indicated in Column 3 of Table 16 to give the amine indicated in Column 4 of Table 16.













TABLE 16





Prep.






Ex.
Column 2
Column 3
Column 4
CMPD







237


embedded image


BH3


embedded image



1H NMR (CDCl3) δ 7.15-6.90 (m, 3H), 3.85 (s, 2H), 1.45 (s, 2H)






238


embedded image


H2


embedded image



1H NMR (CDCl3) δ 8.40 (s, 1H), 7.55 (dd, 1H), 7.10 (d, 1H), 3.85 (s, 2H), 2.50 (s, 3H), 1.70 (bs, 2H)






239


embedded image


BH3


embedded image











Preparative Example 240



embedded image


Prepared by the literature procedure (PCT Int. Appl. WO 0105783): 1H NMR (CDCl3) δ 7.35 (d, 1H), 7.24-7.10 (m, 2H), 7.02 (d, 1H), 3.95 (t, 1H), 3.70 (d, 1H), 3.37 (d, 1H), 2.65 (m, 2H), 2.45 (s, 3H), 1.90 (bs, 2H)


Preparative Example 241
3-(AMINOMETHYL)PIPERIDINE-1-CARBOXAMIDE



embedded image


A. 3-(tert-BUTOXYCARBONYLAMINOMETHYL)PIPERIDINE-1-CARBOXAMIDE



embedded image


3(R/S)-(tert-Butoxycarbonylaminomethyl)piperidine (3 g, 14.0 mmoles) was dissolved in anhydrous dichloromethane (50 mL) and trimethylsilylisocyanate (9.68 g, 11.4 mL, 84.0 mmoles) was added. The mixture was stirred under argon at 25° C. for 68 h. Additional trimethylsilylisocyanate (4.84 g, 5.7 mL, 42.0 mmoles) was added and the mixture was stirred at 25° C. for a total of 90 h. The mixture was evaporated to dryness and chromatographed on a silica gel column (30×5 cm) using 2% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give 3-(tert-butoxycarbonylaminomethyl)piperidine-1-carboxamide (3.05 g, 85%): FABMS: m/z 258.1 (MH+); HRFABMS: m/z 258.1816 (MH+). Calcd. for C12H24O3N3: m/z 258.1818; δH (CDCl3) 1.22 91H, m, CH2), 1.42 (9H, s, —COOC(CH3)3), 1.48 (1H, m, CH2), 1.67 (2H, m, CH2), 1.78 (1H, m, CH), 2.80 (1H, m, CH2), 2.99, 3H, m, CH2), 3.59 (1H, m, CH20 3.69 (1H, m, CH2), 4.76 (2H, bm, CONH2) and 4.98 ppm (1H, bm, NH); δC (CDCl3) CH3: 28.5, 28.5, 28.5; CH2: 24.0, 28.3, 43.2, 45.1, 47.8; CH: 36.5; C: 79.4, 156.3, 158.5.


B. 3-(AMINOMETHYL)PIPERIDINE-1-CARBOXAMIDE



embedded image


3-(tert-Butoxycarbonylaminomethyl)piperidine-1-carboxamide (150 mg, 0.583 mmoles) (prepared as described in Preparative Example 241, Step A above) was dissolved in methanol (3 mL). 10% conc. sulfuric acid in 1,4-dioxane (7.9 mL) was added and the mixture was stirred at 25° C. for 1 h. The mixture was diluted with methanol and BioRad AG1-X8 resin (OH form) was added until the pH was basic. The resin was filtered off, washed with methanol, evaporated to dryness and chromatographed on a silica gel column (15×2 cm) using dichloromethane followed by 15% (10% conc, ammonium hydroxide in methanol)-dichloromethane as the eluant to give the 3-(aminomethyl)piperidine-1-carboxamide (80 mg, 87%): FABMS: m/z 158.1 (MH+); HRFABMS: m/z 158.1294 (MH+). Calcd. for C7H16N3O: m/z 158.1293; δH (CDCl3+drop CD3OD) 1.20 (1H, m, CH2), 1.48 (1H, m, CH2), 1.60 (1H, m, CH), 1.68 (1H, m, CH2), 1.83 (1H, m, CH2), 2.64 (bm, 2H, —CH2NH2), 2.82 (1H, m, CH2), 3.02 (1H, m, CH2), 2.98 (2H, m, CH2), 3.70 (1H, m, —CH2NH2), 3.78 (1H, m, —CH2NH2) and 5.24 ppm (1H, bs, NH); δC (CDCl3+drop CD3OD) CH2: 24.1, 28.6, 44.0, 44.8, 47.9; CH: 38.3; C, 159.0.


Preparative Example 242
3-(2-AMINOETHYL)PIPERIDINE-1-CARBOXAMIDE



embedded image


A. 3-(2-tert-BUTOXYCARBONYLAMINOETHYL)PIPERIDINE-1-CARBOXAMIDE



embedded image


3-(2-tert-Butoxycarbonylaminoethyl)piperidine (500 mg, 2.19 mmoles) was dissolved in anhydrous dichloromethane (10 mL) and trimethylsilylisocyanate (2.96 mL, 21.9 mmoles) was added. The mixture was stirred under argon at 25° C. for 3.35 h. The mixture was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The organic layer was dried (MgSO4), filtered, evaporated to dryness and chromatographed on a silica gel column (15×5 cm) using 5% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give 3-(2-tert-butoxycarbonylaminoethyl)piperidine-1-carboxamide (417.7 mg, 70%): FABMS: m/z 272.0 (MH+); HRFABMS: m/z 272.1979 (MH+). Calcd. for C13H26O3: m/z 272.1974; δH (CDCl3) 1.16 (1H, m, CH2), 1-30-1.60 (5H, m, CH/CH2), 1.46 (9H, s, —COOC(CH3)3), 1.68 (1H, m, CH2), 1 84 (1H, m, CH2), 2.54 (1H, dd, CH2), 2.73 (1H, m, CH2), 3.08 (1H, m, CH2), 3.42 (1H, m, CH2), 4.02 (1H, m, CH2), 4.10 (1H, m, CH2), 4.84 (1H, m, NH) and 4.96 ppm (2H, bm, CONH2); δC (CDCl3) CH3: 28.5, 28.5, 28.5; CH2: 25.2, 31.7, 34.9, 37.3, 44.6, 50.3; CH: 32.9; C: 79.5, 156.4, 158.2.


B. 3-(2-AMINOETHYL)PIPERIDINE-1-CARBOXAMIDE



embedded image


3-(2-tert-Butoxycarbonylaminoethyl)piperidine-1-carboxamide (392.7 mg, 1.45 mmoles) (prepared as described in Preparative Example 242, Step A above) was dissolved in methanol (7.5 mL) and 10% conc. sulfuric acid in 1,4-dioxane (19.5 mL) was added. The mixture was stirred at 25° C. for 1.25 h. The mixture was diluted with methanol and BioRad AG1-X8 resin (OH form) was added until the pH was basic. The resin was filtered off, washed with methanol, evaporated to dryness and chromatographed on a silica gel column (30×2.5 cm) using 15% (10% conc, ammonium hydroxide in methanol)-dichloromethane as the eluant to give 3-(2-aminoethyl)piperidine-1-carboxamide (233 mg, 94%): FABMS: m/z 172.1 (MH+); HRFABMS: m/z 172.1444 (MH+). Calcd for C8H18N3O requires: m/z 172.1450; δH (CDCl3+3% CD3OD) 1.14 (1H, m, CH2), 1.40 (2H, m, CH2), 1.49 (1H, m, CH), 1.58 (1H, m, CH2), 1.69 (1H, m, CH2), 1.85 (1H, m, CH2), 2.55 (1H, m, CH2), 2.67 (5H, m, CH2/NH2), 2.76 (1H, bm, CH2), 2.84 (1H, m, CH2) and 3.82 ppm (2H, m, CONH2); δC (CDCl3+3% CD3OD) CH2: 24.8, 30.9, 36.6, 38.9, 44.9, 50.0; CH: 33.4.


Preparative Example 243
4-(2-AMINOETHYL)PIPERIDINE-1-CARBOXAMIDE



embedded image


A. 4-(2-tert-BUTOXYCARBONYLAMINOETHYL)PIPERIDINE-1-CARBOXAMIDE



embedded image


4-(2-tert-Butoxycarbonylaminoethyl)piperidine (500 mg, 2.19 mmoles) was dissolved in anhydrous dichloromethane (10 mL) and trimethylsilylisocyanate (2.96 mL, 21.9 mmoles) was added. The mixture was stirred under argon at 25° C. for 3.25 h. The mixture was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The organic layer was dried (MgSO4), filtered, evaporated to dryness and chromatographed on a silica gel column (15×5 cm) using 5% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give 4-(2-tert-butoxycarbonylaminoethyl)piperidine-1-carboxamide (308.2 mg, 52%): FABMS: m/z 272.0 (MH+); HRFABMS: m/z 272.1965 (MH+). Calcd. for C13H26O3N3: m/z 272.1974; δH (CDCl3) 1.20 (2H, m, CH2), 1.47 (9H, s, —COOC(CH3)3), 1.45-1.55 (3H, m, CH/CH2), 1.75 (2H, m, CH2), 2.82 (2H, m, CH2), 3.19 (2H, m, CH2), 3.96 (2H, m, CH2), 4.64 (2H, m, CH2) and 4.70 ppm (1H, bm, NH); δC (CDCl3) CH3: 28.5, 28.5, 28.5; CH2: 31.8, 31.8, 36.7, 38.0, 44.5, 44.5; CH: 33.4; C: 79.2, 156.7, 158.1.


A. 3-(2-AMINOETHYL)PIPERIDINE-1-CARBOXAMIDE



embedded image


4-(2-tert-Butoxycarbonylaminoethyl)piperidine-1-carboxamide (283.3 mg, 1.04 mmoles) (prepared as described in Preparative Example 243, Step A above) was dissolved in methanol (5.4 mL) and 10% conc. sulfuric acid in 1,4-dioxane (14.2 mL) was added and the mixture was stirred at 25° C. for 1.25 h. The mixture was diluted with methanol and BioRad AG1-X8 resin (OH form) was added until the pH was basic. The resin was filtered off, washed with methanol, evaporated to dryness and chromatographed on a silica gel column (30×2.5 cm) using 15% (10% conc, ammonium hydroxide in methanol)-dichloromethane as the eluant to give the 3-(2-aminoethyl)piperidine-1-carboxamide (170 mg, 95%): FABMS: m/z 172.1 (MH+); HRFABMS: m/z 172.1442. Calcd for C8H18N3O requires: m/z 172.1450; δH (CDCl3+3% CD3OD) 1.16 (2H, m, CH2), 1.43 (2H, m, CH2), 1.52 (1H, m, CH), 1.70 (2H, m, CH2), 2.70-2.85 (8H, m, CH2) and 3.92 ppm (2H, m, CONH2); δC (CDCl3+3% CD3OD) CH2: 31.9, 31.9, 39.0, 39.7, 44.4, 44.4; CH: 33.5; C, 158.7.


Preparative Example 244
3-(AMINOMETHYL)-1-METHYLPIPERIDINE



embedded image


A. 3-(BROMOMETHYL)-1-METHYLPIPERIDINE



embedded image


3-(Hydroxymethyl)-1-methylpiperidine (2 g, 15.5 mmoles) was dissolved in anhydrous acetonitrile (32 mL) and anhydrous pyridine (2.02 mL, 24.8 mmoles) was added and the solution was cooled to 0° C. Dibromotriphenylphosphorane (8.49 g, 20.2 mmoles) was added at 0° C. and the mixture was allowed to warm up to 25° C. and was stirred for 94 h. The mixture was evaporated to dryness and the residue was chromatographed on a silica gel column (30×5 cm) using gradient elution with dichloromethane, 35% diethyl ether in dichloromethane and 5-10% methanol in dichloromethane as the eluant to give 3-(bromomethyl)-1-methylpiperidine (3.13 g, 100%): FABMS: m/z 192.1 (MH+); δH (CDCl3) 1.52 (1H, m, CH2), 1.99 (2H, m, CH2), 2.43 (1H, m, CH2), 2.75 (2H, m, CH2), 2.82 (1H, m, CH), 2.86/2.88 (3H, s, NCH3), 3.42/3.49 (2H, dd, —CH2Br) and 3.56 ppm (2H, m, CH2); δC (CDCl3) CH3: 44.3; CH2: 22.1, 26.6, 35.4, 54.8, 58.2; CH: 34.6.


A. 3-(Di-tert-BUTOXYCARBONYLAMINOMETHYL)-1-METHYLPIPERIDINE



embedded image


3-(Bromomethyl)-1-methylpiperidine (1.5 g, 7.81 mmoles) (from Preparative Example 244, Step A above) and di-tert-butyliminodicarboxylate (1.697 g, 7.81 mmoles) were dissolved in anhydrous acetonitrile (25 mL). Cesium carbonate (5.1 g, 15.6 mmoles) and lithium iodide (52 mg, 0.391 mmoles) were added and the mixture was stirred at 70° C. for 20 h. The mixture was evaporated to dryness and the residue was partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The organic layer was dried (MgSO4), filtered and evaporated to dryness. the residue was chromatographed on a silica gel column (30×5 cm) using 3% methanol in dichloromethane as the eluant to give 3-(di-tert-butoxycarbonylamino)-1-methylpiperidine (1.331 g, 52%): FABMS: m/z 329.2 (MH+); HRFABMS: m/z 329.2438 (MH+). Calcd. for C17H33N2O4: m/z 329.2440; δH (CDCl3) 1.10 (1H, m, CH2), 1.54 (18H, s, —COOC(CH3)3), 1.86 (2H, m, CH2), 2.01 (1H, m, CH2), 2.19 (1H m, CH), 2.34 (2H, bm, CH2), 2.59 (3H, —NCH3), 3.19 (2H, m, CH2) and 3.52/3.52 ppm (2H, —CH2N—); δC (CDCl3) CH3: 28.5, 28.5, 28.5, 28.5, 28.5, 28.5, 47.2; CH2: 25.4, 28.3, 50.4, 56.8, 60.8; CH: 37.2; C: 83.0, 83.0, 153.5, 153.5.


A. 3-(AMINOMETHYL)-1-METHYLPIPERIDINE



embedded image


3-(Di-tert-butoxycarbonylamino)-1-methylpiperidine (500 mg, 1.52 mmoles) (from Preparative Example 244, Step B above) was dissolved in methanol (7.5 mL) and 10% (v/v) conc. sulfuric acid in 1,4-dioxane (19.75 mL) was added. The solution was stirred at 25° C. for 0.5 h. Methanol (300 mL) was added, followed by BioRad AG1-X8 resin (OH form) until the pH was ˜10. The resin was filtered off and washed with methanol (2×200 mL). The combined eluates were evaporated to dryness and the residue was chromatographed on a silica gel column (30×2.5 cm) using 10% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give 3-(aminomethyl)-1-methylpiperidine (69.2 mg, 35%): FABMS: m/z 129.1 (MH+); HRFABMS: m/z 129.1392 (MH+). Calcd. for C7H17N2: m/z 129.1392; δH (CDCl3) 0.90 (2H, m, CH2), 1.65 (2H, m, CH2), 1.72 (1H, m, CH), 1.79 (1H, m, CH2), 1.91 (1H, m, CH2), 2.30 (3H, s, —NCH3), 2.64 (2H, m, CH2), 2.82 (1H, m, —CH2NH2) and 2.92 ppm (1H, m, —CH2NH2); δC (CDCl3) CH3: 46.7; CH2: 25.2, 28.0, 46.3, 56.4, 60.3; CH: 39.9.


Preparative Example 245
4-(AMINOMETHYL)-1-METHYLPIPERIDINE



embedded image


A. 1-METHYLISONIPECOTAMIDE



embedded image


Isonipecotamide (10 g, 78.0 mmoles) was dissolved in distilled water (100 mL) and 37% aqueous formaldehyde (7.6 mL, equivalent to 2.81 g HCHO, 93.6 mmoles) was added. Wet 10% Pd—C (8 spoon spatulas) was added under argon and the mixture was hydrogenated at 25° C. and 50 psi for 43 h. The catalyst was filtered off through Celite and the latter washed with water and methanol. The combined filtrates were evaporated to dryness and the residue was chromatographed on a silica gel column (60×5 cm) using 8%-10%-20% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give 1-methylisonipecotamide (7.15 g, 64%): FABMS: m/z 143.1 (MH+); HRFABMS: m/z 143.1184 (MH+). Calcd. for C7H15N2O: m/z 143.1184; δH (d6-DMSO) 1.50/1.57 (4H, m, CH2), 1.76/1.94 (4H, m, CH2), 2.10 (3H, s, —NCH3), 2.72 (1H, m, CH) and 6.68/7.18 ppm (2H, m, CONH2); δC (d6-DMSO)CH3: 41.2; CH2: 28.5, 28.5, 54.9, 54.9; CH: 46.2; C, 176.7.


B. 4-(AMINOMETHYL)-1-METHYLPIPERIDINE



embedded image


1-Methylisonipecotamide (6.75 g, 47.5 mmoles) (prepared as described in Preparative Example 245, Step A above) was dissolved in anhydrous THF (350 mL) and the resulting mixture was added in portions to a stirred slurry of lithium aluminum hydride (1.8 g, 47.5 mmoles) in anhydrous THF (100 mL) at 0° C. under nitrogen. The mixture was stirred at 0° C. for 30 min and then heated at 66° C. for 25 h under nitrogen. Distilled water (1.88 mL) was added dropwise to the stirred mixture at 0° C., followed by 20% aqueous sodium hydroxide (1.42 mL) and then distilled water (6.75 mL) and the mixture was stirred for 15 min. The mixture was filtered and the solids were washed with THF and dichloromethane. The combined filtrates were evaporated to dryness and chromatographed on a silica gel column (30×5 cm) using 15%-20% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give 4-(aminomethyl)-1-methylpiperidine (0.678 g, 11%): FABMS: m/z 129.1 (MH+); HRFABMS: m/z 129.1389 (MH+). Calcd. for C7H17N2: m/z 129.1392; δH (d6-DMSO): 2.08 ppm (3H, s, —NCH3); δC (d6-DMSO): CH3: under DMSO peaks; CH2: 29.6, 29.6, 46.7, 55.2, 55.2; CH: 46.2.


Preparative Example 246
3-(AMINOMETHYL)BENZONITRILE



embedded image


A. 3-(Di-tert-BUTOXYCARBONYLAMINO)BENZONITRILE



embedded image


3-(Bromomethyl)benzonitrile (5 g, 25.5 mmoles) and di-tert-butyliminodicarboxylate (5.54 g, 25.5 mmoles) were dissolved in anhydrous THF (50 mL) and cesium carbonate (16.62 g, 25.5 mmoles) and lithium iodide (170.5 mg, 1.275 mmoles) were added. The mixture was stirred at 70° C. for 22 h and the reaction was worked up as described in Preparative Example 89, Step B above. The residue was chromatographed on a silica gel column (60×5 cm) using 5% ethyl acetate in hexane as the eluant to give 3-(di-tert-butoxycarbonylamino)benzonitrile (7.39 g, 87%): FABMS: m/z 333.2 (MH+); HRFABMS: m/z 333.1815 (MH+); Calcd. for C18H25N2O4: m/z 333.1814; δH (CDCl3) 1.52 (18H, s, —COOC(CH3)3), 4.84 (2H, s, CH2), 7.48 (1H, m, Ar—H), 7.60 (2H, m, Ar—H) and 7.65 ppm (1H, m, Ar—H); δC (CDCl3) CH3: 28.1, 28.1, 28.1, 28.1, 28.1, 28.1; CH2: 48.4; CH: 129.2, 131.0, 131.0, 131.9; C: 83.2, 83.2, 112.5, 118.8, 140.1, 152.5, 152.5.


B. 3-(AMINOMETHYL)BENZONITRILE



embedded image


3-(Di-tert-butoxycarbonylamino)benzonitrile (2 g, 6.0 mmoles) (prepared as described in Preparative Example 246, Step A above) was dissolved in methanol (30 mL) and 10% (v/v) (10% conc. sulfuric acid in 1,4-dioxane) (79 mL) was added. The solution was stirred at 25° C. for 0.25 h and worked up as described in Preparative Example 89, Step C above). The residue was chromatographed on a silica gel column (15×5 cm) using 3% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give the title compound (651.4 mg, 82%): FABMS: m/z 133.1 (MH+); HRFABMS: m/z 133.0762 (MH+). Calcd. for C8H9N2: m/z 133.0766; δH (CDCl3) 2.57 (2H, s, —CH2NH2), 3.92 (2H, s, —CH2NH2), 7.46 (1H, m, Ar—H), 7.57 (2H, m, Ar—H) and 7.64 ppm (1H, m, Ar—H); δC (CDCl3) CH2: 45.2; CH: 129.4, 130.7, 130.7, 131.8; C: 112.4, 118.8, 143.8.


Preparative Example 247
4-(AMINOMETHYL)BENZONITRILE



embedded image


A. 3-(Di-tert-BUTOXYCARBONYLAMINOMETHYL)BENZONITRILE



embedded image


4-(Bromomethyl)benzonitrile (5 g, 25.5 mmoles) and di-tert-butyliminodicarboxylate (5.54 g, 25.5 mmoles) were dissolved in anhydrous THF (50 mL) and cesium carbonate (16.62 g, 25.5 mmoles) and lithium iodide (170.5 mg, 1.275 mmoles) were added. The mixture was stirred at 70° C. for 23 h and the reaction was worked up as described in Preparative Example 244, Step B above. The residue was chromatographed on a silica gel column (50×5 cm) using 5% ethyl acetate in hexane as the eluant to give 4-(di-tert-butoxycarbonylaminomethyl)benzonitrile (7.07 g, 83%): FABMS: m/z 333.2 (MH+); HRFABMS: m/z 333.1816 (MH+). Calcd. for C18H25N2O4: m/z 333.1814; δH (CDCl3) 1.45 (18H, s, —COOC(CH3)3), 4.81 (2H, s, CH2), 7.37 (2H, d, Ar—H) and 7.62 ppm (2H, d, Ar—H); δC (CDCl3) CH3: 28.1, 28.1, 28.1, 28.1, 28.1, 28.1; CH2: 49.2; CH: 127.8, 127.8, 132.3, 132.3; C: 83.2, 83.2, 111.1, 118.9, 144.1, 152.4, 152.4.


B. 4-(AMINOMETHYL)BENZONITRILE



embedded image


4-(Di-tert-butoxycarbonylaminomethyl)benzonitrile (2 g, 6.0 mmoles) (prepared as described in Preparative Example 247, Step A above) was dissolved in TFA (4 mL) and the solution was stirred at 25° C. for 0.25 h. The reaction mixture was diluted with dichloromethane and extracted with 1N sodium hydroxide. The organic layer was dried (MgSO4), filtered and evaporated to dryness. The residue was chromatographed on a silica gel column (15×5 cm) using 3% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give 4-(aminomethyl)benzonitrile (108 mg, 68%): FABMS: m/z 133.1 (MH+); HRFABMS: m/z 133.0764 (MH+). Calcd. for C8H9N2: m/z 133.0766; δH (CDCl3) 2.04 (2H, s, —CH2NH2), 3.89 (2H, s, —CH2NH2), 7.40 (2H, d, Ar—H) and 7.59 ppm (2H, d, Ar—H); δC (CDCl3)CH2: 45.7; CH: 127.8, 127.8, 132.4, 132.4; C: 110.6, 118.9, 148.0.


Preparative Example 248



embedded image


To a solution of (1S,2S)-2-benzyloxycyclopentyl amine (1.5 g, 7.84 mmol) in MeOH (50 mL) at rt was added 10% Pd/C (50% wet, 1.0 g) followed by dropwise addition of conc. HCl (0.7 mL). The mixture was stirred under a balloon of H2 for 14 h and the catalyst was filtered off thru a pad of Celite. The pad of Celite washed with MeOH (2×10 mL) and the resulting filtrate was concentrated under reduced pressure to afford 0.97 g (90%) of a yellow semisolid; M+H (free base)=102


Preparative Examples 249-251

In an analogous fashion to Preparative Example 248, the benzyl protected cycloalkyl amines (Column 2) were converted to the desired aminocycloalkanol hydrochloride derivatives (Column 3) as listed in Table 17.












TABLE 17






Column 2
Column 3
CMPD


Ex.
(Amine)
(Cleavage method)
M + H







249


embedded image




embedded image


M + H = 102 (free base)





250


embedded image




embedded image


M + H = 116 (free base)





251


embedded image




embedded image


M + H = 116 (free base)









Preparative Example 252



embedded image


To a solution of ester (prepared according to J. Org. Chem. (1999), 64, 330) (0.5 g, 2.43 mmol) in THF (8 mL) at 0° C. was added LiAlH4 (0.37 g, 9.74 mmol) in one portion. The resulting mixture was heated at reflux for 12 h and was cooled to 0° C. The mixture was treated sequentially with H2O (1 mL), 1 M NaOH (1 mL), and H2O (3 mL). CH2Cl2 (10 ml) was added to the mixture which was stirred vigorously for 30 min. The mixture was filtered thru a pad of Celite which washed generously with CH2Cl2 (3×5 mL). The resulting filtrate was concentrated under reduced pressure to afford 0.41 g (85%) of a yellow/orange solid. M+H=142.


Preparative Example 253



embedded image



Step A:


To a solution of L-proline methyl ester hydrochloride (0.50 g, 3.0 mmol) in CH2Cl2 (15 mL) at 0° C. was added Et3N (1.1 mL, 7.55 mmol) followed by TFAA (0.56 mL, 3.92 mmol). The mixture was stirred for 12 h at rt and 1N HCl (25 mL) was added. The layers were separated and the organic layer washed sequentially with sat. aq. NaHCO3 (1×25 mL), and brine (1×25 mL). The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 0.72 g (100%) of a yellow oil. M+H=226. The crude material was taken onto Step B without further purification.


Step B:


To a solution of the compound prepared in Preparative Example 253, Step A (0.68 g, 3.0 mmol) in THF (20 mL) at 0° C. was added MeMgI (5.1 mL, 3.0M in Et2O) dropwise over 10 min. The resulting solution was stirred for 16 h at rt whereupon the mixture was quenched by addition of sat. aq. NH4Cl. The mixture was concentrated to dryness and the resultant residue was stirred with EtOAc (100 mL) for 45 min and filtered. The filtrate was concentrated under reduced pressure to afford 0.68 g (100%) of a yellow/orange oil. M+H=226. The crude material was taken onto Step C without further purification.


Step C:


To a solution of the compound prepared in Preparative Example 253, Step B (0.68 g, 3.0 mmol) in MeOH (5 mL) was added a solution of KOH (0.68 g, 12.1 mmol) in MeOH (5 mL). The mixture was stirred at reflux for 12 h and rt for 72 h whereupon the mixture was concentrated to dryness. The crude residue was suspended in EtOAc (50 mL) and was stirred vigorously for 30 min and was filtered. This procedure was repeated 2× more and the resultant filtrate was concentrated under reduced pressure to afford 128 mg (33%) of a maroon/orange oil. M+H=130. This material was used without purification in the subsequent coupling step.


Preparative Example 254



embedded image


The aldehyde was prepared according to the procedure of Gupton (J. Heterocyclic Chem. (1991), 28, 1281).


Preparative Example 255



embedded image


Using the aldehyde from Preparative Example 254, the procedure of Gupton (J. Heterocyclic Chem. (1991), 28, 1281) was employed to prepare the title aldehyde.


Preparative Example 256



embedded image


The title aldehyde was prepared according to the procedure of Ragan et. al Synlett (2000), 8, 1172-1174.


Preparative Example 257



embedded image


The reaction of known cyclopentyl guanidine hydrochloride (Org. Lett. (2003), 5, 1369-1372) under the conditions of Ragan (Synlett (2000), 8, 1172-1174) afforded the title aldehyde.


Preparative Example 258



embedded image


The title compound was prepared according to known literature Monatshefte fur Chemie (1973), 104, 1372-1382.


EXAMPLES
Example 1



embedded image


A solution of the product from Preparative Example 127 (0.27 g, 0.875 mmol), 4-aminomethylpyridine (0.12 g, 1.3 eq.), and K2CO3 (0.24 g, 2 eq.) in CH3CN (5 mL) was stirred at room temperature 48 hours. The reaction mixture was diluted with H2O and extracted with CH2Cl2. The combined organics were dried over Na2SO4, filtered and concentrated. The crude product was purified by flash chromatography using a 4% MeOH in CH2Cl2 solution as eluent (0.28 g, 93% yield). LCMS: MH+=380; mp=>205° C. (dec).


Examples 2-210

By following essentially the same procedure set forth in Example 1 only substituting the chlorides shown in Column 2 of Table 18 and the amines shown in Column 3 of Table 18, the compounds in Column 4 of Table 18 were prepared:













TABLE 18





Ex.
Column 2
Column 3
Column 4
Data



















2


embedded image




embedded image




embedded image


LCMS: MH+ = 380; mp = 175-176° C.





3


embedded image




embedded image




embedded image


LCMS: MH+ = 398; mp = 156-157° C.





4


embedded image




embedded image




embedded image


LCMS: MH+ = 398; mp = 45-49° C.





5


embedded image




embedded image




embedded image


LCMS: MH+ = 354; mp = 43-46° C.





6


embedded image




embedded image




embedded image


LCMS: MH+ = 354; mp = 149-150° C.





7


embedded image




embedded image




embedded image


LCMS: MH+ = 414; mp = 86-92° C.





8


embedded image




embedded image




embedded image


LCMS: MH+ = 414; mp = 185-186° C.





9


embedded image




embedded image




embedded image


LCMS: MH+ = 448; mp = 167-168° C.





10


embedded image




embedded image




embedded image


LCMS: MH+ = 346; mp = 57-58° C.





11


embedded image




embedded image




embedded image


LCMS: MH+ = 347; mp = 122.9-125.3° C.





12


embedded image




embedded image




embedded image


LCMS: MH+ = 360; mp = 127-128° C.





13


embedded image




embedded image




embedded image


LCMS: MH+ = 342; mp = 133-135° C.





14


embedded image




embedded image




embedded image


LCMS: MH+ = 344; mp = 152-155° C.





15


embedded image




embedded image




embedded image


LCMS: MH+ = 362; mp = 164-167° C.





16


embedded image




embedded image




embedded image


LCMS: MH+ = 327; mp = 146-155° C.





17


embedded image




embedded image




embedded image


LCMS: MH+ = 332; mp = 71-82° C.





17.1


embedded image




embedded image




embedded image


MS: MH+ = 332.





18


embedded image




embedded image




embedded image


LCMS: MH+ = 346; mp = 58-65° C.





19


embedded image




embedded image




embedded image


LCMS: MH+ = 414; mp = 211-213° C.





20


embedded image




embedded image




embedded image


LCMS: MH+ = 414; mp = 194-197° C.





21


embedded image




embedded image




embedded image


MS: MH+ = 414 m.p. 211-216° C.





22


embedded image




embedded image




embedded image


LCMS: MH+ = 544; mp = 104-107° C.





23


embedded image




embedded image




embedded image


Yield = 83% LCMS: MH+ = 410.





24


embedded image




embedded image




embedded image


Yield = 84% LCMS: MH+ = 410.





25


embedded image




embedded image




embedded image


Yield = 96% LCMS: MH+ = 440.





26


embedded image




embedded image




embedded image


Yield = 99% LCMS: MH+ = 440.





27


embedded image




embedded image




embedded image


Yield = 89% LCMS: MH+ = 448.





28


embedded image




embedded image




embedded image


Yield = 78% LCMS: MH+ = 448.





30


embedded image




embedded image




embedded image


Yield = 96% LCMS: MH+ = 483.





31


embedded image




embedded image




embedded image


Yield = 35% LCMS: MH+ = 483.





32


embedded image




embedded image




embedded image


Yield = 77% LCMS: MH+ = 515.





33


embedded image




embedded image




embedded image


Yield = 100% m.p. 179° C. LCMS: MH+ = 388





34


embedded image




embedded image




embedded image


Yield = 99% m.p. 186° C. LCMS: MH+ = 456





35


embedded image




embedded image




embedded image


Yield = 98% m.p. 181° C. LCMS: MH+ = 401





36


embedded image




embedded image




embedded image


Yield = 63% m.p. 192° C. LCMS: MH+ = 480





37


embedded image




embedded image




embedded image


Yield = 75% m.p. 126-127° C. LCMS: MH+ = 400





38


embedded image




embedded image




embedded image


Yield = 94% m.p. 132-133° C. LCMS: MH+ = 400





39


embedded image




embedded image




embedded image


Yield = 95% m.p. 121-122° C. LCMS: MH+ = 400





40


embedded image




embedded image




embedded image


Yield = 98% LCMS: MH+ = 460





41


embedded image




embedded image




embedded image


Yield = 87% m.p. 170-171° C. LCMS: MH+ = 464





42


embedded image




embedded image




embedded image


Yield = 84% m.p. 216-217° C. LCMS: MH+ = 464





43


embedded image




embedded image




embedded image


Yield = 96% m.p. 214° C. LCMS: MH+ = 464





44


embedded image




embedded image




embedded image


Yield = 95% m.p. 158° C. LCMS: MH+ = 522





45


embedded image




embedded image




embedded image


Yield = 90% LCMS: MH+ = 278





46


embedded image




embedded image




embedded image


Yield = 100%; LCMS: MH+ = 394





47


embedded image




embedded image




embedded image


LCMS: MH+ = 473 m.p. 84-87° C.





48


embedded image




embedded image




embedded image


MS: MH+ = 396 m.p. 91.5-93.3° C.





49


embedded image




embedded image




embedded image


MS: MH+ = 396 m.p. 196-199° C.





50


embedded image




embedded image




embedded image


MS: MH+ = 430 m.p. 242-244° C.





51


embedded image




embedded image




embedded image


MS: MH+ = 430 m.p. 218° C.





52


embedded image




embedded image




embedded image


MS: MH+ = 430 m.p. 230-233° C.





54


embedded image




embedded image




embedded image


MS: MH+ = 405 m.p. 185-188° C.





55


embedded image




embedded image




embedded image


MS: MH+ = 370 m.p. 229-232° C.





56


embedded image




embedded image




embedded image


MS: MH+ = 370 m.p. 85-90° C.





57


embedded image




embedded image




embedded image


MS: MH+ = 386 m.p. 227-230° C.





58


embedded image




embedded image




embedded image


MS: MH+ = 372 m.p. 212-215° C.





59


embedded image




embedded image




embedded image


MS: MH+ = 318 m.p. 169-171° C.





60


embedded image




embedded image




embedded image


MS: MH+ = 332 m.p. 170-173° C.





61


embedded image




embedded image




embedded image


MS: MH+ = 346 m.p. 156-159° C.





62


embedded image




embedded image




embedded image


MS: MH+ = 360 m.p. 114-116° C.





63


embedded image




embedded image




embedded image


MS: MH+ = 348 m.p. 197-200° C.





64


embedded image




embedded image




embedded image


1. mp = 230-232 2. M + H = 396





65


embedded image




embedded image




embedded image


1. mp = 205-207 2. M + H = 402





66


embedded image




embedded image




embedded image


1. mp = 220-223 2. M + H = 414





67


embedded image




embedded image




embedded image


1. mp = 191-193 2. M + H = 431





68


embedded image




embedded image




embedded image


1. mp = 235-237 2. M + H = 397





69


embedded image




embedded image




embedded image


1. mp = >250 2. M + H = 403





70


embedded image




embedded image




embedded image


1. mp = 230-232 2. M + H = 415





71


embedded image




embedded image




embedded image


1. mp = 235-238 2. M + H = 431





72


embedded image




embedded image




embedded image


1. mp = 186-188 2. M + H = 410





73


embedded image




embedded image




embedded image


1. mp = 136-138 2. M + H = 424





74


embedded image




embedded image




embedded image


1. mp = 192-195 2. M + H = 450





75


embedded image




embedded image




embedded image


1. mp = 88-90 2. M + H = 454





76


embedded image




embedded image




embedded image


1. mp = 230-232 2. M + H = 467





77


embedded image




embedded image




embedded image


1. mp = 131-133 2. M + H = 479





78


embedded image




embedded image




embedded image


1. mp = 85-88 2. M + H = 376





79


embedded image




embedded image




embedded image


1. mp = 131-133 2. M + H = 388





80


embedded image




embedded image




embedded image


1. mp = 206-208 2. M + H = 408





81


embedded image




embedded image




embedded image


1. mp = 108-110 2. M + H = 502





82


embedded image




embedded image




embedded image


1. mp = 83-85 2. M + H = 402





83


embedded image




embedded image




embedded image


1. mp = 220 2. M + H = 414





84


embedded image




embedded image




embedded image


1. mp = 154-156 2. M + H = 426





85


embedded image




embedded image




embedded image


1. mp = 152-153 2. M + H = 438





86


embedded image




embedded image




embedded image


1. mp = 159-161 2. M + H = 420





87


embedded image




embedded image




embedded image


1. mp = >220 2. M + H = 455





88


embedded image




embedded image




embedded image


1. mp = 223-225 2. M + H = 425





89


embedded image




embedded image




embedded image


1. mp = 199-201 2. M + H = 419





90


embedded image




embedded image




embedded image


1. mp = 184-186 2. M + H = 426





91


embedded image




embedded image




embedded image


1. mp = 196-198 2. M + H = 420





92


embedded image




embedded image




embedded image


1. mp = 156-159 2. M + H = 440





93


embedded image




embedded image




embedded image


1. mp = 173-176 2. M + H = 434





94


embedded image




embedded image




embedded image


1. mp = 173-175 2. M + H = 452





95


embedded image




embedded image




embedded image


1. mp = 174-176 2. M + H = 469





96


embedded image




embedded image




embedded image


1. mp = 230-234 2. M + H = 434





97


embedded image




embedded image




embedded image


1. mp = 191-193 2. M + H = 441





98


embedded image




embedded image




embedded image


1. mp = 202-205 2. M + H = 434





99


embedded image




embedded image




embedded image


1. mp = 209-212 2. M + H = 453





100


embedded image




embedded image




embedded image


1. mp = 219-221 2. M + H = 469





101


embedded image




embedded image




embedded image


1. mp = 64-66 2. M + H = 403





102


embedded image




embedded image




embedded image


1. mp = 168-170 2. M + H = 420





103


embedded image




embedded image




embedded image


1. mp = 213-216 2. M + H = 411





104


embedded image




embedded image




embedded image


1. mp = 98-100 2. M + H = 561





105


embedded image




embedded image




embedded image


1. mp 70-72 2. M + H = 608





106


embedded image




embedded image




embedded image


1. mp 168-170 2. M + H = 538





107


embedded image




embedded image




embedded image


1. mp 189-191 2. M + H = 592





108


embedded image




embedded image




embedded image


LCMS: MH+ = 458;





109


embedded image




embedded image




embedded image


Yield = 89 LCMS: MH+ = 418 m.p. = 131-132° C.





110


embedded image




embedded image




embedded image


Yield = 95% LCMS: MH+ = 347





111


embedded image




embedded image




embedded image


Yield = 91% 3H); LCMS: MH+ = 484





112


embedded image




embedded image




embedded image


Yield = 87% LCMS: MH+ = 427





113


embedded image




embedded image




embedded image


Yield = 80% LCMS: MH+ = 427





114


embedded image




embedded image




embedded image


Yield = 91% LCMS: MH+ = 378





115


embedded image




embedded image




embedded image


Yield = 92%, 3H); LCMS: MH+ = 520





116


embedded image




embedded image




embedded image


Yield = 98% LCMS: MH+ = 536





117


embedded image




embedded image




embedded image


Yield = 82% LCMS: MH+ = 410





118


embedded image




embedded image




embedded image


Yield = 95% LCMS: MH+ = 347





121


embedded image




embedded image




embedded image


Yield = 65% LCMS: MH+ = 481.02





126


embedded image




embedded image




embedded image


Yield = 71% MH+ = 486





127


embedded image




embedded image




embedded image


Yield = 71% MH+ = 495.1





128


embedded image




embedded image




embedded image


Yield = 55% MH+ = 463





129


embedded image




embedded image




embedded image


Yield = 77% LCMS: MH+ = 455





130


embedded image




embedded image




embedded image



1H NMR (Yield = 75% LCMS: MH+ = 379






131


embedded image




embedded image




embedded image


Yield = 75% LCMS: MH+ = 407





132


embedded image




embedded image




embedded image


Yield = 75% LCMS: MH+ = 421





133


embedded image




embedded image




embedded image


Yield = 70% LCMS: MH+ = 421





134


embedded image




embedded image




embedded image


Yield = 78% LCMS: MH+ = 475





135


embedded image




embedded image




embedded image


Yield = 75% LCMS: MH+ = 476





136


embedded image




embedded image




embedded image


Yield = 65% LCMS: MH+ = 455





137


embedded image




embedded image




embedded image


Yield = 55% LCMS: MH+ = 473)





138


embedded image




embedded image




embedded image


Yield = 60% LCMS: MH+ = 439





139


embedded image




embedded image




embedded image


Yield = 65% LCMS: MH+ = 441





140


embedded image




embedded image




embedded image


Yield = 80% LCMS: MH+ = 432





141


embedded image




embedded image




embedded image


Yield = 60% LCMS: MH+ = 429





142


embedded image




embedded image




embedded image


LCMS: MH+ = 330; mp = 109-111° C.





143


embedded image




embedded image




embedded image


LCMS: MH+ = 346; mp = 186-188° C.





144


embedded image




embedded image




embedded image


LCMS: MH+ = 384; mp = 148-150° C.





145


embedded image




embedded image




embedded image


LCMS: MH+ = 400; mp = 186-188° C.





146


embedded image




embedded image




embedded image


LCMS: M2H+ = 390; mp = 192-194° C.





147


embedded image




embedded image




embedded image


LCMS: M+ = 404; mp = 220-222° C.





148


embedded image




embedded image




embedded image


LCMS: MH+ = 369; mp >230° C.





149


embedded image




embedded image




embedded image


LCMS: MH+ = 364; mp = 186-188° C.





150


embedded image




embedded image




embedded image


LCMS: MH+ = 312; mp = 138-140° C.





151


embedded image




embedded image




embedded image


LCMS: M+ = 380; mp = 172-174° C.





152


embedded image




embedded image




embedded image


LCMS: MH+ = 352; mp = 201-203° C.





153


embedded image




embedded image




embedded image


LCMS: MH+ = 348; mp = 166-168° C.





154


embedded image




embedded image




embedded image


LCMS: M2H+ = 531; mp = 78-80° C.





155


embedded image




embedded image




embedded image


LCMS: M2H+ = 474; mp = 161-163° C.





156


embedded image




embedded image




embedded image


LCMS: M+ = 444; mp = 48-51° C.





157


embedded image




embedded image




embedded image


MH+ = 542.1





158


embedded image




embedded image




embedded image


MH+ = 520.1





159


embedded image




embedded image




embedded image


MH+ = 542.1





160


embedded image




embedded image




embedded image


MH+ = 480.1





161


embedded image




embedded image




embedded image


MH+ = 506.1





162


embedded image




embedded image




embedded image


MH+ = 480.1





163


embedded image




embedded image




embedded image


MH+ = 494.1





164


embedded image




embedded image




embedded image


MH+ = 466.1





165


embedded image




embedded image




embedded image


MH+ = 494.1





166


embedded image




embedded image




embedded image


MH+ = 508.1





167


embedded image




embedded image




embedded image


MH+ = 520.1





168


embedded image




embedded image




embedded image


MH+ = 528.1





169


embedded image




embedded image




embedded image


MH+ = 520.1





170


embedded image




embedded image




embedded image


MH+ = 528.1





171


embedded image




embedded image




embedded image


LCMS: MH+ = 474;





172


embedded image




embedded image




embedded image


LCMS: MH+ = 437;





173


embedded image




embedded image




embedded image


LCMS: MH+ = 472;





174


embedded image




embedded image




embedded image


LCMS: MH+ = 428.1





175


embedded image




embedded image




embedded image


LCMS: MH+ = 426.2





176


embedded image




embedded image




embedded image


LCMS: MH+ = 442.0





177


embedded image




embedded image




embedded image


LCMS: MH+ = 452.0





178


embedded image




embedded image




embedded image


Yield = 90 MH+ = 436 m.pt. = 89.1° C.





179


embedded image




embedded image




embedded image


MH+ = 424 m.pt. = 188.2° C.





180


embedded image




embedded image




embedded image


MH+ = 448 m.pt. = 211.3° C.





181


embedded image




embedded image




embedded image


Yield = quant. MH+ = 464





182


embedded image




embedded image




embedded image


MH+ = 382 m.pt. = 185.8° C.





183


embedded image





embedded image


MH+ = 387 m.pt. = 181-182° C.





184


embedded image




embedded image




embedded image


MH+ = 453





185


embedded image




embedded image




embedded image


MH+ = 401 m.pt. = 178.3° C.





186


embedded image




embedded image




embedded image


MH+ = 402





187


embedded image




embedded image




embedded image


Yield = 91 MH+ = 386 m.pt. = 148.3° C.





188


embedded image




embedded image




embedded image


Yield = 64 MH+ = 402 m.pt. = 174.5° C.





189


embedded image




embedded image




embedded image


MH+ = 379 m.pt. = 82-83° C.





190


embedded image




embedded image




embedded image


MH+ = 379 m.pt. = 50.7° C.





191


embedded image




embedded image




embedded image


Yield = 89 MH+ = 469 m.pt. = 186.7° C.





192


embedded image




embedded image




embedded image


Yield = 93 MH+ = 410 m.pt. = 86.7° C.





193


embedded image




embedded image




embedded image


Yield = 76 MH+ = 333 m.pt. = 120.3° C.





194


embedded image




embedded image




embedded image


Yield = 86 MH+ = 353 m.pt. = 188.9° C.





195


embedded image




embedded image




embedded image


Yield = 11% LCMS: 374 MH+ = 390





196


embedded image




embedded image




embedded image


Yield = 88% LCMS: 374 MH+ = 346





197


embedded image




embedded image




embedded image


Yield = 88% LCMS: 374 MH+ = 346





198


embedded image




embedded image




embedded image


Yield = MH+ = 400 m.pt. = 111.5-112.2° C.





199


embedded image




embedded image




embedded image


MH+ = 416





200


embedded image




embedded image




embedded image


MH+ = 415





201


embedded image




embedded image




embedded image


MH+ = 398 m.p. = 156.5° C.





202


embedded image




embedded image




embedded image


MH+ = 414 m.p. = 89.5° C.





203


embedded image




embedded image




embedded image


MH+ = 413





204


embedded image




embedded image




embedded image


Yield = 86 MH+ = 521 m.p. = 79.9° C.





204.10


embedded image




embedded image




embedded image







204.11


embedded image




embedded image




embedded image


Yield = 87 MH+ = 521 m.p. = 128.6° C.





205


embedded image




embedded image




embedded image


Yield = 99 MH+ = 537 m.p. = 83.5° C.





206


embedded image




embedded image




embedded image


Yield = 94 MH+ = 598 m.p. = 110.8° C.





207


embedded image




embedded image




embedded image


Yield = quant. MH+ = 545





208


embedded image




embedded image




embedded image


Yield = 96 MH+ = 468 m.p. = 69.2° C.





209


embedded image




embedded image




embedded image


MH+ = 498 m.p. = 226.5° C.





210


embedded image




embedded image




embedded image


MH+ = 564 m.p. = 174.2° C.










Additional data for select examples given below.


Example 23


1H NMR (CD3OD) δ 8.63 (d, J=5.7 Hz, 2H), 8.18 (s, 1H), 7.81 (dd, J=8.1 Hz, 2.1 Hz, 1H), 7.58 (d, J=6.0 Hz, 2H), 7.48 (m, 1H), 7.15-7.10 (m, 2H), 6.50 (s, 1H), 4.86 (s, 2H), 3.70 (s, 3H)


Example 24


1H NMR (CDCl3) δ 8.82 (s, 1H), 8.73 (d, J=4.2 Hz, 1H), 8.11 (s, 1H), 8.06 (dd, J=7.8 Hz, 1.8 Hz, 1H), 7.91 (d, J=8.1 Hz, 1H), 7.53-7.47 (m, 2H), 7.20 (m, 1H), 7.08 (d, J=8.1 Hz, 1H), 6.75 (s, 1H), 4.81 (d, J=4.5 Hz, 2H), 3.86 (s, 3H)


Example 25


1H NMR (CDCl3) δ 8.75 (d, J=5.7 Hz, 2H), 8.12 (s, 1H), 7.81 (d, J=2.1 Hz, 1H), 7.53 (dd, J=8.4, 2.1 Hz, 1H), 7.45 (d, J=6.0 Hz, 2H), 6.96 (t, J=6.0 Hz, 2H), 6.33 (s, 1H), 4.85 (d, J=6.0 Hz, 2H), 4.09 (s, 3H), 4.03 (s, 3H)


Example 26


1H NMR (CDCl3) δ 8.82 (s, 1H), 8.72 (s, 1H), 8.09 (m, 1H), 7.87-7.83 (m, 2H), 7.60 (m, 1H), 7.45 (m, 1H), 7.03 (d, J=8.4 Hz, 1H), 6.87 (s, 1H), 6.43 (s, 1H), 4.83 (d, J=4.5 Hz, 2H), 4.11 (s, 3H), 4.04 (s, 3H)


Example 27


1H NMR (CDCl3) δ 8.75 (d, J=4.5 Hz, 2H), 8.19 (s, 1H), 7.63 (d, J=7.8 Hz, 2H), 7.44-7.40 (m, 3H), 7.07 (m, 1H), 6.26 (s, 1H), 4.83 (d, J=5.1 Hz, 2H)


Example 28


1H NMR (CDCl3) δ 8.86 (s, 1H), 8.74 (m, 1H), 8.17 (s, 1H), 7.97 (m, 1H), 7.66-7.63 (m, 2H), 7.62 (m, 1H), 7.41 (m, 1H), 7.07 (m, 1H), 6.35 (s, 1H), 4.87 (d, J=6.0 Hz, 2H)


Example 30


1H NMR (CDCl3) δ 8.16 (s, 1H), 7.66-7.62 (m, 2H), 7.41 (m, 1H), 7.33-7.22 (m, 3H), 6.96 (t, J=6.0 Hz, 1H), 6.33 (s, 1H), 4.73 (d, J=6.0 Hz, 2H)


Example 31


1H NMR (CDCl3) δ 8.13 (s, 1H), 7.66 (d, J=7.8 Hz, 2H), 7.45-7.40 (m, 2H), 7.10-7.04 (m, 2H), 6.93 (t, J=6.6 Hz, 1H), 6.60 (s, 1H), 4.84 (d, J=6.6 Hz, 2H)


Example 32


1H NMR (CDCl3) δ 8.16 (s, 1H), 7.66-7.62 (m, 2H), 7.57-7.55 (m, 2H), 7.41 (t, J=7.8 Hz, 1H), 7.31 (dd, J=7.8, 1.8 Hz, 1H), 6.99 (t, J=6.0 Hz, 1H), 6.32 (s, 1H), 4.73 (d, J=6.0 Hz, 2H)


Example 40


1H NMR (CDCl3) δ 8.01 (s, 1H), 7.31-7.24 (d, J=8.2 Hz, 1H), 6.72-6.64 (br t, J=5.4 Hz, 1H), 6.62-6.52 (m, 2H), 6.05-6.01 (s, 1H), 5.56-4.64 (d, J=6.0 Hz, 2H), 4.03-3.93 (s, 3H), 3.94-3.86 (s, 3H), 2.79-2.70 (d, J=8.1 Hz, 2H), 2.02-1.66 (m, 6H), 1.43-1.22 (m, 3H), 1.20-1.02 (m, 2H)


Example 45


1H NMR (CDCl3) δ 8.73(d, 2H), 8.54(s, 1H), 7.41(d, 2H), 7.02(br, 1H), 5.90(s, 1H), 4.80(s, 2H), 4.48(q, 2H), 2.75(s, 2H), 1.50(t, 2H), 1.06(s, 9H);


Example 46


1H NMR (CDCl3) δ 8.79(s, 1H), 8.72(d, 1H), 8.14(s, 1H), 7.84(d, 1H), 7.54-7.33(m, 4H), 6.97(t, 1H), 6.18(s, 1H), 4.79(d, 2H), 2.47(s, 3H)


Example 108


1H NMR (CDCl3) δ 8.79 (s, 1H), 8.72 (d, J=3.0 Hz, 1H), 8.16 (s, 1H), 7.84 (d, J=7.8 Hz, 1H), 7.74 (d, J=7.5 Hz, 2H), 7.55-7.35 (m, 3H), 6.92 (t, J=6.3 Hz, 1H), 6.42 (s, 1H), 4.81 (d, J=6.3 Hz, 2H)


Example 110


1H NMR (CDCl3) δ 8.18(t, 1H), 8.03(s, 1H), 7.44(m, 1H), 7.30(t, 1H), 7.17(q, 1H), 6.66(s, 1H), 6.56(br, 1H), 4.28(d, 2H), 2.38(s, 1H)


Example 111


1H NMR (CDCl3) δ 8.72(br, 1H), 8.59(d, 1H), 8.11(t, 1H), 8.06(s, 1H), 7.73(d, 1H), 7.44(d, 1H), 7.42-7.21(m, 3H), 7.07(q, 1H), 6.39(d, 1H), 5.21(q, 1H), 4.16(q, 2H), 3.08(d, 2H), 1.22(t, 3H)


Example 112


1H NMR (CDCl3) δ 8.22(t, 1H), 8.15(s, 1H), 7.51-7.33(m, 7H), 7.21(q, 1H), 6.82(d, 1H), 6.51(s, 1H), 4.68(q, 1H), 2.18(m, 2H), 1.17(t, 3H)


Example 113


1H NMR (CDCl3) δ 8.22(t, 1H), 8.14(s, 1H), 7.51-7.33(m, 7H), 7.21(q, 1H), 6.82(d, 1H), 6.51(s, 1H), 4.68(q, 1H), 2.18(m, 2H), 1.17(t, 3H)


Example 114


1H NMR (CDCl3) δ 8.81(s, 1H), 8.75(d, 1H), 8.21(s, 1H), 7.84(d, 1H), 7.47(q, 1H), 6.96(s, 1H), 6.94(t, 1H), 4.85(d, 2H), 4.60(q, 2H), 1.58(t, 3H)


Example 115


1H NMR (CDCl3) δ 8.77(s, 1H), 8.72(d, 1H), 8.14(s, 1H), 7.83(d, 1H), 7.65(d, 1H), 7.44(q, 1H), 7.80(t, 1H), 7.6(d, 1H), 6.18(s, 1H), 4.75(d, 2H), 3.91(s, 3H), 3.81(s, 3H)


Example 116


1H NMR (CDCl3) δ 8.67(s, 1H), 8.55(d, 1H), 8.50(s, 1H), 7.92(d, 1H), 7.90(d, 1H), 7.78(t, 1H), 7.10(d, 1H), 6.97(s, 1H), 5.11(s, 2H), 3.77(s, 6H)


Example 117


1H NMR (CDCl3) δ 8.38(s, 1H), 8.30(d, 1H), 8.17(s, 1H), 7.52-7.37(m, 6H), 6.97(t, 1H), 6.13(s, 1H), 4.77(d, 2H), 2.50(s, 3H)


Example 118


1H NMR (CDCl3) δ 8.18(t, 1H), 8.03(s, 1H), 7.44(m, 1H), 7.30(t, 1H), 7.17(q, 1H), 6.66(s, 1H), 6.56(br, 1H), 4.28(d, 2H), 2.38(s, 1H);


Example 121


1H NMR (CDCl3) δ 8.6 (S, 1H), 8.15 (dt, 1H), 8.1 (s, 1H), 8.0 (d, 2H), 7.5 (d, 2H), 7.4 (dd, 1H), 7.2 (d, 1H), 7.15 (dd, 1H), 6.8 (t, 1H), 6.6 (s, 1H), 4.75 (d, 2H).


Example 126


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.5 (d, 1H), 7.42-7.35 (m, 2H), 7.3-7.2 (m, 2H), 7.15 (dd, 1H), 7.1 (dd, 1H), 7.0 (t, 1H), 6.6 (s, 1H), 4.8 (d, 2H).


Example 127


1H NMR (CDCl3) δ 8.2 (dt, 1H), 8.0 (s, 1H), 7.4 (dd, 1H), 7.3-7.25 (m, 3H), 7.1 (dd, 1H), 6.9-6.85 (m, 2H), 6.7 (t, 1H), 6.6 (s, 1H), 4.6 (d, 2H), 3.2 (m, 4H), 2.6 (m, 4H), 2.3 (s, 3H)


Example 128


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.1 (s, 1H), 8.0 (d, 2H), 7.5 (d, 2H), 7.4 (m, 2H), 7.25 (d, 1H), 7.2 (s, 1H), 7.15 (dd, 1H), 7.0 (s, 1H), 6.8 (t, 1H), 6.6 (s, 1H), 4.75 (d, 2H).


Example 129


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.05 (s, 1H), 8.0 (d, 2H), 7.5 (d, 2H), 7.4 (m, 1H), 7.3 (dd, 1H), 7.15 (dd, 1H), 6.9 (t, 1H), 6.5 (s, 1H), 4.75 (d, 2H), 3.85 (s, 3H)


Example 130


1H NMR (CDCl3) δ 8.2 (dt, 1H), 8.0 (s, 1H), 7.4 (dd, 1H), 7.3 (dd, 1H), 7.15 (dd, 1H), 6.8 (t, 1H), 6.4 (s, 1H), 4.2 (d, 2H), 3.8 (s, 3H).


Example 131


1H NMR (CDCl3) δ 8.2 (dt, 1H), 8.0 (s, 1H), 7.4-7.15 (m, 3H), 6.7 (t, 1H), 4.2 (q, 2H), 3.8 (dt, 2H), 2.8 (t, 2H), 1.2 (t, 3H)


Example 132


1H NMR (CDCl3) δ 8.2 (dt, 1H), 8.0 (s, 1H), 7.4-7.15 (m, 3H), 6.7 (t, 1H), 4.2 (q, 2H), 3.8 (dt, 2H), 2.8 (t, 2H), 2.05 (m, 2H) 1.2 (t, 3H)


Example 133


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.4 (m, 1H), 7.3 (dd 1H), 7.2 (dd, 1H), 6.5 (s, 1H), 6.4 (t, 1H), 3.7 (s, 3H), 3.5 (dd, 2H), 2.4 (t, 2H), 1.8 (m, 4H)


Example 134


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.95 (d, 2H), 7.6 (d, 2H), 7.4 (m, 1H), 7.25 (dd, 1H), 7.1 (dd, 1H), 6.9 (t, 1H), 6.5 (s, 1H), 4.8 (d, 2H), 3.0 (s, 3H)


Example 135


1H NMR (DMSO d6) δ 9.1 (bs, 2H), 8.4 (s, 1H), 8.0 (t, 1H), 7.85 (d, 2H), 7.7 (d, 2H), 7.6 (m, 1H), 7.4 (m, 2H), 6.6 (s, 1H), 4.8 (bs, 2H)


Example 136


1H NMR (CDCl3) δ 8.2 (dt, 1H), 8.0 (s, 1H), 7.4 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 6.9 (m, 3H), 6.7 (t, 1H), 6.5 (s, 1H), 4.5 (d, 2H), 4.2 (s, 4H)


Example 137


1H NMR (CDCl3) δ 8.2 (dt, 1H), 8.0 (s, 1H), 7.4 (m, 1H), 7.3 (dd, 1H), 7.2 (dd, 1H), 6.9 (dd, 1H), 6.8 (t, 1H), 6.7 (m, 1H), 6.6 (s, 1H), 5.3 (s, 2H), 4.85 (s, 2H), 4.6 (d, 2H).


Example 138


1H NMR (CDCl3) δ 8.2 (dt, 1H), 8.0 (s, 1H), 7.9 (d, 1H), 7.8 (d, 1H), 7.4 (m, 2H), 7.3 (dd, 1H), 7.1 (dd, 1H), 6.9 (t, 1H), 6.6 (s, 1H), 4.8 (d, 2H)


Example 139


1H NMR (CDCl3) δ 8.2 (dt, 1H), 8.0 (s, 1H), 7.4 (m, 1H), 7.3 (m, 2H), 7.2 (dd, 1H), 7.1 (dd, 1H), 6.8 (d, 1H), 6.7 (t, 1H), 6.6 (s, 1H), 4.6 (m, 4H), 3.2 (t, 2H)


Example 140


1H NMR (CDCl3) δ 8.45 (s, 1H), 8.2 (dt, 1H), 8.0 (s, 1H), 7.7 (dd, 1H), 7.4-7.3 (m, 3H), 7.15 (dd, 1H), 6.8 (t, 1H), 6.6 (s, 1H), 4.7 (d, 2H)


Example 141


1H NMR (CDCl3) δ 8.2 (dt, 1H), 8.0 (s, 1H), 7.45-7.1 (m, 7H), 6.6 (s, 1H), 4.4 (dt, 2H), 2.6 (t, 2H), 1.8 (m, 2H), 1.4 (m, 2H)


Example 171


1H NMR (CD3OD) δ 8.41 (s, 1H), 8.25 (d, J=6.3 Hz, 1H), 8.15 (s, 1H), 7.67 (d, J=7.8 Hz, 2H), 7.55-7.48 (m, 2H), 7.45 (dd, J=7.5, 1.2 Hz, 1H), 7.34 (dd, J=7.5, 1.8 Hz, 1H), 6.28 (s, 1H), 4.79 (s, 2H).


Example 172


1H NMR (CDCl3) δ 8.64 (s, 1H), 7.68-7.64 (m, 2H), 7.52 (m, 1H), 7.43 (t, J=7.8 Hz, 1H), 6.89 (t, J=6.0 Hz, 1H), 6.51 (s, 1H), 6.48 (m, 2H), 4.74 (d, J=6.0 Hz, 2H).


Example 173


1H NMR (DMSO-d6) δ 8.86 (s, 1H), 8.46 (s, 1H), 8.32-8.28 (m, 2H), 7.97 (m, 1H), 7.87 (m, 1H), 7.52 (m, 1H), 7.35-7.24 (m, 2H), 6.57 (s, 1H), 6.46 (m, 1H), 3.65 (m, 4H).


Example 174


1H NMR (CDCl3) d 8.37 (s, 1H), 8.16 (t, J=7.5 Hz, 1H), 7.45-7.35 (m, 1H), 7.32-7.20 (m, 3H), 7.17-7.07 (m, 1H), 6.92 (t, J=6 Hz, 1H), 6.48 (s, 1H), 4.65 (d, 2H), 2.50 (s, 3H).


Example 175


1H NMR (CDCl3) d 8.16 (t, J=9 Hz, 1H), 8.00 (s, 1H), 7.49 (d, J=9 Hz, 1H), 7.46-7.36 (m, 1H), 7.18-7.08 (m, 1H), 7.00 (d, J=9 Hz, 1H), 6.62-6.50 (m, 2H), 2.60 (s, 3H), 2.55 (s, 3H).


Example 176


1H NMR (CDCl3) d 8.15 (t, J=9 Hz, 1H), 8.00 (s, 1H), 7.45-7.35 (m, 1H), 7.32-7.20 (m, 1H), 7.20-7.05 (m, 3H), 6.80 (t, 1H), 6.50 (s, 1H), 4.65 (d, 2H), 2.65 (s, 3H), 2.50 (s, 3H).


Example 177


1H NMR (CDCl3) d 8.20 (t, 1H), 7.90 (s, 1H), 7.50-7.05 (m, 8H), 6.80 (s, 1H), 5.05-4.90 (m, 2H), 3.80 (d, 1H), 3.45 (d, 1H), 3.00 (dd, 1H), 2.90 (dd, 1H), 2.50 (s, 3H).


Example 181


1H NMR (300 MHz, CDCl3) □ 8.41 (s, 1H), 8.28-8.23 (d, 1H), 8.15 (s, 1H), 7.69-7.60 (d, 1H), 7.62-7.50 (m, 3H), 7.50-7.47 (dd, 1H), 6.35 (s, 1H), 5.36 (s, 1H), 4.80 (s, 2H).


Example 184


1H NMR (300 MHz, CDCl3) custom character8.96-8.90 (s, 1H), 8.08 (s, 1H), 8.04 (d, 1H), 7.72 (d, 1H), 7.70-7.61 (dd, 1H), 7.24-7.20 (dd, 1H), 6.92-6.84 (t, 1H), 6.36 (s, 1H), 4.96-4.89 (d, 2H).


Example 186


1H NMR (300 MHz, CDCl3) custom character8.96-8.90 (s, 1H), 8.08 (s, 1H), 8.44 (s, 1H), 8.27-8.24 (d, 1H), 8.02 (s, 1H), 7.78-7.76 (d, 1H), 7.73-7.70 (d, 1H), 7.58-7.51 (m, 2H), 7.13-7.08 (dd, 1H), 5.51 (s, 2H).


Example 195


1H NMR (CD3OD) δ 8.40(s, 1H), 8.27(d, 1H), 8.03(s, 1H), 7.75-7.50(m, 2H), 6.10(s, 1H), 4.76(s, 2H), 4.05(m, 2H), 3.88(m, 2H), 3.52(m, 1H), 2.33(m, 1H), 2.20(m, 1H).


Example 196


1H NMR (CD3OD) δ 8.73(d, 1H), 8.58(q, 1H), 8.12(s, 1H), 8.00(d, 1H), 7.54(q, 1H), 6.19(s, 1H), 4.86(s, 2H), 4.22-4.08(m, 2H), 4.03-3.93(m, 2H), 3.63(m, 1H), 2.50-2.39(m, 1H), 2.32-2.21(m, 1H).


Example 197


1H NMR (CD3OD) δ 8.73(d, 1H), 8.58(q, 1H), 8.12(s, 1H), 8.00(d, 1H), 7.54(q, 1H), 6.19(s, 1H), 4.86(s, 2H), 4.22-4.08(m, 2H), 4.03-3.93(m, 2H), 3.63(m, 1H), 2.50-2.39(m, 1H), 2.32-2.21(m, 1H).


Example 199


1H NMR (300 MHz, CDCl3) custom character8.29 (s, 1H), 8.15 (br s, 1H), 7.95 (s, 1H), 7.28 (d, 1H), 7.05-6.95 (appt t, 1H), 5.70 (s, 1H), 4.62 (d, 2H), 2.90 (m, 1H), 2.30 (m, 1H), 1.9-1.2 (m, 8H), 0.65 (d, 3H).


Example 200


1H NMR (300 MHz, CDCl3) custom character 18.71 (s, 2H), 8.00 (s, 1H), 6.13 (s, 1H), 3.59 (s, 2H), 3.01-2.58 (m, 1H), 2.51-2.45 (m, 1H), 2.44-2.30 (m, 1H), 2.20 (s, 3H), 2.09-1.95 (m, 2H), 1.85-1.70 (m, 2H), 0.80-0.76 (d, 3H).


Example 203


1H NMR (300 MHz, CDCl3) custom character18.10 (s, 1H), 8.08 (s, 1H), 6.27 (s, 2H), 4.95 (s, 2H), 3.00-2.90 (dd, 2H), 2.60 (m, 2H), 2.48 (br s, 1H), 2.39 (s, 3h), 2.25 m, 1H), 1.95-1.70 (m, 3H).


Example 211



embedded image


To a solution of the compound prepared in Example 156 (100 mg, 0.23 mmol) in dry THF (4 mL) was added LiAlH4 (1.0 M in THF, 0.110 mL, 0.110 mmol) at 0° C. under N2. The mixture was stirred at 0° C. for 1 hr, warmed to 25° C., then additional LiAlH4 (1.0 M in THF, 0.400 mL) was added, the mixture was stirred for 20 min and then quenched with MeOH (2.0 mL). The solvent was evaporated and the crude product was purified by flash chromatography using 10:1 CH2Cl2:MeOH as eluent. White solid (46 mg, 49%) was obtained. LCMS: M+=416. Mp=71-72° C.


Example 212



embedded image


To a solution of the compound prepared in Example 156 (70 mg, 0.16 mmol) in dry THF (3 mL) was added MeMgBr (3.0 M in Et2O, 1.10 mL, 3.20 mmol) under N2. The mixture was stirred at 25° C. for 45 min and then quenched with saturated aqueous NH4Cl (5.0 mL). The mixture was poured into saturated aqueous NH4Cl (30 mL) and extracted with CH2Cl2 (3×20 mL). The extracts were dried over Na2SO4 and filtered. The solvent was evaporated and the crude product was purified by flash chromatography using 20:1 CH2Cl2:MeOH as eluent. White solid (25 mg, 36%) was obtained. LCMS: M+=444. Mp=76-80° C.


Example 213



embedded image


Anhydrous DMF (40 mL) was added under N2 to the compound prepared in Preparative Example 174 (2.50 g, 8.65 mmol) and 60% NaH in mineral oil (346 mg, 8.65 mmol). The mixture was stirred at 25° C. for 1 hr, then 2-chloro-5-chloromethylpyridine N-oxide (1.54 g, 8.65 mmol) in anhydrous DMF (20 mL) was added slowly. The mixture was stirred at 25° C. for 18 hr, the solvent was evaporated and the crude product was purified by flash chromatography using 30:1 CH2Cl2:MeOH as eluent. So obtained solid was triturated by 50 mL of 1:1 EtOAc:hexane. Pale yellow solid (1.25 g, 34%) was obtained. LCMS: MH+=432. Mp=224-226° C.


Examples 214-217

By essentially the same procedure set forth in Example 213 combining the compounds shown in Column 2 of Table 19 with compounds in Column 3 of Table 19, the compounds shown in Column 3 of Table 19 were prepared.













TABLE 19





Ex.
Column 2
Column 3
Column 4
CMPD







214


embedded image




embedded image




embedded image


LCMS: MH+ = 380: mp = ° C.





215


embedded image




embedded image




embedded image


LCMS: MH+ = 450: mp = 218-222° C.





216


embedded image




embedded image




embedded image


LCMS: MH+ = 466; mp = 126-128° C.





217


embedded image




embedded image




embedded image


LCMS: M+ = 523









Example 218



embedded image


CF3CH2OH (3.0 mL) was added under N2 to 60% NaH in mineral oil (40 mg, 1.0 mmol), the mixture was stirred for 20 min, then the product prepared in Example 213 (50 mg, 0.12 mmol) was added. The mixture was refluxed for 20 hr, the solvent was evaporated, and the residue was purified by flash chromatography using 20:1 CH2Cl2:MeOH as eluent to yield pale yellow solid (35 mg, 61%). LCMS: M2H+=496. Mp=208-210° C.


Examples 219-225

By essentially the same procedure set forth in Example 218 combining the compounds shown in Column 1 of Table 20 with the appropriate alcohol, the compounds shown in Column 2 of Table 20 were prepared.












TABLE 20





Ex.
Column 1
Column 2
Data







219


embedded image




embedded image


LCMS: M+ = 426; mp = 126-128° C.





220


embedded image




embedded image


LCMS: M+ = 483; mp = 89-91° C.





221


embedded image




embedded image


LCMS: M2H+ = 442; mp = 112-114° C.





222


embedded image




embedded image


LCMS: MH+ = 462; mp = 121-123° C.





223


embedded image




embedded image


LCMS: MH+ = 444; mp = 112-114° C.





224


embedded image




embedded image


LCMS: M+ = 376; mp = ° C.





225


embedded image




embedded image


LCMS: MH+ =; mp = ° C.









Examples 226



embedded image


A mixture of the product prepared in Example 213 (100 mg, 0.23 mmol) and KOH (95 mg, 1.70 mmol) in 1,2-dimethoxyethane (3 mL) and H2O (1.5 mL) was refluxed under N2 for 20 hr, quenched with acetic acid (0.30 mL), and the solvent was evaporated. The residue was suspended in H2O (15 mL), filtered and the solid washed with H2O (15 mL) and Et2O (10 mL). Then it was mixed with CH2Cl2 (2 mL) and Et2O (2 mL) and filtered. Et2O (5 mL) was added to the filtrate and the mixture was allowed to stand overnight. The solid was removed by filtration, washed with Et2O and then dissolved in MeOH (5 mL). The solution was filtered and the solvent from the filtrate was evaporated. Off-white solid (5 mg, 5%) was obtained. LCMS: M+=412. Mp=206-208° C.


Example 227



embedded image


A mixture of the product prepared in Example 213 (129 mg, 0.30 mmol), N,N-dimethylethylenediamine (0.165 mL, 1.50 mmol), and diisopropylethylamine (0.10 mL) in anhydrous N-methylpyrrolidinone (1.0 mL) was stirred at 100° C. for 24 hr. The solvent was evaporated, and the residue was purified by flash chromatography using 20:1 CH2Cl2:7N NH3 in MeOH as eluent to yield pale yellow solid (110 mg, 76%). LCMS: M+=482. Mp=76-78° C.


Examples 228-233

By essentially the same procedure set forth in Example 227 combining the compounds shown in Column 1 of Table 21 with the appropriate amine, the compounds shown in Column 2 of Table 21 were prepared.












TABLE 21





Ex.
Column 1
Column 2
Data







228


embedded image




embedded image


LCMS: M2H+ = 467; mp 126-128= ° C.





229


embedded image




embedded image


LCMS: M+ = 481; mp = 128-130° C.





230


embedded image




embedded image


LCMS: M+ = 494; mp = 108- 110° C.





231


embedded image




embedded image


LCMS: M2H+ = 482; mp = 129-133° C.





232


embedded image




embedded image


LCMS: M2H+ = 482; mp = 124-126° C.





233


embedded image




embedded image


LCMS: M2H+ = 471; mp = 88-90° C.









Example 234



embedded image


A mixture of the product prepared in Example 213 (80 mg, 0.19 mmol) and 2.0 M methylamine in THF was stirred in a closed pressure vessel at 50° C. for 72 hr. The solvent was evaporated, and the residue was purified by flash chromatography using 10:1 CH2Cl2: MeOH as eluent to yield pale yellow solid (40 mg, 51%). LCMS: M2H+=427. Mp=217-219° C.


Example 235



embedded image


By essentially the same procedure set forth in Example 234, the compound shown above was prepared. LCMS: M2H+=441. Mp=98-101° C.


Example 236



embedded image


The compound prepared in Preparative Example 174 (140 mg, 0.48 mmol) and the aldehyde (71 mg, 0.58 mmol) were stirred in anhydrous THF (4 mL) at 50° C. under N2. Ti(OiPr)4 (0.574 mL, 1.92 mmol) was added, the mixture was stirred at 50° C. 3 hr, and cooled to 25° C. NaBH3CN (181 mg, 2.88 mmol) was added, the mixture was stirred for 2 more hr, then poured into 10% aqueous Na2CO3 (100 mL), and extracted with CH2Cl2 (3×50 mL). Combined extracts were dried over Na2SO4, filtered, and the solvent was evaporated. The residue was purified by flash chromatography using 15:1 CH2Cl2:MeOH as eluent to yield pale yellow solid (40 mg, 21%). LCMS: MH+=398. Mp>230° C.


Examples 237-256

By essentially the same procedure set forth in Example 236 combining the compounds shown in Column 2 and 3 of Table 22, the compounds shown in Column 4 of Table 22 were prepared.













TABLE 22





Ex.
Column 2
Column 3
Column 4
Data







237


embedded image




embedded image




embedded image


LCMS: M+ = 381; mp > 200° C.





238


embedded image




embedded image




embedded image


LCMS: M+ = 387; mp = ° C.





239


embedded image




embedded image




embedded image


LCMS: MH+ = 413; mp = 157- 159° C.





240


embedded image




embedded image




embedded image


LCMS: M2H+ = 419; mp = 77- 79° C.





241


embedded image




embedded image




embedded image


LCMS: M2H+ = 385; mp = 214-216° C.





242


embedded image




embedded image




embedded image


LCMS: MH+ =; mp = ° C.





243


embedded image




embedded image




embedded image


LCMS: M+ = 416; mp = 80-82° C.





244


embedded image




embedded image




embedded image







245


embedded image




embedded image




embedded image







246


embedded image




embedded image




embedded image


LCMS: M+ = 452; mp = 54-56° C.





247


embedded image




embedded image




embedded image


LCMS: MH+ = 401; mp > 200° C.





248


embedded image




embedded image




embedded image


LCMS: M2H+ = 474; mp > 200.0.° C. dec.





249


embedded image




embedded image




embedded image


LCMS: MH+ = 377; mp = 65-67° C.





250


embedded image




embedded image




embedded image


LCMS: M2H+ = 421; mp = 87-93° C.





251


embedded image




embedded image




embedded image


LCMS: MH+ = 361; mp > 225° C.





252


embedded image




embedded image




embedded image


LCMS: MH+ = 346; mp = 270-271° C.





253


embedded image




embedded image




embedded image


LCMS: MH+ = 402; mp = 250-255° C.





254


embedded image




embedded image




embedded image


LCMS: MH+ = 416; mp = 210-215° C.





255


embedded image




embedded image




embedded image


LCMS: MH+ = 428; mp = 145° C.





256


embedded image




embedded image




embedded image


LCMS: MH+ =; mp = ° C.









Example 257



embedded image


A mixture of the compound prepared in Example 242 (100 mg, 0.24 mmol), conc. aqueous HCl (1.0 mL) and acetic acid (2.0 mL) were stirred at 100° C. under N2 for 2 hr, then poured onto Na2CO3 (15 g), and extracted with 1:1 acetone:CH2Cl2 (3×30 mL). Combined extracts were filtered, and the solvent was evaporated. The residue was purified by flash chromatography using 10:1 CH2Cl2:MeOH as eluent to yield pale yellow solid (36 mg, 37%). LCMS: M2H+=398.


Examples 58-260

By essentially the same procedure set forth in Example 257 starting from the compounds shown in Column 1 of Table 23, the compounds shown in Column 2 of Table 23 were prepared.












TABLE 23





Ex.
Column 1
Column 2
Data







258


embedded image




embedded image


LCMS: M+ = 402; mp = 229-231° C.





259


embedded image




embedded image


LCMS: MH+ = 416; mp = 215-218° C.





260


embedded image




embedded image


LCMS: M2H+ = 398; mp > 230° C.









Example 261



embedded image


To a stirred solution of the compound prepared in Example 239 (41 mg, 0.10 mmol) in CH2Cl2 was added 1.0 M BBr3 (0.30 mL, 0.30 mmol) in CH2Cl2 at −78° C. The mixture was stirred at −78° C. for 5 min, then at 24° C. for 3 hr, then MeOH (2.0 mL) was added and the mixture was stirred for 10 min. The solvent was evaporated and the residue was purified by flash chromatography using 5:1:0.1 CH2Cl2:MeOH:conc. NH4OH as eluent to yield white solid (39 mg, 99%). LCMS: M+=397. Mp>230° C.


Example 262



embedded image


A mixture of the product prepared in Example 217 (40 mg, 0.077 mmol) and 5.0 M aqueous NaOH (0.8 mL) in MeOH (3.0 mL) was refluxed under N2 for 1 hr. NaHCO3 (700 mg) was added, the solvent evaporated, and the residue was purified by flash chromatography using 10:1:0.1 CH2Cl2:MeOH:conc. NH4OH as eluent to yield white solid (10 mg, 35%). LCMS: M2H+=371. Mp=237-239° C.


Examples 263-264

By essentially the same procedure set forth in Example 262 starting from the compounds shown in Column 1 of Table 24, the compounds shown in Column 2 of Table 24 were prepared.












TABLE 24





Ex.
Column 1
Column 2
Data







263


embedded image




embedded image


LCMS: M2H+ = 370; mp = 166-168° C.





264


embedded image




embedded image


LCMS: M2H+ = 371; mp = 180-182° C.









Example 265



embedded image


TFA (0.5 mL) was added to a solution of the compound prepared in Preparative Example 197 (0.08 g, 0.16 mmol) in CH2Cl2 (2.0 mL) at 0° C. and the resulting solution stirred 2.5 hours and stored at 4° C. overnight at which time additional TFA (0.5 mL) was added. The resulting solution was stirred 4 hours and concentrated in vacuo. The residue was neutralized with 1N NaOH and extracted with CH2Cl2. The combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography using a 2.5% (10% NH4OH in MeOH) in CH2Cl2 solution as eluent (0.009 g, 15% yield). LCMS: MH+=396; mp=53-54° C.


Example 266



embedded image


A solution of the compound prepared in Preparative Example 182 (26 mg, 0.070 mmol) and potassium thiocyanate (13 mg, 0.14 mmol) in MeOH (1 mL) was cooled in a cold water bath. To it was added a solution of bromine (22 mg, 0.14 mmol) in MeOH (0.7 mL) dropwise. The resulting reaction mixture was stirred for 4 h at room temperature and the volatiles were removed under reduced pressure. The residue obtained was suspended in a small amount of CH2Cl2. The potassium bromide was filtered off and pH of the filtrate was adjusted to about 7 by the addition of aqueous ammonia. It was concentrated under reduced pressure and the residual oil was purified by preparative thin-layer chromatography using 15% MeOH in CH2Cl2 as eluent (26 mg, 87% yield). 1H NMR (CDCl3) δ 8.75 (d, J=4.2 Hz, 2H), 8.38 (s, 1H), 7.68-7.64 (m, 2H), 7.46-7.39 (m, 3H), 7.22 (t, J=6.3 Hz, 1H), 6.43 (s, 1H), 4.84 (d, J=6.3 Hz, 2H); LCMS: MH+=427.


Example 267



embedded image


Boron tribromide (1 M in CH2Cl2, 0.60 mL, 0.60 mmol) was added dropwise to an ice-cold stirred solution of the compound prepared in Example 24 (50 mg, 0.12 mmol) in CH2Cl2 (1.5 mL) under an argon atmosphere. The resulting reaction mixture was stirred at 0° C. for 30 minutes, allowed to warm up to room temperature, and stirred overnight. The mixture was quenched by the addition of a small amount of water and extracted with CH2Cl2. The organic layer was dried over magnesium sulfate and concentrated in vacuo (45 mg, 94% yield). 1H NMR (CD3OD) δ 9.16 (s, 1H), 8.95 (s, 1H), 8.88 (d, J=8.1 Hz, 1H), 8.24 (t, J=6.9 Hz, 1H), 8.18 (s, 1H), 7.95 (d, J=7.8 Hz, 1H), 7.40 (t, J=7.8 Hz, 1H), 7.00-6.96 (m, 2H), 6.86 (s, 1H), 5.28 (s, 2H); LCMS: MH+=396.


Example 268



embedded image


A solution of the compound from Preparative Example 184 (0.05 g, 0.15 mmol), N-methylpiperazine (20 μL, 1.2 eq.) and iPr2Et (52 μL, 2.0 eq.) in dioxane (1 mL) was heated to 70° C. overnight. The reaction mixture was cooled to room temperature and diluted with H2O and saturated NaHCO3. The resulting mixture was extracted with CH2Cl2, the combined organics dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by Preparative TLC using a 5% (10% NH4OH in MeOH) in CH2Cl2 solution as eluent (0.028 g, 47% yield). MS: MH+=402. mp=210° C. (dec.)


Examples 269-275

By essentially the same procedure set forth in Example 268 only substituting the amine in Column 2 of Table 25 and the chlorides in Column 3 of Table 25, the compounds shown in Column 4 of Table 25 are prepared:













TABLE 25





Ex.
Column 2
Column 3
Column 4
CMPD







269


embedded image




embedded image




embedded image


MS: MH+ = 387 m.p. 182-183° C.





270


embedded image




embedded image




embedded image


MS: MH+ = 373 m.p. 190-191° C.





271


embedded image




embedded image




embedded image


MS: MH+ = 403 m.p. 227-230° C.





272


embedded image




embedded image




embedded image


MS: MH+ = 388 m.p. 198-201° C.





273


embedded image




embedded image




embedded image


MS: MH+ = 430 m.p. 100-103° C.





274


embedded image




embedded image




embedded image


MS: MH+ = 456 m.p. 175-178° C.





275


embedded image




embedded image




embedded image


MS: MH+ = 403 m.p. 218° C.









Example 276

Step A:




embedded image


4-Fluorophenyl magnesium bromide (0.68 mL, 1.2 eq.) was added to the compound prepared in Preparative Example 193 (0.20 g, 0.55 mmol) and PdCl2(dppf)2 (0.037 g, 10 mol %) in THF and the resulting solution was stirred at room temperature 72 hours. The reaction mixture was dilute with saturated NH4Cl and extracted with EtOAc. The combined organics were washed with saturated NaCl, dried over Na2SO4, filtered and concentrated. The crude product was purified by flash chromatography using neat EtOAc as eluent (0.15 g, 65% yield). MS: MH+=420.


Step B:




embedded image


By essentially the same procedure set forth in Preparative Example 127 only substituting the compound prepared in Example 276, Step A, the above compound was prepared (0.17 g, 94% yield).


Step C:




embedded image


By essentially the same procedure set forth in Preparative Example 200 only substituting the compound prepared in Example 276, Step B, the above compound was prepared (0.1 g, 100% yield).


Step D:




embedded image


By essentially the same procedure set forth in Example 265 only substituting the compound prepared in Example 276, Step C, the above compound was prepared (0.049 g, 62% yield). MS: MH+=414; mp=110-115° C.


Example 277

Step A:




embedded image


Pd(PPh3)4 (0.065 g, 10 mol %) was added to 3-cyanophenyl zinc iodide (2.2 mL, 0.5 M solution in THF, 2 eq.) and the compound prepared in Preparative Example 193 (0.2 g, 0.56 mmol) in DMF (2.0 mL) and the resulting solution heated to 80° C. g for 144 hours. The reaction mixture was cooled to room temperature, diluted with saturated NH4Cl and extracted with EtOAc. The combined organics were washed with H2O and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography using a neat EtOAC solution as eluent (0.07 g, 29% yield). MS: MH+=427.


Step B Through Step D:




embedded image


By essentially the same procedures set forth in Example 276, Step B through Step D, the above compound was prepared (0.023 g, 53% yield). MS: MH+=421; mp=230° C. (dec.)


Example 278



embedded image


By essentially the same procedure set forth in Example 276 only substituting the appropriate cyclopropylmagnesium bromide in Step A, the compound was prepared. MS: MH+=372; m.p.=96-98° C.


Example 279



embedded image


The palladium-catalyzed zinc cross-coupling reaction was carried out in a manner similar to the procedure described in J. Org. Chem. (1999), 453. A solution of the chloropyrazolopyrimidine (200 mg, 0.458 mmol), Pd(PPh3)4 (53 mg, 0.046 mmol), and exo-2-norbonylzinc bromide (0.5 M in THF, 0.95 mL, 0.47 mmol) in DMF (2 mL) was refluxed at 100° C. (oil bath temp.) overnight. The reaction mixture was quenched with half-saturated NH4Cl and extracted with CH2Cl2. The organic phase was dried over MgSO4 and concentrated under reduced pressure. The residue was purified by flash chromatography using a 50% EtOAc in hexanes solution as eluent. A solution of the obtained N-Boc-protected product (121 mg, 53% yield, LCMS: MH+=498) and TFA (1 mL) in CH2Cl2 (2 mL) was stirred at room temperature for 2 hr. The volatiles were removed under reduced pressure. The residue was dissolved in CH2Cl2, neutralized with saturated NaHCO3, and extracted with CH2Cl2. The organic phase was dried over MgSO4 and concentrated in vacuo (96 mg, 99% yield). LCMS: MH+=398; 1H NMR (CDCl3) δ 8.78 (s, 1H), 8.71 (d, J=4.2 Hz, 1H), 8.04 (d, J=3.9 Hz, 1H), 7.80 (d, J=7.8 Hz, 1H), 7.44 (m, 1H), 6.73 (m, 1H), 5.98 (d, J=7.5 Hz, 1H), 4.74 (d, J=5.4 Hz, 2H), 3.40-1.00 (m, 11H).


Examples 280-294

By following essentially the same procedure set forth in Example 279 only substituting the chlorides shown in Column 2 of Table 26 and the organozinc reagents shown in Column 3 of Table 26, the compounds in Column 4 of Table 26 were prepared:













TABLE 26





Ex.
Column 2
Column 3
Column 4
Data







280


embedded image




embedded image




embedded image


LCMS: MH+ = 395





281


embedded image




embedded image




embedded image


LCMS: MH+ = 400





282


embedded image




embedded image




embedded image


LCMS: MH+ = 412





283


embedded image




embedded image




embedded image


LCMS: MH+ = 452





284


embedded image




embedded image




embedded image


LCMS: MH+ = 422





285


embedded image




embedded image




embedded image


LCMS: MH+ = 408





286


embedded image




embedded image




embedded image


LCMS: MH+ = 404





287


embedded image




embedded image




embedded image


LCMS: MH+ = 404





288


embedded image




embedded image




embedded image


LCMS: MH+ = 408





289


embedded image




embedded image




embedded image


LCMS: MH+ = 386





290


embedded image




embedded image




embedded image


LCMS: MH+ = 464





291


embedded image




embedded image




embedded image


LCMS: MH+ = 480





292


embedded image




embedded image




embedded image


LCMS: MH+ = 424





293


embedded image




embedded image




embedded image


LCMS: MH+ = 424





294


embedded image




embedded image




embedded image


LCMS: MH+ = 426










Additional data for select compounds is shown below.


Example 280


1H NMR (CDCl3) δ 8.65 (s, 1H), 8.57 (d, J=4.2 Hz, 1H), 8.50 (d, J=4.5 Hz, 1H), 8.01 (s, 1H), 7.69 (d, J=7.5 Hz, 1H), 7.61 (d, J=7.8 Hz, 1H), 7.31-7.22 (m, 2H), 6.77 (m, 2H), 4.71 (d, J=5.4 Hz, 2H), 2.68 (s, 3H).


Example 281


1H NMR (CDCl3) δ 8.80 (s, 1H), 8.72 (d, J=4.8 Hz, 1H), 8.08 (s, 1H), 7.85-7.40 (m, 3H), 7.02 (d, J=5.1 Hz, 1H), 6.90 (t, J=6.0 Hz, 1H), 6.29 (s, 1H), 4.79 (d, J=6.0 Hz, 2H), 2.61 (s, 3H).


Example 282


1H NMR (CDCl3) δ 8.67 (s, 1H), 8.61 (d, J=3.9 Hz, 1H), 8.03 (s, 1H), 7.72-7.31 (m, 3H), 7.22-7.00 (m, 2H), 6.81 (t, J=6.0 Hz, 1H), 6.03 (s, 1H), 4.68 (d, J=6.0 Hz, 2H), 2.28 (s, 3H).


Example 283


1H NMR (CDCl3) δ 8.68 (s, 1H), 8.63 (d, J=4.0 Hz, 1H), 8.00 (s, 1H), 7.80-7.72 (m, 2H), 7.54-7.47 (m, 3H), 7.35 (m, 1H), 6.74 (t, J=6.0 Hz, 1H), 6.19 (s, 1H), 4.67 (d, J=6.0 Hz, 2H), 4.21 (q, J=7.2 Hz, 2H), 1.13 (t, J=7.2 Hz, 3H).


Example 284


1H NMR (CDCl3) δ 7.97 (s, 1H), 7.65 (d, J=7.2 Hz, 1H), 7.33-7.15 (m, 5H), 6.73 (t, J=5.4 Hz, 1H), 5.99 (s, 1H), 4.61 (d, J=5.4 Hz, 2H), 3.09 (sept, J=6.9 Hz, 1H), 1.11 (d, J=6.9 Hz, 6H).


Example 285


1H NMR (CDCl3) δ 8.56-8.55 (m, 2H), 7.94 (s, 1H), 7.54 (m, 1H), 7.30-7.22 (m, 6H), 6.59 (t, J=5.7 Hz, 1H), 5.66 (s, 1H), 4.47 (d, J=5.7 Hz, 2H), 4.26 (q, J=7.2 Hz, 1H), 1.68 (d, J=7.2 Hz, 3H).


Example 286


1H NMR (CDCl3) δ 8.67 (m, 2H), 7.94 (s, 1H), 7.69 (d, J=7.8 Hz, 1H), 7.34 (m, 1H), 6.63 (t, J=5.7 Hz, 1H), 5.87 (s, 1H), 4.62 (d, J=5.7 Hz, 2H), 3.64 (s, 3H), 3.13 (m, 2H), 2.82 (m, 1H), 1.22 (m, 3H).


Example 287


1H NMR (CDCl3) δ 8.66 (m, 2H), 7.94 (s, 1H), 7.68 (d, J=7.8 Hz, 1H), 7.34 (m, 1H), 6.62 (t, J=6.0 Hz, 1H), 5.87 (s, 1H), 4.62 (d, J=6.0 Hz, 2H), 3.64 (s, 3H), 3.13 (m, 2H), 2.81 (m, 1H), 1.22 (m, 3H).


Example 288


1H NMR (CDCl3) δ 8.64 (s, 1H), 8.60 (d, J=3.6 Hz, 1H), 8.04 (s, 1H), 7.68 (m, 1H), 7.31 (m, 1H), 7.16 (m, 1H), 7.07-7.05 (m, 2H), 6.80 (t, J=6.3 Hz, 1H), 5.93 (s, 1H), 4.64 (d, J=6.3 Hz, 2H), 2.08 (s, 6H).


Example 289


1H NMR (CDCl3) δ 8.72 (s, 1H), 8.62 (d, J=4.8 Hz, 1H), 7.99-7.97 (m, 2H), 7.73-7.69 (m, 2H), 7.40-7.33 (m, 2H), 6.67 (t, J=6.0 Hz, 1H), 6.29 (s, 1H), 4.71 (d, J=6.0 Hz, 2H).


Example 290


1H NMR (CDCl3) δ 8.73 (s, 1H), 8.62 (d, J=4.5 Hz, 1H), 8.01 (s, 1H), 7.76 (m, 1H), 7.41 (d, J=5.1 Hz, 1H), 7.34 (dd, J=8.1, 5.1 Hz, 1H), 7.05 (d, J=5.1 Hz, 1H), 7.01 (s, 1H), 6.79 (t, J=6.0 Hz, 1H), 4.74 (d, J=6.0 Hz, 2H).


Example 291


1H NMR (DMSO-d6) δ 9.12 (s, 1H), 8.40 (s, 1H), 8.33 (s, 1H), 8.13 (m, 1H), 7.82 (d, J=5.1 Hz, 1H), 7.40-7.39 (m, 2H), 7.22 (d, J=5.1 Hz, 1H), 6.86 (s, 1H), 4.86 (s, 2H).


Example 292


1H NMR (CDCl3) δ 8.23 (s, 1H), 8.16 (d, J=6.0 Hz, 1H), 8.06 (s, 1H), 7.31-7.05 (m, 5H), 6.86 (m, 1H), 5.87 (s, 1H), 4.62 (d, J=6.3 Hz, 2H), 2.09 (s, 6H).


Example 293


1H NMR (CDCl3) δ 8.14 (s, 1H), 8.12 (d, J=6.3 Hz, 1H), 7.94 (s, 1H), 7.29-7.16 (m, 6H), 7.07 (m, 1H), 6.78 (t, J=6.0 Hz, 1H), 5.54 (s, 1H), 4.44 (d, J=6.0 Hz, 2H), 4.24 (t, J=7.2 Hz, 1H), 1.68 (d, J=7.2 Hz, 3H).


Example 294


1H NMR (CDCl3) δ 8.67 (s, 1H), 8.59 (d, J=4.8 Hz, 1H), 8.01 (s, 1H), 7.71 (m, 1H), 7.52 (dd, J=7.8, 1.8 Hz, 1H), 7.40-7.19 (m, 4H), 6.78 (t, J=6.0 Hz, 1H), 6.32 (s, 1H), 4.67 (d, J=6.0 Hz, 2H), 2.38 (s, 3H).


Example 295



embedded image


To a suspension of lithium aluminum hydride (10 mg, 0.26 mmol) in anhydrous THF (2 mL) at 0° C. was added dropwise a solution of the compound prepared in Example 283 (20 mg, 0.044 mmol) in anhydrous THF (2 mL). The resulting mixture was refluxed for 1 hr and stirred at room temperature overnight, neutralized with dilute sulfuric acid, and extracted with EtOAc. The organic phase was dried over MgSO4 and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography using a 5% MeOH in EtOAc solution as eluent (15 mg, 83% yield). LCMS: MH+=410; 1H NMR (CDCl3) δ 8.69 (s, 1H), 8.61 (d, J=3.9 Hz, 1H), 8.05 (d, J=2.1 Hz, 1H), 7.74 (d, J=7.8 Hz, 1H), 7.52-7.31 (m, 5H), 6.97 (t, J=6.3 Hz, 1H), 6.55 (d, J=2.7 Hz, 1H), 6.20 (s, 1H), 4.71 (d, J=6.3 Hz, 2H), 4.52 (s, 2H).


Example 296



embedded image


To a solution of the N-Boc-protected compound prepared in Example 294 (45 mg, 0.085 mmol) in CH2Cl2 (4 mL) at −50° C. was added m-CPBA (18 mg, 0.10 mmol). After stirring for 1 hr at −50° C. more MCPBA (4 mg, 0.02 mmol) was added. The mixture was stirred for a further 2 hr, diluted with CH2Cl2 (20 mL), and washed with saturated NaHCO3 (20 mL). The organic phase was dried over MgSO4 and concentrated under reduced pressure. The residue was purified by preparative thin-layer chromatography using a 2.5% MeOH in CH2Cl2 solution as eluent. A solution of the obtained N-Boc-protected product (37 mg, 80% yield, LCMS: MH+=542) and TFA (1 mL) in CH2Cl2 (2 mL) was stirred at room temperature for 2 hr. The volatiles were removed under reduced pressure. The residue was dissolved in CH2Cl2, neutralized with saturated NaHCO3, and extracted with CH2Cl2. The organic phase was dried over MgSO4 and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography using a 5% MeOH in EtOAc solution as eluent (26 mg, 89% yield). LCMS: MH+=442; 1H NMR (CDCl3) δ 8.71 (s, 1H), 8.64 (d, J=3.9 Hz, 1H), 8.41 (m, 1H), 8.03 (s, 1H), 7.75-7.54 (m, 4H), 7.36 (dd, J=8.1, 5.1 Hz, 1H), 6.81 (t, J=6.0 Hz, 1H), 6.34 (s, 1H), 4.74 (d, J=6.0 Hz, 2H), 3.25 (s, 3H).


Example 297



embedded image


To a solution of the N-Boc-protected compound prepared in Example 294 (56 mg, 0.11 mmol) in CH2Cl2 (4 mL) at 0° C. was added m-CPBA (42 mg, 0.24 mmol). After stirring for 2 hr at room temperature more m-CPBA (13 mg, 0.075 mmol) was added. The mixture was stirred at room temperature overnight, diluted with CH2Cl2 (20 mL), and washed with saturated NaHCO3 (20 mL). The organic phase was dried over MgSO4 and concentrated under reduced pressure. The residue was purified by preparative thin-layer chromatography using a 2.5% MeOH in EtOAc solution as eluent. A solution of the obtained N-Boc-protected product (29 mg, 49% yield, LCMS: MH+=558) and TFA (1 mL) in CH2Cl2 (2 mL) was stirred at room temperature for 2 hr. The volatiles were removed under reduced pressure. The residue was dissolved in CH2Cl2, neutralized with saturated NaHCO3, and extracted with CH2Cl2. The organic phase was dried over MgSO4 and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography using a 2.5% MeOH in EtOAc solution as eluent (21 mg, 90% yield). LCMS: MH+=458; 1H NMR (CDCl3) δ 8.64 (s, 2H), 8.20 (m, 1H), 8.01 (s, 1H), 7.73-7.60 (m, 3H), 7.46 (m, 1H), 7.35 (s, 1H), 6.82 (t, J=5.9 Hz, 1H), 6.17 (s, 1H), 4.65 (d, J=5.7 Hz, 2H), 3.60 (s, 3H).


Example 298



embedded image


By essentially the same procedure set forth in Preparative Example 127 only substituting the compound prepared in Preparative Example 189, the above compound was prepared. MS: MH+=334; mp=170-173° C.


Examples 299-300

By essentially the same procedure set forth in Example 298 only substituting the compound shown in Table 27, Column 2, the compounds shown in Table 27, Column 3 were prepared:












TABLE 27





Ex.
Column 2
Column 3
CMPD







299


embedded image




embedded image


MS: MH+ = 348 m.p. = 73-83° C.





300


embedded image




embedded image


MS: MH+ = 362 m.p. = 165-175° C.









Example 301



embedded image


To a solution of the compound prepared in Preparative Example 186 (0.1 g, 0.21 mmol) in THF (4.0 mL) at −78° C. was added nBuLi (0.57 mL, 2.16M in hexanes, 5.0 eq.) at −78° C. The reaction mixture was stirred 2 hours at −78° C., quenched with H2O, warmed to room temperature, and extracted with EtOAc. The combined organics were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by Preparative TLC using a 2.5% (10% NH4OH in CH3OH) solution in CH2Cl2 as eluent (0.013 g, 20% yield). MS: MH+=326; mp=71-72° C.


Example 302



embedded image


By essentially the same procedure set forth in Example 301 only substituting the compound from Preparative Example 187, the above compound was prepared (0.049 g, 68% yield). MS: MH+=344; mp=69-71° C.


Example 303



embedded image


To a solution of 3-H adduct from Preparative Example 187.1 (0.70 g, 2.32 mmol) in DMF (4.2 mL) at 0° C. was added POCl3 (0.67 mL, 7.2 mmol) dropwise. The mixture was stirred for 14 h at rt, cooled to 0° C., and was quenched by addition of ice. 1N NaOH was carefully added to adjust pH to 8 and the mixture was extracted with CH2Cl2 (3×25 mL). The organic layers were combined, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was recrystallized from EtOAc to afford 0.43 g (56%) of a yellow solid. mp 181-183° C.; M+H=330.


Example 304



embedded image



Step A:


To a solution of aldehyde (100 mg, 0.30 mmol) from Example 303 in THF (1 mL) at 0° C. was added cyclohexyl magnesium bromide (0.46 mL, 2.0M in Et2O) dropwise over 5 min. The resulting mixture was stirred at 0° C. for 2 h and at rt for 12 h. The mixture was cooled to 0° C. and was treated with sat. aq. NH4Cl (3 mL) and CH2Cl2 (5 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×5 mL). The organic layers were combined, washed with brine (1×5 mL), dried (Na2SO4), filtered and concentrated under reduced pressure to afford 110 mg (89%) of a light yellow semisolid. M+H=414. This material was carried on crude to Step B without further purification.


Step B:


To a solution of alcohol (53 mg, 0.13 mmol) in CH2Cl2 (0.5 mL) at 0° C. was added Et3SiH (24 μL, 0.15 mmol) followed by TFA (24 μL, 0.30 mmol). The mixture was stirred for 2 h at 0° C. and rt for 2 h whereupon additional portions of Et3SiH (24 μL, 0.15 mmol) and TFA (24 μL, 0.30 mmol) were added and the mixture was stirred for 3 h at rt (until complete by TLC). The mixture was concentrated under reduced pressure and the crude residue was partitioned between CH2Cl2 (5 mL) and sat. aq. NaHCO3 (2.5 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×5 mL). The organic layers were combined, washed with brine (1×5 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by prep TLC (8×1000 mM) eluting with CH2Cl2/MeOH (22:1) to afford 29 mg (56%) of a yellow semisolid. M+H=398.


Examples 305-312

By essentially the same procedure set forth in Example 304, utilizing the aldehyde from Example 303 and substituting the Grignard or organolithium reagents shown in Column 2 of Table 28, the compounds in Column 3 of Table 28 were prepared:












TABLE 28








CMPD





1. mp (° C.)


Ex.
Column 2 (Organometallic)
Column 3 (Final Structure)
2. M + H







305


embedded image




embedded image


1. yellow oil 2. M + H = 392





306


embedded image




embedded image


1. red oil 2. M + H = 353





307


embedded image




embedded image


1. red oil 2. M + H = 398





308


embedded image




embedded image


1. yellow oil 2. M + H = 406





309


embedded image




embedded image


1. yellow semisolid 2. M + H = 384





310


embedded image




embedded image


1. semisolid 2. M + H = 340





311


embedded image




embedded image


1. mp = 141-143 2. M + H = 358





312


embedded image




embedded image


1. mp = 148-150 2. M + H = 372









Example 313



embedded image


To solution of aldehyde (81 mg, 0.25 mmol) from Example 303 in benzene (2.5 mL) was added carboethoxymethylene triphenyl phosphorane (0.12 g, 0.33 mmol) in one portion. The mixture was heated at reflux for 24 h, cooled to rt, and concentrated under reduced pressure. The mixture was diluted CH2Cl2 (5 mL), brine (2 mL) was added, and the layers were separated. The aqueous layer was extracted with CH2Cl2 (2×4 mL). The organic layers were combined, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative TLC (8×1000 μM) eluting with CH2Cl2/MeOH (20:1) to afford 98 mg (100%) of white solid. mp 151-153° C.; M+H=400.


Example 314



embedded image


To a mixture of benzyltriphenylphosphonium bromide (0.59 g, 1.37 mmol) in THF (3 mL) was added NaH (55 mg, 1.37 mmol) and the mixture was stirred for 30 min. The aldehyde (0.15 g, 0.46 mmol) from Example 303 was added in a single portion and the mixture was heated at reflux for 36 h. The mixture was cooled to rt and was concentrated under reduced pressure. The mixture was diluted CH2Cl2 (5 mL), brine (2 mL) was added, and the layers were separated. The aqueous layer was extracted with CH2Cl2 (2×4 mL). The organic layers were combined, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative TLC (8×1000 μM) eluting with CH2Cl2/MeOH (20:1) to afford 58 mg (32%) of yellow solid. mp 138-141° C.; M+H=404.


Example 315



embedded image


To a solution of aldehyde (0.20 g, 0.60 mmol) from Example 303 in THF (3 mL) was added Ti (i-OPr)4 (0.36 mL, 1.21 mmol) dropwise followed by addition of (S)-(−)-2-methyl-2-propanesulfinamide (74 mg, 0.61 mmol). The resulting mixture was stirred for 18 h at reflux, cooled to rt, and quenched with brine (2 mL). The mixture was filtered thru a pad of Celite which washed with EtOAc (2×2 mL). The layers were separated and the aqueous layer was extracted with EtOAc (2×4 mL). The organic layers were combined, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative TLC (8×1000 μM) eluting with CH2Cl2/MeOH (20:1) to afford 0.21 g (80%) of yellow solid. mp 108-110° C.; M+H=433.


Example 316



embedded image


Prepared in the same fashion as Example 315 except substituting (R)-(−)-2-methyl-2-propanesulfinamide to afford 0.25 g (94%) as a yellow solid. mp 107-109° C.; M+H=433.


Example 317



embedded image



Step A:


To a solution of sulfinimine (50 mg, 0.12 mmol) from Example 316 in CH2Cl2 (2.5 mL) at −40° C. was added MeMgBr (96 mL, 0.29 mmol) dropwise. The mixture was stirred for 5 h at −40° C. and was stirred at rt for 12 h. An additional portion of MeMgBr (96 mL, 0.29 mmol) and the mixture was stirred for 12 h. Sat. aq. NH4Cl (2 mL) was added and the mixture was extracted with EtOAc (3×4 mL). The organic layers were combined, dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 30 mg (58%) of crude residue. This material was taken onto the next step without purification.


Step B:


The crude material from Step A (30 mg, 0.067 mmol) in MeOH (2 mL) was added conc. HCl (2 mL). The mixture was stirred at rt for 12 h and the mixture was concentrated to dryness. The crude material was partitioned between CH2Cl2 (3 mL) and sat. aq. NaHCO3 (2 mL) and the layers were separated. The aqueous layer was extracted with CH2Cl2 (2×3 mL) and the organic layers were combined. The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 6 mg (24%) of the title compound as a light yellow solid. mp 100-102° C.; M+H=345.


Example 318



embedded image


To a solution of aldehyde (75 mg, 0.23 mmol) from Example 300 in THF/CH2Cl2 (5 mL/1 mL) at rt was added MeONH2.HCl (38 mg, 0.46 mmol) followed by dropwise addition of pyridine (46 μL, 0.57 mmol). The mixture was stirred for 72 h at rt whereupon the mixture was concentrated to dryness. The crude material was partitioned between CH2Cl2 (3 mL) and sat. aq. NaHCO3 (2 mL) and the layers were separated. The aqueous layer was extracted with CH2Cl2 (2×3 mL) and the organic layers were combined. The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative TLC (3×1000 μM) eluting with CH2Cl2/MeOH (22:1) to afford 90 mg (100%) of light yellow solid. mp 173-175° C.; M+H=359.


Example 319



embedded image


To solution of aldehyde (60 mg, 0.18 mmol) from Example 303 at EtOH (2.5 mL) was added oxindole (48 mg, 0.37 mmol) followed by piperidine (3 drops). The mixture was heated at reflux for 14 h and the mixture was cooled to rt. The resultant precipitate was filtered and washed with cold EtOH (2×2 mL). The product was dried under high vacuum to afford 81 mg (100%) of the title compound as an orange/brown solid. mp 182-185° C.; M+H=445.


Example 320



embedded image


To a solution of 3-H analog (106 mg, 0.35 mmol) from Preparative Example 187.10 in AcOH (2 mL) was added 37% aqueous formaldehyde (1.5 ml; 1.40 mmol) followed by piperidine (100 μL; 0.37 mmol). The resulting mixture was stirred at rt for 24 h and the AcOH was removed under reduced pressure. The mixture was diluted with water (2 mL) and neutralized with 2M NaOH until pH=8. The aqueous layer was extracted with CH2Cl2 (3×7 mL) and the organic layers were combined. The organic layer washed with brine (1×4 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 96 mg (69%) of an off-white solid. mp 88-90° C.; M+H 399.


Examples 321-322

By essentially the same procedure set forth in Example 320 only substituting the amines in Column 2 of Table 29 and employing the 3-H adduct from Preparative Example 187.10, the compounds in Column 3 of Table 29 were prepared:












TABLE 29








CMPD





1. mp (° C.)


Ex.
Column 2 (Amine)
Column 3 (Final Structure)
2. M + H







321


embedded image




embedded image


1. mp = 178-180 2. M + H = 401





322


embedded image




embedded image


1. mp = 102-104 2. M + H = 414









Example 323



embedded image


To a solution of 3-H analog (113 mg, 0.38 mmol) from Preparative Example 187.10 in CH2Cl2 (5 mL) at rt was added AlCl3 (215 mg, 1.61 mmol) followed by AcCl (100 mL, 1.40 mmol). The mixture was heated at reflux for 12 h and was cooled to rt. The mixture was treated sequentially with 3M HCl (3 mL) followed by sat. aq. NaHCO3 (until pH=8). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×5 mL). The organic layers were combined, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative TLC (8×1000 mM) eluting with CH2Cl2/MeOH (20:1) to afford 68 mg (52%) of white solid. mp 220-221° C.; M+H=344.


Example 324



embedded image


Utilizing the method described in Example 323, except employing benzoyl chloride, the title compound was prepared in 61% yield as a white solid. mp 172-175° C.; M+H=406.


Example 325



embedded image


To a solution of ketone (100 mg, 0.29 mmol) from Example 323 in CH2Cl2 (2.5 mL) at 0° C. was added MeMgBr (0.35 mL, 3.0M in Et2O) dropwise. The resulting mixture was stirred for 18 h at rt and was carefully quenched by addition of sat. aq. NH4Cl (2 mL) and CH2Cl2 (2 mL) were added. The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×4 mL). The organic layers were combined, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative TLC (8×1000 μM) eluting with CH2Cl2/MeOH (10:1) to afford 68 mg (52%) of a yellow solid. mp 160-162° C.; M+H=360.


Example 326



embedded image


To a solution of ketone (84 mg, 0.24 mmol) from Example 323 in MeOH/THF (1:1; 2 mL total) at 0° C. was added NaBH4 (12 mg, 0.30 mmol) in one portion. The resulting mixture was stirred for 18 h at rt whereupon and additional portion of NaBH4 (12 mg, 0.30 mmol) was added. The mixture was stirred for 12 h whereupon the mixture was quenched with ice followed by addition of 1M NaOH to adjust the pH=9. The mixture was diluted with CH2Cl2 (5 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×4 mL). The organic layers were combined, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative TLC (8×1000 μM) eluting with CH2Cl2/MeOH (10:1) to afford 25 mg (30%) of a yellow solid. mp 148-150° C.; M+H=346.


Example 327



embedded image


Using the same procedure as outlined in Example 326, the ketone (84 mg, 0.21 mmol) was converted to 53 mg (62%) as a light yellow solid. mp 78-80° C.; M+H=408.


Example 328



embedded image


To a solution of 3-H adduct (1.3 g, 4.31 mmol) from Preparative Example 187.10 in CH2Cl2 (50 mL) was added Eschenmoser's salt (0.79 g, 4.31 mmol) followed by dropwise addition of TFA (0.56 mL, 7.33 mmol). The mixture was stirred at rt for 48 h and was diluted with CH2Cl2 (250 mL). The organic layer washed with sat. aq. NaHCO3 (2×125 mL) to afford 1.41 h (92%) of a yellow solid. mp 231-233° C.; M+H=359.


Example 329



embedded image


To a solution of tertiary amine adduct (100 mg, 0.28 mmol) from Example 328 in 50% aq. DMF (5 mL) in a pressure tube was added KCN (0.15 g, 2.32 mmol). The tube was capped and heated at 100° C. for 96 h. The mixture was cooled to rt and was diluted with EtOAc (25 mL). The organic layer washed with brine (1×5 mL) and water (1×5 mL). The organic layers was dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative TLC (4×1000 μM) eluting with EtOAc to afford 21 mg (30%) of brown solid. mp 152-155° C.; M+H=341.


Example 330



embedded image


To a solution of alcohol (45 mg, 0.14 mmol) from Example 17.10 in CH2Cl2 (0.7 mL) at 0° C. was added Et3SiH (26 μL, 0.16 mmol) followed by TFA (25 μL, 0.33 mmol). The mixture was stirred for 2 h at 0° C. and rt for 2 h whereupon additional portions of Et3SiH (26 μL, 0.16 mmol) and TFA (25 μL, 0.33 mmol) were added and the mixture was stirred for 4 h at rt (until complete by TLC). The mixture was concentrated under reduced pressure and the crude residue was partitioned between CH2Cl2 (3 mL) and sat. aq. NaHCO3 (1.5 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×4 mL). The organic layers were combined, washed with brine (1×5 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by prep TLC (4×1000 mM) eluting with CH2Cl2/MeOH (20:1) to afford 21 mg (48%) of a yellow solid. mp 146-148° C.; M+H=316.


Example 331



embedded image


To a solution of 3-H adduct (90 mg, 0.30 mmol) from Preparative Example 187.10 in conc. H2SO4 (2 mL) at 0° C. was added fuming HNO3 (30 μL, 0.72 mmol) dropwise. The resulting mixture was stirred for 1 h at 0° C. whereupon ice (˜1 g) was added to the mixture. The resulting precipitate was collected and was washed with water (2×2 mL) and CH2Cl2 (2×2 mL). The crude product was dried under high vacuum to afford 67 mg (60%) of the monosulfate salt as a yellow/orange solid. mp 250° C.; M+H (free base)=392.


Example 332

Step A:




embedded image


To a solution of aldehyde (0.10 g, 0.39 mmol) from Preparative Example 168 in THF (2.5 mL) at 0° C. was added CF3TMS (64 mL, 0.43 mmol) followed by CsF (10 mg). The resulting mixture was stirred for 2 h at 0° C. and 2 h at rt. 1M HCl (5 mL) was added and the mixture was diluted with CH2Cl2 (10 mL). The layers were separated, the aqueous layer was extracted with CH2Cl2 (2×10 mL), and the organic layers were combined. The organic layer washed with brine (1×10 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 127 mg (99%) of a yellow semisolid. M+H=328. The crude product was carried on without further purification.


Step B:




embedded image


By utilizing the general procedure set forth in Example 1, the 7-Cl adduct (127 mg, 0.39 mmol) from Example 332, Step A was reacted with 3-(aminomethyl)pyridine (73 μL, 0.43 mmol) to afford 80 mg (51%) of the title compound as a light yellow solid. mp 68-72° C.; M+H=400.


Example 333



embedded image


To a solution of aniline (200 mg, 0.69 mmol) from Preparative Example 174 in THF (6 mL) at rt was added aldehyde (114 mg, 0.83 mmol) from Preparative Example 256 followed by dropwise addition of Ti (i-OPr)4 (0.82 mL, 2.77 mmol). The mixture was stirred at reflux for 4 h and was cooled to rt. NaCNBH3 (347 mg, 5.53 mmol) was added and the mixture was stirred for 2 h at rt. The mixture was cooled to 0° C., treated with 1M NaOH (4 mL) and brine (1 mL) and stirred for 30 min. The mixture was extracted with CH2Cl2 (3×10 mL) and the organic layers were combined. The organic layer washed with brine (1×7 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (8×1000 υM plates) eluting with CH2Cl2/MeOH (25:1) to afford 89 mg (31%) of the title compound as a yellow solid. mp 210-213° C.; M+H=411.


Examples 334-337

By essentially the same procedure set forth in Example 333 only by utilizing the anilines shown in Column 2 of Table 30 and the aldehydes shown in Column 3 of Table 30, the compounds in Column 4 of Table 30 were prepared:













TABLE 30









CMPD






1. mp (° C.)


Ex.
Column 2 (Aniline)
Column 3 (Aldehyde)
Column 4 (Final Structure)
2. M + H







334


embedded image




embedded image




embedded image


1. mp = 85-87 2. M + H = 425





335


embedded image




embedded image




embedded image


1. mp = 160-162 2. M + H = 451





336


embedded image




embedded image




embedded image


1. mp = 117-119 2. M + H = 382





337


embedded image




embedded image




embedded image


1. mp = 171-175 2. M + H = 400









Example 338



embedded image



Step A:


Reaction of aniline (0.20 g, 0.69 mmol) with aldehyde (0.13 g, 0.83 mmol) under the reaction conditions described in Example 333 afforded 70 mg (23%) of thiomethyl derivative as a yellow solid. M+H=428.


Step B:


To a solution of thiomethyl derivative (60 mg, 0.14 mmol) from Example 338, Step A in dioxane (2 mL) was added Boc2O (61 mg, 0.28 mmol) followed by DMAP (21 mg, 0.17 mmol). The mixture was stirred for 14 h at rt and was concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (6×1000 μM plates) eluting with hexanes/EtOAc (4:1) to afford 61 mg (83%) of the title compound as a yellow solid. M+H=528.


Step C:


To a solution of thiomethyl derivative from Example 338, Step B (41 mg, 0.078 mmol) in CH2Cl2 (2 mL) was added MCPBA (33 mg, 0.19 mmol) in one portion. The resulting mixture was stirred for 3 h at rt and the mixture was diluted with CH2Cl2 (5 mL) and sat. aq. NaHCO3 (2.5 mL). The layers were separated, the aqueous layer was extracted with CH2Cl2 (2×5 mL), and the organic layers were combined. The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 40 mg (92%) of the sulfone adduct as a light yellow solid. M+H=560.


Step D:


To a flask charged with sulfone from Example 338, Step C (75 mg, 0.13 mmol) and a stir bar was added morpholine (2 ml; 22 mmol). The mixture was heated at reflux for 12 h, cooled to rt, and concentrated to dryness under high vacuum. The crude product was purified by preparative thin-layer chromatography (6×1000 μM plates) eluting with CH2Cl2/MeOH (40:1) to afford 41 mg (68%) of the title compound as a yellow solid. mp 209-210° C.; M+H=466.


Example 339



embedded image


The title compound was prepared according to the procedure outlined in Example 338 except using benzyl amine to afford 12 mg (70%) of a white solid. mp 194-196; M+H=487.


Example 340



embedded image



Step A:


To a solution of 5-chloro adduct (0.15 g, 0.34 mmol) in dioxane/DIPEA (2.5 mL/1.0 mL) at rt was added cyclopentylamine (0.041 μL, 0.41 mmol) dropwise. The resulting solution was stirred at reflux for 16 h, cooled to rt, and concentrated under reduced pressure. The crude material was purified by preparative thin-layer chromatography (8×1000 μM) eluting with CH2Cl2/MeOH (25:1) to afford 148 mg (89%) of a yellow oil. M+H=489.


Step B: Removal of the t-Butoxycarbonyl Protecting Group with TFA


To a solution of the compound prepared in Example 340, Step A (135 mg, 0.28 mmol) in CH2Cl2 (2 mL) at rt was added TFA (0.54 mL, 7.0 mmol) dropwise. The resulting solution was stirred for 18 h at rt and was concentrated under reduced pressure. The crude material was redissolved in CH2Cl2 (5 mL) and the organic layer was sequentially washed with sat. aq. NaHCO3 (2×2 mL) and brine (1×2 mL). The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude material was purified by preparative thin-layer chromatography (8×1000 μM) eluting with CH2Cl2/MeOH (20:1) to afford 105 mg (97%) of white solid. mp 120-122° C.; M+H=389.


Example 341



embedded image



Step A:


By essentially the same procedure set forth in Example 340 only substituting the appropriate amine, the above compound was prepared. MS: MH+=431.


Step B: Removal to t-Butoxycarbonyl Protecting Group with KOH.




embedded image


To a mixture of the compound prepared in Example 341, Step A (0.14 g, 0.26 mmol) in EtOH:H2O (3 mL, 2:1) was added KOH (0.29 g, 20 eq.) in one portion. The resulting solution was stirred at reflux 14 hours, cooled to room temperature, and concentrated under reduced pressure. The residue was taken up in CH2Cl2 (5 mL) and diluted with saturated NaHCO3 (2 mL). The layers were separated and the aqueous layer extracted with CH2Cl2 (2×4 mL). The combined organics were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by preparative TLC (8×1000 μM) eluting with 5% MeOH in CH2Cl2 solution (0.066 g, 59% yield). MS: MH+=432; mp=219-221° C.


Examples 342-397

By essentially the same procedure set forth in Example 340 only substituting the chlorides in Column 2 of Table 31 and removing the t-butoxycarbonyl protecting group by the method shown in Column 3 of Table 31, the compounds shown in Column 4 of Table 31 were prepared.













TABLE 31





Ex.
Column 2
Column 3
Column 4
CMPD



















342


embedded image


HCl


embedded image


MS: MH+ = 403 m.p. 151-157° C.





343


embedded image


HCl


embedded image


MS: MH+ = 466 m.p. 212-217° C.





344


embedded image


HCl


embedded image


MS: MH+ = 405 m.p. 53-58° C.





345


embedded image


HCl


embedded image


MS: MH+ = 405 m.p. 63-69° C.





346


embedded image


HCl


embedded image


MS: MH+ = 363 m.p. 170-171° C.





347


embedded image


HCl


embedded image


MS: MH+ = 407 m.p. 148-151° C.





348


embedded image


HCl


embedded image


MS: MH+ = 435 m.p. 56-59° C.





349


embedded image


HCl


embedded image


MS: MH+ = 445 m.p. 66-68° C.





350


embedded image


KOH


embedded image


MS: MH+ = 417 m.p. 149-151° C.





351


embedded image


KOH


embedded image


MS: MH+ = 431 m.p. 111-114° C.





352


embedded image


KOH


embedded image


MS: MH+ = 417 m.p. 53-58° C.





353


embedded image


KOH


embedded image


MS: MH+ = 456 m.p. 186-189° C.





354


embedded image


KOH


embedded image


MS: MH+ = 416 m.p. 210-213° C.





355


embedded image


TFA


embedded image


1. mp = 68-70 2. M + H = 494





356


embedded image


KOH


embedded image


1. mp = 181-183 2. M + H = 404





357


embedded image


TFA


embedded image


1. mp = 69-71 2. M + H = 494





358


embedded image


KOH


embedded image


1. mp = 182-184 2. M + H = 404





359


embedded image


KOH


embedded image


1. mp = 202-204 2. M + H = 418





360


embedded image


TFA


embedded image


1. mp = 160-162 2. M + H = 402





361


embedded image


TFA


embedded image


1. mp = 151-153 2. M + H = 416





362


embedded image


KOH


embedded image


1. mp = 140-143 2. M + H = 418





363


embedded image


KOH


embedded image


1. mp = 139-142 2. M + H = 418





364


embedded image


KOH


embedded image


1. mp = 115-117 2. M + H = 418





366


embedded image


TFA


embedded image


1. mp = 102-104 2. M + H = 445





367


embedded image


TFA


embedded image


1. mp = 118-120 2. M + H = 474





368


embedded image


TFA


embedded image


1. mp = 106-108 2. M + H = 474





369


embedded image


TFA


embedded image


1. mp = 160-161 2. M + H = 464





370


embedded image


TFA


embedded image


1. mp = 93-95 2. M + H = 432





371


embedded image


KOH


embedded image


1. mp = 108-110 2. M + H = 432





372


embedded image


KOH


embedded image


1. mp = 180-182 2. M + H = 418





373


embedded image


TFA


embedded image


1. mp = 169-170 2. M + H = 417





374


embedded image


TFA


embedded image


1. mp = 77-79 2. M + H = 479





375


embedded image


TFA


embedded image


1. mp = 76-79 2. M + H = 479





376


embedded image


TFA


embedded image


1. mp = 105-107 2. M + H = 389





377


embedded image


TFA


embedded image


1. mp = 105-107 2. M + H = 389





378


embedded image


TFA


embedded image


1. mp = 130-133 2. M + H = 389





379


embedded image


TFA


embedded image


1. mp = 132-135 2. M + H = 431





380


embedded image


TFA


embedded image


1. mp = 135-137 2. M + H = 372





381


embedded image


KOH


embedded image


1. mp = 78-82 2. M + H = 432





382


embedded image


TFA


embedded image


1. mp = 101-103 2. M + H = 432





383


embedded image


TFA


embedded image


1. mp = 92-95 2. M + H = 472





384


embedded image


TFA


embedded image


1. mp = 107-111 2. M + H = 444





384.10


embedded image


TFA


embedded image


1. mp = 2. M + H = 417





384.11


embedded image


TFA


embedded image


1. mp = 210-212 2. M + H = 391





385


embedded image


TFA


embedded image


1. mp = 122-124 2. M + H = 403





386


embedded image


TFA


embedded image


1. mp = 186-188 2. M + H = 491





387


embedded image


TFA


embedded image


1. mp = 173-175 2. M + H = 483





388


embedded image


TFA


embedded image


1. mp = 167-169 2. M + H = 450





389


embedded image


TFA


embedded image


1. mp = 90-92 2. M + H = 374





390


embedded image


TFA


embedded image


1. mp = 113-115 2. M + H = 404





391


embedded image


TFA


embedded image


1. mp = 114-116 2. M + H = 404





392
HNMe2
TFA


embedded image


LCMS: MH+ = 347;





393
H2NMe
TFA


embedded image


LCMS: MH+ = 333;





394


embedded image


TFA


embedded image


LCMS: MH+ = 359;





395


embedded image


TFA


embedded image


LCMS: MH+ = 405;





396


embedded image


TFA


embedded image


LCMS: MH+ = 405;





397


embedded image


TFA


embedded image


LCMS: MH+ = 391;










Additional data for select example shown below:


Example 392


1H NMR (DMSO-d6) δ 8.65 (s, 1H), 8.46 (d, J=3.3 Hz, 1H), 8.21 (t, J=6.6 Hz, 1H), 7.90 (s, 1H), 7.80 (d, J=7.8 Hz, 1H), 7.35 (dd, J=7.8, 4.8 Hz, 1H), 5.46 (s, 1H), 4.61 (d, J=6.9 Hz, 2H), 3.01 (s, 6H).


Example 393


1H NMR (CDCl3) δ 8.65 (s, 1H), 8.60 (d, J=4.8 Hz, 1H), 7.76 (s, 1H), 7.70 (m, 1H), 7.32 (dd, J=8.1, 4.8 Hz, 1H), 6.43 (t, J=6.0 Hz, 1H), 5.08 (s, 1H), 4.80 (m, 1H), 4.56 (d, J=6.0 Hz, 2H), 2.96 (d, J=5.1 Hz, 3H).


Example 394


1H NMR (CDCl3) δ 8.68 (s, 1H), 8.60 (d, J=4.8 Hz, 1H), 7.76 (s, 1H), 7.72 (m, 1H), 7.32 (dd, J=7.8, 5.4 Hz, 1H), 6.55 (t, J=5.7 Hz, 1H), 5.53 (s, 1H), 5.35 (s, 1H), 4.62 (d, J=5.7 Hz, 2H), 2.49 (m, 1H), 0.75 (m, 2H), 0.51 (m, 2H).


Example 395


1H NMR (CDCl3) δ 8.65 (s, 1H), 8.60 (d, J=4.0 Hz, 1H), 7.75 (s, 1H), 7.69 (m, 1H), 7.33 (dd, J=8.1, 5.1 Hz, 1H), 6.45 (t, J=6.0 Hz, 1H), 5.07 (s, 1H), 4.69 (m, 1H), 4.54 (d, J=6.0 Hz, 2H), 3.98 (m, 1H), 3.79 (dd, J=10.8, 2.4 Hz, 1H), 3.59 (dd, J=11.1, 7.2 Hz, 1H), 1.59-1.36 (m, 4H), 0.94 (t, J=6.9 Hz, 3H).


Example 396


1H NMR (CDCl3) δ 8.60 (s, 1H), 8.56 (d, J=4.2 Hz, 1H), 7.73 (s, 1H), 7.66 (m, 1H), 7.31 (dd, J=7.8, 4.8 Hz, 1H), 6.51 (t, J=6.0 Hz, 1H), 5.05 (s, 1H), 4.86 (d, J=6.6 Hz, 1H), 4.50 (d, J=6.0 Hz, 2H), 3.94 (m, 1H), 3.78 (dd, J=11.1, 2.4 Hz, 1H), 3.57 (dd, J=11.1, 7.2 Hz, 1H), 1.57-1.34 (m, 4H), 0.91 (t, J=7.2 Hz, 3H).


Example 397


1H NMR (CDCl3) δ 8.65 (s, 1H), 8.59 (d, J=4.5 Hz, 1H), 7.75 (s, 1H), 7.69 (m, 1H), 7.31 (m, 1H), 6.43 (t, J=6.0 Hz, 1H), 5.06 (s, 1H), 4.88 (m, 1H), 4.55 (d, J=6.0 Hz, 2H), 3.70 (m, 2H), 3.38 (m, 2H), 1.79-1.61 (m, 4H).


Examples 398-416

By essentially the same conditions set forth in Example 341, Steps A and B only substituting the compound prepared in Preparative Example 193.10, the compounds in Column 4 of Table 32 were prepared.













TABLE 32





Ex.
Column 2
Column 3
Column 4
CMPD







398


embedded image





embedded image


MS: MH+ = 419 m.p. 102-105° C.





399


embedded image





embedded image


MS: MH+ = 421 m.p. 79-81° C.





400


embedded image





embedded image


MS: MH+ = 421 m.p. 78-79° C.





401


embedded image





embedded image


MS: MH+ = 433 m.p. 228-231° C.





402


embedded image





embedded image


MS: MH+ = 447 m.p. 97-102° C.





403


embedded image





embedded image


MS: MH+ = 421 m.p. ° C.





404


embedded image





embedded image


MS: MH+ = 421 m.p. ° C.





405


embedded image





embedded image


MS: MH+ = 386 m.p. ° C.





407


embedded image


KOH


embedded image


1. mp = 98-100 2. M + H = 390





408


embedded image


TFA


embedded image


1. mp = 170-173 2. M + H = 404





409


embedded image


KOH


embedded image


1. mp = 219-221 2. M + H = 420





410


embedded image


KOH


embedded image


1. mp = 110-112 2. M + H = 448





411


embedded image


TFA


embedded image


1. mp = 81-83 2. M + H = 448





412


embedded image


TFA


embedded image


1. mp = 136-138 2. M + H = 448





413
NaOMe
KOH


embedded image


1. mp = 107-110 2. M + H = 351





414


embedded image





embedded image


LCMS: MH+ = 375;










Additional data for select examples shown below:


Example 414


1H NMR (DMSO-d6) δ 8.26 (s, 1H), 8.23 (m, 1H), 8.13 (m, 1H), 7.90 (s, 1H), 7.40-7.27 (m, 3H), 5.34 (s, 1H), 4.49 (d, J=6.3 Hz, 2H), 2.56 (m, 1H), 0.67 (m, 2H), 0.35 (m, 2H).


Example 403


1H NMR (DMSO-d6+CDCl3) δ 8.08 (s, 1H), 7.90 (d, J=6.3 Hz, 1H), 7.49 (s, 1H), 7.34 (t, J=6.3 Hz, 1H), 7.16-7.09 (m, 2H), 5.65 (d, J=6.6 Hz, 1H), 4.97 (s, 1H), 4.90 (s, 1H), 4.29 (d, J=6.3 Hz, 2H), 3.70 (m, 1H), 3.46 (m, 1H), 3.34 (m, 1H), 1.35-1.17 (m, 4H), 0.71 (t, J=7.2 Hz, 3H).


Example 404


1H NMR (DMSO-d6) δ 8.21 (s, 1H), 8.12 (d, J=6.6 Hz, 1H), 8.06 (m, 1H), 7.86 (s, 1H), 7.38 (t, J=7.8 Hz, 1H), 7.30 (d, J=7.5 Hz, 1H), 6.73 (d, J=8.7 Hz, 1H), 5.28 (s, 1H), 4.70 (t, J=5.1 Hz, 1H), 4.41 (d, J=6.6 Hz, 2H), 4.00 (s, 1H), 3.39 (m, 1H), 1.53 (m, 1H), 1.36-1.25 (m, 3H), 0.86 (t, J=7.0 Hz, 3H).


Examples 417-421

By the procedure set forth in Chem. Pharm. Bull. 1999, 47, 928-938. utilizing the oxygen or sulfur nucleophiles shown in Column 2 as described of Table 33 and by employing the cleavage method listed in Column 3 of Table 33, the compounds in Column 4 of Table 33 were prepared:













TABLE 33









CMPD






1. mp.


Ex.
Column 2 (Nucleophile)
Column 3 (Cleavage method)
Column 4 (Final Structure)
2. M + H







417
NaSMe
TFA


embedded image


1. mp = 172-175 2. M + H = 351





418
NaSt—Bu
TFA


embedded image


1. mp = 165-168 2. M + H = 392





419
NaSPh
TFA


embedded image


1. mp = 154-156 2. M + H = 412





420
NaOMe
TFA


embedded image


1. mp = 161-163 2. M + H = 335





421
NaOPh
TFA


embedded image


1. mp = 64-66 2. M + H = 397









Example 422



embedded image


To a solution of amino compound (18 mg, 0.043 mmol) from Example 373 in CH2Cl2 (1 mL) at rt was added DIPEA (10 μL, 0.056 mmol) followed by MeSO2Cl (4 mL, 0.052 mmol). The mixture was stirred at rt for 12 h and was diluted with CH2Cl2 (2 mL) and sat. aq. NaHCO3 (2 mL). The layers were separated and the organic layer was extracted with brine (1×2 mL). The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude material was purified by preparative thin-layer chromatography (4×1000 μM) eluting with CH2Cl2/MeOH (20:1) to afford 16 mg (75%) of white solid. mp 152-154° C.; M+H=495.


Examples 423-424

Utilizing the procedure outlined in Example 422, the amino compounds (Column 2) were converted to the corresponding methylsulfonamides (Column 3) in Table 34.












TABLE 34








CMPD





1. mp.


Ex.
Column 2 (Amine)
Column 3 (Final Structure)
2. M + H







423


embedded image




embedded image


1. mp = 166-168 2. M + H = 467





424


embedded image




embedded image


1. mp = 165-168 2. M + H = 467









Example 425

Step A:




embedded image


A mixture of the compound prepared in Preparative Example 194 (132 mg, 0.25 mmol), tributylvinyltin (95 mg, 0.30 mmol) and tetrakis(triphenylphospine)palladium (29 mg, 0.025 mmol) in anhydrous dioxane (5 mL) was refluxed under N2 for 24 hr. The solvent was evaporated and the residue was purified by flash chromatography using 2:1 CH2Cl2:EtOAc as eluent to yield yellow waxy solid (53 mg, 50%). LCMS: MH+=428.


Step B:




embedded image


A mixture of the compound prepared in Example 425, Step A (50 mg, 0.12 mmol) and KOH (100 mg, 1.80 mmol) in ethanol (3 mL) and H2O (0.6 mL) was stirred at 70° C. under N2 for 24 hr. NaHCO3 (1.0 g), Na2SO4 (2.0 g), and CH2Cl2 (20 mL) were added, the mixture was shaken and then filtered. The solvent was evaporated and the residue was purified by flash chromatography using 20:1:0.1 CH2Cl2:MeOH:conc.NH4OH as eluent to yield yellow waxy solid (17 mg, 45%). LCMS: MH+=328. Mp=48-51° C.


Example 426

Step A:




embedded image


By essentially the same procedure set forth in Example 425, Step A only using tributylmethylethynyltin, the compound shown above was prepared.


Step B:




embedded image


A mixture of the compound prepared in Example 426, Step A (150 mg, 0.34 mmol) and PtO2 (30 mg, 0.13 mmol) in glacial acetic acid (5 mL) was stirred under 1 atmosphere of H2 for 20 hr. The mixture was filtered, fresh PtO2 (30 mg, 0.13 mmol) was added and the mixture was stirred under 1 atmosphere of H2 for 2.5 hr. The mixture was poured onto Na2CO3 (20 g) and H2O (200 mL) and it was extracted with CH2Cl2 (4×20 mL). The combined extracts were dried over Na2SO4 and filtered. The solvent was evaporated and the residue was purified by flash chromatography using 1:1 CH2Cl2:EtOAc as eluent to yield yellow waxy solid (68 mg, 45%).


Step C:




embedded image


By essentially the same procedure set forth in Example 425, Step B only substituting the compound prepared in Example 426, Step B, the compound shown above was prepared, MS: MH+=344. Mp=110-112° C.


Example 427

Step A:




embedded image


A mixture of the compound prepared in Preparative Example 194 (527 mg, 1.00 mmol), triethyl(trifluoromethyl)silane (666 mg, 3.60 mmol), potassium fluoride (210 mg, 3.60 mmol), and CuI (850 mg, 4.46 mmol) in anhydrous DMF (4 mL) was stirred in a closed pressure vessel at 80° C. for 72 hr. CH2Cl2 (80 mL) was added and the mixture was filtered through Celite. The solvent was evaporated and the residue was purified by flash chromatography using 2:1 CH2Cl2:EtOAc as eluent to yield pale orange waxy solid (70 mg, 15%). LCMS: M+=470.


Step B:




embedded image


TFA (0.70 mL) was added at 0° C. under N2 to a stirred solution of the compound prepared in Example 427, Step A (70 mg, 0.15 mmol), in anhydrous CH2Cl2 (3 mL). The mixture was stirred at 0° C. for 10 min, then at 25° C. for 2 hr. It was poured into 10% aqueous Na2CO3 (50 mL), extracted with CH2Cl2 (3×15 mL), dried over Na2SO4, and filtered. The solvent was evaporated and the residue was purified by flash chromatography using EtOAc as eluent to yield off-white solid (40 mg, 73%). LCMS: M+=370. Mp=156-158° C.


Example 428

Step A:




embedded image


A mixture of the compound prepared in Preparative Example 193 (100 mg, 0.28 mmol), tetracyclopropylltin (91 mg, 0.32 mmol), Pd2 dba3 (8.0 mg, 0.009 mmol) and Pd(Pt-Bu3)2 (9.0 mg, 0.017 mmol) in anhydrous dioxane (3 mL) was refluxed under N2 for 27 hr. The solvent was evaporated and the residue was purified by flash chromatography using 1:1 CH2Cl2:EtOAc as eluent to yield colorless waxy solid (38 mg, 38%). LCMS: MH+=366.


Step B:




embedded image


A mixture of the compound prepared in Example 428, Step A (36 mg, 0.10 mmol) and KOH (300 mg, 5.40 mmol) in ethanol (3 mL), 1,2-dimethoxyethane (3.0 mL) and H2O (0.8 mL) was refluxed under N2 for 4 hr. It was poured into saturated aqueous NaHCO3 (100 mL), extracted with CH2Cl2 (5×10 mL), dried over Na2SO4, and filtered. The solvent was evaporated and the residue was purified by flash chromatography using 30:1 EtOAc:MeOH as eluent to yield colorless waxy (18 mg, 69%). LCMS: MH+=266.


Step C:




embedded image


N-bromosuccinimide (12 mg, 0.068 mmol) in anhydrous CH3CN (2 mL) was added under N2 to a stirred solution of the compound prepared in Example 428, Step B (18 mg, 0.068 mmol), in anhydrous CH3CN (2 mL). The mixture was stirred at 25° C. for 2 hr. The solvent was evaporated and the residue was purified by flash chromatography using EtOAc as eluent to yield 5 mg (17%) of the dibromo compound (white solid, LCMS: MH+=370, mp=150-152° C.) and 8 mg (34%) of the monobromo compound (colorless solid, LCMS: M+=344, mp=196-198° C.).


Example 429

Step A:




embedded image


1,3-propanesultam (72 mg, 0.60 mmol) in anhydrous DMF (3 mL) was added under N2 to 60% NaH in mineral oil (36 mg, 0.90 mmol). The mixture was stirred for 20 min, then the compound prepared in Preparative Example 196 (200 mg, 0.46 mmol) was added. The mixture was stirred at 100° C. for 30 min, the solvent was evaporated and the residue was purified by flash chromatography using EtOAc as eluent to yield colorless solid (150 mg, 63%). LCMS: M+=523.


Step B:




embedded image


TFA (1.5 mL) was added at 0° C. under N2 to a stirred solution of the compound prepared in Preparative Example 196 (140 mg, 0.27 mmol), in anhydrous CH2Cl2 (5 mL). The mixture was stirred at 0° C. for 10 min, then at 25° C. for 2 hr. It was poured onto Na2CO3 (10 g), extracted with CH2Cl2 (3×50 mL), and filtered. The solvent was evaporated and the residue was purified by flash chromatography using 40:1 EtOAc:MeOH as eluent to yield white solid (32 mg, 28%). LCMS: M+=423. Mp=218-220° C.


Example 430



embedded image


3-Bromo-7-chloro-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine (1 equivalent) (prepared as described in Preparative Example 129), or 3-Bromo-7-chloro-5-phenylpyrazolo[1,5-a]pyrimidine (1 equivalent) (prepared as described in Preparative Example 127), R1NH2 (1.2 equivalents) and diisopropyl ethylamine (2 equivalents) were dissolved in anhydrous 1,4-dioxane and the mixture was heated at 75° C. for the time given in Table 97. The solution was evaporated to dryness and the residue was chromatographed on a silica gel column as described in Table 97, to give the title compound.


Using the appropriate reactants and essentially the same procedure as described above, the products of Examples 431 to 438 were prepared. Variations in the reaction conditions are noted in Table 35.















TABLE 35





Ex.
Structure
MW
FABMS MH+
Reaction Conditions
Yield
Chromatographic Data







431


embedded image


463.8
463.0
75° C./ 26 h
52%
15 × 2.5 cm 0.5-2% (10% Conc. ammonium hydroxide in methanol)- dichloromethane





432


embedded image


429.3
429.2
75° C./ 26 h 25° C./ 39 h
53%
15 × 5 cm Dichloromethane; 1.5% (10% Conc. ammonium hydroxide in methanol)- dichloromethane





433


embedded image


477.8
477.1
75° C./ 26 h
48%
15 × 5 cm Dichloromethane; 3.5-15% (10% Conc. ammonium hydroxide in methanol)- dichloromethane





434


embedded image


477.8
477.0
75° C./ 26 h
50%
15 × 5 cm Dichloromethane; 3.5-15% (10% Conc. ammonium hydroxide in methanol)- dichloromethane





435


embedded image


434.8
434.1
75° C./ 24 h 25° C./ 65 h
53%
15 × 2.5 cm 3% (10% Conc. ammonium hydroxide in methanol)- dichloromethane





436


embedded image


434.8
434.2
75° C./ 27 h
31%
15 × 2.5 cm 3% (10% Conc. ammonium hydroxide in methanol)- dichloromethane





437


embedded image


438.7
438.1
75° C./ 21 h 25° C./ 46 h
97%
15 × 2.5 cm 0.25% (10% Conc. ammonium hydroxide in methanol)- dichloromethane





438


embedded image


438.7
438.1
75° C./ 28 h −20° C./ 72 h
95%
60 × 2.5 cm 20% Ethyl acetate in hexane










Additional physical data for the compounds are given below:


Example 431

Reactants: 3-Bromo-7-chloro-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine (110 mg, 0.318 mmoles) (prepared as described in Preparative Example 129); 3-(aminomethyl)piperidine-1-carboxamide (60 mg, 0.382 mmoles) (prepared as described in Preparative Example 241 above); diisopropyl ethylamine (0.111 mL, 0.636 mmoles); anhydrous 1,4-dioxane (2.5 mL). Physical properties: HRFABMS: m/z 463.0628 (MH+). Calcd. for C19H21N6OBrCl: m/z 463.0649: δH (CDCl3) 1.38 (1H, m, CH2), 1.52 (1H, m, CH2), 1.73 (1H, m, CH), 1.93 (1H, m, CH2), 2.02 (1H, m, CH2), 2.98 (1H, m, CH2), 3.06 (1H, m, CH2), 3.37 (2H, m, CH2), 3.58 (1H, m, CH2), 3.82 (1H, m, CH2), 4.87 (2H, bm, CONH2), 6.28 (1H, s, H6), 7.02 (1H, m, NH), 7.36 (2H, m, Ar—H), 7.45 (1H, m, Ar—H), 7.68 (1H, m, Ar—H) and 8.00 ppm (1H, s, H2); δC (CDCl3) CH2: 23.7, 28.1, 44.6, 45.5, 47.2; CH: 35.2, 87.4, 127.2, 130.1, 130.3, 131.6, 143.9: C: 83.1, 132.1, 138.6, 145.5, 146.5, 158.0, 158.4.


Example 432

Reactants: 3-Bromo-7-chloro-5-phenylpyrazolo[1,5-a]pyrimidine (500 mg, 1.62 mmoles) (prepared as described in Preparative Example 127); 3-(aminomethyl)piperidine-1-carboxamide (306 mg, 1.944 mmoles) (prepared as described in Preparative Example 241 above); diisopropyl ethylamine (0.566 mL, 3.24 mmoles); anhydrous 1,4-dioxane (13 mL). Physical properties: HRFABMS: m/z 429.1031 (MH+). Calcd. for C19H22N6OBr: m/z 429.1038; δH (CDCl3) 1.44 (1H, m, CH2), 1.59 (1H, m, CH2), 1.79 (1H, m, CH), 2.01 (1H, m, CH2), 2.08 (1H, m, CH2), 3.03 (1H, m, CH2), 3.13 (1H, m, CH2), 3.39 (1H, m, CH2), 3.47 (1H, m, CH2), 3.63 (1H, m, CH2), 3.90 (1H, m, CH2), 4.88 (2H, bm, CONH2), 6.40 (1H, s, H6), 6.90 (1H, m, NH), 7.53 (2H, m, Ar—H), 8.02 (1H, s, H2) and 8.12 (1H, m, Ar—H); δC (CDCl3) CH2: 23.7, 28.2, 44.7, 45.5, 47.3; CH: 35.2, 82.9, 127.5, 127.5, 128.7, 128.7, 130.0, 143.9; C: 83.0, 138.5, 145.8, 147.1, 158.3, 158.5.


Example 433

Reactants: 3-Bromo-7-chloro-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine (347 mg, 1.01 mmoles) (prepared as described in Preparative Example 129); 3-(aminoethyl)piperidine-1-carboxamide (208 mg, 1.21 mmoles) (prepared as described in Preparative Example 242 above); diisopropyl ethylamine (0.393 mL, 2.02 mmoles); anhydrous 1,4-dioxane (9 mL). Physical properties: δH (CDCl3) 1.24 (1H, m, CH2), 1.55 (1H, m, CH), 1.72 (4H, m, CH2), 1.93 (1H, m, CH2), 2.69 (1H, m, CH2), 2.94 (1H, m, CH2), 3.55 (2H, m, CH2), 3.73 (1H, m, CH2), 3.98 (1H, m, CH2), 4.83 (2H, bm, CONH2), 6.55 (1H, s, H6), 6.78 (1H, m, NH), 7.41 (2H, m, Ar—H), 7.50 (1H, m, Ar—H), 7.75 (1H, m, Ar—H) and 8.04 ppm (1H, s, H2); δC (CDCl3) CH2: 24.6, 30.7, 32.6, 39.9, 45.3, 49.3; CH: 33.3, 87.5, 127.4, 130.1, 130.2, 131.6, 143.8; C: 83.2, 132.1, 138.8, 145.7, 146.2, 158.1, 158.1.


Example 434

Reactants: 3-Bromo-7-chloro-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine (275 mg, 0.803 mmoles) (prepared as described in Preparative Example 129); 4-(aminoethyl)piperidine-1-carboxamide (165 mg, 0.963 mmoles) (prepared as described in Preparative Example 243 above); diisopropyl ethylamine (0.311 mL, 0.963 mmoles); anhydrous 1,4-dioxane (7.2 mL). Physical properties: δH (d6-DMSO) 1.00 (2H, m, CH2), 1.50 (1H, m, CH), 1.59 (2H, m, CH2), 1.67 (2H, m, CH2), 2.60 (2H, m, CH2), 3.48 (2H, m, CH2), 3.70 (2H, m, CH2), 5.84 (2H, bs, CONH2), 6.43 (1H, s, H6), 7.50 (2H, m, Ar—H), 7.62 (2H, m, Ar—H), 8.30 (1H, s, H2) and 8.36 ppm (1H, m, NH); δC (d6-DMSO)CH2: 31.5, 31.5, 34.8, 43.5, 43.5, 43.5; CH: 32.8, 86.8, 127.1, 129.7, 130.3, 131.0, 143.3; CH: 81.3, 131.0, 138.7, 145.1, 146.4, 157.3, 157.8.


Example 435

Reactants: 3-Bromo-7-chloro-5-phenylpyrazolo[1,5-a]pyrimidine (174 mg, 0.507 mmoles) (prepared as described in Preparative Example 129) and 3-(aminomethyl)-1-methylpiperidine (65 mg, 0.507 mmoles) (prepared as described in Preparative Example 244 above); diisopropyl ethylamine (0.178 mL, 1.014 mmoles); anhydrous 1,4-dioxane (2.5 mL). Physical properties: HRFABMS: m/z 434.0742 (MH+). Calcd. for C19H22N5BrCl: m/z 434.0747; δH (CDCl3) 1.18 (1H, m, CH2), 1.68 (1H, m, CH2), 1.80 (1H, m, CH2), 1.87 (1H, m, CH2), 1.96 (1H, m, CH), 2.14 (2H, m, CH2), 2.32 (3H, s, NCH3), 2.75 (1H, m, CH2), 2.29 (1H, m, CH2), 3.42 (2H, m, —NHCH2CH), 6.36 (1H, s, H6), 6.64 (1H, bm, NH), 7.41 (2H, m, Ar—H), 7.51 (1H, m, Ar—H), 7.74 (1H, m, Ar—H) and 8.06 ppm (1H, s, H2); δC (CDCl3) CH3: 46.6; CH2: 24.4, 27.9, 46.1, 56.1, 59.6; CH: 36.0, 87.4, 127.1, 130.1, 130.2, 131.6, 143.8; C: 83.2, 132.1, 138.9, 145.6, 146.4, 158.2.


Example 436

Reactants: 3-Bromo-7-chloro-5-phenylpyrazolo[1,5-a]pyrimidine (111.4 mg, 0.325 mmoles) (prepared as described in Preparative Example 129); 4-(aminomethyl)-1-methylpiperidine (50 mg, 0.39 mmoles) (prepared as described in Preparative Example 245 above); diisopropyl ethylamine (0.1135 mL, 0.65 mmoles); anhydrous 1,4-dioxane (1.5 mL). Physical data: HRFABMS: m/z 434.0735 (MH+). Calcd. for C19H22N5BrCl: m/z 434.0747; δH (CDCl3) 1.42 (2H, m, CH2), 1.72 (1H, m, CH), 1.82 (2H, m, CH2), 1.93 (2H, m, CH2), 2.20 (3H, s, NCH3), 2.89 (2H, m, CH2), 3.34 (2H, m, —NHCH2CH), 6.31 (1H, s, H6), 6.46 (1H, m, NH), 7.36 (2H, m, Ar—H), 7.46 (1H, m, Ar—H), 7.70 (1H, m, Ar—H) and 8.00 ppm (1H, s, H2); δC (CDCl3) CH3: 46.4; CH2: 30.2, 30.2, 48.0, 55.3, 55.3; CH: 35.4, 87.5, 127.2, 130.2, 130.2, 131.6, 143.8; C: 83.3, 132.2, 138.9, 145.7, 146.4, 158.1.


Example 437

Reactants: 3-Bromo-7-chloro-5-phenylpyrazolo[1,5-a]pyrimidine (191 mg, 0.557 mmoles) (prepared as described in Preparative Example 129); 3-(aminomethyl)benzonitrile (88.3 mg, 0.668 mmoles) (prepared as described in Preparative Example 246 above); diisopropyl ethylamine (0.192 mL, 1.114 mmoles); anhydrous 1,4-dioxane (4.5 mL). Physical data: HRFABMS: m/z 438.0125 (MH+). Calcd. for C19H12N5BrCl: m/z 438.0121; δH (CDCl3) 4.76 (2H, d, —CH2NH—), 6.32 (1H, s, H6), 7.00 (1H, m, —CH2NH—), 7.40 (2H, m, Ar—H), 7.46 (1H, m, Ar—H), 7.55 (1H, m, Ar—H), 7.67 (2H, m, Ar—H), 7.71 (1H, m, Ar—H), 7.75 (1H, m Ar—H) and 8.10 ppm (1H, s, H2); δC (CDCl3) CH2: 45.5; CH: 88.2, 127.2, 130.0, 130.2, 130.4, 130.6, 131.4, 131.6, 131.9, 144.1; C: 83.8, 113.4, 118.3, 132.0, 137.8, 138.3, 145.6, 145.9, 158.0.


Example 438

Reactants: 3-Bromo-7-chloro-5-phenylpyrazolo[1,5-a]pyrimidine (233.5 mg, 0.681 mmoles) (prepared as described in Preparative Example 129); 4-(aminomethyl)benzonitrile (108 mg, 0.817 mmoles) (prepared as described in Preparative Example 247 above); diisopropyl ethylamine (0.235 mL, 1.362 mmoles); anhydrous 1,4-dioxane (5.3 mL). Physical data: HRFABMS: m/z 438.0117 (MH+) Calcd. for C20H14N5BrCl: m/z 438.0121; δH (CDCl3) 4.80 (2H, d, CH2), 6.30 (1H, s, H6), 7.01 (1H, m, NH), 7.40 (2H, m, Ar—H), 7.47 (1H, m, Ar—H), 7.70 (2H, m, Ar—H), 7.72 (2H, m, Ar—H), 7.80 (1H, m, Ar—H) and 8.10 ppm (1H, s, H2); δC (CDCl3) CH2: 45.8; CH: 88.2, 127.2, 127.7, 127.7, 130.2, 130.4, 131.6, 132.9, 132.9, 144.1; C: 83.8, 112.2, 118.4, 132.0, 138.2, 141.5, 145.5, 146.0, 158.0.


Example 439



embedded image


3-Bromo-7-chloro-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine (50 mg, 0.146 mmoles) (prepared as described in Preparative Example 129) was dissolved in anhydrous 1,4-dioxane (5 mL) in a GeneVac Technologies carousel reaction tube. PS-diisopropyl ethylamine resin (161 mg, 0.5828 mmoles) was added to each tube. A freshly prepared 1M solution of the appropriate amine R1NH2 in anhydrous 1,4-dioxane (0.2185 mL, 0.2185 mmoles) was added to each tube and the tubes were sealed and heated at 70° C. for 78 h with magnetic stirring in the reaction block. Each tube was filtered and the resin washed with anhydrous 1,4-dioxane and then dichloromethane. The combined individual filtrates from each tube were evaporated to dryness and the residues were each re-dissolved in anhydrous 1,4-dioxane (5 mL) and placed in GeneVac reaction tubes. To each tube was added PS-isocyanate resin (594 mg, 0.8742 mmoles) and PS-trisamine resin (129 mg, 0.4371 mmoles) and the tubes were stirred at 25° C. for 20 h in the reaction block. The resins were filtered off and washed with anhydrous 1,4-dioxane and dichloromethane. The filtrates from each tube were evaporated to dryness and the residues were each chromatographed on a silica gel column using the column size and the eluant shown in Table 36, to give the title compounds.














TABLE 36





Ex.
Structure
MW
FABMS MH+
Yield
Chromatographic Data







440


embedded image


428.7
428.0
81%
15 × 2.5 cm Dichloromethane; 0.5% Methanol in dichloromethane





441


embedded image


428.7
428.0
48%
20 × 2 cm Dichloromethane; 1.5% Methanol in dichloromethane





442


embedded image


428.7
428.0
24%
15 × 2.5 cm Dichloromethane; 1.5% Methanol in dichloromethane





443


embedded image


463.8
463.0
44%
15 × 2.2 cm Dichloromethane; 5% Methanol in dichloromethane





444


embedded image


434.8
434.1
63%
15 × 2.5 cm 5% Methanol in dichloromethane





445


embedded image


448.8
448.2
65%
15 × 2.5 cm 5% Methanol in dichloromethane





446


embedded image


448.8
448.1
40%
15 × 2.5 cm Dichloromethane; 0.5% Methanol in dichloromethane





447


embedded image


436.7
436.1
72%
15 × 2.5 cm 0.5% Methanol in dichloromethane





448


embedded image


450.8
450.0
53%
20 × 2 cm Dichloromethane; 0.5% Methanol in dichloromethane





449


embedded image


381.7
381.0
44%
20 × 2 cm 1.5% Methanol in dichloromethane










Additional physical data for the compounds are given below:


Example 440

Physical properties: HRFABMS: m/z 428.0272 (MH+). Calcd. for C19H16N5BrCl: m/z 428.0278; δH (CDCl3) 3.28 (2H, dd, C5H4NCH2CH2NH—), 3.94 (2H, ddd, C5H4NCH2CH2NH—), 6.40 (1H, s, H6), 7.22-7.29 (3H, m, Ar—H), 7.38-7.44 (2H, m, Ar—H), 7.51 (1H, m, Ar—H), 7.68 (1H, ddd, Ar—H), 7.73 (1H, Ar—H), 8.18 (1H, s, H2) and 8.68 ppm (1H, NH); δC (CDCl3) CH2: 36.4, 41.5; CH: 87.3, 122.1, 123.6, 127.1, 130.1, 130.1, 131.6, 137.0, 143.8, 149.5; C: 83.1, 132.1, 138.9, 145.7, 146.3, 158.0, 158.1.


Example 441

Physical properties: HRFABMS: m/z 428.0272 (MH+). Calcd. for C19H16N5BrCl: m/z 428.0278; δH (CDCl3) 3.12 (2H, dd, C5H4NCH2CH2NH—), 3.77 (2H, ddd, C5H4NCH2CH2NH—), 6.40 (1H, s, H6), 6.59 (1H, m, Ar—H), 7.34 (1H, bm, Ar—H), 7.39-7.45 (2H, m, Ar—H), 7.52 (1H, m, Ar—H), 7.62 (1H, m, Ar—H), 7.75 (1H, m, Ar—H), 8.05 (1H, s, H2) and 8.63 ppm (1H, m, NH); δC (CDCl3) CH2: 32.7, 43.1; CH: 87.5, 127.2, 130.2, 130.3, 131.6, 136.4, 142.9, 148.3, 149.8; C: 83.5, 132.0, 138.6, 145.6, 145.9, 158.1.


Example 442

Physical properties: HRFABMS: m/z 428.0275 (MH+). Calcd. for C19H16N5BrCl: m/z 428.0278; δH (CDCl3) 3.13 (2H, dd, C5H4NCH2CH2NH—), 3.80 (2H, ddd, C5H4NCH2CH2NH—), 6.42 (1H, s, H6), 6.53 (1H, m, Ar—H), 7.23 (2H, m, Ar—H), 7.40-7.46 (2H, m, Ar—H), 7.62 (1H, m, Ar—H), 7.76 (1H, m, Ar—H), 8.07 (1H, s, H2) and 8.63 ppm (1H, m, NH); δC (CDCl3) CH2: 34.7, 42.5; CH: 87.4, 124.5, 124.5, 127.2, 130.2, 130.3, 131.6, 144.0, 150.2, 150.2; C: 83.5, 132.0, 138.6, 145.6, 145.9, 146.6, 158.1.


Example 443

Physical properties: HRFABMS: m/z 463.1003 (MH+). Calcd. for C20H25N6BrCl: m/z 463.1013; δH (CDCl3) 1.98 (2H, m, ═NCH2CH2CH2NH—), 2.43 (3H, s, NCH3), 2.67 (2H, m, ═NCH2CH2CH2NH—), 2.70 (8H, piperazine CH2), 3.58 (2H, m, ═NCH2CH2CH2NH—), 6.32 (1H, s, H6), 7.37-7.43 (2H, m, Ar—H), 7.50 (1H, m, Ar—H), 7.73 (1H, m, Ar—H), 8.06 (1H, s, H2) and 8.60 ppm (1H, m, NH); δC (CDCl3) CH3: 46.1; CH2: 24.1, 42.8, 53.3, 54.6, 54.6, 57.5, 57.5; CH: 87.1, 127.0, 130.0, 130.1, 131.5, 143.4; C: 82.7, 132.1, 139.2, 145.7, 146.7, 158.0.


Example 444

Physical properties: HRFABMS: m/z 434.0742 (MH+). Calcd. for C19H22N5BrCl: m/z 434.0747; δH (CDCl3) 1.72 (1H, m, CH/CH2), 1.78-1.90 (2H, m, CH/CH2), 2.02 (3H, m, CH/CH2), 2.50 (1H, m, CH/CH2), 2.45 (3H, s, NCH3), 2.51 (1H, m, CH/CH2), 3.23 (1H, m, CH/CH2), 3.54 (1H, m, CH/CH2), 3.60 (1H, m, CH/CH2), 6.32 (1H, s, H6), 7.38-7.44 (2H, m, Ar—H), 7.51 (1H, m, Ar—H), 7.75 (1H, m, Ar—H), 7.96 (1H, bm, NH) and 8.05 ppm (1H, s, H2); δC (CDCl3) CH3: 40.7; CH2: 22.7, 29.3, 30.1, 39.4, 57.0; CH: 64.2, 87.1, 127.1, 130.0, 130.1, 131.6, 143.8; C: 82.8, 132.1, 139.1, 145.7, 146.4, 158.0.


Example 445

Physical properties: HRFABMS: m/z 448.0910 (MH+). Calcd. for C20H24N5BrCl: m/z 448.0904; δH (CDCl3) 1.90 (4H, m, CH2), 2.00 (4H, m, CH2), 2.84 (2H, m, CH2), 2.95 (4H, m, CH2), 3.51 (2H, m, CH2), 6.32 (1H, s, H6), 7.05 (1H, bm, NH), 7.37-7.43 (2H, m, Ar—H), 7.50 (1H, m, Ar—H), 7.73 (1H, m, Ar—H) and 8.04 ppm (1H, s, H2); δC (CDCl3) CH2: 23.4, 23.4, 24.8, 26.4, 41.8, 53.9, 53.9, 55.2; CH: 87.3, 127.1, 130.1, 130.2, 131.6, 143.7; C: 83.0, 132.0, 138.9, 145.7, 146.3, 158.1.


Example 446

Physical properties: HRFABMS: m/z 448.0548 (MH+). Calcd. for C19H20N5OBrCl: m/z 448.0540; δH (CDCl3) 1.94 (2H, m, CH2), 2.09 (2H, m, CH2), 2.49 (2H, m, CH2), 3.45 (2H, m, CH2), 3.51 (4H, m, CH2), 6.32 (1H, s, H6), 7.37-7.44 (3H, m, Ar—H/NH), 7.51 (1H, m, Ar—H), 7.75 (1H, m, Ar—H) and 8.10 ppm (1H, s, H2); δC (CDCl3) CH2: 18.0, 26.3, 30.8, 39.2, 39.9, 47.5; CH: 87.0, 127.1, 130.1, 130.1, 131.6, 144.1; C: 82.9, 132.1, 138.9, 145.6, 146.2, 157.9, 176.2.


Example 447

Physical properties: HRFABMS: m/z 436.0532 (MH+). Calcd. for C18H20N5OBrCl: m/z 436.0540; δH (CDCl3) 2.60 (4H, bm, —N(CH2CH2)2O), 2.83 (2H, m, ═NCH2CH2NH—), 3.57 (2H, m, ═NCH2CH2NH—), 3.83 (4H, m, —N(CH2CH2)2O), 6.37 (1H, s, H6), 6.99 (1H, bm, NH), 7.38-7.45 (2H, m, Ar—H), 7.51 (1H, m, Ar—H), 7.75 (1H, m, Ar—H) and 8.09 ppm (1H, s, H2); δC (CDCl3) CH2: 38.2, 53.3, 53.3, 56.2, 66.9, 66.9; CH: 87.6, 127.1, 130.1, 130.2, 131.6, 143.9; C; 83.1, 132.1, 138.9, 145.7, 146.2, 158.1.


Example 448

Physical properties: HRFABMS: m/z 450.0688 (MH+). Calcd. for C19H22N5OBrCl: m/z 450.0696; δH (CDCl3) 1.98 (2H, m, ═NCH2CH2CH2NH—), 2.58 (4H, m, —N(CH2CH2)2O), 2.67 (2H, m, ═NCH2CH2CH2NH—), 3.59 (2H, m, ═NCH2CH2CH2NH—), 3.94 (4H, m, —N(CH2CH2)2O), 6.31 (1H, s, H6), 7.37-7.44 (2H, Ar—H), 7.51 (1H, m, Ar—H), 7.78 (1H, m, Ar—H), 8.08 (1H, s, H2) and 8.60 ppm (1H, bm, NH); δC (CDCl3) CH2: 23.7, 42.7, 52.9, 52.9, 58.0, 66.6, 66.6; CH: 87.0, 127.1, 130.0, 130.1, 131.5, 143.6; C: 82.8, 132.1, 139.1, 145.7, 146.7, 158.0.


Example 449

Physical properties: HRFABMS: m/z 381.0114 (MH+). Calcd. for C15H15N4OBrCl: m/z 381.0118; δH (CDCl3) 1.39 (3H, d, CHCH3), 2.76 (1H, bm, —OH), 3.71 (1H, m, ═CHCH2OH), 3.81 (1H, m, ═CHCH2OH), 3.88 (1H, m, ═CHCH2OH), 6.38 (1H, s, H6), 7.38 (2H, m, Ar—H), 7.48 (1H, m, Ar—H), 7.68 (1H, m, Ar—H) and 8.02 ppm (1H, s, H2); δC (CDCl3) CH3: 16.9; CH2: 65.0; CH: 50.0, 88.0, 127.1, 130.1, 130.3, 131.4, 143.8; C: 83.0, 132.0, 138.5, 145.6, 146.0, 158.2.


Example 450



embedded image


3-Bromo-7-chloro-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine (50 mg, 0.146 mmoles) (prepared as described in Preparative Example 129) was dissolved in anhydrous 1,4-dioxane (5 mL) in a GeneVac Technologies carousel reaction tube. PS-diisopropyl ethylamine resin (161 mg, 0.5828 mmoles) was added to each tube. A freshly prepared solution of the appropriate amine R1NH2 (0.219 mmoles) in anhydrous 1,4-dioxane (0.3 mL) was added to each tube, with the exception of Example 99-5 in which the amine was dissolved in 10% MeOH in 1,4-dioxane (0.3 mL), and the tubes were sealed and heated at 70° C. for 74 h with magnetic stirring in the reaction block. Each tube was filtered and the resin washed with anhydrous 1,4-dioxane and then dichloromethane. The combined individual filtrates from each tube were evaporated to dryness and the residues were each re-dissolved in anhydrous 1,4-dioxane (5 mL) and placed in GeneVac reaction tubes. To each tube was added PS-isocyanate resin (594 mg, 0.8742 mmoles) and PS-trisamine resin (129 mg, 0.4371 mmoles) and the tubes were stirred at 25° C. for 20 h in the reaction block. The resins were filtered off and washed with anhydrous 1,4-dioxane and dichloromethane. The filtrates from each tube were evaporated to dryness and the residues were each chromatographed on a silica gel column using the column size and the eluant shown in Table 37, to give the title compounds.














TABLE 37





Ex.
Structure
MW
FABMS MH+
Yield
Chromatographic Data







451


embedded image


381.7
380.9
66%
15 × 2.5 cm; 0.5% Methanol in dichloromethane





452


embedded image


381.7
380.9
60%
20 × 2 cm; 0.5% Methanol in dichloromethane





453


embedded image


381.7
380.9
69%
15 × 2.5 cm; 0.35% Methanol in dichloromethane





454


embedded image


381.7
380.9
75%
15 × 2.5 cm; 0.35% Methanol in dichloromethane





455


embedded image


397.7
397.2
84%
15 × 2.5 cm; 1.5% Methanol in dichloromethane





456


embedded image


397.7








457


embedded image


395.7
395.0
60%
15 × 2.5 cm; 0.35% Methanol in dichloromethane





458


embedded image


395.7
396.3
50%
15 × 2.5 cm; 0.35% Methanol in dichloromethane





459


embedded image


395.7
396.0
76%
15 × 2.5 cm; 0.35% Methanol in dichloromethane










Additional physical data for the compounds are given below:


Example 451

Physical properties: HRFABMS: m/z 381.0115 (MH+). Calcd. for C15H15N4OBrCl: m/z 381.0118; [α]D25° C.+1.4° (c=0.25, MeOH); δH (CDCl3) 1.44 (3H, d, —CHCH3), 3.77 3.89 (1H, dd, CHCH2OH), (1H, dd, CHCH2OH), 3.94 (1H, m, CHCH2OH), 6.41 (1H, s, H6), 6.58 (1H, d, NH), 7.41 (2H, m, Ar—H), 7.51 (1H, m, Ar—H), 7.74 (1H, m, Ar—H) and 8.04 ppm (1H, s, H2); δC (CDCl3) CH3: 17.1; CH2: 65.5; CH: 49.9, 88.0, 127.1, 130.1, 130.2, 131.6, 143.8; C: 83.2, 132.1, 138.7, 145.6, 145.8, 158.1.


Example 452

Physical properties: HRFABMS: m/z 381.0115 (MH+). Calcd. for C15H15N4OBrCl: m/z 381.0118; [α]D25° C.+6.5° (c=0.32, MeOH); δH (CDCl3) 1.44 (3H, d, —CHCH3), 3.78 (1H, dd, CHCH2OH), 3.89 (1H, dd, CHCH2OH), 3.96 (1H, m, CHCH2OH), 6.41 (1H, s, H6), 6.58 (1H, d, NH), 7.41 (2H, m, Ar—H), 7.51 (1H, m, Ar—H), 7.75 (1H, m, Ar—H) and 8.04 ppm (1H, s, H2); δC (CDCl3) CH3: 17.1; CH2: 65.5; CH: 49.9, 88.0, 127.1, 130.1, 130.3, 131.6, 143.8; C: 83.2, 132.1, 138.6, 145.6, 145.8, 158.1.


Example 453

Physical properties: HRFABMS: m/z 381.0115 (MH+). Calcd. for C15H15N4OBrCl: m/z 381.0118; [α]D25° C.+9.4° (c=0.27, MeOH); δH (CDCl3) 1.33 (3H, d, CH3), 2.25 (1H, bs, OH), 3.37 (1H, dd, CH2), 3.51 (1H, m, CH2), 4.16 (1H, m, CHOH), 6.35 (1H, s, H6), 6.93 (1H, m, NH), 7.40 (2H, m, Ar—H), 7.50 (1H, m, Ar—H), 7.70 (1H, m, Ar—H) and 8.04 ppm (1H, s, H2); δC (CDCl3) CH3: 20.8; CH2: 49.2; CH: 65.7, 87.8, 127.1, 130.1, 130.2, 131.2, 143.9; C: 83.1, 132.1, 138.5, 145.6, 146.6, 158.3.


Example 454

Physical properties: HRFABMS: m/z 381.0112 (MH+). Calcd. for C15H15N4OBrCl: m/z 381.0118; [α]D25° C.−3.2° (c=0.29, MeOH); δH (CDCl3) 1.32 (3H, d, CH3), 2.48 (1H, bs, OH), 3.35 (1H, dd, CH2), 3.49 (1H, m, CH2), 4.15 (1H, m, CHOH), 6.34 (1H, s, H6), 6.93 (1H, m, NH), 7.39 (2H, m, Ar—H), 7.49 (1H, m, Ar—H), 7.68 (1H, m, Ar—H) and 8.03 ppm (1H, s, H2); δC (CDCl3) CH3: 20.8; CH2: 49.2; CH: 65.7, 87.7, 127.1, 130.1, 130.3, 131.4, 143.9; C: 83.0, 132.0, 138.6, 145.6, 146.6, 158.3.


Example 455

Physical properties: HRFABMS: m/z 397.0054 (MH+). Calcd. for C15H15N4O2BrCl: m/z 397.0067; [α]D25° C.−95° (c=0.28, MeOH); δH (CDCl3) 3.18 (2H, bs, OH), 3.47 (1H, dd, CH2), 3.58 (1H, dd, CH2), 3.63 (1H, dd, CH2OH), 3.70 (1H, dd, CH2OH), 3.98 (1H, m, CH), 6.35 (1H, s, H6), 7.10 (1H, m, NH), 7.37 (2H, m, Ar—H), 7.46 (1H, m, Ar—H), 7.64 (1H, m, Ar—H) and 8.01 ppm (1H, s, H2); δC (CDCl3) CH2: 44.7, 64.0; CH: 69.7, 87.7, 127.0, 130.1, 130.3, 131.3, 143.9; C: 82.9, 132.0, 138.4, 145.4, 146.7, 158.3.


Example 456

This enantiomer may be prepared by essentially the same manner as described above.


Example 457

Physical properties: HRFABMS: m/z 395.0260 (MH+). Calcd. for C16H17N4OBrCl: m/z 395.0274; [α]D25° C. −34.3° (c=0.28, MeOH); δH (CDCl3) 1.08 (3H, dd, CH3), 1.78 (1H, m, CH2), 1.86 (1H, m, CH2), 2.35 (1H, bs, CH2OH), 3.71 (1H, m, CHNH), 3.81 (1H, dd, CH2OH), 3.90 (1H, dd, CH2OH), 6.42 (1H, s, H6), 6.53 (1H, m, NH), 7.41 (2H, m, Ar—H), 7.51 (1H, Ar—H), 7.75 (1H, m, Ar—H) and 8.04 ppm (1H, s, H2); δC (CDCl3) CH3: 10.5; CH2: 24.5, 63.7; CH: 55.9, 88.0, 127.1, 130.1, 130.2, 131.6, 143.8; C: 83.2, 132.1, 138.6, 145.6, 146.3, 158.1.


Example 458

Physical properties: HRFABMS: m/z 395.0274 (MH+). Calcd. for C16H17N4OBrCl: m/z 395.0274; [α]D25° C.+27.5° (c=0.25, MeOH); δH (CDCl3) 1.05 (3H, dd, CH3), 1.76 (1H, m, CH2), 1.85 (1H, m, CH2), 2.28 (1H, bs, CH2OH), 3.67 (1H, m, CHNH), 3.77 (1H, dd, CH2OH), 3.84 (1H, dd, CH2OH), 6.49 (1H, s, H6), 6.66 (1H, m, NH), 7.39 (2H, m, Ar—H), 7.49 (1H, Ar—H), 7.71 (1H, m, Ar—H) and 8.04 ppm (1H, s, H2); δC (CDCl3) CH3: 10.5; CH2: 24.3, 63.3; CH: 56.1, 88.0, 127.1, 130.1, 130.3, 131.5, 143.8; C: 83.0, 132.1, 138.6, 145.6, 146.3, 158.2.


Example 459

Physical properties: HRFABMS: m/z 395.0264 (MH+). Calcd. for C16H17N4OBrCl: m/z 395.0274; δH (CDCl3) 1.77 (2H, m, —NHCH2CH2CH2CH2OH), 1.90 (1H, bm, —NHCH2CH2CH2CH2OH), 1.93 (2H, m, —NHCH2CH2CH2CH2OH), 3.54 (2H, m, —NHCH2CH2CH2CH2OH), 3.77 (2H, m, —NHCH2CH2CH2CH2OH), 6.37 (1H, s, H6), 6.72 (1H, m, —NHCH2CH2CH2CH2OH), 7.41 (2H, m, Ar—H), 7.51 (1H, m, Ar—H), 7.75 (1H, m, Ar—H) and 8.06 ppm (1H, s, H2); δC (CDCl3) CH2: 25.7, 29.7, 42.2, 62.2; CH: 87.4, 127.1, 130.1, 130.2, 131.6, 143.8; C: 83.1, 132.1, 138.8, 145.6, 146.3, 158.1.


Example 460
4-{[3-BROMO-5-(2-CHLOROPHENYL)PYRAZOLO[1,5-a]PYRIMIDIN-7-YLAMINO]METHYL}PIPERIDINE-1-CARBOXYLIC ACID AMIDE



embedded image


A. 4-{[3-BROMO-5-(2-CHLOROPHENYL)PYRAZOLO[1,5-a]PYRIMIDIN-7-YLAMINO]METHYL}PIPERIDINE-1-CARBOXYLIC ACID tert-BUTYL ESTER



embedded image


3-Bromo-7-chloro-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine (300 mg, 0.875 mmoles) (prepared as described in Preparative Example 129) was dissolved in anhydrous 1,4-dioxane (6.8 mL). 4-(aminomethyl)piperidine-1-carboxylic acid tert-butyl ester (225 mg, 1.05 mmoles) and diisopropyl ethylamine (0.3055 mL, 1.75 mmoles) were added and the mixture was heated at 75° C. for 24 h. The solution was evaporated to dryness and the residue was chromatographed on a silica gel column (15×5 cm) using dichloromethane as the eluant to give 4-{[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino]methyl}piperidine-1-carboxylic acid tert-butyl ester (461.2 mg, 100%): FABMS: m/z 520.1 (MH+); HRFABMS: m/z 520.1111 (MH+). Calcd. for C23H28N5O2BrCl: m/z 520.1115; δH (CDCl3) 1.30 (2H, m, CH2), 1.51 (9H, s, —COOC(CH3)3), 1.85 (2H, d, CH2), 1.95 (1H, m, CH), 2.76 (2H, m, CH2), 3.40 (2H, m, CH2), 6.37 (1H, s, H6), 6.55 (1H, m, NH), 7.42 (2H, m, Ar—H), 7.52 (1H, m, Ar—H), 7.76 (1H, m, Ar—H) and 8.07 ppm (1H, s, H2); δC (CDCl3) CH3: 28.5, 28.5, 28.5; CH2: 29.1, 29.1, 43.5, 43.5, 47.9; CH: 36.3, 87.5, 127.2, 130.2, 130.3, 131.6, 143.9; C: 79.7, 83.3, 132.1, 138.6, 145.4, 146.3, 154.7, 158.1.


B. [3-BROMO-5-(2-CHLOROPHENYL)PYRAZOLO[1,5-a]PYRIMIDIN-7-YL]PIPERIDIN-4-YLMETHYLAMINE



embedded image


4-{[3-Bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino]methyl}piperidine-1-carboxylic acid tert-butyl ester (441 mg, 0.847 mmoles) (prepared as described in Example 460, Step A above) was dissolved in methanol (4.5 mL) and 10% (v/v) conc. sulfuric acid in 1,4-dioxane (11.46 mL) was added. The mixture was stirred at 25° C. for 0.5 h. The product was worked up as described in Preparative Example 241, step B and chromatographed on a silica gel column (15×5 cm) using 8% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give [3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]piperidin-4-ylmethylamine (314.4 mg, 88%): FABMS: m/z 420.0 (MH+); HRFABMS: m/z 420.0585 (MH+). Calcd. for C18H20N5BrCl: m/z 420.0591; δH (CDCl3) 1.34 (2H, m, CH2), 1.86 (2H, m, CH2), 1.91 (1H, m, CH), 2.10 (1H, bm, piperidine-NH), 2.67 (2H, m, CH2), 3.18 (2H, m, CH2), 3.38 (2H, m, CH2), 6.37 (1H, s, H6), 6.53 (1H, m, NH), 7.42 (2H, m, Ar—H), 7.52 (1H, m, Ar—H), 7.76 (1H, m, Ar—H) and 8.06 ppm (1H, s Ar—H); δC (CDCl3) CH2: 31.2, 31.2, 46.2, 46.2, 48.4; CH: 36.4, 89.5, 127.1, 130.1, 130.5, 131.6, 143.8; C: 83.2, 132.1, 138.9, 145.6, 146.4, 158.1.


C. 4-{[3-BROMO-5-(2-CHLOROPHENYL)PYRAZOLO[1,5-a]PYRIMIDIN-7-YLAMINO]METHYL}PIPERIDINE-1-CARBOXYLIC ACID AMIDE



embedded image


[3-Bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]piperidin-4-ylmethylamine (57 mg, 0.136 mmoles) (prepared as described in Example 460, Step B above) was dissolved in anhydrous dichloromethane (1.2 mL) and trimethylsilylisocyanate (0.091 mL, 0.679 mmoles) was added. The mixture was stirred at 25° C. for 2.5 h. The mixture was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The organic layer was dried (MgSO4), filtered and evaporated to dryness. The residue was chromatographed on a silica gel column (30×2.5 cm) using 3% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give 4-{[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino]methyl}piperidine-1-carboxylic acid amide (53.7 mg, 86%): FABMS: m/z 463.1 (MH+); HRFABMS: m/z 463.0647 (MH+). Calcd. for C19H21N6OBrCl: m/z 463.0649; δH (d6-DMSO) 1.09 (2H, m, CH2), 1.63 (2H, m, CH2), 1.87 (1H, m, CH), 2.60 (2H, m, CH2), 3.53 (2H, bm, CONH2), 3.91 (2H, d, CH2), 6.52 (1H, s, H6), 7.50 (2H, m, Ar—H), 7.62 (2H, m, Ar—H), 8.33 (1H, s, H2) and 8.52 ppm (1H, m, NH); δC (d6-DMSO)CH2: 30.1, 30.1, 44.2, 44.2, 47.7; CH: 36.4, 88.2, 128.1, 130.7, 131.4, 132.1, 147.9; C: 82.1, 132.1, 139.4, 145.7, 147.9, 158.1, 158.8.


Example 461
2-{2-[3-BROMO-5-(2-CHLOROPHENYL)PYRAZOLO[1,5-a]PYRIMIDIN-7-YLAMINO]ETHYL}PIPERIDINE-1-CARBOXYLIC ACID AMIDE



embedded image


A. 2-{2-[3-BROMO-5-(2-CHLOROPHENYL)PYRAZOLO[1,5-a]PYRIMIDIN-7-YLAMINO]ETHYL}PIPERIDINE-1-CARBOXYLIC ACID tert-BUTYL ESTER



embedded image


3-Bromo-7-chloro-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidine (400 mg, 1.166 mmoles) (prepared as described in Preparative Example 129) was dissolved in anhydrous 1,4-dioxane (5.7 mL). 2-Aminoethylpiperidine-1-carboxylic acid tert-butyl ester (266 mg, 1.166 mmoles) and diisopropyl ethylamine (0.409 mL, 2.33 mmoles) were added and the mixture was heated at 75° C. for 48 h. Additional diisopropyl ethylamine (0.204 mL, 1.166 mmoles) was added and the heating was continued for a total of 58 h. The solution was evaporated to dryness and the residue was chromatographed on a silica gel column (15×5 cm) using dichloromethane followed by 0.3% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give 2-{[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino]ethyl}piperidine-1-carboxylic acid tert-butyl ester (491.1 mg, 79%): FABMS: m/z 534.1 (MH+); HRESIMS: m/z 534.12797 (MH+). Calcd. for C24H30N5O2BrCl: m/z 534.12714; δH (CDCl3) 1.50 (1H, m, CH2), 1.51 (9H, s, COOC(CH3)3), 1.57 (2H, m, CH2), 1.68 (2H, m, CH2), 1.76 (2H, m, CH2), 2.24 (1H, bm, CH2), 2.82/3.40/3.54/4.08/4.51 (5H, m, CH/CH2), 6.34 (1H, s, H6), 7.41 (2H, m, Ar—H), 7.51 (1H, m, Ar—H), 7.76 (1H, m, Ar—H) and 8.08 ppm (1H, s, H2); δC (CDCl3) CH3: 28.5, 28.5, 28.5; CH2: 19.2, 25.5, 29.2, 29.2, 39.2, 67.1; CH: ˜47.4, 87.1, 127.1, 130.1, 130.1, 131.6, 143.9; C: 80.0, 83.0, 132.1, 138.9, 145.7, 146.2, 158.0.


B. [3-BROMO-5-(2-CHLOROPHENYL)PYRAZOLO[1,5-a]PYRIMIDIN-7-YL]-(2-PIPERIDIN-2-YLETHYL)AMINE



embedded image


2-{[3-Bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino]ethyl}piperidine-1-carboxylic acid tert-butyl ester (465 mg, 0.869 mmoles) (prepared as described in Example 461, Step A above) was dissolved in methanol (4.5 mL) and 10% (v/v) conc. sulfuric acid in 1,4-dioxane (11.76 mL) was added. The mixture was stirred at 25° C. for 1.5 h. The product was worked up as described in Preparative Example 241, step B and chromatographed on a silica gel column (15×5 cm) using 3.5% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give [3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]piperidin-2-ylethyl)amine (365.6 mg, 97%): FABMS: m/z 434.1 (MH+); HRFABMS: m/z 434.0726 (MH+). Calcd. for C19H22N5BrCl: m/z 434.0747; δH (CDCl3) 1.24 (1H, m, CH2), 1.41 (1H, m, CH2), 1.49 (1H, m, CH2), 1.66 (1H, m, CH2), 1.73 (1H, m, CH2), 1.81 (1H, m, CH2), 1.88 (2H, m, CH2), 2.68 (1H, m, CH2), 2.78 (1H, m, CH2), 3.20 (1H, m, CH), 3.55 (1H, m, CH2), 3.60 (1H, m, CH2), 6.32 (1H, s, H6), 7.41 (2H, m, Ar—H), 7.51 (1H, m, Ar—H), 7.74 (1H, m, Ar—H), 7.78 (1H, m, NH) and 8.05 ppm (1H, s, H2); δC (CDCl3) CH2: 24.7, 26.8, 33.1, 35.2, 40.3, 47.0; CH: 55.7, 87.2, 127.1, 130.0, 130.1, 131.5, 143.8; C: 82.9, 132.1, 139.0, 145.7, 146.5, 158.1.


C. 2-{2-[3-BROMO-5-(2-CHLOROPHENYL)PYRAZOLO[1,5-a]PYRIMIDIN-7-YLAMINO]ETHYL}PIPERIDINE-1-CARBOXYLIC ACID AMIDE



embedded image


[3-Bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]piperidin-2-ylethyl)amine (200 mg, 0.46 mmoles) (prepared as described in Example 461, Step B above) was dissolved in anhydrous dichloromethane (2 mL) and trimethylsilylisocyanate (0.31 mL, 2.3 mmoles) was added. The mixture was stirred at 25° C. for 1.25 h. Additional trimethylsilylisocyanate (0.155 mL, 1.15 mmoles) was added and the stirring was continued for a total of 3 h. The mixture was diluted with dichloromethane and washed with saturated aqueous sodium bicarbonate. The organic layer was dried (MgSO4), filtered and evaporated to dryness. The residue was chromatographed on a silica gel column (30×2.5 cm) using 2% (10% conc. ammonium hydroxide in methanol)-dichloromethane as the eluant to give 2-{2-[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino]ethyl}piperidine-1-carboxylic acid amide (106.3 mg, 48%): FABMS: m/z 477.0 (MH+); HRFABMS: m/z 477.0804 (MH+). Calcd. for C20H23N6OBrCl: m/z 477.0805; δH (d6-DMSO) 1.29 (1H, m, CH2), 1.52 (5H, m, CH2), 1.72 (1H, m, CH2), 2.05 (1H, m, CH2), 2.51 (2H, s, CONH2), 2.79 (1H, dd, CH), 3.31 (1H, m, CH2), 3.34 (1H, m, CH2), 3.76 (1H, m, CH2), 4.30 (1H, bm, CH2), 6.42 (1H, s, H6), 7.50 (2H, m, Ar—H), 7.60 (1H, m, Ar—H), 7.63 (1H, m, Ar—H), 8.29 (1H, s, H2) and 8.38 ppm (1H, dd, NH); δC (d6-DMSO)CH2: 18.6, 25.2, 28.2, 38.4, 38.6, 54.8; CH: 46.7, 86.6, 127.1, 129.7, 130.3, 131.0, 143.4; C: 81.2, 131.0, 138.7, 145.1, 146.4, 158.2.


Example 462



embedded image


To a solution of the compound prepared in Example 204 (1.11 g, 2.12 mmol) in anhydrous acetonitrile (20 mL) was added TMSI (1.70 g, 8.52 mmol), dropwise at ambient temperature. After 10 minutes the acetonitrile was removed in vacuo. The resulting yellow foam was treated with 2 N HCl solution (7 mL) and then washed immediately with Et2O (5×). The pH of the aqueous was adjusted to 10 with 50% NaOH (aq) and the product was isolated by saturation of the solution with NaCl (s) followed by extraction with CH2Cl2 (5×) to give the crystalline product (733 mg, 89% yield). MH+=387; m.p.=207.5° C.


Examples 463-472

By essentially the same procedure set forth in Example 462 only substituting the compounds shown in Column 2 of Table 38, the compounds shown in Column 3 of Table 38 were prepared.












TABLE 38





Ex.
Column 2
Column 3
CMPD


















463


embedded image




embedded image


MH+ = 403 1H NMR(300 MHz, CDCl3) δ 8.52(s, 1H), 8.38(d, 1H), 8.04(s, 1H), 7.78(d, 1H), 7.65(t, 1H), 6.18(s, 1H), 4.89(s, 2H), 3.26-3.21(d, 2H), 2.96-2.70(m, 3H), 2.05-1.78(m, 4H).





464


embedded image




embedded image


MH+ = 454 m.p. = 175.4° C.





465


embedded image




embedded image


Yield = 87 MH+ = 470 m.p. = 220° C. m. pt (hydrochloride salt) = 164.3° C.





466


embedded image




embedded image


MH+ = 464 m.p. = 206° C.





467


embedded image




embedded image


MH+ = 411 m.p. = 169.5° C.





468


embedded image




embedded image


MH+ = 334 m.p. = 176.2° C.





469


embedded image




embedded image


MH+ = 465 m.p. = 250.4° C.





470


embedded image




embedded image


MH+ = 387 m.p. = 68.5° C.





471


embedded image




embedded image


MH+ = 387 m.p. = 59.4° C.





472


embedded image




embedded image


1. mp = 230-232 2. M + H = 396





472.10


embedded image




embedded image


1. mp = 157-160 2. M + H = 427









Example 473

Step A:




embedded image


A solution of the sulfonic acid (560 mg, 1.17 mmol) in 5 mL of dry DMF was cooled to 0° C. and SOCl2 (278 mg, 2.34 mmol) was added. The reaction mixture was brought to RT and stirred overnight. The next day the contents were poured on ice and the pH was carefully adjusted to 8. The product was extracted in to EtOAc and the solvent was removed after drying (Na2SO4) to provide 240 mg (41%) of the crude sulfonyl chloride which was used for the next step without further purification. 1H NMR (CDCl3) δ 8.20-8.10 (m, 1H), 8.10-7.95 (m, 3H), 7.65 (d, 2H), 7.45-7.35 (m, 1H), 7.35-7.20 (m, 1H), 7.15-7.05 (m, 1H), 6.95 (t, 1H), 4.85 (d, 2H).


Step B:




embedded image


A solution of compound prepared in Example 473, Step A (120 mg, 0.24 mmol) in 10 mL of THF was treated with 2 mL of 1 M MeNH2 (2.00 mmol) in THF at RT overnight. The solvent was removed and the residue was purified by chromatography (silica, hexane:EtOAc (4:1→1:1)) to provide 56 mg (48%) of the sulfonamide. 1H NMR (DMSO-d6) δ 9.05 (t, J=9 Hz, 1H), 8.35 (s, 1H), 7.90 (t, J=7.5 Hz, 1H), 7.75 (d, J=9 Hz, 2H), 7.62 (d, J=9 Hz, 2H), 7.55-7.46 (m, 1H), 7.45-7.38 (m, 1H), 7.38-7.25 (m, 1H), 6.50 (s, 1H), 4.80 (d, 2H), 3.30 (s, 3H) LCMS: MH+=492.1


Example 474



embedded image


By essentially the same procedure set forth in Example 473, only substituting dimethylamine, the above compound was prepared. 1H NMR (CDCl3) δ 8.14 (t, J=9 Hz, 1H), 8.00 (s, 1H), 7.76 (d, J=9 Hz, 2H), 7.54 (d, J=9 Hz, 2H), 7.34-7.44 (m, 1H), 7.26 (t, J=9 Hz, 1H), 7.14-7.04 (m, 1H), 6.93 (t, J=6 Hz, 1H), 6.45 (s, 1H), 4.75 (d, 2H), 2.70 (s, 6H)


LCMS: MH+=504.2


Example 475



embedded image


A mixture of the compound prepared in Example 129 (300 mg, 0.66 mmol), NaOH (5 g), CH3OH—H2O (100 mL, 90:10) was stirred at 25 C for about 15 h. Progress of hydrolysis was checked by TLC. Reaction mixture was concentrated to remove methanol. The concentrate was diluted with 50 mL water, and extracted with ether to remove any un-reacted ester. Aqueous solution, thus obtained, was neutralized with 3 N HCl to pH 4 to obtain free acid, filtered and washed repeatedly with water. The acid was dried under vacuum (270 mg, 93%) and used without further purification.


Example 476-479

By essentially the same procedure set forth in Example 475 only substituting the compounds in Column 2 of Table 39, the compounds in Column 3 of Table 39 were prepared.












TABLE 39





Ex.
Column 2
Column 3
CMPD







476


embedded image




embedded image


Yield = 82% LCMS: MH+ = 365





477


embedded image




embedded image


Yield = 82% LCMS: MH+ = 379





478


embedded image




embedded image


Yield = 72% LCMS: MH+ = 393





479


embedded image




embedded image


Yield = 70% LCMS: MH+ = 407










Additional data for select examples shown below:


Example 476


1H NMR (CDCl3) δ 8.15 (m, 2H), 8.0 (m, 1H), 7.6 (m, 1H), 7.3 (m, 2H), 6.6 (s, 1H), 4.2 (d, 2H).


Example 477


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.4 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 7.0 (t, 1H), 6.5 (s, 1H), 3.8 (dt, 2H), 2.6 (t, 2H).


Example 479


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.4 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 6.8 (t, 1H), 3.5 (dt, 2H), 2.4 (t, 2H), 1.8 (m, 4H).


Example 480



embedded image


A mixture of the acid from Example 475 (85 mg, 0.193 mmol) and Et3N (20 mg, 0.193 mmol) in THF (20 mL) was stirred at 25 C for 15 min. Isobutyryl chloroformate (28 mg, 0.205 mmol) was added to the reaction mixture and stirred for 10 min followed by addition of NH4OH solution (0.5 mL). The reaction mixture was stirred for 1 hr and concentrated to dryness. The dry mass was purified by column chromatography.


Examples 481-509

By essentially the same procedure set forth in Example 480 only substituting the carboxylic acid shown in Column 2 of Table 40 and the amine shown in Column 3 of Table 40, the compounds shown in Column 4 of Table 40 were prepared.













TABLE 40





Ex.
Column 2
Column 3
Column 4
CMPD



















481


embedded image


CH3NH2


embedded image


Yield = 88% LCMS: MH+ = 454





482


embedded image


(CH3)2NH


embedded image


Yield = 80% LCMS MH+ = 468





483


embedded image


CH3NH2


embedded image


Yield = 70% LCMS MH+ = 454.





484


embedded image




embedded image




embedded image


Yield = 75% LCMS MH+ = 482.1





485


embedded image




embedded image




embedded image


Yield = 71% LCMS MH+ = 480.1





486


embedded image




embedded image




embedded image


Yield = 75% LCMS MH+ = 494.1





487


embedded image




embedded image




embedded image


Yield = 75% MH+ = 494.1





488


embedded image




embedded image




embedded image


Yield = 75% MH+ = 496.1





489


embedded image




embedded image




embedded image


Yield = 75% LCMS MH+ = 508.1





490


embedded image




embedded image




embedded image


Yield = 78% LCMS MH+ = 524.1





491


embedded image




embedded image




embedded image


Yield = 73% LCMS MH+ = 508.1





492


embedded image




embedded image




embedded image


Yield = 73% LCMS MH+ = 510.1





493


embedded image




embedded image




embedded image


Yield = 76% LCMS MH+ = 526.1





494


embedded image




embedded image




embedded image


Yield = 76% MH+ = 523.1





495


embedded image




embedded image




embedded image


Yield = 76% MH+ = 523.1





496


embedded image




embedded image




embedded image


Yield = 51% LCMS MH+ = 484.1





497


embedded image




embedded image




embedded image


Yield = 66% MH+ = 537.1





498


embedded image




embedded image




embedded image


Yield = 76% LCMS MH+ = 551.2





499


embedded image




embedded image




embedded image


Yield = 79% LCMS MH+ = 552.1





500


embedded image




embedded image




embedded image


Yield = 80% MH+ = 549.1





501


embedded image




embedded image




embedded image


Yield = 80% LCMS MH+ = 478.1





502


embedded image




embedded image




embedded image


Yield = 80% LCMH+ = 468.1





503


embedded image




embedded image




embedded image


Yield = 80% MH+ = 522.1





504


embedded image




embedded image




embedded image


Yield = 82% LCMS MH+ = 528.1





505


embedded image


CH3NH2


embedded image


Yield = 60% MH+ = 392





506


embedded image




embedded image




embedded image


Yield = 60% LCMH+ = 448.1





507


embedded image




embedded image




embedded image


Yield = 70% MH+ = 464.1





508


embedded image




embedded image




embedded image


Yield = 50% LCMS MH+ = 436.1





508.10


embedded image


CH3NH2


embedded image


Yield = 92 MH+ = 577










Additional data for select examples given below:


Example 481


1H NMR (CDCl3) δ8.15 (dt, 1H), 8.0 (s, 1H), 7.7 (b, 2H), 7.4 (s, 1H), 7.35 (m, 2H), 7.25 (d, 1H), 7.15 (dd, 1H), 6.95 (t, 1H), 6.5 (s, 1H), 6.25 (bs, 1H), 4.7 (d, 2H), 3.0 (d, 3H).


Example 482


1H NMR (CDCl3) δ8.15 (d, 1H), 8.0 (s, 1H), 7.45-7.35 (m, 4H), 7.25 (m, 2H), 7.15 (dd, 1H), 6.7 (t, 1H), 6.5 (s, 1H), 4.7 (d, 2H), 3.1 (s, 3H), 3.0 (s, 3H).


Example 483


1H NMR (CDCl3) δ8.15 (dt, 1H), 8.0 (s, 1H), 7.8 (bs, 1H), 7.7 (d, 1H), 7.5-7.3 (m, 3H), 7.25 (d, 1H), 7.15 (dd, 1H), 6.75 (t, 1H), 6.5 (s, 1H), 6.2 (bs, 1H), 4.7 (d, 2H), 3.0 (d, 3H).


Example 484


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.7 (d, 2H), 7.4 (d, 2H), 7.35 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 6.8 (t, 1H), 6.5 (s, 1H), 6.0 bs, 1H), 4.7 (d, 2H), 4.25 (m, 1H), 1.2 (d, 6H).


Example 485


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.7 (d, 2H), 7.4 (d, 2H), 7.35 (s, 1H), 7.25 (dd, 1H), 7.1 (dd, 1H), 6.9 (t, 1H), 6.5 (s, 1H), 6.3 (t, 1H), 4.7 (d, 2H), 2.9 (m, 1H), 0.8 (bt, 2H), 0.6 (bt, 2H).


Example 486


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.8 (d, 2H), 7.4 (d, 2H), 7.35 (d, 1H), 7.25 (dd, 1H), 7.1 (dd, 1H), 6.9 (t, 1H), 6.5 (s, 1H), 6.2 (t, 1H), 4.7 (d, 2H), 3.3 (dd, 2H), 1.05 (m, 1H), 0.5 (m, 2H), 0.25 (m, 2H).


Example 487


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.7 (d, 2H), 7.4 (d, 2H), 7.35 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 6.85 (t, 1H), 6.5 (s, 1H), 6.2 (bs, 1H), 4.7 (d, 2H), 4.6 (m, 1H), 2.4 (m, 2H), 1.95 (m, 1H), 1.75 (m, 2H).


Example 488


1H NMR (CDCl3) δ 8.5 (t, 1H), 8.15 (dt, 1H), 8.0 (s, 1H), 7.7 (d, 2H), 7.4 (d, 2H), 7.35 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 6.8 (t, 1H), 6.5 (s, 1H), 5.9 (bs, 1H), 4.7 (d, 2H), 1.4 (s, 9H).


Example 489


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.7 (d, 2H), 7.4 (d, 2H), 7.35 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 6.8 (t, 1H), 6.5 (s, 1H), 6.0 bs, 1H), 4.7 (d, 2H), 4.4 (m, 1H), 2.05 (m, 2H), 1.7 (m, 4H), 1.4 (m, 2H).


Example 490


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.7 (d, 2H), 7.4 (d, 2H), 7.35 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 6.8 (t, 1H), 6.5 (s, 1H), 6.5 (bs, 2H), 4.7 (d, 2H), 4.1 (m, 1H), 3.9-3.7 (m, 3H), 3.3 (m, 1H), 2.0-1.9 (m, 4H).


Example 491


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.45-7.35 (m, 5H), 7.25 (dd, 1H), 7.1 (dd, 1H), 6.8 (t, 1H), 6.5 (s, 1H), 4.7 (d, 2H), 3.7 (bs, 2H), 3.3 (bs, 2H), 1.7 (bs, 4H), 1.5 (bs, 2H).


Example 492


1H NMR (CDCl3) δ8.15 (dt, 1H), 8.0 (s, 1H), 7.45-7.35 (m, 5H), 7.25 (dd, 1H), 7.1 (dd, 1H), 6.85 (t, 1H), 6.5 (s, 1H), 4.7 (d, 2H), 3.8-3.4 (bm, 8H).


Example 493


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.45-7.35 (m, 5H), 7.25 (dd, 1H), 7.1 (dd, 1H), 6.80 (t, 1H), 6.5 (s, 1H), 4.7 (d, 2H), 4.0 (m, 2H), 3.6 (m, 2H), 2.8-2.45 (m, 4H).


Example 494


1H NMR (CH3OD) δ 8.15 (s, 1H), 8.0 (dt, 1H), 7.45-7.35 (m, 5H), 7.25 (dd, 1H), 7.1 (dd, 1H), 6.80 (t, 1H), 6.5 (s, 1H), 4.7 (d, 2H), 3.7 (bs, 2H), 3.4 (bs, 2H), 2.5-2.4 (m, 4H), 2.2 (s, 3H).


Example 495


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.45-7.35 (m, 5H), 7.25 (dd, 1H), 7.1 (dd, 1H), 6.80 (t, 1H), 6.5 (s, 1H), 4.7 (d, 2H), 3.75 (bs, 2H), 3.35 (bs, 2H), 2.4 (bs, 2H), 2.3 (s, 3H), 2.2 (bs, 2H).


Example 496


1H NMR (CDCl3) δ 7.95 (s, 1H), 7.9 (dt, 1H), 7.8 (t, 1H), 7.7 (d, 2H), 7.15 (m, 4H), 7.05 (dd, 1H), 6.9 (dd, 1H), 6.2 (s, 1H), 4.5 (d, 2H), 3.6 (t, 2H), 3.3 (dt, 2H).


Example 497


1H NMR (CH3OD) δ 8.1 (s, 1H), 7.9 (dt, 1H), 7.8 (d, 2H), 7.5 (d, 2H), 7.4 (m, 1H), 7.3 (dd, 1H), 7.2 (dd, 1H), 6.4 (s, 1H), 4.7 (d, 2H), 3.5 (t, 2H), 2.7 (m, 2H), 2.6 (bs, 4H), 1.8 (bs, 4H).


Example 498


1H NMR (CDCl3) δ 8.5 (t, 1H), 8.15 (dt, 1H), 8.0 (s, 1H), 7.8 (d, 2H), 7.4 (d, 2H), 7.35 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 6.8 (t, 1H), 6.5 (s, 1H), 4.7 (d, 2H), 3.7-2.5 (m, 4H), 2.35 (s, 3H), 2.2 (m, 1H), 1.9-1.6 (m, 6H).


Example 499


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.8 (d, 2H), 7.4 (d, 2H), 7.35 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 6.8 (t, 1H), 6.5 (s, 1H), 4.7 (d, 2H), 3.7 (m, 4H), 3.5 (dt, 2H), 2.6 (t, 2H), 2.5 (m, 4H).


Example 500


1H NMR (CH3OD) δ 8.15 (s, 1H), 7.9 (dt, 1H), 7.8 (d, 2H), 7.45 (d, 2H), 7.4 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 6.4 (s, 1H), 4.75 (d, 2H), 4.2 (m, 1H), 3.4-2.8 (m, 7H), 1.9-1.6 (m, 4H).


Example 501


1H NMR (CDCl3) δ 8.05 (dt, 1H), 8.0 (s, 1H), 7.6 (d, 2H), 7.4 (s, 1H), 7.35 (d, 2H), 7.25 (dd, 1H), 7.1 (dd, 1H), 6.9 (t, 1H), 6.5 (s, 1H), 6.4 (t, 1H), 4.7 (d, 2H), 4.2 (d, 2H), 2.3 (bs, 1H).


Example 502


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.75 (d, 2H), 7.45 (s, 1H), 7.4 (d, 2H), 7.3 (dd, 1H), 7.1 (dd, 1H), 6.8 (t, 1H), 6.5 (s, 1H), 6.1 (bs, 1H), 4.7 (d, 2H), 3.5 (dq, 2H), 1.2 (t, 3H).


Example 503


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.8 (d, 2H), 7.4 (d, 2H), 7.35 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 6.9 (t, 1H), 6.5 (s, 1H), 6.4 (t, 1H), 4.75 (d, 2H), 4.1 (m, 2H).


Example 504


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.8 (d, 2H), 7.45 (d, 2H), 7.4 (m, 1H), 7.25 (dd, 1H), 7.1 (dd, 1H), 6.8 (t, 1H), 6.6 (t, 1H), 6.5 (s, 1H), 4.7 (d, 1H), 3.6 (m, 2H), 2.8 (t, 2H), 2.6 (q, 2H), 1.3 (t, 3H).


Example 505


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.4 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 7.0 (t, 1H), 6.5 (s, 1H), 3.8 (m, 2H), 2.7 (t, 2H), 3.0 (d, 3H).


Example 506


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.4 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 7.0 (t, 1H), 6.5 (s, 1H), 3.8 (m, 2H), 3.6 (m, 6H), 3.4 (m, 2H), 2.7 (t, 2H).


Example 507


1H NMR (CDCl3) δ 8.15 (dt, 1H), 8.0 (s, 1H), 7.4 (m, 1H), 7.25 (dd, 1H), 7.15 (dd, 1H), 7.0 (t, 1H), 6.5 (s, 1H), 3.9 (t, 2H), 3.8 (dt, 2H), 3.7 (t, 2H), 2.7 (t, 2H), 2.6 (m, 4H).


Example 508


1H NMR (CH3OD) δ 8.1 (s, 1H), 7.95 (dt, 1H), 7.5 (m, 1H), 7.35-7.2 (m, 2H), 6.5 (s, 1H), 3.6 (m, 4H), 3.25 (m, 4H), 2.4 (t, 2H), 2.05 (dt, 2H).


Example 509



embedded image


A solution of NaOH (59 mg, 1.47 mmol) in 1 mL of water was added to a suspension of NH2OH.HCl (102 mg, 1.47 mmol) in 10 mL of methanol at 0° C. After 5 min, the compound prepared in Example 210.10 (208 mg, 0.49 mmol) was added and the reaction mixture was refluxed overnight. The solvent was removed in vacuo and the residue was partitioned between water and EtOAc. The EtOAc layer was dried (Na2SO4) and the solvent was evaporated. The resulting crude amidoxime was suspended in trimethyl orthoformate containing catalytic amount of PTS acid and refluxed overnight. The solvent was removed and the residue was taken up in EtOAc. The EtOAc layer washed with aq NaHCO3 followed by water and brine. The solvent was evaporated and the residue was purified by chromatography (silica, hexane:EtOAc (1:1)) to provide 80 mg (35%) of the oxadiazole. 1H NMR (CDCl3) δ 8.75 (s, 1H), 8.20-8.10 (m, 3H), 8.03 (s, 1H), 7.53 (d, J=9 Hz, 2H), 7.45-7.36 (m, 1H), 7.30-7.22 (m, 2H), 7.16-7.08 (m, 1H), 6.80 (t, J=5 Hz, 1H), 6.56 (s, 1H).


LCMS: MH+=465.2


Example 510



embedded image


By essentially the same procedure set forth in Example 509 only substituting the compound prepared in Preparative Example 192, the above compound was prepared. yield=75; MH+=453; m.p.=79.3° C.


Example 511



embedded image


A mixture of the nitrile (235 mg, 0.56 mmol) and Me3SnN3 (343 mg, 1.67 mmol) in 20 mL of dry toluene was refluxed for 2 days under Ar. The solvent was removed in vacuo and the residue was dissolved in dry methanol. HCl gas was bubbled through the solution for 15 min and the reaction mixture allowed to stand at overnight at RT. The next day, the solvent was removed, the residue was taken in water and the pH was adjusted to 5. The precipitated product was extracted into EtOAc. Evaporation of the EtOAc layer after drying (Na2SO4) provided the residue which was purified by chromatography (silica, DCM:MeOH (98:2→95:5)) to yield 50 mg (19%) of the pure tetrazole. 1H NMR (CD3OD) δ 8.10 (s, 1H), 8.00 (d, J=9 Hz, 2H), 7.90 (t, J=7 Hz, 1H), 7.65 (d, J=9 Hz, 2H), 7.50-7.40 (m, 1H), 7.30-7.10 (m, 2H), 6.45 (s, 1H), 4.80 (s, 2H); LCMS: MH+=465.0


Example 512



embedded image


By essentially the same procedure set forth in Example 511 only substituting the compound prepared in Example 192, the above compound was prepared. Yield=64; MH+=453; m.p.=238.9° C.


Example 513



embedded image


The compound prepared in Example 157 was dissolved in dioxane (30 mL) and a HCl-dioxane solution (4 M, 30 mL) was added. The reaction mixture was stirred at room temperature for 4 h. The reaction mixture was evaporated under reduced pressure and ethyl acetate (200 mL) was added. The organic solution washed with 1 N sodium hydroxide followed by saturated brine. The organic layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure. MH+=442.1


Example 514-526

By essentially the same procedure set forth in Example 513, only substituting the compounds shown in Column 2 of Table 41, the compounds shown in Column 3 of Table 41 were prepared.












TABLE 41





Ex.
Column 2
Column 3
CMPD


















514


embedded image




embedded image


MH+ = 420.1





515


embedded image




embedded image


MH+ = 442.1





516


embedded image




embedded image


MH+ = 380.1





517


embedded image




embedded image


MH+ = 406.1





518


embedded image




embedded image


MH+ = 380.1





519


embedded image




embedded image


MH+ = 394.1





520


embedded image




embedded image


MH+ = 366





521


embedded image




embedded image


MH+ = 394





522


embedded image




embedded image


MH+ = 408.1





523


embedded image




embedded image


MH+ = 420.1





524


embedded image




embedded image








525


embedded image




embedded image


MH+ = 420.1





526


embedded image




embedded image


MH+ = 428.1





526.10


embedded image




embedded image











Examples 528-564

General Procedure for 5-Piperidinyl Parallel Library Formation:


To a mixture of the starting material (80 mg, 0.21 mmol) shown in Column 2 of Table 42 in anhydrous CH2Cl2 (1.5 mL) was added DIPEA (75 μL, 0.42 mmol) and the appropriate capping reagent (1.1 equiv., 0.23 mmol). After 1 to 2 h, the reaction mixture was applied to 1000 micron preparatory TLC plate and was subsequently developed using a 8-10% EtOH—CH2Cl2 as eluent to afford the compounds shown in Column 3 of Table 42.












TABLE 42





Ex.
Column 2
Column 3
CMPD







528


embedded image




embedded image


MH+ = 608 m.p. = 230.1° C.





529


embedded image




embedded image


Yield = 82 MH+ = 614 m.p. = 235.4° C.





530


embedded image




embedded image


MH+ = 486 m.p. = 60.5° C.





531


embedded image




embedded image


MH+ = 500 m.p. = 113.6° C.





532


embedded image




embedded image


MH+ = 430 m.p. = 158.3- 159.2° C.





533


embedded image




embedded image


MH+ = 531 m.p. = 105.9° C.





534


embedded image




embedded image


MH+ = 486





535


embedded image




embedded image


MH+ = 500





536


embedded image




embedded image


MH+ = 430





537


embedded image




embedded image


MH+ = 531





538


embedded image




embedded image


MH+ = 486 m.p. = 69.6° C.





539


embedded image




embedded image


MH+ = 500 m.p. = 82.3° C.





540


embedded image




embedded image


MH+ = 430 m.p. = 223.6° C.





541


embedded image




embedded image


MH+ = 531 m.p. = 118.1° C.





542


embedded image




embedded image


MH+ = 455 m.p. = 109- 110° C.





543


embedded image




embedded image


MH+ = 429 m.p. = 111.5° C.





544


embedded image




embedded image


MH+ = 455





545


embedded image




embedded image


MH+ = 429





546


embedded image




embedded image


MH+ = 455 m.p. = 80.1° C.





547


embedded image




embedded image


MH+ = 429 m.p. = 64.7° C.





548


embedded image




embedded image


MH+ = 494 m.p. = 76.5° C.





549


embedded image




embedded image


MH+ = 493 m.p. = 83.6° C.





550


embedded image




embedded image


MH+ = 465 m.p. = 207.5° C.





551


embedded image




embedded image


MH+ = 494





552


embedded image




embedded image


MH+ = 493





553


embedded image




embedded image


MH+ = 465





554


embedded image




embedded image


MH+ = 481 m.p. = 102.7° C.





555


embedded image




embedded image


MH+ = 494 m.p. = 85.3° C.





556


embedded image




embedded image


MH+ = 493 m.p. = 89.1° C.





557


embedded image




embedded image


MH+ = 465 m.p. = 83.8° C.





558


embedded image




embedded image


Yield = quant. MH+ = 443 m.p. = 98.3° C. (HCl salt)





559


embedded image




embedded image


MH+ = 454





560


embedded image




embedded image


Yield = quant. MH+ = 429 m.p. = 111.5- 112.6° C.





561


embedded image




embedded image


MH+ = 460 m.p. = 122.7° C.





562


embedded image




embedded image


MH+ = 460 m.p. = 95.4° C.





563


embedded image




embedded image


MH+ = 460





564


embedded image




embedded image


MH+ = 460 m.p. = 95.4° C.










Additional data for select examples given below.


Example 534


1H NMR (300 MHz, CDCl3) δ 8.66-8.62 (s, 1H), 8.62-8.58 (d, 1H), 7.95 (s, 1H), 7.72-7.68 (d, 1H), 7.36-7.31 (dd, 1H), 6.66-6.62 (t, 1H), 5.93 (s, 1H), 4.65-4.62 (d, 2H), 3.86-3.82 (d, 1H), 3.65-3.58 (m, 1H), 3.26-3.12 (dd, 4H), 3.02-2.80 (m, 3H), 2.10-2.00 (m, 1H), 1.67-1.57 (m, 3H).


Example 535


1H NMR (300 MHz, CDCl3) δ 8.66-8.62 (s, 1H), 8.62-8.58 (d, 1H), 7.95 (s, 1H), 7.72-7.67 (d, 1H), 7.36-7.30 (dd, 1H), 6.70-6.64 (t, 1H), 5.90 (s, 1H), 4.63-4.61 (d, 2H), 3.93-3.86 (m, 1H), 3.69-3.61 (m, 4H), 3.27-3.23 (m, 4H), 3.10-3.01 (dd, 1H), 2.93-2.84 (m, 2H), 2.08-2.03 (m, 1H), 1.90-1.57 (m, 4H).


Example 536


1H NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 8.62-8.58 (d, 1H), 7.96 (s, 1H), 7.72-7.68 (d, 1H), 7.36-7.30 (dd, 1H), 6.79-6.72 (t, 1H), 5.96 (s, 1H), 4.86 (br s, 2H), 4.66-4.63 (d, 2H), 3.89-3.73 (m, 2H), 3.55-3.32 (m, 2H), 3.00-2.89 (m, 1H), 2.10-1.97 (m, 2H), 1.70-1.53 (m, 2H).


Example 537


1H NMR (300 MHz, CDCl3) δ 8.66 (s, 1H), 8.62-8.58 (d, 1H), 7.98 (s, 1H), 7.77-7.76 (t, 1H), 7.72-7.69 (d, 1H), 7.63-7.59 (m, 1H), 7.56 (s, 1H), 7.36-7.29 (dd, 1H), 6.83-6.79 (t, 1H), 5.96 (s, 1H), 4.67-4.64 (d, 2H), 3.98-3.93 (dd, 1H), 3.79-3.68 (m, 2H), 3.37-3.28 (m, 1H), 3.03-2.94 (m, 1H), 2.12-1.99 (m, 1H), 1.76-1.56 (m, 3H).


Example 544


1H NMR (300 MHz, CDCl3) δ 8.66-8.62 (d, 1H), 8.61-8.58 (dd, 1H), 7.95 (s, 1H), 7.72-7.67 (d, 1H), 7.36-7.30 (dd, 1H), 6.80-6.62 (br s, 1H), 5.88 (s, 1H), 4.63 (s, 2H), 3.08-2.95 (m, 2H), 2.87-2.80 (m, 2H), 2.04 (m, 1H), 1.85-1.78 (m, 4H), 1.52-1.44 (m, 1H), 0.87-0.82 (m, 2H), 0.72-0.66 (m, 2H).


Example 545


1H NMR (300 MHz, CDCl3) δ 8.66 (s, 1H), 8.62-8.58 (br t, 1H), 7.97 (s, 1H), 7.73-7.68 (d, 1H), 7.36-7.30 (br t, 1H), 6.79-6.72 (br t, 1H), 5.96 (s, 1H), 4.64 (br s, 2H), 4.59-4.46 (br d, 1H), 3.95-3.74 (br m, 1H), 3.57-3.49 (dd, 1H), 3.10-3.01 (dd, 1H), 2.86-2.70 (m, 2H), 2.13 (s, 3H), 2.06-2.00 (m, 2H), 1.65-1.48 (m, 2H).


Example 551


1H NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 8.63-8.59 (d, 1H), 7.96 (s, 1H), 7.74-7.69 (d, 1H), 7.36-7.30 (dd, 1H), 6.69-6.64 (t, 1H), 5.95 (s, 1H), 4.67-4.63 (d, 2H), 3.85 3.65 (m, 1H), 3.75-3.65 (m, 1H), 3.25-3.18 (dd, 1H), 3.03-2.90 (m, 2H), 2.81 (s, 6H), 2.03-1.95 (m, 1H), 1.89-1.68 (m, 3H).


Example 552


1H NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 8.62-8.59 (d, 1H), 7.95 (s, 1H), 7.74-7.69 (d, 1H), 7.36-7.31 (dd, 1H), 6.67-6.60 (t, 1H), 5.98 (s, 1H), 4.67-4.63 (d, 2H), 3.92-3.86 (m, 1H), 3.85-3.75 (m, 1H), 3.40-3.30 (dd, 1H), 3.27-3.16 (m, 1H), 3.10-2.86 (m, 2H), 2.10-1.78 (m, 3H), 1.40-1.30 (d, 6H).


Example 553


1H NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 8.62 (br s, 1H), 7.96 (s, 1H), 7.74-7.69 (d, 1H), 7.36-7.31 (dd, 1H), 6.70-6.66 (t, 1H), 5.98 (s, 1H), 4.67-4.63 (d, 2H), 3.88-3.81 (m, 1H), 3.71-3.65 (m, 1H), 3.20-3.11 (dd, 1H), 3.02-2.91 (m, 1H), 2.90-2.80 (m, 4H), 2.01-1.80 (m, 3H).


Example 559


1H NMR (300 MHz, CDCl3) δ 8.66-8.60 (d, 1H), 8.50-8.44 (dd, 1H), 8.01 (s, 1H), 7.93 (m, 1H), 7.48-7.40 (dd, 1H), 6.08 (s, 1H), 4.80-7.74 (s, 2H), 4.32-4.19 (br d, 2H), 3.10-2.86 (m, 2H), 1.95-1.68 (m, 4H).


Example 563


1H NMR (300 MHz, CDCl3) δ 8.66 (s, 1H), 8.62-8.58 (d, 1H), 7.96 (s, 1H), 7.73-7.68 (d, 1H), 7.36-7.30 (dd, 1H), 6.96-6.86 (br s, 1H), 6.79-6.74 (t, 1H), 6.00 (s, 1H), 4.67-4.64 (d, 2H), 4.37-4.30 (dd, 1H), 4.22-4.13 (m, 1H), 3.97-3.86 (dd, 1H), 3.73-3.64 (m, 1H), 3.17-3.14 (d, 3H), 3.07-2.99 (m, 1H), 2.20-1.97 (m, 2H), 1.68-1.48 (m, 2H).


General Procedure 1: Procedure for the Amide Formation Parallel Synthesis:




embedded image


Parallel synthesis was conducted in polypropylene 96-well reaction blocks with removable top seal and fixed bottom seal. Each reaction well was fitted with a 20 micron polypropylene bottom frit and the maximum volume was 3 mL. Collection block was not fitted with bottom frit. To each reaction well was added a solution of an amine (0.021 mmol) dissolved in a DMF-THF-MeCN mixture (4:3:3 v/v, 0.95 mL), EDC resin (P-EDC, Polymer Laboratories Ltd., 43 mg, 0.063 mmol), 1-hydroxybenzotriazole (HOBt, 5.67 mg, 0.042 mmol) and a solution of a carboxylic acid in dimethylformamide (1 M, 0.0315 mL, 0.0315 mmol). The reaction mixture was agitated at room temperature for 16 h. The crude product solution was filtered into a reaction well loaded with trisamine resin (P—NH2, Argonaut Tech. Inc., 30 mg, 0.126 mmol) and isocyanate resin (P—NCO, Argonaut Tech. Inc., 35 mg, 0.063 mmol). The reaction mixture was agitated at room temperature for 16 h and filtered into the collection block. The product solution was evaporated under reduced pressure to afford the desired amide product.


General Procedure 2: Procedure for the Sulfonamide Formation Parallel Synthesis




embedded image


Parallel synthesis was conducted in polypropylene 96-well reaction blocks with removable top seal and fixed bottom seal. Each reaction well was fitted with a 20 micron polypropylene bottom frit and the maximum volume was 3 mL. Collection block was not fitted with bottom frit. To each reaction well was added a solution of an amine (0.021 mmol) dissolved in a DMF-THF-MeCN mixture (3:2:2 v/v, 0.95 mL), DIEA resin (P-DIEA, Argonaut Tech. Inc., 18 mg, 0.063 mmol) and a solution of a sulfonyl chloride in dimethylformamide (1 M, 0.0315 mL, 0.0315 mmol). The reaction mixture was agitated at room temperature for 16 h. The crude product solution was filtered into a reaction well loaded with trisamine resin (P—NH2, Argonaut Tech. Inc., 30 mg, 0.126 mmol) and isocyanate resin (P—NCO, Argonaut Tech. Inc., 35 mg, 0.063 mmol). The reaction mixture was agitated at room temperature for 16 h and filtered into the collection block. The product solution was evaporated under reduced pressure to afford the desired sulfonamide product.


General Procedure 3: Procedure for the Urea Formation Parallel Synthesis




embedded image


Parallel synthesis was conducted in polypropylene 96-well reaction blocks with removable top seal and fixed bottom seal. Each reaction well was fitted with a 20 micron polypropylene bottom frit and the maximum volume was 3 mL. Collection block was not fitted with bottom frit. To each reaction well was added a solution of an amine (0.021 mmol) dissolved in a DMF-MeCN mixture (1:1 v/v, 0.95 mL) and a solution of an isocyanate in dichloromethane (0.33 M, 0.126 mL, 0.042 mmol). The reaction mixture was agitated at room temperature for 16 h. The crude product solution was filtered into a reaction well loaded with trisamine resin (P—NH2, Argonaut Tech. Inc., 30 mg, 0.126 mmol) and isocyanate resin (P—NCO, Argonaut Tech. Inc., 35 mg, 0.063 mmol). The reaction mixture was agitated at room temperature for 16 h and filtered into the collection block. The product solution was evaporated under reduced pressure to afford the desired urea product.


General Procedure 4: Procedure for the Reductive Alkylation Parallel Synthesis




embedded image


Parallel synthesis was conducted in polypropylene 96-well reaction blocks with removable top seal and fixed bottom seal. Each reaction well was fitted with a 20 micron polypropylene bottom frit and the maximum volume was 3 mL. Collection block was not fitted with bottom frit. To each reaction well was added a solution of an amine (0.021 mmol) dissolved in AcOH-DCE mixture (1:99 v/v, 0.5 mL), a solution of an aldehyde or ketone in dichloroethane (1 M, 0.147 mL, 0.147 mmol), and a solution of tetramethylammonium triacetoxyborohydride (11 mg, 0.042 mmol) dissolved in AcOH-DCE mixture 1:99 v/v, 0.5 mL). The reaction mixture was agitated at room temperature for 3 days. The crude product solution was filtered into a reaction well loaded with sulfonic acid resin Lanterns (P—SO3H, MimotopesPty Ltd., 0.3 mmol). The reaction mixture was agitated at room temperature for 2 h and decanted. The product resin Lanterns were washed with methanol (1 mL) for three times. A solution of ammonia in methanol (2 M, 1.2 mL) was added. The reaction mixture was agitated at room temperature for 30 min. and filtered into the collection block. The product solution was evaporated under reduced pressure to afford the desired tertiary amine product.


General Procedure 5: Procedure for the Parallel Synthesis of 7,N-Substituted pyrazolo[1,5a]pyrimidines




embedded image


To 3-bromo-7-chloro-5-(2-chloro-phenyl)-pyrazolo[1,5-a]pyrimidine (9.0 mg, 0.03 mmol) in tetrahydrofuran were added di-iso-propylethylamine (12 μL, 0.07), followed by cyclopropylmethylamine (70 μL, 0.07 mmol; 1M solution in DMF). The reaction mixture was heated to 70° C. for 36 h and then cooled to rt. The mixture was treated with (P—NCO, Argonaut Tech. Inc 70 mg, 0.12 mmol), and P—CO3 (Argonaut Tech. Inc 70 mg, 0.24 mmol) and shaken at rt for 12-18 h. The solution was filtered and evaporated to dryness to provide the product. observed m/z 375.21.


General Procedure 6: Procedure for the Parallel Synthesis of 5,N-Substituted pyrazolo[1,5a]pyrimidines


General Protocols:


Parallel synthesis was performed in a 96 well polypropylene blocks as described elsewhere. In the instance that heating was required, reactions were conducted in 2.5 mL glass tubes individually sealed with a polypropylene mat and heating achieved by a 96 well heat transfer block.




embedded image



Step A:


To the 3-bromo-5-chloro-7-N-Boc-alkylamino-pyrazolo[1,5-a]pyrimidine (17 mg, 0.04 mmol) in p-dioxane were added DIEA (9 μL, 0.05), followed by cyclopropyl-methylamine (80 μL, 0.08 mmol; 1M solution in isopropanol). The reaction mixture was heated to 90° C. for 36 h and then cooled to rt. The mixture was treated with P—NCO (Argonaut Tech. Inc. 70 mg, 0.12 mmol) and P—CO3 (Argonaut Tech. Inc. 70 mg, 0.24 mmol) and shaken at rt for 12-18 h. The solution was filtered and evaporated to dryness to provide the product.


Step B (Acidic):


The product from STEP A was taken up in 35% TFA/DCM and agitated for 4 h followed by concentration under high vacuum. The residue was treated with 10% HCl(aq) in MeOH agitated for 2 h and then concentrated to give the desired product. observed m/z 375.21.


Step B (Basic):


The product from step A was taken up in EtOH and treated with Ambersep® 900-OH ion exchange resin (Acros, 100 mg), heated at reflux for 48 h with gently stirring. The reaction mixture was cooled to rt, filtered and concentrated to provide the desired product.


Example 565

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 462 shown below, the compounds with the observed m/z shown in Table 43 were prepared.




embedded image


Example 566

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 471 shown below, the compounds shown in Table 44 with the observed m/z were prepared.




embedded image


Example 567

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 515 shown below, the compounds shown in Table 45 with the observed m/z were prepared.




embedded image


Example 568

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 513 shown below, the compounds shown in Table 46 with the observed m/z were prepared.




embedded image


Example 569

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 526 shown below, the compounds shown in Table 47 with the observed m/z were prepared.




embedded image


Example 570

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 524 shown below, the compounds shown in Table 48 with the observed m/z were prepared.




embedded image


Example 571

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 525 shown below, the compounds shown in Table 49 with the observed m/z were prepared.




embedded image


Example 572

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 526.10 shown below, the compounds shown in Table 50 with the observed m/z were prepared.




embedded image


Example 573

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 518 shown below, the compounds shown in Table 51 with the observed m/z were prepared.




embedded image


Example 574

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 519 shown below, the compounds shown in Table 52 with the observed m/z were prepared.




embedded image


Example 575

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 520 shown below, the compounds shown in Table 53 with the observed m/z were prepared.




embedded image


Example 576

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 522 shown below, the compounds shown in Table 54 with the observed m/z were prepared.




embedded image


Example 577

By utilizing the procedure set forth in General Procedure 1 and the compound from Example 523 shown below, the compounds shown in Table 55 with the observed m/z were prepared.




embedded image


Example 578

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 462 shown below, the compounds shown in Table 56 with the observed m/z were prepared.




embedded image


Example 579

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 471 shown below, the compounds shown in Table 57 with the observed m/z were prepared.




embedded image


Example 580

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 515 shown below, the compounds shown in Table 58 with the observed m/z were prepared.




embedded image


Example 581

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 513 shown below, the compounds shown in Table 59 with the observed m/z were prepared.




embedded image


Example 582

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 513 shown below, the compounds shown in Table 60 with the observed m/z were prepared.




embedded image


Example 583

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 524 shown below, the compounds shown in Table 61 with the observed m/z were prepared.




embedded image


Example 584

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 525 shown below, the compounds shown in Table 62 with the observed m/z were prepared.




embedded image


Example 585

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 526.10 shown below, the compounds shown in Table 63 with the observed m/z were prepared.




embedded image


Example 586

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 518 shown below, the compounds shown in Table 64 with the observed m/z were prepared.




embedded image


Example 587

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 519 shown below, the compounds shown in Table 65 with the observed m/z were prepared.




embedded image


Example 588

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 520 shown below, the compounds shown in Table 67 with the observed m/z were prepared.




embedded image


Example 589

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 521 shown below, the compounds shown in Table 68 with the observed m/z were prepared.




embedded image


Example 590

By utilizing the procedure set forth in General Procedure 2 and the compound from Example 523 shown below, the compounds shown in Table 69 with the observed m/z were prepared.




embedded image


Example 591

By utilizing the procedure set forth in General Procedure 3 and the compound from Example 462 shown below, the compounds shown in Table 70 with the observed m/z were prepared.




embedded image


Example 592

By utilizing the procedure set forth in General Procedure 3 and the compound from Example 471 shown below, the compounds shown in Table 71 with the observed m/z were prepared.




embedded image


Example 593

By utilizing the procedure set forth in General Procedure 3 and the compound from Example 513 shown below, the compounds shown in Table 72 with the observed m/z were prepared.




embedded image


Example 594

By utilizing the procedure set forth in General Procedure 3 and the compound from Example 524 shown below, the compounds shown in Table 73 with the observed m/z were prepared.




embedded image


Example 595

By utilizing the procedure set forth in General Procedure 3 and the compound from Example 524 shown below, the compounds shown in Table 74 with the observed m/z were prepared.




embedded image


Example 596

By utilizing the procedure set forth in General Procedure 3 and the compound from Example 519 shown below, the compounds shown in Table 75 with the observed m/z were prepared.




embedded image


Example 597

By utilizing the procedure set forth in General Procedure 3 and the compound from Example 520 shown below, the compounds shown in Table 76 with the observed m/z were prepared.




embedded image


Example 598

By utilizing the procedure set forth in General Procedure 3 and the compound from Example 521 shown below, the compounds shown in Table 77 with the observed m/z were prepared.




embedded image


Example 599

By utilizing the procedure set forth in General Procedure 3 and the compound from Example 523 shown below, the compounds shown in Table 78 with the observed m/z were prepared.




embedded image


Example 600

By utilizing the procedure set forth in General Procedure 4 and the compound from Example 462 shown below, the compounds shown in Table 79 with the observed m/z were prepared.




embedded image


Example 601

By utilizing the procedure set forth in General Procedure 4 and the compound from Example 471 shown below, the compounds shown in Table 80 with the observed m/z were prepared.




embedded image


Example 602

By utilizing the procedure set forth in General Procedure 4 and the compound from Example 525 shown below, the compounds shown in Table 81 with the observed m/z were prepared.




embedded image


Example 603

By utilizing the procedure set forth in General Procedure 4 and the compound from Example 526.10 shown below, the compounds shown in Table 82 with the observed m/z were prepared.




embedded image


Example 604

By utilizing the procedure set forth in General Procedure 4 and the compound from Example 521 shown below, the compounds shown in Table 83 with the observed m/z were prepared.




embedded image


Example 605

By utilizing the procedure set forth in General Procedure 4 and the compound from Example 523 shown below, the compounds shown in Table 84 with the observed m/z were prepared.




embedded image


Example 606

By utilizing the procedure set forth in General Procedure 5 and the compound from Preparative Example 81 shown below, the compounds shown in Table 85 with the observed m/z were prepared.




embedded image


Example 607

By utilizing the procedure set forth in General Procedure 6 and the compound from Preparative Example 196, the compounds shown in Table 86 with the observed m/z were prepared.




embedded image


Preparative Example 500



embedded image


Piperidine-2-ethanol (127 g, 980 mmol) in 95% EtOH (260 mL) was added to (S)-(+)-camphorsulfonic acid (228.7 g, 1.0 eq.) in 95% EtOH (150 mL) and the resulting solution was warmed to reflux. To the warm solution was added Et2O (600 mL) and the solution cooled to room temperature and let stand 3 days. The resulting crystals were filtered and dried in vacuo (25 g): mp 173-173° C. (lit. 168° C.). The salt was then dissolved in NaOH (3M, 100 mL) and stirred 2 hours and the resulting solution was extracted with CH2Cl2 (5×100 mL). The combined organics were dried over Na2SO4, filtered, filtered and concentrated under reduced pressure to give (S)-piperidine-2-ethanol (7.8 g) a portion of which was recrystallized from Et2O: mp=69-70° C. (lit. 68-69° C.); [α]D=14.09° (CHCl3, c=0.2).


Preparative Example 501



embedded image


Bye essentially the same procedure set forth in Preparative Example 500 only substituting (R)-(−)-camphorsulfonic acid, (R)-piperidine-2-ethanol was prepared. (1.27 g): [α]D=11.3° (CHCl3, c=0.2).


Preparative Example 502



embedded image


To pressure bottle charged with a solution of cis-(1R,2S)-(+)-2-(Benzylamino)cyclohexanemethanol (1 g, 4.57 mmol) in MeOH (35 mL) was added 20% wt Pd(OH)2 (0.3 g, >50% wet) in one portion. The mixture was shaken under 50 psi of H2 in a Parr hydrogenation apparatus for 12 h. The mixture was purged to N2 and was filtered through a pad of Celite. The pad was generously washed with MeOH (2×25 mL) and the resulting filtrate was concentrated under reduces pressure to afford 0.57 g (97%) of a white solid. M+H=130.


Preparative Example 503



embedded image



Step A:


To a solution of 3-Br adduct (1.1 g, 4.1 mmol) from Preparative Example 142 in THF (40 mL) at 0° C. was added CH3SNa (0.32 g, 4.53 mmol) in one portion. The heterogenous mixture was stirred for 72 h at rt and the mixture was concentrated under reduced pressure. The crude product was partitioned between water (10 mL) and EtOAc (30 mL) and the layers were separated. The organic layer washed with brine (1×10 mL) and dried (Na2SO4). The organic layer was filtered and concentrated under reduced pressure to afford 1.0 g (88%) of a yellow solid. mp 150-152° C.; M+H=280. This material was taken onto Step B without further purification.


Step B:


To a solution of thiomethyl derivative (1.5 g, 5.37 mmol) from Step A in dioxane/DIPEA (15 mL/4 mL) at rt was added amino alcohol (1.3 g, 8.06 mmol) from Preparative Example 10. The mixture was heated at reflux for 48 h, cooled to rt, and concentrated under reduced pressure. The crude product was purified by flash chromatography using CH2Cl2/MeOH (30:1) as eluent to afford 1.8 g of product (90%) as a yellow crystalline solid. mp 167-169° C.; M+H=373.


Step C:


To a solution of thiomethyl derivative (2.2 g, 5.92 mmol) from Step B in CH2Cl2 (20 mL) at 0° C. was added MCPBA (1.53 g, 8.9 mmol) in one portion. The resulting mixture was stirred for 2 h at 0° C. whereupon the mixture was diluted with CH2Cl2 (20 mL) and sat. aq. NaHCO3 (15 mL). The layers were separated and the organic layer washed with sat. aq. NaHCO3 (15 mL) and brine (1×15 mL). The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 2.0 g of a brown solid (87%). mp 181-183° C.; M+H=388.


Preparative Example 504



embedded image


The title compound (racemic) was prepared according to the procedure set forth in Preparative Example 503 except substituting the commercially available cis-hydroxymethyl-1-cyclohexylamine hydrochloride in Step B.


Preparative Example 505



embedded image



Step A:


Treatment of thiomethyl derivative (2.0 g, 7.2 mmol) from Step A of Preparative Example 503 with (S)-piperidine-2-ethanol (1.2 g, 9.3 mmol) from Preparative Example 500 under the identical conditions as described in Step B of Preparative Example 503, 0.90 g (34%) of the title compound was prepared semisolid. mp 173-175° C. M+H=372.


Step B:


Following the procedure from Step C in Preparative Example 503, the thiomethyl derivative (0.30 g, 0.81 mmol) was treated with MCPBA (0.21 g, 1.2 mmol) to afford 0.31 g (99%) the title compound as a yellow viscous oil. M+H=388.


Preparative Example 506



embedded image


The title compound (racemic) was prepared according to the procedure set forth in Preparative Example 505 except substituting the commercially available piperidine-2-ethanol. M+H=388.


Preparative Example 507



embedded image


t-BuOK (112.0 g, 1.00 mol) was stirred under N2 in dry Et2O (3.0 L) in a 5 L flask equipped with an addition funnel. A mixture of butyronitrile (69.0 g, 1.00 mol) and ethylformate (77.7 g, 1.05 mol) was added dropwise during 3 hrs, the reaction mixture was then stirred overnight at room temperature. The mixture was cooled to 0° C., AcOH (57 mL) was added, the mixture was filtered, and the solid washed with Et2O (500 mL). The combined filtrates were evaporated at room temperature on a rotovap to give pale yellow oil (95.1 g).


The oil was dissolved in dry EtOH (100 mL), 99% hydrazine monohydrate (48 mL) was added, then AcOH (14 mL) was added, and the mixture was refluxed under N2 overnight. The solvents were evaporated and the resulting oil was chromatographed on silica gel with CH2Cl2:7N NH3 in MeOH. 22.4 g (20%) of 3-amino-4-ethylpyrazole was obtained as clear oil that solidified upon standing.


Preparative Example 508



embedded image



Step, A:


The pyrazole from Preparative Example 507 (9.80 g) and dimethylmalonate (45 mL) were stirred and refluxed under N2 for 3 hrs. The excess of dimethylmalonate was evaporated in a vacuum and the residue was chromatographed with 15:1 CH2Cl2:MeOH to yield pale yellow solid (10.6 g, 57%). LCMS: MH+=212.


Step B:




embedded image


Dry MeOH (200 mL) was added under N2 to a mixture of the amide from Step A (11.9 g, 56.4 mmol) and sodium methoxide (4.57 g, 84.6 mmol). The mixture was stirred and refluxed under N2 for 5 hrs, cooled to rt, and conc. HCl (20 mL) was added. The solvents were evaporated and the residue was suspended in H2O (300 mL). The solid was filtered off, washed on filter with 2×300 mL of H2O, and dried in a vacuum at 100° C. 7.40 g (73%) of cream-colored solid was obtained. LCMS: MH+=180.


Step C:




embedded image


POCl3 (100 mL) and N,N-dimethylaniline (20 mL) were added under N2 to the diketone from Step B (7.70 g), and the mixture was stirred and refluxed for 20 hrs under N2. Then it was cooled to rt, carefully poured onto 1 L of crushed ice, and extracted with EtOAc (2×500 mL). The extracts were washed with H2O (500 mL), dried over Na2SO4, filtered, and the solvent was evaporated. The residue was chromatographed with CH2Cl2 to yield pale yellow solid (8.20 g, 90%). LCMS: MH+=216.


Preparative Example 508.10



embedded image


By essentially the same procedure set forth in Preparative Example 508, only substituting the compound from Preparative Example 1, the above compound was prepared. LCMS: MH+=228.


Preparative Example 509



embedded image


A mixture of the dichloride from Preparative Example 508 (3.13 g, 14.5 mmol), the amine.HCl from Preparative Example (3.00 g, 18.9 mmol), DIPEA (7.5 mL), and dry NMP (40 mL) plus dry dioxane (40 mL) was stirred at 60° C. for 4 days under N2. The solvents were then distilled off in a vacuum and the residue was chromatographed with 6:1 EtOAc:MeOH and then rechromatographed with 12:1 CH2Cl2:MeOH. So obtained solid was suspended in H2O (100 mL), filtered, washed on filter with H2O (2×100 mL), and dried in a vacuum. Pale rose solid (2.37 g, 54%) was obtained. M+H=304.


Preparative Examples 510-516

By essentially the same procedure set forth in Preparative Example 509 only substituting the amines in Column 2 of Table 500 and the chlorides shown in Column 3 of Table 500, the compounds shown in Column 4 of Table 500 were prepared.













TABLE 500





Prep. Ex.
Column 2
Column 3
Column 4
CMPD



















510


embedded image




embedded image




embedded image


M + H = 316





512


embedded image




embedded image




embedded image


M + H = 318





513


embedded image




embedded image




embedded image


M + H = 318





514


embedded image




embedded image




embedded image







515


embedded image




embedded image




embedded image


M + H = 332





516


embedded image




embedded image




embedded image











Preparative Example 517

By essentially the same procedure set forth in Preparative Example 184 only substituting the amines in Column 2 of Table 501, the compounds shown in Column 3 of Table 501 were prepared.












TABLE 501





Prep.





Ex.
Column 2
Column 3
CMPD







518


embedded image




embedded image


M + H = 422.1





519


embedded image




embedded image











Preparative Examples 520-521

By essentially the same procedure set forth in Preparative Example 192 only substituting the compounds in Column 2 of Table 502, the compounds shown in Column 3 of Table 502 were prepared.












TABLE 502





Prep. Ex.
Column 2
Column 3
CMPD







520


embedded image




embedded image


M + H = 522.1





521


embedded image




embedded image


M + H = 539.1









Example 1000



embedded image


A mixture of the compound prepared in Preparative Example 509 (1.50 g, 4.94 mmol) with the aminoalcohol from Preparative Example 500 (1.91 g, 14.8 mmol) in dry NMP (3 mL) was stirred under N2 at 160° C. for 48 hr. The NMP was distilled off in a vacuum and the residue was chromatographed first with 5:1 EtOAc:MeOH, then the crude product was rechromatographed with 10:1 CH2Cl2:MeOH. White solid (460 mg, 24%) was obtained. LCSM: MH+=397; mp=113-115° C.


Example 1001

Major side product isolated (540 mg, 29%) was deoxygenated product (LCMS: MH+=381; mp=49-52° C.:




embedded image


Examples 1002-1014

By essentially the same procedure set forth in Example 1000 only substituting the amines in Column 2 of Table 1000 and the chlorides in Column 3 of Table 1000 the compounds in column 4 of Table 1000 were prepared.













TABLE 1000





Ex.
Column 2
Column 3
Column 4
CMPD







1002


embedded image




embedded image




embedded image


MH+ = 409; mp = 165-171° C.





1003


embedded image




embedded image




embedded image


MH+ = 397; mp = 219-221° C.





1004


embedded image




embedded image




embedded image


MH+ = 409; mp = 138-142° C.





1005


embedded image




embedded image




embedded image


MH+ = 411; mp = 194-196° C.





1006


embedded image




embedded image




embedded image


MH+ = 411; mp = 118-120° C.





1007


embedded image




embedded image




embedded image


MH+ = 411; mp = 85-87° C.





1008


embedded image




embedded image




embedded image


MH+ = 411; mp = 105-108° C.





1009


embedded image




embedded image




embedded image


MH+ = 397; mp = 173-177° C.





1010


embedded image




embedded image




embedded image


MH+ = 397; mp = 169-173° C.





1011


embedded image




embedded image




embedded image


MH+ = 425





1012


embedded image




embedded image




embedded image


MH+ = 425; mp = 232-234° C.





1013


embedded image




embedded image




embedded image







1014


embedded image




embedded image




embedded image











Example 1015



embedded image


To a solution of sulfoxide from Preparative Example 505 (0.10 g, 0.28 mmol) in n-BuOH in a sealed tube was added Et3N (0.13 mL, 1.0 mmol) followed by the amine dihydrochloride (0.13 g, 0.65 mmol) from Preparative Example 216. The tube was sealed and was heated to 100° C., cooled to room temperature, and was concentrated under reduced pressure. The crude residue was purified by preparative TLC (6×1000 μM) eluting with CH2Cl2/MeOH (20:1) to afford 50 mg (40%) of a pale white solid. mp 182-185° C.; M+H=446.


Examples 1016-1026

By essentially the same procedure set forth in Example 1015 only substituting the sulfoxide shown in Column 2 of Table 1001 and the amine in Column 3 of Table 1001, the compounds shown in Column 4 of Table 1001 were prepared.













TABLE 1001





Ex.
Column 2
Column 3
Column 4
CMPD







1016


embedded image




embedded image




embedded image


mp = 182- 185° C.; M + H = 448





1017


embedded image




embedded image




embedded image


mp = 187- 189° C.; M + H = 445





1018


embedded image




embedded image




embedded image


mp = 139- 143° C.; M + H = 453





1020


embedded image




embedded image




embedded image


mp = 186- 189° C.; M + H = 485





1021


embedded image




embedded image




embedded image


mp = 154- 157° C.; M + H = 448





1022


embedded image




embedded image




embedded image


mp = 103- 105° C.; M + H = 485





1023


embedded image




embedded image




embedded image


mp = 203- 205° C.; M + H = 432





1024


embedded image




embedded image




embedded image


mp = 210- 212° C.; M + H = 395





1025


embedded image




embedded image




embedded image


mp = 82-84° C.; M + H = 446





1026


embedded image




embedded image




embedded image


mp = 86-90° C.; M + H = 462









Examples 1027-1038

By essentially the same conditions set forth in Example 341, Steps A and B only substituting the amines in Column 2 of Table 1002 and the compound prepared in Preparative Example 193.10, the compounds in Column 4 of Table 1002 were prepared.












TABLE 1002





Ex.
Column 2
Column 4
CMPD







1027


embedded image




embedded image


mp = 160- 163° C.; M + H = 434





1028


embedded image




embedded image


mp = 122- 124° C.; M + H = 434





1029


embedded image




embedded image


mp = 153- 156° C.; M + H = 408





1030


embedded image




embedded image


mp = 170- 174° C.; M + H = 448





1031


embedded image




embedded image


mp = 166- 169° C.; M + H = 434





1032


embedded image




embedded image


mp = 167- 168° C.; M + H = 434





1033


embedded image




embedded image


MH+ = 393





1034


embedded image




embedded image


mp = 157- 160° C.; M + H = 447





1035


embedded image




embedded image


mp = 164- 168° C.; M + H = 448





1036


embedded image




embedded image


mp = 165- 168° C.; M + H = 448





1037


embedded image




embedded image


mp = 131- 135° C.; M + H = 447





1038


embedded image




embedded image











Preparative Examples 1039-1041

By essentially the same procedure set forth in Example 340 only substituting the amines in Column 2 of Table 1003, the compounds shown in Column 4 of Table 1003 were prepared.












TABLE 1003





Ex.
Column 2
Column 4
CMPD







1039


embedded image




embedded image


mp = 210-212° C.; M + H = 392





1040


embedded image




embedded image


mp = 128-130° C.; M + H = 432





1041


embedded image




embedded image


mp = 148-151° C.; M + H = 18









Preparative Examples 1042-1057

By essentially the same procedure set forth in Example 340 only using the appropriate 5-chloroderivative and substituting the amines in Column 2 of Table 1004, the compounds shown in Column 4 of Table 1004 were prepared.












TABLE 1004





Ex.
Column 2
Column 4
CMPD







1042


embedded image




embedded image


M + H = 500.3





1043


embedded image




embedded image


M + H = 514.1





1044


embedded image




embedded image


M + H = 460.3





1045


embedded image




embedded image


M + H = 477.1





1046


embedded image




embedded image


M + H = 505.1





1047


embedded image




embedded image


M + H = 505.1





1048


embedded image




embedded image


M + H = 531.1





1049


embedded image




embedded image


M + H = 477.1





1050


embedded image




embedded image


M + H = 505.1





1051


embedded image




embedded image


M + H = 505.1





1052


embedded image




embedded image


M + H = 531.1





1053


embedded image




embedded image


M + H = 514.1





1054


embedded image




embedded image


M + H = 488.3





1055


embedded image




embedded image


M + H = 488.3





1056


embedded image




embedded image


M + H = 488.1





1057


embedded image




embedded image


M + H = 488.1









Preparative Example 10-K



embedded image


SOCl2 (18.5 mL) was added slowly under N2 to a stirred mixture of the acid (50.0 g, 218 mmol) and pyridine (44.0 mL) in anhydrous CH2Cl2 (60 mL). The mixture was stirred at 25° C. for 20 min, then Meldrum's acid (35.0 g, 243 mmol) and DMAP (66.6 g, 546 mmol) were added and the mixture was stirred under N2 for 1 hr. Then Et2O (2 L) was added, the mixture washed with 1 M HCl (3×500 mL), brine (500 mL), and the organic layer was dried over Na2SO4, filtered, and the solvent was evaporated. The residue was dissolved in MeOH (580 mL), and the mixture was refluxed for 4 hr. The solvent was evaporated and the residue was purified by column chromatography on silica gel with 10:1 CH2Cl2/EtOAc as eluent. Pale yellow oil (26.5 g, 43%) was obtained.


Preparative Examples 10-K-40-K

By essentially same procedure set forth in Preparative Example 10-K, the compounds given in Column 2 of Table 10-K were prepared.











TABLE 10-K






Prep.




Ex.
Column 2








20-K


embedded image








30-K


embedded image








40-K


embedded image











Preparative Example 100-K



embedded image


A mixture of the b-ketoester from Preparative Example 10-K (20.0 g, 70.1 mmol) and 3-aminopyrazole (5.40 g, 65.0 mmol) in anhydrous toluene (60 mL) was stirred and refluxed under N2 for 24 hr. The solvent was evaporated and the residue was purified by column chromatography on silica gel with 20:1 CH2Cl2/MeOH as eluent. White solid (15.0 g, 73%) was obtained. LC-MS: 319 [M+H].


Preparative Example 101-K-104-K

By essentially same procedure set forth in Preparative Example 100-K, combining 3-aminopyrazole with the corresponding β-ketoesters, compounds given in Column 2 of Table 100-K were prepared.











TABLE 100-K






Prep.




Ex.
Column 2








101-K


embedded image








102-K


embedded image








103-K


embedded image








104-K


embedded image











Preparative Example 200-K



embedded image


A mixture of the product from Preparative Example 100-K (12.50 g, 39.3 mmol), N,N-dimethylaniline (15.5 mL), and POCl3 (125 mL) was stirred at 25° C. for 4 days. Excess of POCl3 was evaporated and the residue was poured into saturated aqueous NaHCO3 (600 mL). The mixture was extracted with CH2Cl2 (3×200 mL), the combined extracts were dried over Na2SO4, filtered, and the solvent was evaporated. The residue was purified by column chromatography on silica gel with 8:1 CH2Cl2/EtOAc as eluent. Pale yellow wax (9.41 g, 71%) was obtained. LC-MS: 337 [M+].


Preparative Example 201-K-204-K

By essentially same procedure set forth in Preparative Example 200-K, compounds given in Column 2 of Table 200-K were prepared.











TABLE 200-K






Prep.




Ex.
Column 2








201-K


embedded image








202-K


embedded image








203-K


embedded image








204-K


embedded image











Preparative Example 300-K



embedded image


A solution of NBS (4.03 g, 22.7 mmol) in anhydrous CH3CN (40 mL) was added under N2 to a stirred solution of the product from Preparative Example 200-K (7.63 g, 22.7 mmol) in anhydrous CH3CN (60 mL) and CH2Cl2 (20 mL). The mixture was stirred for 2 hr, the solvents were evaporated, and the residue was purified by column chromatography on silica gel with 20:1 CH2Cl2/EtOAc as eluent. Pale yellow solid foam (9.20 g, 97%) was obtained. LC-MS: 417 [M+H].


Preparative Example 301-K-304-K

By essentially same procedure set forth in Preparative Example 300-K only substituting the compounds shown in Column 2 of Table 300-K, the compounds given in Column 3 of Table 300-K were prepared.











TABLE 300-K





Prep.




Ex.
Column 2
Column 3







301-K


embedded image




embedded image







302-K


embedded image




embedded image







303-K


embedded image




embedded image







304-K


embedded image




embedded image











Preparative Example 303-K



embedded image


By essentially the same procedure set forth in Preparative Example 300-K only substituting N-iodosuccinimide the above compound was prepared.


Preparative Example 400-K



embedded image


A mixture of the product from Preparative Example 300-K (8.00 g, 19.3 mmol) and MeONa (2.16 g, 40.0 mmol) in anhydrous MeOH (100 mL) was stirred for 20 hr. CH2Cl2 (200 mL) was then added, the mixture was filtered through Celite, the solvent was evaporated, and the residue was purified by column chromatography on silica gel with 2:1 CH2Cl2/EtOAc as eluent. White solid (7.75 g, 98%) was obtained.


Preparative Examples 401-K-405-K

By essentially the same procedure set forth in Preparative Example 400-K, only substituting the compound shown in Column 2 of Table 400-K, the compounds shown in Column 3 of Table 400-K were prepared.











TABLE 400-K





Prep.




Ex.
Column 2
Column 3







401-K


embedded image




embedded image







402-K


embedded image




embedded image







403-K


embedded image




embedded image







404-K


embedded image




embedded image







405-K


embedded image




embedded image











Preparative Example 500-K



embedded image


A mixture of the product from Preparative Example 400-K (600 mg, 1.46 mmol), 2-thienylboronic acid (230 mg, 1.80 mmol), Pd[PPh3]4 (160 mg, 0.14 mmol), and Na2CO3 (466 mg, 4.40 mmol) in 1,2-dimethoxyethane (20 mL) and H2O (4 mL) was stirred and refluxed under N2 for 20 hr. The solvents were evaporated and the residue was purified by column chromatography on silica gel with 2:1 CH2Cl2/EtOAc as eluent. Pale yellow solid (355 mg, 59%) was obtained. LC-MS: 415 [M+].


Preparative Examples 501-511-K

By essentially same procedure set forth in Preparative Example 500-K only substituting the appropriate boronic acid, the compounds given in Column 2 of Table 500-K were prepared.











TABLE 500-K





Prep.




Ex.
Column 2
Data







501-K


embedded image


LCMS: MH+ = 373





502-K


embedded image


LCMS: MH+ = 415





503-K


embedded image


LCMS: MH+ = 409





504-K


embedded image


LCMS: MH+ = 555





505-K


embedded image


LCMS: MH+ = 429





506-K


embedded image








507-K


embedded image


LCMS: MH+ = 399





508-K


embedded image


LCMS: MH+ = 410





510-K


embedded image


LCMS: MH+ = 425





511-K


embedded image


LCMS: MH+ = 452









Preparative Example 520-K



embedded image


A mixture of the product from Preparative Example 400-K (1.23 g, 3.00 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)1-H-pyrazole (850 mg, 4.00 mmol), Pd[PPh3]4 (348 mg, 0.30 mmol), and Na2CO3 (1.27 g, 12.0 mmol) in 1,2-dimethoxyethane (36 mL) and H2O (7.5 mL) was stirred and refluxed under N2 for 20 hr. The solvents were evaporated and the residue was purified by column chromatography on silica gel with 20:1 EtOAc/MeOH as eluent. Pale orange solid (740 mg, 60%) was obtained. LC-MS: 413 [M+H].


Preparative Example 530-K-533-K

By essentially same procedure set forth in Preparative Example 520-K, the compounds shown in Column 2 of Table 530-K were prepared.











TABLE 530-K





Prep.




Ex.
Column 2
Data







530-K


embedded image


LC-MS: 429 [M + H].





531-K


embedded image








532-K


embedded image








533-K


embedded image











Preparative Example 550-K



embedded image


A mixture of the compound from Preparative Example 512-K (230 mg, 0.50 mmol), tributylphenyltin (235 mg, 0.60 mmol), and Pd[PPh3]4 (58 mg, 0.05 mmol) in anhydrous dioxane (5 mL) was stirred under N2 at 90° C. for 3 hr. The solvent was evaporated and the residue was purified by column chromatography on silica gel with 20:1 CH2Cl2/EtOAc as eluent. Pale yellow wax (46 mg, 21%) was obtained. LC-MS: 433 [M+].


Preparative Examples 551-K-552-K

By essentially same procedure set forth in Preparative Example 550-K, only substituting the appropriate tributyltin reagent, the compounds given in Column 2 of Table 550-K were prepared.











TABLE 550-K





Prep.




Ex.
Column 2
Data







551-K


embedded image


LCMS: MH+ = 371





552-K


embedded image


LCMS: MH+ = 416









Preparative Example 600-K



embedded image


A mixture of the product from Preparative Example 500-K (350 mg, 0.85 mmol), 2.0 M NH3 in 2-propanol (7.5 mL), and conc. aqueous NH4OH (0.75 mL) was stirred in a closed pressure vessel at 75° C. for 3 days. The solvents were evaporated and the residue was purified by column chromatography on silica gel with 50:1 CH2Cl2/MeOH as eluent. Pale yellow solid (143 mg, 42%) was obtained. LC-MS: 400 [M+].


Preparative Example 601-K-615-K

By essentially same procedure set forth in Preparative Example 600-K only substituting the compounds in Column 2 of Table 600-K, the compounds given in Column 3 of Table 600-K were prepared.












TABLE 600-K





Prep. Ex.
Column 2
Column 3
Data







601-K


embedded image




embedded image


LCMS: MH+ = 359





602-K


embedded image




embedded image


LCMS: MH+ = 400





603-K


embedded image




embedded image







604-K


embedded image




embedded image


LCMS: MH+ = 540





605-K


embedded image




embedded image


LCMS: MH+ = 414





606-K


embedded image




embedded image


LCMS: M+ = 434





607-K


embedded image




embedded image


LCMS: MH+ = 414





608-K


embedded image




embedded image


LCMS: MH+ = 356





609-K


embedded image




embedded image


LCMS: MH+ = 418





610-K


embedded image




embedded image


LCMS: MH+ = 401





611-K


embedded image




embedded image


LCMS: MH+ = 398





612-K


embedded image




embedded image


LCMS: MH+ = 384





613-K


embedded image




embedded image


LCMS: MH+ = 395





614-K


embedded image




embedded image


LCMS: MH+ = 425





615-K


embedded image




embedded image


LCMS: MH+ = 437





616-K


embedded image




embedded image







617-K


embedded image




embedded image







618-K


embedded image




embedded image











Preparative Example 650-K



embedded image


A mixture of the product from Preparative Example 201-K (100 mg, 0.37 mmol), 2.0 M NH3 in 2-propanol (2.0 mL), and conc. aqueous NH4OH (0.2 mL) was stirred in a closed pressure vessel at 50° C. for 2 days. The solvents were evaporated and the residue was purified by column chromatography on silica gel with 30:1 CH2Cl2/MeOH as eluent. White solid (38 mg, 41%) was obtained. LC-MS: 257 [M+2H].


Preparative Example 660-K



embedded image


A mixture of the starting material (2.16 g, 10.0 mmol), 2.0 M NH3 in 2-propanol (50.0 mL), and conc. aqueous NH4OH (10.0 mL) was stirred in a closed pressure vessel at 50° C. for 2 days. The solvents were evaporated, the solid was suspended in H2O (100 mL), filtered, washed on filter with H2O (100 mL), and dried in a vacuum at 100° C. Slightly beige solid (1.80 g, 91%) was obtained.


Preparative Example 661-K

By essentially same procedure set forth in Preparative Example 660-K, compound given below was prepared.




embedded image


Preparative Example 662-K



embedded image


A mixture of the product from Preparative Example 660-K (600 mg, 3.05 mmol), the amine (837 mg, 4.50 mmol), and NaHCO3 (756 mg, 9.00 mmol) in anhydrous N-methylpyrrolidone (4 mL) was stirred under N2 at 140° C. for 18 hr. The mixture was cooled to 25° C., CH2Cl2 (15 mL) was added and the mixture was filtered. The solvents from the filtrate were distilled off and the residue was purified by column chromatography on silica gel with 2:1 CH2Cl2/EtOAc as eluent. White solid (1.01 g, 95%) was obtained.


Preparative Example 663-K

By essentially same procedure set forth in Preparative Example 662-K, compounds given below were prepared.




embedded image


LC-MS: 401 [M+H].


Preparative Example 664-K



embedded image


A solution of NBS (142 mg, 0.80 mmol) in anhydrous CH3CN (5 mL) was added under N2 to a stirred solution of the product from Preparative Example 662-K (400 mg, 0.90 mmol) in anhydrous CH3CN (5 mL) and CH2Cl2 (5 mL). The mixture was stirred for 18 hr, the solvents were evaporated, and the residue was purified by column chromatography on silica gel with 3:1 CH2Cl2/EtOAc as eluent. White solid (330 mg, 67%) was obtained.


Preparative Example 665-K

By essentially same procedure set forth in Preparative Example 664-K, compound given below was prepared.




embedded image


Preparative Example 700-K



embedded image


A solution of Br2 (16 mg) in CH2Cl2 (0.5 mL) was added under N2 to a stirred solution of the product from Preparative Example 600-K (40 mg, 0.10 mmol) in t-BuNH2 (2.0 mL). The mixture was stirred for 1 hr, the solvents were evaporated, and the residue was purified by column chromatography on silica gel with 10:1 CH2Cl2/EtOAc as eluent. Off-white solid (18 mg, 38%) was obtained. LC-MS: 480 [M+H].


Preparative Example 701-712-K

By essentially the same procedure set forth in Preparative Example 700-K only substituting the compounds in Column 2 of Table 700-K, the compounds in Column 3 of Table 700-K were prepared.












TABLE 700-K





Prep. Ex.
Column 2
Column 3
Data







701-K


embedded image




embedded image


LCMS: MH+ =





702-K


embedded image




embedded image







703-K


embedded image




embedded image


LCMS: MH+ =





704-K


embedded image




embedded image


LCMS: M+ =





705-K


embedded image




embedded image


LCMS: MH+ =





706-K


embedded image




embedded image


LCMS: MH+ =





707-K


embedded image




embedded image


LCMS: M+ = 479





708-K


embedded image




embedded image


LCMS: M+ = 476





709-K


embedded image




embedded image


LCMS: M+ = 462





710-K


embedded image




embedded image


LCMS: M+ = 473





711-K


embedded image




embedded image


LCMS: M+ = 503





712-K


embedded image




embedded image


LCMS: M+H = 517





713-K


embedded image




embedded image







714-K


embedded image




embedded image







715-K


embedded image




embedded image











Preparative Example 750-K



embedded image


A solution of N-chlorosuccinimide (23 mg, 0.17 mmol) in anhydrous CH3CN (2 mL) was added under N2 to a stirred solution of the product from Preparative Example 611-K (73 mg, 0.17 mmol) in anhydrous CH3CN (2 mL). The mixture was stirred for 24 hr, the solvents were evaporated, and the residue was purified by column chromatography on silica gel with 1:1 CH2Cl2/EtOAc as eluent. White solid (54 mg, 68%) was obtained. LC-MS: 432 [M+].


Preparative Example 800-K



embedded image


To a solution of dichloride (3.0 g, 16.0 mmol) prepared as described earlier in THF (25 mL) was added NaSMe (1.1 g, 16.0 mmol) in one portion. The resulting mixture was stirred for 12 h at rt and was concentrated under reduced pressure. The crude product was partitioned between EtOAc (150 mL) and H2O (30 mL) and the layers were separated. The organic layer washed sequentially with H2O (2×30 mL) and brine (1×30 mL). The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 3.0 g (94% yield) of a tan solid. LC-MS: 200.1 [M+H], purity 99%.


Preparative Example 900-K



embedded image


Prepared the procedure outlined in Preparative Example 800-K except starting with the dichloride shown above (7.4 g, 27.7 mmol) prepared as described earlier and NaSMe (2.1 g, 30.5 mmol) afforded 7.4 g (96% yield) of the title compound as a light orange solid. LC-MS: 278.1 [M+H], purity 95%.


Preparative Example 1000-K



embedded image


To a solution of thiomethyl derivative from Preparative Example 800-K (1.5 g, 7.5 mmol) in H2SO4 (9 mL) at 0° C. was added 60% HNO3 (4.5 mL) dropwise. The resulting solution was stirred for 2 h at 0° C. and 2 h at rt. The reaction mixture was poured into beaker containing ice (˜15 g) and the heterogeneous mixture was stirred for 45 min. The resulting ppt was collected by filtration and washed sequentially with H2O (2×3 mL) and Et2O (2×3 mL). The ppt was placed under high vacuum to remove trace volatiles to afford 1.1 g (60%) of an orange solid. LC-MS: 245.0 [M+H], purity 90%.


Preparative Example 1100-K



embedded image


To a solution of thiomethyl derivative (0.20 g, 1.0 mmol) from Preparative Example 800-K in CH2Cl2 (5 mL) at 0° C. was added AlCl3 (0.70 g, 5.3 mmol) followed by benzoyl chloride (0.40 mL, 3.5 mmol). The mixture was heated at reflux for 12 h at rt whereupon the mixture was carefully quenched at 0° C. with sat. aq. NaHCO3 (3 mL). CH2Cl2 (5 mL) was added, the layers were separated, and the aqueous layer was extracted with CH2Cl2 (2×5 mL). The organic layers were combined, washed with brine (1×5 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 0.27 g (88% crude yield) of a brown solid. LC-MS: 304.0 [M+H], purity 85%.


Preparative Example 1200-K



embedded image


To a solution of thiomethyl derivative (0.4 g, 1.63 mmol) from Preparative Example 1000-K in dioxane/DIPEA (7 ml/2 mL) at room temperature was added (S)-(−)-3-(Boc-amino)pyrrolidine (0.36 g, 1.96 mmol) in a single portion. The mixture was stirred at reflux for 12 h and was cooled to rt. The mixture was filtered and washed with CH2Cl2 (2×2 mL) and Et2O (2×2 mL). The resultant ppt was dried under vacuum to afford 0.57 g (90% yield) of a yellow solid. LC-MS: 395.1 [M+H], purity 90%.


Preparative Example 1300-K



embedded image


The above compound was prepared according to the procedure outlined in Preparative Example 1200-K utilizing thiomethyl derivative from Preparative Example 1000 (66 mg, 0.27 mmol) and (S)-(−)-1-(Boc-amino)pyrrolidine (65 mg, 0.35 mmol) to afford 83 mg (77% yield) of a yellow solid. LC-MS: 395.1 [M+H], purity 99%.


Preparative Example 1400-K



embedded image


The title compound was prepared according to the procedure outlined in Preparative Example 1200-K utilizing thiomethyl derivative (0.30 g, 1 mmol) from Preparative Example 1100-K and (S)-(−)-1-(Boc-amino)pyrrolidine (0.24 g, 1.3 mmol) to afford 160 mg (35% yield) of a yellow solid. LC-MS: 454.1 [M+H], purity 60%.


Preparative Example 1500-K



embedded image


To a solution of thiomethyl adduct (0.17 g, 0.42 mmol) from Preparative Example 1200-K in CH2Cl2 (2 mL) at 0° C. was added MCPBA (0.11 g, 0.63 mmol) in one portion. The mixture was stirred for 2 h at 0° C. and 1 h at rt whereupon an additional portion of MCPBA (54 mg, 0.32 mmol) was added. The mixture was stirred for 2 h at rt where upon CH2Cl2 (3 mL) and sat. aq. NaHCO3 (3 mL) were added. The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×5 mL). The organic layers were combined and washed with brine (1×3 mL). The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 0.17 (98% crude yield) of a yellow solid. This material was used directly without further purification. LC-MS: 411.1 [M+H], purity 85%.


Preparative Example 1600-K



embedded image


The title compound was prepared according to the procedure outlined in Preparative Example 1500-K utilizing thiomethyl derivative (82 mg, 0.21 mmol) from Preparative Example 1300-K 0 to afford 84 mg (98% yield) of a yellow solid. This material was used directly without further purification. LC-MS: 411.1 [M+H], purity 89%.


Preparative Example 1700



embedded image


The title compound was prepared according to the procedure outlined in Preparative Example 1500-K utilizing thiomethyl derivative (0.15 g, 0.33 mmol) from Preparative Example 1400-K to afford 152 mg (98% yield) of a yellow solid. This material was used directly without further purification. LC-MS: 470.1 [M+H], purity 40%.


Preparative Example 1800-K



embedded image


To a pressure tube charged with a stir bar was added sulfoxide (0.15 g, 0.36 mmol) from Preparative Example 1500-K followed by 2M NH3 in IPA (4 mL) and conc. NH4OH (1 mL). The tube was capped and was heated to 85° C. and stirred for 14 h. The mixture was cooled to room temperature, concentrated under reduced pressure, and placed under high vacuum to remove trace volatiles. The crude product was purified by preparative thin-layer chromatography (4×1000 μM) plates using a 20:1 mixture of CH2Cl2/MeOH as eluent to afford 105 mg (80% yield) of a yellow/orange solid. LC-MS: 364.2 [M+H], purity 99%.


Preparative Example 1900-K



embedded image


The title compound was prepared according to the procedure outlined in Preparative Example 1800-K utilizing thiomethyl derivative (60 mg, 0.15 mmol) from Preparative Example 1600-K to afford 21 mg (39% yield) of an off-white solid. LC-MS: 364.1 [M+H], purity 90%.


Preparative Example 2000-K



embedded image


The title compound was prepared according to the procedure outlined in Preparative Example 1800-K utilizing thiomethyl derivative (140 mg, 0.30 mmol) from Preparative Example 1700-K to afford 30 mg (24% yield) of yellow crystalline solid. LC-MS: 423.1 [M+H], purity 93%.


Preparative Example 2100-K



embedded image


To a pressure tube charged with dichloride (5 g, 26.7 mmol) and a stir bar was added conc. NH4OH (110 mL). The tube was sealed and heated to 70° C. The mixture was stirred for 5 h, cooled to rt, and concentrated to dryness under reduced pressure. The resultant solid was suspended in H2O (70 mL), filtered, and the solid washed with Et2O (100 mL). The crude material was dried under reduced pressure to afford 4.2 g (93% yield) of a yellow solid that was used without purification. LC-MS: 169.0 [M+H], purity 99%.


Preparative Example 2200-K



embedded image


The title compound was prepared according to the procedure outlined in Preparative Example 2100-K except utilizing the 3-bromo derivative (2.0 g, 7.5 mmol) to afford 1.7 g (92% yield) of a white solid. mp>215° C.; LC-MS: 249.0 [M+H], purity 99%.


Preparative Example 2300-K



embedded image


To a solution of 7-amino adduct (4.2 g, 24.8 mmol) from Preparative Example 2100-K in CH2Cl2 (50 mL) at rt was added Boc2O (5.9 g, 27.3 mmol) and DMAP (3.3 g, 27.3 mmol). The resulting solution was stirred for 12 h at rt and was diluted with CH2Cl2 (50 mL) and sat. aq. NaHCO3 (25 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×30 mL). The combined organic layers were washed with brine (1×30 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. The crude product was purified by 40M Flash Elute using a gradient (1 L of CH2Cl2 to 2.5 L of 1% MeOH (7M NH3):CH2Cl2 to afford 6.3 g (95% yield) of a white solid. LC-MS: 269.0 [M+H], purity 99%.


Preparative Example 2400-K



embedded image


The title compound was prepared according to the procedure outlined in Preparative Example 2300-K except utilizing the 3-bromo derivative (2.0 g, 8.1 mmol) from Preparative Example 2200-K to afford 2.5 g (89% yield) of a white solid; LC-MS: 349.1 [M+H], purity 95%.


Preparative Example 2500-K



embedded image


To a solution of Boc derivative (0.10 g, 0.37 mmol) from Preparative Example 2300-K in dioxane/DIPEA (3 ml/0.5 mL) at rt was added benzylamine (61 μL, 0.56 mmol) dropwise. The mixture was stirred at reflux for 12 h, cooled to rt, and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (4×1000 μM plates) using a 30:1 mixture of CH2Cl2/MeOH as eluent to afford 65 mg (52% yield) of a yellow solid. LC-MS: 340.1 [M+H], purity 99%.


Preparative Examples 2501-K-2525-K

Following the procedure set forth in Preparative Example 2500-K but substituting commercially available amines, the compounds in Column 3 of Table 2500-K.












TABLE 2500-K








1. Yield (%)


Prep. Ex.
Column 2
Column 3
2. LC-MS







2501-K


embedded image




embedded image


1. 12 2. 368.1





2502-K


embedded image




embedded image


1. 30 2. 346.1





2503-K


embedded image




embedded image


1. 69 2. 463.1





2504-K


embedded image




embedded image


1. 98 2. 464.1





2505-K


embedded image




embedded image


1. 46 2. 449.1





2506-K


embedded image




embedded image


1. 72 2. 412.1





2507-K


embedded image




embedded image


1. 94 2. 419.2





2508-K


embedded image




embedded image


1. 90 2. 499.1





2509-K


embedded image




embedded image


1. 47 2. 420.1





2510-K


embedded image




embedded image


1. 57 2. 427.1





2511-K


embedded image




embedded image


1. 85 2. 525.1





2512-K


embedded image




embedded image


1. 80 2. 525.1





2513-K


embedded image




embedded image


1. 53 2. 494.1





2514-K


embedded image




embedded image


1. 49 2. 434.1





2515-K


embedded image




embedded image


1. 95 2. 499.1





2516-K


embedded image




embedded image


1. 54 2. 513.1





2517-K


embedded image




embedded image


1. 84 2. 513.1





2618-K


embedded image




embedded image


1. 79 2. 499.1





2519-K


embedded image




embedded image


1. 78 2. 513.1





2520-K


embedded image




embedded image


1. 82 2. 513.1





2521-K


embedded image




embedded image


1. 92 2. 513.1





2522-K


embedded image




embedded image


1. 12 2. 485.3





2523-K


embedded image




embedded image


1. 28 2. 525.1





2524-K


embedded image




embedded image


1. 30 2. 525.1





2525-K


embedded image




embedded image


1. 89 2. 511.3









Preparative Example 2600-K



embedded image


To a solution of Boc derivative (0.53 g, 1.27 mmol) from Preparative Example 2507-K in MeOH (4 mL) at 0° C. was added KSCN (0.15 g, 1.52 mmol) followed by Br2 (75 μL, 1.52 mmol). The mixture was allowed to warm to rt, stir for 12 h, and was concentrated under reduced pressure. The crude residue was suspended in EtOAc (7 mL) and sat. aq. NaHCO3 (2 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (2×7 mL) and the organic layers were combined. The organic layer washed with brine (1×5 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by column chromatography using a 20:1 mixture of CH2Cl2/MeOH as eluent to afford 0.37 g (65% yield) as a light yellow solid. LCMS: 476.3 [M+H] 99% purity.


Preparative Example 2700-K



embedded image


To a solution of thiocyanate (100 mg, 0.21 mmol) from Preparative Example 2600-K in THF (2 mL) at 0° C. was added Pd(PPh3)4 (24 mg, 0.021 mmol) followed by dropwise addition of PhMgBr (1.0 M in THF, 1.26 mL). The mixture was stirred for 12 h at rt and was treated with sat. aq NH4Cl (2 mL) and CH2Cl2 (5 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×5 mL). The organic layers were combined, washed with brine (1×3 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (4×1000 μM plates) using a 3:1 mixture of hexanes/EtOAc as eluent to afford 66 mg (60% yield) of a yellow semisolid. LC-MS: 527.1 [M+H], purity 99%.


Preparative Example 2800-K



embedded image


To a solution of thiocyanate (100 mg, 0.21 mmol) from Preparative Example 2600-K in MeOH (1.5 mL) at rt was added PPh3 (55 mg, 0.21 mmol) in a single portion. The mixture was heated to reflux, stirred for 12 h, cooled and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (4×1000 μM plates) using a 3:1 mixture of hexanes/EtOAc as eluent to afford 66 mg (68% yield) of a white solid. LC-MS: 465.3 [M+H], purity 99%.


Preparative Example 2900-K



embedded image


To a solution of thiocyanate (0.15 g, 0.32 mmol) from Preparative Example 2600-K in EtOH (2.5 mL) at rt was added a 0.1 M soln. of KH2PO4 (0.1 mL) followed by DTT (0.19 g, 1.26 mmol). The resulting mixture was stirred for 12 h at rt and was concentrated under reduced pressure. The resulting semisolid was dissolved in CH2Cl2 (5 mL) and washed sequentially with H2O (3×2 mL) and brine (3×2 mL). The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 0.13 g (90% crude yield) of a light yellow semisolid. This material was taken on crude without purification.


Preparative Example 3000-K



embedded image


To a solution of the crude sulfhydryl derivative (80 mg, 0.18 mmol) from Preparative Example 2900-K in DMF (1.5 mL) at 0° C. was added K2CO3 (73 mg, 0.53 mmol) followed by bromoethanol (37 μL, 0.53 mmol). The resulting mixture was stirred for 72 h at rt where upon the mixture was diluted with EtOAc (5 mL) and water (2 mL). The layers were separated and the organic layer washed with H2O (3×2 mL) and brine (3×2 mL). The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure to afford a yellow semisolid. The crude product was purified by preparative thin-layer chromatography (4×1000 μM plates) using a 1:1 mixture of hexanes/EtOAc as eluent to afford 37 mg (41% yield) of a light brown semisolid. LC-MS: 495.1 [M+H], purity 99%.


Preparative Example 3100-K



embedded image


The title compound was prepared according to the procedure outlined in Preparative Example 2300-K except utilizing the 3-nitro derivative (0.20 g, 0.55 mmol) from Preparative Example 1800-K to afford 0.25 g (97% yield) of a yellow semisolid. LC-MS: 464.3 [M+H], purity 99%.


Preparative Example 3200-K



embedded image


To a solution of 3-nitro adduct (70 mg, 0.15 mmol) from Preparative Example 3100-K in MeOH (2 mL) at rt was added Pd/C (10%, 25 mg dry). The mixture was stirred under H2 (1 atm) for 12 h whereupon the mixture was filtered thru a pad of Celite. The pad washed generously with MeOH (2×4 mL) and the filtrate was concentrated under reduced pressure to afford 64 mg (98% yield) of a pink solid. LC-MS: 434.1 [M+H], purity 90%.


Preparative Example 3300-K



embedded image


To a solution of 3-amino adduct (60 mg, 0.14 mmol) from Preparative Example 3200-K in CH2Cl2 (3 mL) at 0° C. was added Et3N (29 μL, 0.21 mmol) followed by AcCl (12 μL, 0.17 mmol). The resulting mixture was stirred at rt for 12 h and was diluted with brine (3 mL) and CH2Cl2 (3 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×3 mL). The organic layers were combined, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (2×1000 μM plates) using a 20:1 mixture of CH2Cl2/MeOH as eluent to afford 65 mg (68% yield) of a pink semisolid. LC-MS: 476.1 [M+H], purity 99%.


Preparative Example 3400-K



embedded image


To a solution of 3-amino adduct (69 mg, 0.16 mmol) from Preparative Example 3200-K in CH2Cl2 (1 mL)/AcOH (0.1 mL) at 0° C. was added 2-thiophenecarboxaldehyde (18 μL, 0.19 mmol) followed by NaB(OAc)3H (41 mg, 0.19 mmol). The resulting mixture was stirred at rt for 12 h and was diluted with 1N NaOH (1 mL) and CH2Cl2 (3 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×3 mL). The organic layers were combined, dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (2×1000 μM plates) using a 30:1 mixture of CH2Cl2/MeOH as eluent to afford 97 mg (96% yield) of a brown/orange oil. LC-MS: 626.1 [M+H], purity 96%.


Preparative Example 3500-K



embedded image


To a solution of 3-amino adduct (90 mg, 0.21 mmol) from Preparative Example 3200-K in CH2Cl2 (1.5 mL) at 0° C. was added Et3N (32 μL, 0.31 mmol) followed by PhNCO (27 μL, 0.25 mmol). The resulting mixture was stirred at rt for 12 h and was diluted with sat. aq. NaHCO3 (2 mL) and CH2Cl2 (5 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×3 mL). The organic layers were combined, washed with brine (1×3 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (2×1000 μM plates) using a 20:1 mixture of CH2Cl2/MeOH as eluent to afford 110 mg (95% yield) of a white solid. LC-MS: 553.1 [M+H], purity 99%.


Preparative Example 3600-K



embedded image


To a solution of 3-H adduct (0.15 g, 0.36 mmol) from Preparative Example 2507-K in CH3CN (2 mL) at 0° C. was added NCS (48 mg, 0.36 mmol) in a single portion. The mixture was stirred for 3 h at 0° C. whereupon the mixture was concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (4×1000 μM plates) using a 2:1 mixture of hexanes/EtOAc as eluent to afford 0.16 g (98% yield) of a light yellow semisolid. LC-MS: 453.1 [M+H], purity 83%.


Preparative Example 3700-K



embedded image


The title compound was prepared according to the procedure outlined in Preparative Example 3600-K utilizing the 3-H derivative (0.20 g, 0.55 mmol) from Preparative Example 2507-K and NIS (0.13 g, 0.60 mmol) to afford 0.25 g (97% yield) of a yellow semisolid. LC-MS: 464.3 [M+H], purity 99%.


Example 100-K



embedded image


TFA (0.3 mL) was added under N2 to a stirred solution of the product from Preparative Example 700-K (18 mg, 0.04 mmol) in CH2Cl2 (1.5 mL). The mixture was stirred for 1 hr, the solvent was evaporated, and the residue was mixed with solid Na2CO3 (100 mg) and 10:1 CH2Cl2/MeOH (2.0 mL). The mixture was stirred under N2 for 10 min, the solution was withdrawn and loaded onto a silica gel preparative TLC plate, which was then developed with 10:1 CH2Cl2/7N NH3 in MeOH. Pale yellow solid (5 mg, 35%) was obtained. LC-MS: 380 [M+H]. Mp=106-109° C. SCH 773943


Examples 101-K-123-K

By essentially the same procedure set forth in Example 100-K only substituting the compounds shown in Column 2 of Table 800-K, the compounds shown in Column 3 of Table 800-K were prepared.












TABLE 800-K





Ex.
Column 2
Column 2
Data







101-K


embedded image




embedded image


LCMS: MH+ = 258 mp = 200- 202° C.





102-K


embedded image




embedded image


LCMS: MH+ = 300 mp = 104- 106° C.





103-K


embedded image




embedded image


LCMS: MH+ = 380





104-K


embedded image




embedded image


LCMS: MH+ = 300 mp = 191- 193° C.





105-K


embedded image




embedded image







106-K


embedded image




embedded image


mp = 157- 159° C.





107-K


embedded image




embedded image


LCMS: MH+ = 414 mp = 96-99° C.





108-K


embedded image




embedded image


LCMS: M2H+ = 394





109-K


embedded image




embedded image


LCMS: MH+ = 256 wax





110-K


embedded image




embedded image


LCMS: MH+ = 318 wax





111-K


embedded image




embedded image


LCMS: M+ = 379 mp = 247- 249° C.





112-K


embedded image




embedded image


LCMS: MH+ = 247 mp = 148- 150° C.





113-K


embedded image




embedded image


LCMS: MH+ = 327 mp = 114- 116° C.





114-K


embedded image




embedded image


LCMS: MH+ = 301 mp = 227- 229° C.





115-K


embedded image




embedded image


LCMS: MH+ = 379 mp = 156- 158° C.





118-K


embedded image




embedded image


LCMS: M+ = 376 mp = 95-98° C.





119-K


embedded image




embedded image


LCMS: M+ = 362 mp = 161- 163° C.





120-K


embedded image




embedded image


LCMS: M+ = 373 mp = 220- 222° C.





121-K


embedded image




embedded image


LCMS: M+ = 403 mp = 95-98° C.





122-K


embedded image


get,0141
LCMS: M+ = 415 mp = 90-93° C.





123-K


embedded image




embedded image


LCMS: M+ = 332 mp = 200- 203° C.





124-K


embedded image




embedded image







125-K


embedded image




embedded image







126-K


embedded image




embedded image











Example 200-K



embedded image


TFA (0.5 mL) was added under N2 to a stirred solution of the product from Preparative Example 604-K (30 mg, 0.056 mmol) in CH2Cl2 (1.0 mL). The mixture was stirred for 4 hr, the solvent was evaporated, and the residue was mixed with solid NaHCO3 (200 mg) and 4:1 CH2Cl2/MeOH (5 mL). The mixture was stirred under N2 for 30 min, additional CH2Cl2 (5 mL) was then added, the mixture was filtered through Celite, and the solvent was evaporated. Pale brown wax (31 mg) was obtained. LC-MS: 284 [M+2H].


Example 300-K



embedded image


A mixture of the product from Example 112-K (70 mg, 0.29 mmol) and tert-butyl N-(2-oxoethyl)carbamate (45 mg, 0.29 mmol) in anhydrous CH2Cl2 (2 mL) was stirred under N2 at 25° C. for 1 hr. Then NaBH(OAc)3 (106 mg, 0.50 mmol) was added, the mixture was stirred for 1 hr, and then quenched with MeOH (2 mL). The solvents were evaporated and the residue was purified by column chromatography on silica gel with 20:1 CH2Cl2/7 N NH3 in MeOH as eluent. White solid (84 mg, 76%) was obtained. LC-MS: 390 [M+H]. Mp=75-78° C.


Example 401-K-402-K

By essentially same procedure set forth in Example 300-K only substituting the compounds shown in Column 2 of Table 900-K, the compounds shown in Column of Table 900-K were prepared.












TABLE 900-K





Ex.
Column 2
Column 3
Data







401-K


embedded image




embedded image


white solid LC-MS: 440 [M+].





402-K


embedded image




embedded image


pale yellow wax. LC-MS: 443 [M + H].









Example 500-K



embedded image


A solution of NBS (23 mg, 0.13 mmol) in anhydrous CH3CN (1.0 mL) was added under N2 to a stirred solution of the product from Example 300-K (50 mg, 0.13 mmol) in anhydrous CH3CN (2.0 mL) and CH2Cl2 (1.0 mL). The mixture was stirred for 20 hr, the solvents were evaporated, and the residue was purified by column chromatography on silica gel with 20:1 CH2Cl2/MeOH as eluent. White solid (38 mg, 63%) was obtained. LC-MS: 468 [M+]. Mp=150-152° C.


Example 500-K-502-K

By essentially same procedure set forth in Example 500-K, compounds shown in Column 2 of Table 930-K were prepared.











TABLE 930-K





Ex.
Column 2
Data







501- K


embedded image


colorless solid. LC-MS: 520 [M + H].





502- K


embedded image


pale yellow wax LC-MS: 523 [M + H]. SCH 785438









Example 701-K-702-K

By essentially same procedure set forth in Example 500-K only substituting N-chlorosuccinimide, compounds shown in Column 2 of Table 940-K were prepared.













TABLE 940-K







Ex.
Column 2
Data









701-K


embedded image


LCMS: M+ = mp =







702-K


embedded image


white solid. LC-MS: 476 [M + H].










Example 800-K



embedded image


TFA (0.4 mL) was added under N2 to a stirred solution of the product from Example 500-K (30 mg, 0.064 mmol) in CH2Cl2 (2.0 mL). The mixture was stirred for 1 hr, the solvent was evaporated, and the residue was mixed with solid Na2CO3 (200 mg) and 10:1 CH2Cl2/MeOH (2.0 mL). The mixture was stirred under N2 for 10 min, the solution was withdrawn and loaded onto a silica gel preparative TLC plate, which was then developed with 10:1 CH2Cl2/7N NH3 in MeOH. White solid (10 mg, 42%) was obtained. LC-MS: 368 [M+]. Mp=132-135° C.


Examples 801-K-803-K

By essentially same procedure set forth in Example 800-K, compounds shown in Column 2 of Table 950-K were prepared:











TABLE 950-K





Ex.
Column 2
Data







801- K


embedded image


pale yellow solid LC-MS: 421 [M + H]. Mp = 148- 150° C.





802- K


embedded image


white solid LC- MS: 420 [M + H]. Mp = 92-95° C.





803- K


embedded image


pale yellow solid. LC-MS: 376 [M + H]. Mp = 138- 140° C.









Example 900-K



embedded image


A solution of 37% HCHO (0.002 mL) in H2O (0.02 mL) was added under N2 to a stirred solution of the product from Preparative Example 823-K (9 mg, 0.027 mmol) in anhydrous THF (1 mL) an MeOH (0.3 mL) and then the mixture was stirred under N2 at 25° C. for 5 hr. Then NaBH(OAc)3 (8 mg, 0.038 mmol) was added and the mixture was stirred for 1 hr. The solvents were evaporated and the residue was purified by preparative TLC on silica gel with 10:1 CH2Cl2/7 N NH3 in MeOH as eluent. White solid 8 mg, 85%) was obtained. LC-MS: 346 [M+]. Mp=92-95° C.


Preparative Example 3800-K



embedded image


To a mixture of 7-amino adduct (65 mg, 0.19 mmol) from Preparative Example 2500-K in CH2Cl2 (2 mL) at 0° C. was added TFA (1 mL) dropwise. The resulting mixture was stirred for 12 h at rt and was concentrated under reduced pressure. The crude material was partitioned between EtOAc (5 mL) and sat. aq. Na2CO3 (2 mL) and the layers were separated. The aqueous layer was extracted with EtOAc (2×5 mL) and the organic layers were combined. The organic layer washed with brine (1×3 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (4×1000 μM plates) using a 20:1 mixture of CH2Cl2/MeOH (7M NH3) as eluent to afford 41 mg (89% yield) as a brown solid. mp 111-113° C.; LC-MS: 240.0 [M+H], purity 98%.


Examples 1000-1025-K

By essentially the same procedure set forth in Preparative Example 3800-K but utilizing the appropriate Boc derivatives, the compounds in Column 2 of Table 1000-K were prepared.











TABLE 1000-K







1. Yield




(%)




2. LC-MS


Ex.
Column 2
3. mp







1000- K


embedded image


1. 10 2. 297.1 3. 138-141





1001- K


embedded image


1. 95 2. 320.1 3. 115-117





1002- K


embedded image


1. 70 2. 327.1 3. 110-113





1003- K


embedded image


1. 26 2. 325.1 3. 114-117





1004- K


embedded image


1. 46 2. 325.1 3. 105-107





1005- K


embedded image


1. 81 2. 394.1 3. 166-168





1006- K


embedded image


1. 90 2. 334.1 3. 43-45





1007- K


embedded image


1. 45 2. 299.1 3. 115-117





1008- K


embedded image


1. 73 2. 313.1 3. 131-133





1009- K


embedded image


1. 62 2. 313.1 3. 130-134





1010- K


embedded image


1. 88 2. 299.1 3. 114-117





1011- K


embedded image


1. 67 2. 313.1 3. 169-171





1012- K


embedded image


1. 36 2. 313.1 3. 90-93





1013- K


embedded image


1. 89 2. 313.1 3. 154-156





1014- K


embedded image


1. 30 2. 285.3





1015- K


embedded image


1. 83 2. 325.1 3. 115-117





1016- K


embedded image


1. 80 2. 325.1 3. 105-107





1017- K


embedded image


1. 64 2. 311.1 3. 98-102





1018- K


embedded image


1. 79 2. 253.1 3. 188-190





1019- K


embedded image


1. 20 2. 345.2 3. 127-129





1020- K


embedded image


1. 70 2. 265.1 3. 120-122





1021- K


embedded image


1. 87 2. 327.1 3. xxx-xxx





1022- K


embedded image


1. 21 2. 295.1 3. xxx-xxx





1023- K


embedded image


1. 17 2. 276.1





1024- K


embedded image


1. 21 2. 295.1 3. xxx-xxx





1025- K


embedded image


1. 20 2. 353.2 3. >200









Example 1100-K



embedded image


To a solution of 7-amino adduct (20 mg, 0.067 mmol) from Example 1010-K in CH3CN at 0° C. was added NBS (12 mg, 0.067 mmol) in a single portion. The mixture was stirred for 2 hours at rt and was concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (2×1000 μM plates) using a 10:1 mixture of CH2Cl2/MeOH(7M NH3) as eluent to afford 20 mg (79% yield) as a light orange solid. mp 159-161° C. LC-MS: 377.1 [M+H], purity 99%.


Examples 1101-K-1112-K

Following the procedure set forth in Example 1100-K and utilizing either NBS, NCS, or NIS the compounds in Column 3 of Table 1100-K were prepared.












TABLE 1100-K








1. Yield (%)


Prep.


2. LC-MS


Ex.
Column 2
Column 3
3. mp (° C.)







1101-K
NCS


embedded image


1. 41 2. 333.2 3. 123-125





1102-K
NCS


embedded image


1. 64 2. 333.2 3. 122-125





1103-K
NBS


embedded image


1. 66 2. 377.2 3. 159-161





1104-K
NBS


embedded image


1. 38 2. 344.1 3. xxx-xxx





1105-K
NBS


embedded image


1. 89 2. 403.1 3. 66-68





1106-K
NBS


embedded image


1. 90 2. 403.1 3. 170-172





1107-K
NBS


embedded image


1. 53 2. 389.1 3. xxx-xxx





1108-K
NBS


embedded image


1. 48 2. 391.1 3. 142-144





1109-K
NBS


embedded image


1. 59 2. 407.2 3. 156-158





1110-K
NBS


embedded image


1. 75 2. 375.1 3. 134-136





1111-K
NBS


embedded image


1. 63 2. 333.1 3. 153-155





1112-K
NCS


embedded image


1. 15 2. 287.1 3. >200









Preparative Example 3900-K



embedded image


To a solution of 7-methoxy adduct (0.10 g, 0.30 mmol) from Preparative Example 402-K in AcOH at rt was added morpholine (29 μL, 0.33 mmol) followed by 40% formaldehyde in H2O (1 mL). The resulting mixture was stirred at rt for 12 h whereupon the mixture was concentrated under reduced pressure. The crude semisolid was partitioned between CH2Cl2 (5 mL) and sat. aq. NaHCO3 (3 mL) and the layers were separated. The aqueous layer was extracted with CH2Cl2 (2×5 mL) and the organic layers were combined. The organic layer was washed with brine (1×3 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 0.11 g (84% crude yield) of a light yellow semisolid. LC-MS: 432.1 [M+H], purity 94%.


Preparative Example 4000-K



embedded image


To a pressure tube charged with a stir bar was added 7-methoxy (96 mg, 0.22 mmol) from Preparative Example 3900-K followed by 2M NH3 in IPA (2 mL) and conc. NH4OH (2 mL). The tube was capped and was heated to 85° C. and stirred for 14 h. The mixture was cooled to rt, concentrated under reduced pressure, and placed under high vacuum to remove trace volatiles. The crude product was purified by preparative thin-layer chromatography (4×1000 μM) plates using a 10:1 mixture of CH2Cl2/MeOH as eluent to afford 40 mg (43% yield) of a yellow semisolid. LC-MS: 417.1 [M+H], purity 89%.


Example 1200-K



embedded image


To a mixture of 7-amino adduct (40 mg, 0.096 mmol) from Preparative Example 4000-K was added 4N HCl/dioxane (3 mL) dropwise. The resulting mixture was stirred for 12 h at rt and was concentrated under reduced pressure. The crude material was taken up in CH2Cl2 (5 mL) and was concentrated under reduced pressure and this procedure was repeated 3×. The resulting solid was triturated with Et2O (3×3 m) and was concentrated under reduced pressure to afford 26 mg (75% yield) of a light yellow solid. mp 190-193° C.; LC-MS: 317.1 [M+H], purity >90%.


Preparative Example 4100-K



embedded image


The title compound was prepared from 7-chloro adduct (2.6 g, 7.7 mmol) from Preparative Example 200-K and NaSMe (0.65 g, 9.3 mmol) according to the procedure outlined in Preparative Example 1 to afford 2.6 g (98% yield) of a pale white solid. LC-MS: 349.1 [M+H], purity 98%.


Preparative Example 4200-K



embedded image


The above compound was prepared from 7-thiomethyl adduct (1.1 g, 3.1 mmol) from Preparative Example 4100-K according to the procedure outlined in Example 1 to afford 0.70 g (90% yield) of a yellow semisolid. LC-MS: 249.1 [M+H], purity 98%.


Preparative Example 4300-K



embedded image


To a solution of thiomethyl adduct (1.3 g, 3.13 mmol) from Preparative Example 4200-K in CH2Cl2 (20 mL) at 0° C. was added Et3N (0.65 mL, 4.7 mmol) followed by CbzCl (0.48 mL, 3.4 mmol). The resulting mixture was stirred for 12 h at rt and the mixture was diluted CH2Cl2 (15 mL) and sat. aq. NaHCO3 (5 mL) and the layers were separated. The aqueous layer was extracted with CH2Cl2 (2×10 mL) and the organic layers were combined. The organic layer washed with brine (1×5 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by flash chromatography using CH2Cl2 as eluent to afford 0.96 g (80% yield) of a yellow oil. LC-MS: 383.1 [M+H], purity 91%.


Preparative Example 4400-K



embedded image


To a solution of 7-thiomethyl adduct (0.29 g, 0.75 mmol) from Preparative Example 4300-K in DMF (3 ml) at 0° C. was added POCl3 (0.10 mL, 1.1 mmol). The resulting mixture was allowed to warm to rt and stir for 12 h. The mixture was cooled to 0° C. and was treated with ice water (2 ml) and CH2Cl2 (5 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×5 mL). The organic layers were combined, washed with brine (1×5 mL). The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure to afford 0.28 g (91% yield) of a yellow solid. LC-MS: 433.2 [M+H], purity 84%.


Preparative Example 4500-K



embedded image


To a mixture of benzyltriphenylphosphonium bromide (0.64 g, 1.48 mmol) and NaH (59 mg, 1.48 mmol) in dry THF (3 mL) at rt was added thiomethyl adduct (0.21 g, 0.50 mmol) from Preparative Example 4400-K. The mixture was heated at reflux for 12 h, cooled to rt, and diluted with CH2Cl2 (5 mL) and brine (2 mL). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×5 mL). The organic layers were combined, washed with brine (1×5 mL). The organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (2×1000 μM plates) using a 1:1 mixture of hexanes/EtOAc as eluent to afford 100 mg (42% yield) as a light orange solid.


Preparative Example 4600-K



embedded image


The title compound was prepared from 7-thiomethyl adduct (0.10 g, 0.21 mmol) from Preparative Example 4500-K according to the procedure outlined in Preparative Example 1500-K to afford 0.11 g (quantitative yield) of a yellow solid. LC-MS: 501.3 [M+H], purity 63%.


Preparative Example 4700-K



embedded image


The title compound was prepared from 7-sulfoxide adduct (0.11 g, 0.21 mmol) from Preparative Example 4600-K according to the procedure outlined in Preparative Example 1800-K to afford 83 mg (40% yield) of a yellow solid. LC-MS: 454.1 [M+H], purity 90%.


Example 1300-K



embedded image


To a solution of 7-amino adduct (38 mg, 0.083 mmol) from Preparative Example 4700-K in CH3CN (3 mL) at 0° C. was added TMSI (0.12 mL, 0.83 mmol) dropwise. The mixture was stirred for 12 h at rt whereupon 1N NaOH (2 mL) was added. The mixture was extracted with EtOAc (5×5 mL) and the organic layers were combined. The organic layer washed with brine (1×3 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude product was purified by preparative thin-layer chromatography (2×1000 μM plates) using a 10:1 mixture of CH2Cl2/MeOH(7M NH3) as eluent to afford 15 mg (56% yield) as a light yellow solid. mp 144-146° C. LCMS: 319.4 [M+H] 90% purity.


Example 1400-K-1500-K



embedded image


The compound prepared in Example 118-K was separated into individual enantiomers by semi-preparative HPLC using a ChiralPak OD column (flow rate=9 mL/min) and a gradient of 85:15 hexanes:isopropanol with 0.2% diethylamine to 75:25 hexanes:isopropanol solution with 0.2% diethylamine as eluent.


Example 1400-K

(first eluting isomer, (R)): LCMS: M+=376.




embedded image


Example 1500-K

(second eluting isomer, (S)): M+=LCMS: 376:




embedded image


Example 1600-K, Example 1700-K, Example 1800-K and Example 1900-K

By a similar procedure, the following compounds can also be prepared:




embedded image



Assay:

  • Baculovirus Constructions: Cyclins A and E were cloned into pFASTBAC (Invitrogen) by PCR, with the addition of a GluTAG sequence (EYMPME) at the amino-terminal end to allow purification on anti-GluTAG affinity columns. The expressed proteins were approximately 46 kDa (cyclin E) and 50 kDa (cyclin A) in size. CDK2 was also cloned into pFASTBAC by PCR, with the addition of a haemaglutinin epitope tag at the carboxy-terminal end (YDVPDYAS). The expressed protein was approximately 34 kDa in size.
  • Enzyme Production: Recombinant baculoviruses expressing cyclins A, E and CDK2 were infected into SF9 cells at a multiplicity of infection (MOI) of 5, for 48 hrs. Cells were harvested by centrifugation at 1000 RPM for 10 minutes. Cyclin-containing (E or A) pellets were combined with CDK2 containing cell pellets and lysed on ice for 30 minutes in five times the pellet volume of lysis buffer containing 50 mM Tris pH 8.0, 0.5% NP40, 1 mM DTT and protease/phosphatase inhibitors (Roche Diagnostics GmbH, Mannheim, Germany). Mixtures were stirred for 30-60 minutes to promote cyclin-CDK2 complex formation. Mixed lysates were then spun down at 15000 RPM for 10 minutes and the supernatant retained. 5 ml of anti-GluTAG beads (for one liter of SF9 cells) were then used to capture cyclin-CDK2 complexes. Bound beads were washed three times in lysis buffer. Proteins were competitively eluted with lysis buffer containing 100-200 ug/mL of the GluTAG peptide. Eluate was dialyzed overnight in 2 liters of kinase buffer containing 50 mM Tris pH 8.0, 1 mM DTT, 10 mM MgCl2, 100 uM sodium orthovanadate and 20% glycerol. Enzyme was stored in aliquots at −70° C.
  • In Vitro Kinase Assay: CDK2 kinase assays (either cyclin A or E-dependent) were performed in low protein binding 96-well plates (Corning Inc, Corning, N.Y.). Enzyme was diluted to a final concentration of 50 μg/ml in kinase buffer containing 50 mM Tris pH 8.0, 10 mM MgCl2, 1 mM DTT, and 0.1 mM sodium orthovanadate. The substrate used in these reactions was a biotinylated peptide derived from Histone H1 (from Amersham, UK). The substrate was thawed on ice and diluted to 2 μM in kinase buffer. Compounds were diluted in 10% DMSO to desirable concentrations. For each kinase reaction, 20 μl of the 50 μg/ml enzyme solution (1 μg of enzyme) and 20 μl of the 1 μM substrate solution were mixed, then combined with 10 μl of diluted compound in each well for testing. The kinase reaction was started by addition of 50 μl of 4 μM ATP and 1 μCi of 33P-ATP (from Amersham, UK). The reaction was allowed to run for 1 hour at room temperature. The reaction was stopped by adding 200 μl of stop buffer containing 0.1% Triton X-100, 1 mM ATP, 5 mM EDTA, and 5 mg/ml streptavidine coated SPA beads (from Amersham, UK) for 15 minutes. The SPA beads were then captured onto a 96-well GF/B filter plate (Packard/Perkin Elmer Life Sciences) using a Filtermate universal harvester (Packard/Perkin Elmer Life Sciences.). Non-specific signals were eliminated by washing the beads twice with 2M NaCl then twice with 2 M NaCl with 1% phosphoric acid. The radioactive signal was then measured using a TopCount 96 well liquid scintillation counter (from Packard/Perkin Elmer Life Sciences).
  • IC50 Determination: Dose-response curves were plotted from inhibition data generated, each in duplicate, from 8 point serial dilutions of inhibitory compounds. Concentration of compound was plotted against % kinase activity, calculated by CPM of treated samples divided by CPM of untreated samples. To generate IC50 values, the dose-response curves were then fitted to a standard sigmoidal curve and IC50 values were derived by nonlinear regression analysis. The thus-obtained IC50 values for the compounds of the invention are shown in Table 87. These kinase activities were generated by using cyclin A or cyclin E using the above-described assay.











TABLE 87





CMPD
Example
IC50 (μM)



















embedded image


1
0.020 0.029







embedded image


3
0.032 0.024







embedded image


4
0.011







embedded image


5
0.021







embedded image


8
0.003







embedded image


6
0.064 0.029







embedded image


7
0.01 0.006







embedded image


10
0.042







embedded image


12
0.17







embedded image


16
0.62







embedded image


1
5.6







embedded image


3
0.14









As demonstrated above by the assay values, the compounds of the present invention exhibit excellent CDK inhibitory properties.


While the present invention has been described with in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.











TABLE 43







Ex.
Compound
m/z





4301


embedded image


457.25





4302


embedded image


471.26





4303


embedded image


477.26





4304


embedded image


483.27





4305


embedded image


487.27





4306


embedded image


487.27





4307


embedded image


487.27





4308


embedded image


494.27





4309


embedded image


499.27





4310


embedded image


500.27





4311


embedded image


503.28





4312


embedded image


505.28





4313


embedded image


509.28





4314


embedded image


512.28





4315


embedded image


513.28





4316


embedded image


513.28





4317


embedded image


518.28





4318


embedded image


518.28





4319


embedded image


519.29





4320


embedded image


521.29





4321


embedded image


523.29





4322


embedded image


523.29





4323


embedded image


523.29





4324


embedded image


525.29












1. Ex.


Product
2. m/z







embedded image


1. 4325 2. 527.29







embedded image


1. 4326 2. 527.29







embedded image


1. 4327 2. 532.29







embedded image


1. 4328 2. 532.29







embedded image


1. 4329 2. 532.29







embedded image


1. 4330 2. 533.29







embedded image


4331







embedded image


1. 4332 2. 533.29







embedded image


1. 4333 2. 533.29







embedded image


1. 4334 2. 537.3







embedded image


1. 4335 2. 537.3







embedded image


1. 4336 2. 537.3







embedded image


1. 4337 2. 539.3







embedded image


1. 4338 2. 539.3







embedded image


1. 4339 2. 539.3







embedded image


1. 4340 2. 541.3







embedded image


1. 4341 2. 543.3







embedded image


1. 4342 2. 546.3







embedded image


1. 4343 2. 547.3







embedded image


1. 4344 2. 547.3







embedded image


1. 4345 2. 549.3







embedded image


1. 4346 2. 550.3







embedded image


1. 4347 2. 551.3







embedded image


1. 4348 2. 551.3







embedded image


1. 4349 2. 551.3







embedded image


1. 4350 2. 553.3







embedded image


1. 4351 2. 557.31







embedded image


1. 4352 2. 557.31







embedded image


1. 4353 2. 558.31







embedded image


1. 4354 2. 561.31







embedded image


1. 4355 2. 561.31







embedded image


1. 4356 2. 561.31







embedded image


1. 4357 2. 561.31







embedded image


1. 4358 2. 561.31







embedded image


1. 4359 2. 569.31







embedded image


1. 4360 2. 569.31







embedded image


1. 4361 2. 574.32







embedded image


1. 4362 2. 573.32







embedded image


1. 4363 2. 573.32







embedded image


1. 4364 2. 575.32







embedded image


1. 4365 2. 575.32







embedded image


1. 43666 2. 575.32







embedded image


1. 4367 2. 574.32







embedded image


1. 43688 2. 583.32







embedded image


1. 4369 2. 583.32







embedded image


1. 43700 2. 585.32







embedded image


1. 4371 2. 583.32







embedded image


1. 4372 2. 585.32







embedded image


1. 4373 2. 585.32







embedded image


1. 4374 2. 597.33







embedded image


1. 4375 2. 499.27







embedded image


1. 4376 2. 493.27







embedded image


1. 4377 2. 535.29

















TABLE 44






1. Ex.


Product
2. m/z









embedded image


1. 4401 2. 471.3







embedded image


1. 4402 2. 475.26







embedded image


1. 4403 2. 483.27







embedded image


1. 4404 2. 481.26







embedded image


1. 4405 2. 485.27







embedded image


1. 4406 2. 487.27







embedded image


1. 4407 2. 487.27







embedded image


1. 4408 2. 487.27







embedded image


1. 4409 2. 494.3







embedded image


1. 4410 2. 496.27







embedded image


1. 4411 2. 499.27







embedded image


1. 4412 2. 499.27







embedded image


1. 4413 2. 500.27







embedded image


1. 4414 2. 503.28







embedded image


1. 4415 2. 505.28







embedded image


1. 4416 2. 507.28







embedded image


1. 4417 2. 509.3







embedded image


1. 4418 2. 512.28







embedded image


1. 4419 2. 513.28







embedded image


1. 4420 2. 513.28







embedded image


1. 4421 2. 513.28







embedded image


1. 4422 2. 513.28







embedded image


1. 4423 2. 518.28







embedded image


1. 4424 2. 518.28







embedded image


1. 4425 2. 519.3







embedded image


1. 4426 2. 521.29







embedded image


1. 4428 2. 521.29







embedded image


1. 4428 2. 523.29







embedded image


1. 4429 2. 523.29







embedded image


1. 4430 2. 523.29







embedded image


1. 4431 2. 523.29







embedded image


1. 4432 2. 525.29







embedded image


1. 4433 2. 525.3







embedded image


1. 4434 2. 527.29







embedded image


1. 4435 2. 527.29







embedded image


1. 4436 2. 527.29







embedded image


1. 4437 2. 532.29







embedded image


1. 4438 2. 532.29







embedded image


1. 4439 2. 532.29







embedded image


1. 4440 2. 531.29







embedded image


1. 4441 2. 533.3







embedded image


1. 4442 2. 531.29







embedded image


1. 4443 2. 533.29







embedded image


1. 4444 2. 535.29







embedded image


1. 4445 2. 537.3







embedded image


1. 4446 2. 537.3







embedded image


1. 4447 2. 537.3







embedded image


1. 4448 2. 539.3







embedded image


1. 4449 2. 539.3







embedded image


1. 4450 2. 539.3







embedded image


1. 4451 2. 541.3







embedded image


1. 4451 2. 543.3







embedded image


1. 4453 2. 546.3







embedded image


1. 4454 2. 547.3







embedded image


1. 4455 2. 547.3







embedded image


1. 4456 2. 549.3







embedded image


1. 4457 2. 550.3







embedded image


1. 4458 2. 550.3







embedded image


1. 4459 2. 551.3







embedded image


1. 4460 2. 551.3







embedded image


1. 4461 2. 549.3







embedded image


1. 4462 2. 553.3







embedded image


1. 4463 2. 557.3







embedded image


1. 4464 2. 557.31







embedded image


1. 4465 2. 558.31







embedded image


1. 4466 2. 561.31







embedded image


1. 4467 2. 561.31







embedded image


1. 4468 2. 561.31







embedded image


1. 4469 2. 561.31







embedded image


1. 4470 2. 562.3







embedded image


1. 4471 2. 569.31







embedded image


1. 4472 2. 569.31







embedded image


1. 4473 2. 572.31







embedded image


1. 4474 2. 572.31







embedded image


1. 4475 2. 575.32







embedded image


1. 4476 2. 572.31







embedded image


1. 4477 2. 573.32







embedded image


1. 4478 2. 574.32







embedded image


1. 4479 2. 576.32







embedded image


1. 4480 2. 583.32







embedded image


1. 4481 2. 583.32







embedded image


1. 4482 2. 583.32







embedded image


1. 4483 2. 585.32







embedded image


1. 4484 2. 585.32







embedded image


1. 4485 2. 585.3







embedded image


1. 4486 2. 585.32







embedded image


1. 4487 2. 597.33







embedded image


1. 4488 2. 499.27

















TABLE 45






1. Ex.


Product
2. m/z









embedded image


1. 4501 2. 512.28







embedded image


1. 4502 2. 526.29







embedded image


1. 4503 2. 532.29







embedded image


1. 4504 2. 538.3







embedded image


1. 4505 2. 538.3







embedded image


1. 4506 2. 540.3







embedded image


1. 4507 2. 542.3







embedded image


1. 4508 2. 542.3







embedded image


1. 4509 2. 542.3







embedded image


1. 4510 2. 549.3







embedded image


1. 4511 2. 551.3







embedded image


1. 4512 2. 554.3







embedded image


1. 4513 2. 554.3







embedded image


1. 4514 2. 555.31







embedded image


1. 4515 2. 558.31







embedded image


1. 4516 2. 560.31







embedded image


1. 4517 2. 562.31







embedded image


1. 4518 2. 564.31







embedded image


1. 4519 2. 567.31







embedded image


1. 4520 2. 568.31







embedded image


1. 4521 2. 568.31







embedded image


1. 4522 2. 568.31







embedded image


1. 4523 2. 568.31







embedded image


1. 4524 2. 573.32







embedded image


1. 4525 2. 573.32







embedded image


1. 4526 2. 574.32







embedded image


1. 4527 2. 576.32







embedded image


1. 4528 2. 576.32







embedded image


1. 4529 2. 578.32







embedded image


1. 4530 2. 578.32







embedded image


1. 4531 2. 578.32







embedded image


1. 4532 2. 578.32







embedded image


1. 4533 2. 580.32







embedded image


1. 4534 2. 580.32







embedded image


1. 4535 2. 582.32







embedded image


1. 4536 2. 582.32







embedded image


1. 4537 2. 582.32







embedded image


1. 4538 2. 587.32







embedded image


1. 4539 2. 587.32







embedded image


1. 4540 2. 587.32







embedded image


1. 4541 2. 588.32







embedded image


1. 4542 2. 588.32







embedded image


1. 4543 2. 588.32







embedded image


1. 4544 2. 588.32







embedded image


1. 4545 2. 590.32







embedded image


1. 4546 2. 588.32







embedded image


1. 4547 2. 588.32







embedded image


1. 4548 2. 588.32







embedded image


1. 4549 2. 588.32







embedded image


1. 4550 2. 590.32







embedded image


1. 4551 2. 592.33







embedded image


1. 4552 2. 592.33







embedded image


1. 4553 2. 592.33







embedded image


1. 4554 2. 594.33







embedded image


1. 4555 2. 594.33







embedded image


1. 4556 2. 593.33







embedded image


1. 4557 2. 596.33







embedded image


1. 4558 2. 596.33







embedded image


1. 4559 2. 598.33







embedded image


1. 4560 2. 601.33







embedded image


1. 4561 2. 602.33







embedded image


1. 4562 2. 602.33







embedded image


1. 4563 2. 604.33







embedded image


1. 4564 2. 603.3







embedded image


1. 4565 2. 605.33







embedded image


1. 4665 2. 605.33







embedded image


1. 4567 2. 606.33







embedded image


1. 4568 2. 606.33







embedded image


1. 4569 2. 606.33







embedded image


1. 4570 2. 608.33







embedded image


1. 4571 2. 612.34







embedded image


1. 4572 2. 612.34







embedded image


1. 4573 2. 613.34







embedded image


1. 4574 2. 616.34







embedded image


1. 4575 2. 616.34







embedded image


1. 4576 2. 616.34







embedded image


1. 4577 2. 616.34







embedded image


1. 4578 2. 616.34







embedded image


1. 4579 2. 616.34







embedded image


1. 4580 2. 624.34







embedded image


1. 4581 2. 624.34







embedded image


1. 4582 2. 629.35







embedded image


1. 4583 2. 629.35







embedded image


1. 4584 2. 630.35







embedded image


1. 4585 2. 630.35







embedded image


1. 4586 2. 630.35







embedded image


1. 4587 2. 630.35







embedded image


1. 4588 2. 630.35







embedded image


1. 4589 2. 631.35







embedded image


1. 4590 2. 638.35







embedded image


1. 4591 2. 638.35







embedded image


1. 4592 2. 640.35







embedded image


1. 4593 2. 640.35







embedded image


1. 4594 2. 640.35







embedded image


1. 4595 2. 640.35







embedded image


1. 4596 2. 652.36







embedded image


1. 4597 2. 486.27







embedded image


1. 4598 2. 554.3







embedded image


1. 4599 2. 548.3







embedded image


1. 45100 2.

















TABLE 46






1. Ex.


Product
2. m/z









embedded image


1. 4601 2. 512.28







embedded image


1. 4602 2. 526.29







embedded image


1. 4603 2. 532.29







embedded image


1. 4604 2. 538.3







embedded image


1. 4605 2. 536.3







embedded image


1. 4606 2. 540.3







embedded image


1. 4607 2. 542.3







embedded image


1. 4608 2. 542.3







embedded image


1. 4609 2. 542.3







embedded image


1. 4610 2. 547.3







embedded image


1. 4611 2. 551.3







embedded image


1. 4612 2. 552.3







embedded image


1. 4613 2. 552.3







embedded image


1. 4614 2. 555.31







embedded image


1. 4615 2. 558.31







embedded image


1. 4616 2. 560.31







embedded image


1. 4617 2. 562.31







embedded image


1. 4618 2. 562.3







embedded image


1. 4619 2. 567.31







embedded image


1. 4620 2. 568.31







embedded image


1. 4621 2. 568.31







embedded image


1. 4622 2. 568.31







embedded image


1. 4623 2. 568.31







embedded image


1. 4624 2. 573.32







embedded image


1. 4625 2. 573.32







embedded image


1. 4626 2. 574.32







embedded image


1. 4627 2. 576.32







embedded image


1. 4628 2. 576.32







embedded image


1. 4629 2. 578.32







embedded image


1. 4630 2. 578.32







embedded image


1. 4631 2. 578.32







embedded image


1. 4632 2. 578.32







embedded image


1. 4633 2. 580.32







embedded image


1. 4634 2. 580.32







embedded image


1. 4635 2. 582.32







embedded image


1. 4636 2. 582.32







embedded image


1. 4637 2. 582.32







embedded image


1. 4638 2. 587.32







embedded image


1. 4639 2. 585.3







embedded image


1. 4640 2. 585.3







embedded image


1. 4641 2. 588.32







embedded image


1. 4642 2. 588.32







embedded image


1. 4643 2. 588.32







embedded image


1. 4644 2. 588.32







embedded image


1. 4645 2. 590.32







embedded image


1. 4646 2. 592.33







embedded image


1. 4647 2. 592.33







embedded image


1. 4648 2. 592.33







embedded image


1. 4649 2.







embedded image


1. 4650 2. 594.33







embedded image


1. 4651 2. 594.33







embedded image


1. 4652 2. 596.33







embedded image


1. 4653 2. 596.3







embedded image


1. 4654 2. 598.33







embedded image


1. 4655 2. 601.33







embedded image


1. 4656 2. 602.33







embedded image


1. 4657 2. 602.33







embedded image


1. 4658 2. 604.33







embedded image


1. 4659 2. 603.3







embedded image


1. 4660 2. 605.33







embedded image


1. 4661 2. 605.33







embedded image


1. 4662 2. 606.33







embedded image


1. 4663 2. 606.33







embedded image


1. 4664 2. 606.33







embedded image


1. 4665 2. 608.33







embedded image


1. 4666 2. 612.34







embedded image


1. 4667 2. 612.34







embedded image


1. 4668 2. 613.34







embedded image


1. 4669 2. 616.34







embedded image


1. 4670 2. 616.34







embedded image


1. 4671 2. 616.34







embedded image


1. 4672 2. 616.34







embedded image


1. 4673 2. 616.34







embedded image


1. 4674 2. 616.34







embedded image


1. 4675 2. 624.34







embedded image


1. 4676 2. 624.34







embedded image


1. 4677 2. 629.35







embedded image


1. 4678 2. 629.35







embedded image


1. 4679 2. 630.35







embedded image


1. 4680 2. 630.35







embedded image


1. 4681 2. 630.35







embedded image


1. 4682 2. 630.35







embedded image


1. 4683 2. 630.35







embedded image


1. 4684 2. 631.35







embedded image


1. 4685 2. 638.35







embedded image


1. 4686 2. 638.35







embedded image


1. 4687 2. 640.35







embedded image


1. 4688 2. 640.35







embedded image


1. 4689 2.







embedded image


1. 4690 2. 640.35







embedded image


1. 4691 2. 652.36







embedded image


1. 4692 2. 484.3







embedded image


1. 4693 2. 554.3







embedded image


1. 4694 2. 548.3







embedded image


1. 4695 2. 590.32

















TABLE 47






1. Ex.


Product
2. m/z









embedded image


1. 4701 2. 498.27







embedded image


1. 4702 2. 512.28







embedded image


1. 4703 2. 518.28







embedded image


1. 4704 2. 524.29







embedded image


1. 4705 2. 528.29







embedded image


1. 4706 2. 528.29







embedded image


1. 4707 2. 528.29







embedded image


1. 4708 2. 535.29







embedded image


1. 4709 2. 540.3







embedded image


1. 4710 2. 541.3







embedded image


1. 4711 2. 544.3







embedded image


1. 4712 2. 546.3







embedded image


1. 4713 2. 548.3







embedded image


1. 4714 2. 550.3







embedded image


1. 4715 2. 553.3







embedded image


1. 4716 2. 554.3







embedded image


1. 4717 2. 554.3







embedded image


1. 4718 2. 554.3







embedded image


1. 4719 2. 559.31







embedded image


1. 4720 2. 559.31







embedded image


1. 4721 2. 562.31







embedded image


1. 4722 2. 562.31







embedded image


1. 4723 2. 564.31







embedded image


1. 4724 2. 564.31







embedded image


1. 4725 2. 566.31







embedded image


1. 4726 2. 568.31







embedded image


1. 4727 2. 568.31







embedded image


1. 4728 2. 568.31







embedded image


1. 4729 2. 573.32







embedded image


1. 4730 2. 574.32







embedded image


1. 4731 2. 574.32







embedded image


1. 4732 2. 576.32







embedded image


1. 4733 2. 578.32







embedded image


1. 4734 2. 578.32







embedded image


1. 4735 2. 580.32







embedded image


1. 4736 2. 580.32







embedded image


1. 4737 2. 582.32







embedded image


1. 4738 2. 584.32







embedded image


1. 4739 2. 585.32







embedded image


1. 4740 2. 588.32







embedded image


1. 4741 2. 588.32







embedded image


1. 4742 2. 590.32







embedded image


1. 4743 2. 591.33







embedded image


1. 4744 2. 592.33







embedded image


1. 4745 2. 592.33







embedded image


1. 4746 2. 592.33







embedded image


1. 4747 2. 598.33







embedded image


1. 4748 2. 598.33







embedded image


1. 4749 2. 602.33







embedded image


1. 4750 2. 602.33







embedded image


1. 4751 2. 602.33







embedded image


1. 4752 2. 615.34







embedded image


1. 4753 2. 615.34







embedded image


1. 4754 2. 616.34







embedded image


1. 4755 2. 616.34







embedded image


1. 4756 2. 624.34







embedded image


1. 4757 2. 624.34







embedded image


1. 4758 2. 626.34







embedded image


1. 4759 2. 624.34







embedded image


1. 4760 2. 626.34







embedded image


1. 4761 2. 638.35







embedded image


1. 4762 2. 472.26







embedded image


1. 4763 2. 534.29

















TABLE 48






1. Ex.


Product
2. m/z









embedded image


1. 4801 2. 498.27







embedded image


1. 4802 2. 512.28







embedded image


1. 4803 2. 524.29







embedded image


1. 4804 2. 524.29







embedded image


1. 4805 2. 526.29







embedded image


1. 4806 2. 528.29







embedded image


1.. 4807 2. 528.29







embedded image


1. 4808 2. 528.29







embedded image


1. 4809 2. 540.3







embedded image


1. 4810 2. 540.3







embedded image


1. 4811 2. 544.3







embedded image


1. 4812 2. 548.3







embedded image


1. 4813 2. 553.3







embedded image


1. 4814 2. 554.3







embedded image


1. 4815 2. 560.31







embedded image


1. 4816 2. 562.31







embedded image


1. 4817 2. 562.31







embedded image


1. 4818 2. 564.31







embedded image


1. 4819 2. 564.31







embedded image


1. 4820 2. 568.31







embedded image


1. 4821 2. 568.31







embedded image


1. 4822 2. 573.32







embedded image


1. 4821 2. 574.32







embedded image


1. 4824 2. 574.32







embedded image


1. 4825 2. 574.32







embedded image


1. 4826 2. 574.32







embedded image


1. 4828 2. 576.32







embedded image


1. 4829 2. 578.32







embedded image


1. 4829 2. 580.32







embedded image


1. 4830 2. 584.32







embedded image


1. 4831 2. 588.32







embedded image


1. 4832 2. 602.33







embedded image


1. 4833 2. 602.33







embedded image


1. 4834 2. 602.33







embedded image


1. 4835 2. 610.34







embedded image


1. 4836 2. 616.34







embedded image


1. 4837 2. 624.34







embedded image


1. 4838 2. 626.34







embedded image


1. 4839 2. 626.34







embedded image


1. 4840 2. 564.31







embedded image


1. 4841 2. 535.29







embedded image


1. 4842 2. 541.3







embedded image


1. 4843 2. 559.31







embedded image


1. 4844 2. 559.31







embedded image


1. 4845 2. 564.31







embedded image


1. 4846 2. 568.31







embedded image


1. 4847 2. 578.32







embedded image


1. 4848 2. 580.32







embedded image


1. 4849 2. 580.32







embedded image


1. 4850 2. 584.32







embedded image


1. 4851 2. 590.32







embedded image


1. 4852 2. 591.33







embedded image


1. 4853 2. 610.34







embedded image


1. 4854 2. 615.34







embedded image


1. 4855 2. 615.34







embedded image


1. 4856 2. 616.34







embedded image


1. 4857 2. 624.34







embedded image


1. 4858 2. 626.34







embedded image


1. 4859 2. 537.3







embedded image


1. 4860 2. 550.3







embedded image


1. 4861 2. 554.3







embedded image


1. 4862 2. 566.31







embedded image


1. 4863 2. 566.31







embedded image


1. 4864 2. 578.32







embedded image


1. 4865 2. 582.32







embedded image


1. 4866 2. 587.32







embedded image


1. 4867 2. 588.32







embedded image


1. 4868 2. 592.33







embedded image


1. 4869 2. 592.33







embedded image


1. 4870 2. 573.32







embedded image


1. 4871 2. 616.34







embedded image


1. 4872 2. 616.34







embedded image


1. 4873 2. 624.34







embedded image


1. 4874 2. 638.35







embedded image


1. 4875 2. 546.3







embedded image


1. 4876 2. 594.33







embedded image


1. 4877 2. 598.33







embedded image


1. 4878 2. 592.33







embedded image


1. 4879 2. 569.31







embedded image


1. 4880 2. 583.32

















TABLE 49






1. Ex.


Product
2. m/z









embedded image


1. 4901 2. 490.27







embedded image


1. 4902 2. 504.28







embedded image


1. 4903 2. 510.28







embedded image


1. 4904 2. 516.28







embedded image


1. 4905 2. 516.28







embedded image


1. 4906 2. 518.28







embedded image


1. 4907 2. 520.29







embedded image


1. 4908 2. 520.29







embedded image


1. 4909 2. 520.29







embedded image


1. 4910 2. 527.29







embedded image


1. 4911 2. 529.29







embedded image


1. 4912 2. 532.29







embedded image


1. 4913 2. 532.29







embedded image


1. 4914 2. 533.29







embedded image


1. 4915 2. 536.29







embedded image


1. 4916 2. 538.3







embedded image


1. 4917 2. 540.3







embedded image


1. 4918 2. 542.3







embedded image


1. 4919 2. 545.3







embedded image


1. 4920 2. 546.3







embedded image


1. 4921 2. 546.3







embedded image


1. 4922 2. 546.3







embedded image


1. 4923 2. 546.3







embedded image


1. 4924 2. 551.3







embedded image


1. 4925 2. 551.3







embedded image


1. 4926 2. 552.3







embedded image


1. 4927 2. 554.3







embedded image


1. 4928 2. 554.3







embedded image


1. 4929 2. 556.31







embedded image


1. 4930 2. 556.31







embedded image


1. 4931 2. 556.31







embedded image


1. 4932 2. 556.31







embedded image


1. 4933 2. 558.31







embedded image


1. 4934 3. 558.31







embedded image


1. 4935 2. 560.31







embedded image


1. 4936 2. 560.31







embedded image


1. 4937 2. 560.31







embedded image


1. 4938 2. 565.31







embedded image


1. 4939 2. 565.3







embedded image


1. 4940 2. 565.31







embedded image


1. 4941 2. 566.31







embedded image


1. 4942 2. 566.31







embedded image


1. 4943 2. 566.31







embedded image


1. 4944 2. 566.31







embedded image


1. 4945 2. 568.31







embedded image


1. 4946 2. 570.31







embedded image


1. 4947 2. 570.31







embedded image


1. 4948 2. 570.31







embedded image


1. 4949 2. 572.31







embedded image


1. 4950 2. 572.31







embedded image


1. 4951 2. 571.31







embedded image


1. 4952 2. 574.32







embedded image


1. 4953 2. 576.32







embedded image


1. 4954 2. 576.32







embedded image


. 4955 2. 579.32







embedded image


1. 4956 2. 580.32







embedded image


1. 4957 2. 580.32







embedded image


1. 4958 2. 582.32







embedded image


1. 4959 2. 583.32







embedded image


1. 4960 2. 583.32







embedded image


1. 4961 2. 583.32







embedded image


1. 4962 2. 584.32







embedded image


1. 4963 2. 584.32







embedded image


1. 4964 2. 584.32







embedded image


1. 4965 2. 586.32







embedded image


1. 4966 2. 590.32







embedded image


1. 4967 2. 590.32







embedded image


1. 4968 2. 591.3







embedded image


1. 4969 2. 594.33







embedded image


1. 4970 2. 594.33







embedded image


1. 4971 2. 594.33







embedded image


1. 4972 2. 594.33







embedded image


1. 4973 2. 594.33







embedded image


1. 4974 2. 594.33







embedded image


1. 4975 2. 602.33







embedded image


1. 4976 2. 602.33







embedded image


1. 4977 2. 607.33







embedded image


1. 4978 2. 607.33







embedded image


1. 4979 2. 605.33







embedded image


1. 4980 2. 608.33







embedded image


1. 4981 2. 608.33







embedded image


1. 4982 2. 608.33







embedded image


1. 4983 2. 608.33







embedded image


1. 4984 2. 609.33







embedded image


1. 4985 2. 616.34







embedded image


1. 4986 2. 616.34







embedded image


1. 4987 2. 618.34







embedded image


1. 4988 2. 618.34







embedded image


1. 4089 2. 618.34







embedded image


1. 4990 2. 618.34







embedded image


1. 4991 2. 630.35







embedded image


1. 4992 2. 464.26







embedded image


1. 4993 2. 532.29







embedded image


1. 4994 2. 526.29







embedded image


1. 4995 2. 568.31

















TABLE 50






1. Ex.


Product
2. m/z









embedded image


1. 5001 2. 476.26







embedded image


1. 5002 2. 490.27







embedded image


1. 5003 2. 496.27







embedded image


1. 5004 2. 502.28







embedded image


1. 5005 2. 502.28







embedded image


1. 5006 2. 504.28







embedded image


1. 5007 2. 506.28







embedded image


1. 5008 2. 506.28







embedded image


1. 5009 2. 506.28







embedded image


1. 5010 2. 513.28







embedded image


1. 5011 2. 515.28







embedded image


1. 5012 2. 518.28







embedded image


1. 5013 2. 518.28







embedded image


1. 5014 2. 519.29







embedded image


1. 5015 2. 522.29







embedded image


1. 5016 2. 524.29







embedded image


1. 5017 2. 526.29







embedded image


1. 5018 2. 528.29







embedded image


1. 5019 2. 531.29







embedded image


1. 5020 2. 532.29







embedded image


1. 5021 2. 532.99







embedded image


1. 5022 2. 532.29







embedded image


1. 5023 2. 532.29







embedded image


1. 5024 2. 537.3







embedded image


1. 5025 2. 537.3







embedded image


1. 5026 2. 538.3







embedded image


1. 5027 2. 540.3







embedded image


1. 5028 2. 540.3







embedded image


1. 5029 2. 542.3







embedded image


1. 5030 2. 542.3







embedded image


1. 5031 2. 542.3







embedded image


1. 5032 2. 542.3







embedded image


1. 5033 2. 544.3







embedded image


1. 5034 2. 544.3







embedded image


1. 5035 2. 546.3







embedded image


1. 5036 2. 546.3







embedded image


1. 5037 2. 546.3







embedded image


1. 5038 2. 551.3







embedded image


1. 5039 2. 551.3







embedded image


1. 5040







embedded image


1. 5041 2. 552.3







embedded image


1. 5042 2. 552.3







embedded image


1. 5043 2. 552.3







embedded image


1. 5044 2. 552.3







embedded image


1. 5045 2. 554.3







embedded image


1. 5046 2. 556.31







embedded image


1. 5047 2. 556.31







embedded image


1. 5048 2. 556.31







embedded image


1. 5049 2. 558.31







embedded image


1. 5050 2. 558.31







embedded image


1. 5051 2. 558.31







embedded image


1. 5052 2. 560.31







embedded image


1. 5053 2. 562.31







embedded image


1. 5054 2. 562.31







embedded image


1. 5055 2. 565.31







embedded image


1. 5056 2. 566.31







embedded image


1. 5057 2. 566.31







embedded image


1. 5058 2. 568.31







embedded image


1. 5059 2. 569.31







embedded image


1. 5060 2. 569.31







embedded image


1. 5061







embedded image


1. 5062 2. 570.31







embedded image


1. 5063 2. 570.31







embedded image


1. 5064 2. 570.31







embedded image


1. 5065 572.31







embedded image


1. 5066 2. 576.32







embedded image


1. 5067 2. 576.32







embedded image


1. 5068 2. 577.32







embedded image


1. 5069 2. 580.32







embedded image


1. 5070 2. 580.32







embedded image


1. 5071 2. 580.32







embedded image


1. 5072 2. 580.32







embedded image


1 5073 2. 580.32







embedded image


1 5074 2. 580.32







embedded image


1 5075 2. 588.32







embedded image


1 5076 2. 588.32







embedded image


1. 5077 2. 593.33







embedded image


1 5078 2. 593.33







embedded image


1. 5079 2. 594.33







embedded image


1. 5080 2. 594.33







embedded image


1. 5081 2. 594.33







embedded image


1. 5082 2. 594.33







embedded image


1. 5083 2. 594.33







embedded image


1. 5084 2. 595.33







embedded image


1. 5085 2. 602.33







embedded image


1. 5086 2. 602.33







embedded image


1. 5087 2. 604.33







embedded image


1. 5088 2. 604.33







embedded image


1. 5089 2. 604.33







embedded image


1. 5090 2. 604.33







embedded image


1. 5091 2. 616.34







embedded image


1. 5092 2. 450.25







embedded image


1. 5093 2. 518.28







embedded image


1. 5094 2. 512.28







embedded image


1. 5095 2. 554.3

















TABLE 51






1. Ex.


Product
2. m/z









embedded image


1. 5101 2. 448.8







embedded image


1. 5102 2. 462.8







embedded image


1. 5103 2. 468.8







embedded image


1. 5104 2. 474.7







embedded image


1. 5105 2. 474.7







embedded image


1. 5106 2. 476.8







embedded image


1. 5107 2. 478.8







embedded image


1. 5108 2. 478.8







embedded image


1. 5109 2. 478.8







embedded image


1. 5110 2. 490.8







embedded image


1. 5111 2. 490.8







embedded image


1. 5112 2. 494.8







embedded image


1. 5113 2. 498.8







embedded image


1. 5114 2. 503.8







embedded image


1. 5115 2. 504.8







embedded image


1. 5116 2. 504.8







embedded image


1. 5117 2. 504.9







embedded image


1. 5118 2. 510.8







embedded image


1. 5119 2. 512.8







embedded image


1. 5120 2. 512.8







embedded image


1. 5121 2. 514.8







embedded image


1. 5122 2. 514.8







embedded image


1. 5123 2. 519.2







embedded image


1. 5124 2. 519.2







embedded image


1. 5125 2. 523.8







embedded image


1. 5126 2. 524.8







embedded image


1. 5127 2. 524.9







embedded image


1. 5128 2. 524.9







embedded image


1. 5129 2. 524.9







embedded image


1. 5130 2. 526.9







embedded image


1. 5131 2. 528.8







embedded image


1. 5132 2. 530.9







embedded image


1. 5133 2. 534.8







embedded image


1. 5134 2. 538.9







embedded image


1. 5135 2. 552.8







embedded image


1. 5136 2. 552.8







embedded image


1. 5137 2. 553.7







embedded image


1. 5138 2. 553.7







embedded image


1. 5139 2. 560.9







embedded image


1. 5140 2. 566.9







embedded image


1. 5141 2. 567.8







embedded image


1. 5142 2. 574.9







embedded image


1. 5143 2. 576.9







embedded image


1. 544 2. 576.9







embedded image


1. 5145 2. 514.8







embedded image


1. 5146 2. 485.8







embedded image


1. 5147 2. 491.8







embedded image


1. 5148 2. 509.8







embedded image


1. 5149 2. 509.8







embedded image


1. 5150 2. 514.8







embedded image


1. 5151 2. 519.2







embedded image


1. 5152 2. 523.8







embedded image


1. 5153 2. 528.8







embedded image


1. 5154 2. 530.9







embedded image


1. 5155 2. 530.9







embedded image


1. 5156 2. 534.8







embedded image


1. 5157 2. 540.9







embedded image


1. 5158 2. 541.8







embedded image


1. 5159 2. 541.8







embedded image


1. 5160 2. 560.9

















TABLE 52






1. Ex.


Product
2. m/z









embedded image


1. 5201 2. 462.8







embedded image


1. 5202 2. 476.8







embedded image


1. 5203 2. 482.8







embedded image


1. 5204 2. 488.8







embedded image


1. 5205 2. 488.8







embedded image


1. 5206 2. 490.8







embedded image


1. 5207 2. 492.8







embedded image


1. 5208 2. 492.8







embedded image


1. 52009 2. 492.9







embedded image


1. 5210 2. 504.8







embedded image


1. 5211 2. 504.8







embedded image


2. 5212 2. 508.8







embedded image


1. 5213 2. 512.8







embedded image


1. 5214 2. 517.8







embedded image


1. 5215 2. 518.9







embedded image


1. 5216 2. 518.9







embedded image


1. 5217 2. 518.9







embedded image


1. 5218 2. 524.9







embedded image


1. 5219 2. 526.9







embedded image


1. 5220 2. 526.9







embedded image


1. 5221 2. 528.8







embedded image


1. 5222 2. 528.8







embedded image


1. 5223 2. 533.3







embedded image


1. 5224 2. 533.3







embedded image


1. 5225 2. 537.9







embedded image


1. 5226 2. 538.8







embedded image


1. 5227 2. 538.9







embedded image


1. 5228 2. 538.9







embedded image


1. 5229 2. 538.9







embedded image


1. 5230 2. 540.9







embedded image


1. 5231 2. 542.9







embedded image


1. 5232 2. 544.9







embedded image


1. 5233 2. 548.9







embedded image


1. 5234 2. 552.9







embedded image


1. 5235 2. 566.8







embedded image


1. 5236 2. 566.8







embedded image


1. 5237 2. 567.7







embedded image


1. 5238 2. 567.7







embedded image


1. 5239 2. 574.9







embedded image


1. 5240 2. 581







embedded image


1. 5241 2. 533.3







embedded image


1. 5242 2. 537.9







embedded image


1. 5243 2. 542.8







embedded image


1. 5244 2. 544.9







embedded image


1. 5245 2. 544.9







embedded image


1. 5246 2. 548.9







embedded image


1. 5247 2. 554.9







embedded image


1. 5248 2. 555.9







embedded image


1. 5249 2. 555.9







embedded image


1. 5250 2. 574.9







embedded image


1. 5251 2. 579.9







embedded image


1. 5252 2. 579.9







embedded image


1. 5253 2. 581







embedded image


1. 5254 2. 588.9







embedded image


1. 5255 2. 590.9







embedded image


1. 5256 2. 501.8







embedded image


1. 5257 2. 514.8







embedded image


1. 5258 2. 518.9







embedded image


1. 5259 2. 530.9







embedded image


1. 5260 2. 530.9







embedded image


1. 5261 2. 538.9







embedded image


1. 5262 2. 542.9







embedded image


1. 5263 2. 547.3







embedded image


1. 5264 2. 551.9







embedded image


1. 5265 2. 552.9







embedded image


1. 5266 2. 556.9







embedded image


1. 5267 2. 556.9







embedded image


1. 5268 2. 537.9







embedded image


1. 5269 2. 566.9







embedded image


1. 5270 2. 581







embedded image


1. 5271 2. 581.7







embedded image


1. 5272 2. 581.7







embedded image


1. 5273 2. 588.9







embedded image


1. 5274 2. 602.9







embedded image


1. 5275 2. 510.8







embedded image


1. 5276 2. 559.3







embedded image


1. 5277 2. 562.9







embedded image


1. 5278 2. 556.9







embedded image


1. 5279 2. 499.8







embedded image


1. 5280 2. 499.8

















TABLE 53






1. Ex.


Product
2. m/z









embedded image


1. 5301 2. 434.7







embedded image


1. 5302 2. 448.8







embedded image


1. 5303 2. 454.8







embedded image


1. 5304 2. 460.7







embedded image


1. 5305 2. 460.7







embedded image


1. 5306 2. 462.8







embedded image


1. 5307 2. 464.8







embedded image


1. 5308 2. 464.8







embedded image


1. 5309 2. 464.8







embedded image


1. 5310 2. 476.8







embedded image


1. 5311 2. 476.8







embedded image


1. 5312 2. 480.8







embedded image


1. 5313 2. 484.8







embedded image


1. 5314 2. 489.8







embedded image


1. 5315 2. 490.8







embedded image


1. 5316 2. 490.8







embedded image


1. 5317 2. 490.8







embedded image


1. 5318 2. 496.8







embedded image


1. 5319 2. 498.8







embedded image


1. 5320 2. 498.8







embedded image


1. 5321 2. 500.8







embedded image


1. 5322 2. 500.8







embedded image


1. 5323 2. 505.2







embedded image


1. 5324 2. 505.2







embedded image


1. 5325 2. 509.8







embedded image


1. 5326 2. 510.8







embedded image


1. 5327 2. 510.8







embedded image


1. 5328 2. 510.8







embedded image


1. 5329 2. 510.8







embedded image


1. 5330 2. 512.8







embedded image


1. 5331 2. 514.8







embedded image


1. 5332 2. 516.9







embedded image


1. 5333 2. 520.8







embedded image


1. 5334 2. 524.9







embedded image


1. 5335 2. 538.8







embedded image


1. 5336 2. 538.8







embedded image


1. 5337 2. 539.6







embedded image


1. 5338 2. 539.6







embedded image


1. 5339 2. 546.9







embedded image


1. 5340 2. 552.9







embedded image


1. 5341 2. 553.8







embedded image


1. 5342 2. 560.9







embedded image


1. 5343 2. 562.9







embedded image


1. 5344 2. 562.9







embedded image


1. 5345 2. 500.8







embedded image


1. 5346 2. 471.7







embedded image


1. 5347 2. 477.8







embedded image


1. 5348 2. 495.8







embedded image


1. 5349 2. 495.8







embedded image


5350 2. 500.8







embedded image


1. 5351 2. 505.2







embedded image


1. 5352 2. 509.8







embedded image


1. 5353 2. 514.8







embedded image


1. 5355 2. 516.9







embedded image


1. 5356 2. 516.9







embedded image


1. 5356 2. 520.8







embedded image


1. 5357 2. 526.8







embedded image


1. 5358 2. 527.8







embedded image


1. 5359 2. 527.8







embedded image


1. 5360 2. 546.9







embedded image


1. 5361 2. 551.8







embedded image


1. 5362 2. 551.8







embedded image


1. 5363 2. 552.9







embedded image


1. 5364 2. 560.9







embedded image


1. 5365 2. 562.9







embedded image


1. 5366 2. 473.8







embedded image


1. 5367 2. 486.8







embedded image


1. 5368 2. 490.8







embedded image


1. 5369 2. 502.8







embedded image


1. 5370 2. 502.8







embedded image


1. 5371 2. 510.8







embedded image


1. 5372 2. 514.8







embedded image


1. 5373 2. 519.2







embedded image


1. 5374 2. 523.8







embedded image


1. 5375 2. 524.8







embedded image


1. 5376 2. 528.8







embedded image


1. 5377 2. 528.8







embedded image


1. 5378 2. 509.8







embedded image


1. 5379 2. 538.9







embedded image


1. 5380 2. 552.9







embedded image


1. 5381 2. 553.7







embedded image


1. 5382 2. 553.7







embedded image


1. 5383 2. 560.9







embedded image


1. 5384 2. 574.9







embedded image


1. 5385 2. 482.8







embedded image


1. 5386 2. 531.2







embedded image


1. 5387 2. 534.8







embedded image


1. 5388 2. 528.8







embedded image


1. 5389 2. 538.8







embedded image


1. 5390 2. 471.7

















TABLE 54






1. Ex.


Product
2. m/z









embedded image


1. 5401 2. 463.3







embedded image


1. 5402 2. 477.3







embedded image


1. 5403 2. 483.3







embedded image


1. 5404 2. 489.3







embedded image


1. 5405 2. 489.3







embedded image


1. 5406 2. 491.3







embedded image


1. 5407 2. 493.3







embedded image


1. 5408 2. 493.3







embedded image


1. 5409 2. 493.3







embedded image


1. 5410 2. 505.3







embedded image


1. 5411 2. 505.3







embedded image


1. 5412 2. 509.3







embedded image


1. 5413 2. 513.3







embedded image


1. 5414 2. 518.3







embedded image


1. 5415 2. 519.3







embedded image


1. 5416 2. 519.3







embedded image


1. 5417 2. 519.3







embedded image


1. 5418 2. 525.3







embedded image


1. 5419 2. 527.3







embedded image


1. 5420 2. 527.3







embedded image


1. 5121 2. 529.3







embedded image


1. 5422 2. 529.3







embedded image


1. 5423 2. 533.3







embedded image


1. 5424 2. 533.3







embedded image


1. 5425 2. 538.3







embedded image


1. 5426 2. 539.3







embedded image


1. 5427 2. 539.3







embedded image


1. 5428 2. 539.3







embedded image


1. 5429 2. 539.3







embedded image


1. 5430 2. 541.3







embedded image


1. 5431 2. 543.3







embedded image


1. 5432 2. 545.3







embedded image


1. 5433 2. 549.3







embedded image


1. 5434 2. 553.3







embedded image


1. 5435 2. 567.3







embedded image


1. 5436 2. 567.3







embedded image


1. 5437 2. 567.3







embedded image


1. 5438 2. 567.3







embedded image


1. 5439 2. 575.3







embedded image


1. 5440 2. 581.3







embedded image


1. 5441 2. 582.3







embedded image


1. 5442 2. 589.3







embedded image


1. 5443 2. 591.3







embedded image


1. 5444 2. 591.3







embedded image


1. 5445 2. 529.3







embedded image


1. 5446 2. 500.3







embedded image


1. 5447 2. 830.5







embedded image


1. 5448 2. 524.3







embedded image


1. 5449 2. 524.3







embedded image


1. 5450 2. 529.3







embedded image


1. 5451 2. 533.3







embedded image


1. 54525 2. 719.4







embedded image


1. 5453 2. 543.3







embedded image


1. 5454 2. 545.3







embedded image


1. 5455 2. 545.3







embedded image


1. 5456 2. 549.3







embedded image


1. 5457 2. 555.3







embedded image


1. 5458 2. 556.3







embedded image


1. 5459 2. 556.3







embedded image


1. 5460 2. 575.3







embedded image


1. 5461 2. 580.3







embedded image


1. 5462 2. 580.3







embedded image


1. 5463 2. 581.3







embedded image


1. 5464 2. 589.3







embedded image


1. 5465 2. 591.3







embedded image


1. 5466 2. 502.3







embedded image


1. 5467 2. 515.3







embedded image


1. 5468 2. 519.3







embedded image


1. 5469 2. 531.3







embedded image


1. 5470 2. 531.3







embedded image


1. 5471 2. 539.3







embedded image


1. 5472 2. 543.3







embedded image


1. 5473 2. 547.3







embedded image


1. 5474 2. 552.3







embedded image


1. 5475 2. 553.3







embedded image


1. 5476 2. 557.3







embedded image


1. 5477 2. 557.3







embedded image


1. 5478 2. 538.3







embedded image


1. 5479 2. 567.3







embedded image


1. 5480 2. 581.3







embedded image


1. 5481 2. 581.3







embedded image


1. 5482 2. 589.3







embedded image


1. 5483 2. 511.3







embedded image


1. 5484 2. 559.3







embedded image


1. 5485 2. 563.3







embedded image


. 5486 2.







embedded image


1. 5487 2. 891.5







embedded image


1. 5488 2. 500.3







embedded image


1. 5489 2. 500.3







embedded image


1. 5490 2. 501.3

















TABLE 55






1. Ex.


Product
2. m/z









embedded image


1. 5501 2. 488.81







embedded image


1. 5502 2. 502.84







embedded image


1. 5503 2. 508.87







embedded image


1. 5504 2. 514.81







embedded image


1. 5505 2. 514.81







embedded image


1. 5506 2. 516.87







embedded image


1. 5507 2. 518.84







embedded image


1. 5508 2. 518.84







embedded image


1. 5509 2. 518.88







embedded image


1. 5510 2. 530.87







embedded image


1. 5511 2. 530.87







embedded image


1. 5512 2. 534.84







embedded image


1. 5513 2. 538.87







embedded image


1. 5514 2. 543.85







embedded image


1. 5515 2. 544.9







embedded image


1. 5516 2. 544.9







embedded image


1. 5517 2. 544.92







embedded image


1. 5518 2. 550.89







embedded image


1. 5519 2. 552.9







embedded image


1. 5520 2. 552.9







embedded image


1. 5521 2. 554.87







embedded image


1. 5522 2. 554.87







embedded image


1. 5523 2. 559.29







embedded image


1. 5524 2. 559.29







embedded image


1. 5525 2. 563.88







embedded image


1. 5526 2. 564.87







embedded image


1. 5527 2. 564.91







embedded image


1. 5528 2. 564.91







embedded image


1. 5529 2. 564.91







embedded image


1. 5530 2. 566.93







embedded image


1. 5531 2. 568.9







embedded image


1. 5532 2. 574.91







embedded image


1. 5533 2. 578.94







embedded image


1. 5534 2. 592.85







embedded image


1. 5535 2. 592.85







embedded image


1. 5536 2. 600.95







embedded image


1. 5537 2. 606.99







embedded image


1. 5538 2. 614.97







embedded image


1. 5539 2. 616.95







embedded image


1. 5540 2. 616.95







embedded image


1. 5541







embedded image


1. 5542 2. 525.83







embedded image


1. 5543 2. 581.9







embedded image


1. 5544 2. 581.9







embedded image


1. 5545 2. 605.92







embedded image


1. 5546 2. 573.32







embedded image


1. 5547 2. 582.88







embedded image


1. 5548 2. 607.76







embedded image


1. 5549 2. 607.76







embedded image


1. 5550 2. 536.86







embedded image


1. 5551 2. 525.83







embedded image


1. 5552 2. 526.82







embedded image


1. 5553 2. 573.92

















TABLE 56






1. Ex.


Product
2. m/z









embedded image


1. 5601 2. 481.26







embedded image


1. 5602 2. 495.27







embedded image


1. 5603 2. 535.29







embedded image


1. 5604 2. 543.3







embedded image


1. 5605 2. 543.3







embedded image


1. 5606 2. 548.3







embedded image


1. 5607 2. 554.3







embedded image


1. 5608 2. 554.3







embedded image


1. 5609 2. 555.31







embedded image


1. 5610 2. 559.31







embedded image


1. 5611 2. 565.31







embedded image


1. 5612 2. 565.31







embedded image


1. 5613 2. 565.31







embedded image


1. 5614 2. 569.31







embedded image


1. 5615 2. 571.31







embedded image


1. 5616 2. 579.32







embedded image


1. 5617







embedded image


1. 5618







embedded image


1. 5619







embedded image


1. 5620







embedded image


1. 5621 2. 615.34







embedded image


2. 5622 2. 680.37







embedded image


1. 5623 2. 529.29







embedded image


1. 5624 2. 543.3







embedded image


1. 5625 2. 547.3







embedded image


1. 5626 2. 547.3







embedded image


1. 5627 2. 547.3







embedded image


1. 5628 2. 554.3







embedded image


1. 5629 2. 555.31







embedded image


1. 5630 2. 559.31







embedded image


1. 5631 2. 561.31







embedded image


1. 5632 2. 563.31







embedded image


1. 5633 2. 563.31







embedded image


1. 5634 2. 563.31







embedded image


1. 5635 2. 563.31







embedded image


1. 5636 2. 565.31







embedded image


1. 5637 2. 579.32







embedded image


1. 5638 2. 581.32







embedded image


1. 5639 2. 581.32







embedded image


1. 5640 2. 585.32







embedded image


1. 5641 2. 587.32







embedded image


1. 5642 2. 589.32







embedded image


1. 5643 2. 589.32







embedded image


1. 5644 2. 593.33







embedded image


1. 5645 2. 597.33







embedded image


1. 5646







embedded image


1. 5647 2. 597.33







embedded image


1. 5648 2. 597.33







embedded image


1. 5649 2. 597.33







embedded image


1. 5650 2. 597.33







embedded image


1. 5651 2. 597.33







embedded image


1. 5652 2. 599.33







embedded image


1. 5653 2. 603.33







embedded image


1. 5654 2. 605.33







embedded image


1. 5655 2. 607.33







embedded image


1. 5656 2. 607.33







embedded image


1. 5657 2. 607.33







embedded image


1. 5658 2. 607.33







embedded image


1. 5659 2. 621.34







embedded image


1. 5660 2. 631.35







embedded image


1. 5661 2. 631.35







embedded image


1. 5662 2. 631.35







embedded image


1. 5663 2. 642.35







embedded image


1. 5664 2. 665.37







embedded image


1. 5665 2. 571.31

















TABLE 57






1. Ex.


Product
2. m/z









embedded image


1. 5701 2. 535.29







embedded image


1. 5702 2. 540.3







embedded image


1. 5703 2. 543.3







embedded image


1. 5704 2. 543.3







embedded image


1. 5705 2. 547.3







embedded image


1. 5706 2. 547.3







embedded image


1. 5707 2. 547.3







embedded image


1. 5708 2. 554.3







embedded image


1. 5709 2. 555.31







embedded image


1. 5710 2. 555.31







embedded image


1. 5711 2. 559.31







embedded image


1. 5712 2. 559.31







embedded image


1. 5713 2. 561.31







embedded image


1. 5714 2. 562.31







embedded image


1. 5715 2. 563.31







embedded image


1. 5716 2. 563.31







embedded image


1. 5717 2. 565.31







embedded image


1. 5718 2. 565.31







embedded image


1. 5719 2. 565.31







embedded image


1. 5720 2. 565.31







embedded image


1. 5721 2. 569.31







embedded image


1. 5722 2. 571.31







embedded image


1. 5723 2. 579.32







embedded image


1. 5724 2. 579.32







embedded image


1. 5725 2. 581.32







embedded image


1. 5726 2. 581.32







embedded image


1. 5727 2. 585.32







embedded image


1. 5728 2. 587.32







embedded image


1. 5729 2. 589.32







embedded image


1. 5730 2. 589.32







embedded image


1. 5731 2. 591.33







embedded image


1. 5732 2. 597.33







embedded image


1. 5733 2. 595.33







embedded image


1. 5734 2. 597.33







embedded image


1. 5735 2. 597.33







embedded image


1. 5736 2. 597.33







embedded image


1. 5737 2. 597.33







embedded image


1. 5738 2. 596.33







embedded image


1. 5739 2. 597.33







embedded image


1. 5740 2. 581.32







embedded image


1. 5741 2. 605.33







embedded image


1. 5742 2. 607.33







embedded image


1. 5743 2. 607.33







embedded image


1. 5744 2. 607.33







embedded image


1. 57454 2. 613.34







embedded image


1. 5746 2. 613.34







embedded image


1. 5747 2. 615.34







embedded image


1. 5748 2. 621.34







embedded image


1. 5749 2. 631.35







embedded image


1. 5750 2. 680.37

















TABLE 58






1. Ex.


Product
2. m/z









embedded image


1. 5801 2. 550.3







embedded image


1. 5802 2. 590.32







embedded image


1. 5803 2. 598.33







embedded image


1. 5804 2. 598.33







embedded image


1. 5805 2. 598.33







embedded image


1. 5806 2. 598.33







embedded image


10 5807 2. 602.33







embedded image


1. 5808 2. 602.33







embedded image


1. 5809 2. 602.33







embedded image


1. 5810 2. 602.33







embedded image


1. 5811 2. 609.33







embedded image


1. 5812 2. 610.34







embedded image


1. 5813 2. 612.34







embedded image


1. 5814 2. 614.34







embedded image


1. 5815 2. 614.34







embedded image


1. 5816 2. 618.34







embedded image


1. 5817 2. 624.34







embedded image


1. 5818 2. 626.34







embedded image


1. 5819 2. 634.35







embedded image


1. 5820 2. 632.35







embedded image


1. 5821 2. 636.35







embedded image


1. 5822 2. 640.35







embedded image


1. 5823 2. 642.35







embedded image


1. 5824 2. 644.35







embedded image


1. 5825 2. 644.35







embedded image


1. 5826 2. 648.36







embedded image


1. 5827 2. 654.36







embedded image


1. 5828 2. 660.36







embedded image


1. 5829 2. 670.37







embedded image


1. 5830 2. 676.37







embedded image


1. 5831 2. 735.4







embedded image


1. 5832 2. 522.29







embedded image


1. 5833 2. 584.32

















TABLE 59






1. Ex.


Product
2. m/z









embedded image


1. 5901 2. 536.29







embedded image


1. 5902 2. 550.3







embedded image


1. 5903 2. 590.32







embedded image


1. 5904 2. 598.33







embedded image


1. 5905 2. 598.33







embedded image


1. 5906 2. 598.33







embedded image


1. 5907 2. 598.33







embedded image


1. 5908 2. 602.33







embedded image


1. 5909 2. 602.33







embedded image


1. 5910 2. 602.33







embedded image


1. 5911 2. 603.33







embedded image


1. 5912 2. 609.33







embedded image


1. 5913 2. 609.33







embedded image


1. 5914 2. 610.34







embedded image


1. 5915 2. 612.34







embedded image


1. 5916 2. 614.34







embedded image


1. 5917 2. 614.34







embedded image


1. 5918 2. 616.34







embedded image


1. 5919 2. 618.34







embedded image


1. 5920 2. 618.34







embedded image


1. 5921 2. 618.34







embedded image


1. 5922 2. 620.34







embedded image


1. 5923 2. 620.34







embedded image


1. 5924 2. 620.34







embedded image


1. 5925 2. 620.34







embedded image


1. 5926 2. 620.34







embedded image


1. 5927 2. 624.34







embedded image


1. 5928 2. 626.34







embedded image


1. 5929 2. 626.34







embedded image


1. 5930 2. 632.35

















TABLE 60






1. Ex.


Product
2. m/z









embedded image


1. 6001 2. 536.29







embedded image


1. 6002 2. 576.32







embedded image


1. 6003 2. 584.32







embedded image


1. 6004 2. 584.32







embedded image


1. 6005 2. 584.32







embedded image


1. 6006 2. 588.32







embedded image


1. 6007 2. 588.32







embedded image


1. 6008 2. 588.32







embedded image


1. 6009 2. 589.32







embedded image


1. 6010 2. 595.33







embedded image


1. 6011 2. 595.33







embedded image


1. 6012 2. 595.33







embedded image


1. 6013 2. 596.33







embedded image


1. 6014 2. 598.33







embedded image


1. 6015 2. 600.33







embedded image


1. 6016 2. 600.33







embedded image


1. 6017 2. 602.33







embedded image


1. 6018 2. 604.33







embedded image


1. 6019 2. 604.33







embedded image


1. 6020 2. 604.33







embedded image


1. 6021 2. 606.33







embedded image


1. 6022 2. 606.33







embedded image


1. 6023 2. 606.33







embedded image


1. 6024 2. 606.33







embedded image


1. 6025 2. 606.33







embedded image


1. 6026 2. 612.34







embedded image


1. 6027 2. 620.34







embedded image


1. 6028 2. 620.34







embedded image


1. 6029 2. 622.34







embedded image


1. 6030 2. 626.34







embedded image


1. 6031 2. 628.35







embedded image


1. 6032 2. 630.35







embedded image


1. 6033 2. 630.35







embedded image


1. 6034 2. 634.35







embedded image


1. 6035 2. 638.35







embedded image


1. 6036 2. 638.35







embedded image


1. 6037 2. 638.35







embedded image


1. 6038 2. 638.35







embedded image


1. 6039 2. 622.34







embedded image


1. 6040 2. 646.36







embedded image


1. 6041 2. 648.36







embedded image


1. 60425 2. 648.36







embedded image


1. 6043 2. 648.36







embedded image


1. 6044 2. 648.36







embedded image


1. 6045 2. 654.36







embedded image


1. 6046 2. 654.36







embedded image


1. 6047 2. 656.36







embedded image


1. 6048 2. 662.36







embedded image


1. 6049 2. 721.4







embedded image


1. 6050 2. 570.31

















TABLE 61






1. Ex.


Product
2. m/z









embedded image


1. 6101 2. 584.32







embedded image


1. 6102 2. 584.32







embedded image


1. 6103 2. 584.32







embedded image


1. 6104 2. 588.32







embedded image


1. 6105 2. 588.32







embedded image


1. 6106 2. 588.32







embedded image


1. 6107 2. 595.33







embedded image


1. 6108 2. 600.33







embedded image


1. 6109 2. 602.33







embedded image


1. 6110 2. 604.33







embedded image


1. 6111 2. 604.33







embedded image


1. 6112 2. 604.33







embedded image


1. 6113 2. 606.33







embedded image


1. 6114 2. 606.33







embedded image


1. 6115 2. 606.33







embedded image


1. 6116 2. 606.33







embedded image


1. 6117 2. 606.33







embedded image


1. 6118 2. 648.36







embedded image


1. 6119 2. 721.4







embedded image


1. 6120 2. 570.31
















TABLE 62







Error! Objects cannot be created from editing field codes.









1. Ex.


Product
2. m/z







embedded image


1. 6216 2. 590.32







embedded image


1. 6217 2. 592.33







embedded image


1. 6218 2. 592.33







embedded image


1. 6219 2. 592.33







embedded image


1. 6220 2. 594.33







embedded image


1. 6221 2. 596.33







embedded image


1. 6222 2. 596.33







embedded image


1. 6223 2. 598.33







embedded image


1. 6224 2. 596.33







embedded image


1. 6225 2. 598.33







embedded image


1. 6226 2. 598.33







embedded image


1. 6227 2. 596.33







embedded image


1. 6228 2. 602.33







embedded image


1. 6229 2. 604.33







embedded image


1. 6230 2. 604.33







embedded image


1. 6231 2. 610.34







embedded image


1. 6232 2. 610.34







embedded image


1. 6233 2. 612.34







embedded image


1. 6234 2. 612.34







embedded image


1. 6235 2. 614.34







embedded image


1. 6236 2. 614.34







embedded image


1. 6237 2. 618.34







embedded image


1. 6238 2. 622.34







embedded image


1. 6239 2. 622.34







embedded image


1. 6240 2. 626.34







embedded image


1. 6241 2. 630.35







embedded image


1. 6242 2.







embedded image


1. 6243 2. 630.35







embedded image


1. 6244 2. 630.35







embedded image


1. 6245 2. 630.35







embedded image


1. 6246 2. 630.35







embedded image


1. 6247 2. 630.35







embedded image


1. 6248 2. 630.35







embedded image


1. 6249 2. 630.35







embedded image


1. 6250 2. 632.35







embedded image


1. 6251 2. 636.35







embedded image


1.0 6252 2. 638.35







embedded image


1. 6253 2. 640.35







embedded image


1. 6254 2. 640.35







embedded image


1. 6255 2. 638.35







embedded image


1. 6256 2. 646.36







embedded image


1. 6257 2. 646.36







embedded image


1. 6258 2. 648.36







embedded image


1. 6259 2. 654.36







embedded image


1. 6260 2. 713.39







embedded image


1. 6261 2. 500.27







embedded image


1. 6262 2. 562.31







embedded image


1. 6263 2. 604.33

















TABLE 63






1. Ex.


Product
2. m/z









embedded image


1. 6301 2. 500.27







embedded image


1. 6302 2. 514.28







embedded image


1. 6303 2. 554.3







embedded image


1. 6304 2. 562.31







embedded image


1. 6305 2. 562.31







embedded image


1. 6306 2. 562.31







embedded image


1. 6307 2. 562.31







embedded image


1. 6308 2. 566.31







embedded image


1. 6309 2. 566.31







embedded image


1. 6310 2. 566.31







embedded image


1. 6311 2. 567.31







embedded image


1. 6312 2. 573.32







embedded image


1. 6313 2. 573.32







embedded image


1. 6314 2. 573.32







embedded image


1. 6315 2. 574.32







embedded image


1. 6316 2. 576.32







embedded image


1. 6317 2. 578.32







embedded image


1. 6318 2. 578.32







embedded image


1. 6319 2. 580.32







embedded image


1. 6320 2. 582.32







embedded image


1. 6321 2. 582.32







embedded image


1. 6322 2. 582.32







embedded image


1. 6323 2. 584.32







embedded image


1. 6324 2. 582.32







embedded image


1. 6325 2. 584.32







embedded image


1. 6326 2. 584.32







embedded image


1. 6327 2. 584.32







embedded image


1. 6328 2. 588.32







embedded image


1. 6329 2. 590.32







embedded image


1. 6330 2. 596.33







embedded image


1. 6331 2. 598.33







embedded image


1. 6332 2. 598.33







embedded image


1. 6333 2. 600.33







embedded image


1. 6334 2. 600.33







embedded image


1. 6335 2. 604.33







embedded image


1. 6336 2. 606.33







embedded image


1. 6337 2. 608.33







embedded image


1. 6338 2. 608.33







embedded image


1. 6339 2. 612.34







embedded image


1. 6340 2. 616.34







embedded image


1. 6341 2. 616.34







embedded image


1. 6342 2. 616.34







embedded image


1. 6343 2. 616.34







embedded image


1. 6344 2. 616.34







embedded image


1. 6345 2. 616.34







embedded image


1. 6346 2. 616.34







embedded image


1. 6347 2. 616.34







embedded image


1. 6348 2. 616.34







embedded image


1. 6349 2. 618.34







embedded image


1. 6350 2. 600.33







embedded image


1. 6351 2. 622.34







embedded image


1. 6352 2. 624.34







embedded image


1. 6353 2. 626.34







embedded image


1. 6354 2. 626.34







embedded image


1. 6355 2. 626.34







embedded image


1. 6356 2. 626.34







embedded image


1. 6357 2. 632.35







embedded image


1. 6358 2. 632.35







embedded image


1. 6359 2. 634.35







embedded image


1. 6360 2. 640.35







embedded image


1. 6361 2. 650.36







embedded image


1. 6362 2. 650.36







embedded image


1. 6363 2. 661.36







embedded image


1. 6364 2. 684.38







embedded image


1. 6365 2. 699.38







embedded image


1. 6366 2. 486.27







embedded image


1. 6367 2. 548.3







embedded image


1. 6368 2. 590.32

















TABLE 64






1. Ex.


Product
2. m/z









embedded image


1. 6401 2. 474.26







embedded image


1. 6402 2. 488.27







embedded image


1. 6403 2. 528.29







embedded image


1. 6404 2. 536.29







embedded image


1. 6405 2. 536.29







embedded image


1. 6406 2. 536.29







embedded image


1. 6407 2. 536.29







embedded image


1. 6408 2. 540.3







embedded image


1. 6409 2. 540.3







embedded image


1. 6410 2. 540.3







embedded image


1. 6411 2. 541.3







embedded image


1. 6412 2. 547.3







embedded image


1. 6413 2. 547.3







embedded image


1. 6414 2. 548.3







embedded image


1. 6415 2. 550.3







embedded image


1. 6416 2. 552.3







embedded image


1. 6417 2. 552.3







embedded image


1. 6418 2. 554.3







embedded image


1. 6419 2. 556.31







embedded image


1. 6420 2. 556.31







embedded image


1. 6421 2. 556.31







embedded image


1. 6122 2. 558.31







embedded image


1. 6423 2. 558.31







embedded image


1. 6424 2. 558.31







embedded image


1. 6425 2. 558.31







embedded image


1. 6426 2. 558.31







embedded image


1. 6427 2. 564.31







embedded image


1. 6428 2. 572.31







embedded image


1. 6429 2. 572.31







embedded image


1. 6430 2. 574.32







embedded image


1. 6431 2. 574.32







embedded image


1. 6432 2. 578.32







embedded image


1. 6433 2. 580.32







embedded image


1. 6434 2. 582.32







embedded image


1. 6435 2. 582.32







embedded image


1. 6436 2. 586.32







embedded image


1. 6437 2. 590.32







embedded image


1. 6438 2. 590.32







embedded image


1. 6439 2. 590.32







embedded image


1. 6440 2. 589.32







embedded image


1. 6441 2. 590.32







embedded image


1. 6442 2. 590.32







embedded image


1. 6443 2. 590.32







embedded image


1. 6444 2. 590.32







embedded image


1. 6445 2. 590.32







embedded image


1. 6446 2. 592.33







embedded image


1. 6447 2. 574.32







embedded image


1. 6448 2. 598.33







embedded image


1. 6449 2. 600.33







embedded image


1. 6450 2. 600.33







embedded image


1. 6451 2. 600.33







embedded image


1. 6452 2. 600.33







embedded image


1. 6453 2. 606.33







embedded image


1. 6454 2. 606.33







embedded image


1. 6455 2. 608.33







embedded image


1. 6456 2. 614.34







embedded image


1. 6447 2. 673.37







embedded image


1. 6458 2. 460.25







embedded image


 6459 2.







embedded image


1. 6460 2. 564.31

















TABLE 65






1. Ex.


Product
2. m/z









embedded image


1. 6501 2. 488.27







embedded image


1. 6502 2. 502.28







embedded image


1. 6503 2. 542.3







embedded image


1. 6504 2. 550.3







embedded image


1. 6505 2. 550.3







embedded image


1. 6506 2. 550.3







embedded image


1. 6507 2. 554.3







embedded image


1. 6508 2. 554.3







embedded image


1. 6509 2. 554.3







embedded image


1. 6510 2. 555.31







embedded image


1. 6511 2. 561.31







embedded image


1. 6512 2. 561.31







embedded image


1. 6513 2. 561.31







embedded image


1. 6514 2. 562.31







embedded image


1. 6515 2. 564.31







embedded image


1. 6516 2. 566.31







embedded image


1. 6517 2. 566.31







embedded image


1. 6518 2. 568.31







embedded image


1. 6519 2. 570.31







embedded image


1. 6520 2. 570.31







embedded image


1. 6521 2. 570.31







embedded image


1. 6522 2. 572.31







embedded image


1. 6523 2. 572.31







embedded image


1. 6524 2. 572.31







embedded image


1. 6525 2. 572.31







embedded image


1. 6526 2. 576.32







embedded image


1. 6527 2. 578.32







embedded image


1. 6528 2. 586.32







embedded image


1. 6529 2. 586.32







embedded image


1. 6530 2. 588.32







embedded image


1. 6531 2. 588.32







embedded image


1. 6532 2. 592.33







embedded image


1. 6533 2. 594.33







embedded image


1. 6534 2. 596.33







embedded image


1. 6535 2. 596.33







embedded image


1. 6536 2. 600.33







embedded image


1. 6537 2. 604.33







embedded image


1. 6538 2. 604.33







embedded image


1. 6539 2. 604.33







embedded image


1. 6540 2. 604.33







embedded image


1. 6541 2. 604.33







embedded image


1. 6542 2. 604.33







embedded image


1. 6543 2. 604.33







embedded image


1. 6544 2. 606.33







embedded image


1. 6545 2. 588.32







embedded image


1. 6546 2. 612.34







embedded image


1. 6547 2. 614.34







embedded image


1. 6548 2. 614.34







embedded image


1. 6549 2. 614.34







embedded image


1. 6550 2. 614.34







embedded image


1. 6551 2. 620.34







embedded image


1. 6552 2. 620.34







embedded image


1. 6553 2. 622.34







embedded image


1. 6554 2. 628.35







embedded image


1. 6555 2. 687.38







embedded image


1. 6556 2. 474.26







embedded image


1. 6557 2. 536.29







embedded image


1. 6558 2. 578.32

















TABLE 67






1. Ex.


Product
2. m/z









embedded image


1. 6701 2. 474.26







embedded image


1. 6702 2. 514.28







embedded image


1. 6703 2. 522.29







embedded image


1. 6704 2. 522.29







embedded image


1. 6705 2. 22.29







embedded image


1. 6706 2. 526.29







embedded image


1. 6707 2. 526.29







embedded image


1. 6708 2. 526.29







embedded image


1. 6709 2. 533.29







embedded image


1. 6710 2. 534.29







embedded image


1. 6711 2. 536.29







embedded image


1. 6712 2. 538.3







embedded image


1. 6713 2. 538.3







embedded image


1. 6714 2.







embedded image


1. 6715 2. 542.3







embedded image


1. 6716 2. 542.3







embedded image


1. 6717 2. 542.3







embedded image


1. 6718 2. 544.3







embedded image


1. 6719 2. 544.3







embedded image


1. 6720 2. 544.3







embedded image


1. 6721 2. 550.3







embedded image


1. 6722 2. 558.31







embedded image


1. 6723 2. 558.31







embedded image


1. 6724 2. 560.31







embedded image


1. 6725 2. 560.31







embedded image


1. 6726 2. 564.31







embedded image


1. 6727 2. 566.31







embedded image


1. 6728 2. 568.31







embedded image


1. 6729 2. 568.31







embedded image


1. 6730 2. 572.31







embedded image


1. 6731 2. 576.32







embedded image


1. 6732 2. 576.32







embedded image


1. 6733 2. 576.32







embedded image


1. 6734 2. 576.32







embedded image


1. 6735 2. 576.32







embedded image


1. 6736 2. 576.32







embedded image


1. 6737 2. 576.32







embedded image


1. 6738 2. 576.32







embedded image


1. 6739 2. 584.32







embedded image


1. 6740 2. 586.32







embedded image


1. 6741 2. 586.32







embedded image


1. 6742 2. 586.32







embedded image


1. 6743 2. 592.33







embedded image


1. 6744 2. 592.33







embedded image


1. 6745 2. 600.33

















TABLE 68






1. Ex.


Product
2. m/z









embedded image


1. 6801 2. 488.27







embedded image


1. 6802 2. 502.28







embedded image


1. 6803 2. 542.3







embedded image


1. 6804 2. 550.3







embedded image


1. 68058 2. 550.3


Error! Objects cannot be created from editing field codes.








embedded image


1. 6806 2. 550.3







embedded image


1. 6807 2. 554.3







embedded image


1. 6808 2. 554.3







embedded image


1. 6809 2. 554.3







embedded image


1. 6810 2. 555.31







embedded image


1. 6811 2. 561.31







embedded image


1. 6812 2. 561.31







embedded image


1. 6813 2. 562.31







embedded image


1. 6814 2. 564.31







embedded image


1. 6815 2. 566.31







embedded image


1. 6816 2. 566.31







embedded image


1. 6817 2. 568.31







embedded image


1. 6818 2. 570.31







embedded image


1. 6819 2. 570.31







embedded image


1. 6820 2. 570.31







embedded image


1. 6821 2. 571.31







embedded image


1. 6822 2. 572.31







embedded image


1. 6823 2. 572.31







embedded image


1. 6824 2. 572.31







embedded image


1. 6825 2. 572.31







embedded image


1. 6826 2. 576.32







embedded image


1. 6827 2. 578.32







embedded image


1. 6828 2. 586.32







embedded image


1. 6829 2. 586.32







embedded image


1. 6830 2. 588.32







embedded image


1. 6831 2. 588.32







embedded image


1. 6832 2. 592.33







embedded image


1. 6833 2. 614.34







embedded image


1. 6834 2. 596.33







embedded image


1. 6835 2. 596.33







embedded image


1. 6836 2. 600.33







embedded image


1. 6837 2. 602.33







embedded image


1. 6838 2. 604.33







embedded image


1. 6839 2. 604.33







embedded image


1. 6840 2. 604.33







embedded image


1. 6841 2. 604.33







embedded image


1. 6842 2. 604.33







embedded image


1. 6843 2. 605.33







embedded image


1. 6844 2. 604.33







embedded image


1. 6845 2. 604.33







embedded image


1. 6846 2. 606.33







embedded image


1. 6847 2. 588.32







embedded image


1. 6848 2. 610.34







embedded image


1. 6849 2. 612.34







embedded image


1. 6850 2. 594.33







embedded image


1. 6851 2. 614.34







embedded image


1. 6852 2. 614.34







embedded image


1. 6853 2. 614.34







embedded image


1. 6854 2. 620.34







embedded image


1. 6855 2. 620.34







embedded image


1. 6856 2. 620.34







embedded image


1. 6856 2. 628.35







embedded image


1. 6857 2. 687.38







embedded image


1. 6859 2. 474.26







embedded image


1. 6860 2. 536.29

















TABLE 69






1. Ex.


Product
2. m/z









embedded image


1. 6901 2. 514.28







embedded image


1. 6902 2. 568.31







embedded image


1. 6903 2. 576.32







embedded image


1. 6904 2. 576.32







embedded image


1. 6905 2. 576.32







embedded image


1. 6906 2. 580.32







embedded image


1. 6907 2. 580.32







embedded image


1. 6908 2. 580.32







embedded image


1. 6909 2. 581.32







embedded image


1. 6910 2. 587.32







embedded image


1. 6911 2. 587.32







embedded image


1. 6912 2. 588.32







embedded image


1. 6913 2. 590.32







embedded image


1. 6914 2. 592.33







embedded image


1. 6915 2. 592.33







embedded image


1. 6916 2. 594.33







embedded image


1. 6917 2. 596.33







embedded image


1. 6918 2. 596.33







embedded image


1. 6919 2. 596.33







embedded image


1. 6920 2. 598.33







embedded image


1. 6921 2. 598.33







embedded image


1. 6922 2. 598.33







embedded image


1. 6923 2. 598.33







embedded image


1. 6924 2. 598.33







embedded image


1. 6925 2. 602.33







embedded image


1. 6926 2. 604.33







embedded image


1. 6927 2. 612.34







embedded image


1. 6928 2. 612.34







embedded image


1. 6929 2. 614.34







embedded image


1. 6930 2. 614.34







embedded image


1. 6931 2. 618.34







embedded image


1. 6932 2. 620.34







embedded image


1. 6933 2. 622.34







embedded image


1. 6934 2. 622.34







embedded image


1. 6935 2. 626.34







embedded image


1. 6936 2. 630.35







embedded image


1. 6937 2. 630.35







embedded image


1. 6938 2. 630.35







embedded image


1. 6939 2. 630.35







embedded image


1. 6940 2. 630.35







embedded image


1. 6941 2. 630.35







embedded image


1. 6942 2. 630.35







embedded image


1. 6943 2. 630.35







embedded image


1. 6944 2. 632.35







embedded image


1. 6945 2. 614.34







embedded image


1. 6946 2. 636.35







embedded image


1. 6947 2. 638.35







embedded image


1. 6948 2. 640.35







embedded image


1. 6949 2. 640.35







embedded image


1. 6950 2. 640.35







embedded image


1. 6951 2. 640.35







embedded image


1. 6952 2. 646.36







embedded image


1. 6953 2. 646.36







embedded image


1. 6954 2. 648.36







embedded image


1. 6955 2. 654.36







embedded image


1. 6956 2. 675.23







embedded image


1. 6957 2. 713.39







embedded image


1. 6958 2. 500.27







embedded image


1. 6959 2. 562.31







embedded image


1. 6960 2. 604.33

















TABLE 70






1. Ex.


Product
2. m/z









embedded image


1. 7001 2. 472.26







embedded image


1. 7002 2. 488.27







embedded image


1. 7003 2. 488.27







embedded image


1. 7004 2. 500.27







embedded image


1. 7005 2. 520.29







embedded image


1. 7006 2. 522.29







embedded image


1. 7007 2. 520.29







embedded image


1. 7008 2. 520.29







embedded image


1. 7009 2. 526.29







embedded image


1. 7010 2. 533.29







embedded image


1. 7011 2. 536.29







embedded image


1. 7012 2. 536.29







embedded image


1. 7013 2. 536.29







embedded image


1. 7014 2. 536.29







embedded image


1. 7015 2. 536.29







embedded image


1. 7016 2. 538.3







embedded image


1. 7017 2. 540.3







embedded image


1. 7018 2. 542.3







embedded image


1. 7019 2. 544.3







embedded image


1. 7020 2. 544.3







embedded image


1. 7021 2. 548.3







embedded image


1. 7022 2. 552.3







embedded image


1. 7023 2. 552.3







embedded image


1. 7024 2. 556.31







embedded image


1. 7025 2. 558.31







embedded image


1. 7026 2. 566.31







embedded image


1. 7027 2. 568.31







embedded image


1. 7028 2. 572.31







embedded image


1. 7029 2. 576.32







embedded image


1.7030 2. 576.32







embedded image


1. 7031 2. 576.32







embedded image


1. 7032 2. 576.32







embedded image


1. 7033 2. 590.32







embedded image


1. 7034 2. 486.27







embedded image


1. 7035 2. 594.33







embedded image


1. 7036 2. 598.33







embedded image


1. 7037 2. 598.33







embedded image


1. 7038 2. 610.34

















TABLE 71






1. Ex.


Product
2. m/z









embedded image


1. 7101 2. 474.26







embedded image


1. 7102 2. 488.27







embedded image


1. 7103 2. 500.27







embedded image


1. 7104 2. 522.29







embedded image


1. 7105 2. 522.29







embedded image


1. 7106 2. 522.29







embedded image


1. 7107 2. 522.29







embedded image


1. 7108 2. 526.3







embedded image


1. 7109 2. 533.29







embedded image


1. 7110 2. 536.29







embedded image


1. 7111 2. 536.29







embedded image


1. 7112 2. 536.29







embedded image


1. 7113 2. 536.29







embedded image


1. 7114 2. 536.29







embedded image


1. 7115 2. 536.3







embedded image


1. 7116 2. 538.3







embedded image


1. 7117 2. 540.3







embedded image


1. 7118 2. 542.3







embedded image


1. 7119 2. 542.3







embedded image


1.7120 2. 542.3







embedded image


1. 7121 2. 546.3







embedded image


1. 7122 2. 550.3







embedded image


1. 7123 2. 552.3







embedded image


1. 7124 2. 552.3







embedded image


1. 7125 2. 556.31







embedded image


1. 7126 2. 558.31







embedded image


1. 7127 2. 550.3







embedded image


1. 7128 2. 566.31







embedded image


1. 7129 2. 565.31







embedded image


1. 7130 2. 572.31







embedded image


1. 7131 2. 576.32







embedded image


1. 7132 2. 576.32







embedded image


1. 7133 2. 576.32







embedded image


1. 7134 2. 584.32







embedded image


1. 7135 2. 585.3







embedded image


1. 7136 2. 590.32







embedded image


1. 7137 2. 590.32







embedded image


1. 7138 2. 598.33







embedded image


1. 7139 2. 598.33

















TABLE 72






1. Ex.


Product
2. m/z









embedded image


1. 7201 2. 529.29







embedded image


1. 7202 2. 543.3







embedded image


1. 7203 2. 543.3







embedded image


1. 7204 2. 555.31







embedded image


1. 7205 2. 577.32







embedded image


1. 7206 2. 577.32







embedded image


1. 7207 2. 577.32







embedded image


1. 7208 2. 577.32







embedded image


1. 7209 2. 581.32







embedded image


1. 7210 2. 581.32







embedded image


1. 7211 2. 588.32







embedded image


1. 7212 2. 588.32







embedded image


1. 7213 2. 591.33







embedded image


1. 7214 2. 591.33







embedded image


1. 7215 2. 591.33







embedded image


1. 7216 2. 591.33







embedded image


1. 7217 2. 593.33







embedded image


1. 7218 2. 593.33







embedded image


1. 7219 2. 593.33







embedded image


1. 7220 2. 595.33







embedded image


1. 7221 2. 597.33







embedded image


1. 7222 2. 597.33







embedded image


1. 7223 2. 597.33







embedded image


1. 7224 2. 599.33







embedded image


1. 7225 2. 599.33







embedded image


1. 7226 2. 603.33







embedded image


1. 7227 2. 603.33







embedded image


1. 7228 2. 607.33







embedded image


1. 7229 2. 607.14







embedded image


1. 7230 2. 611.34







embedded image


1. 7231 2. 613.34







embedded image


1. 7232 2. 605.33







embedded image


1. 7233 2. 621.34







embedded image


1. 7234 2. 623.34







embedded image


1. 7235 2. 627.34







embedded image


1. 7236 2. 631.35







embedded image


1. 7237 2. 631.35







embedded image


1. 7238 2. 631.35







embedded image


1. 7239 2. 631.35







embedded image


1. 7240 2. 631.35







embedded image


1. 7241 2. 639.35







embedded image


1. 7242 2. 641.35







embedded image


1. 7243 2. 645.35







embedded image


1. 7244 2. 541.3







embedded image


1. 7245 2. 649.36







embedded image


1. 7246 2. 653.36







embedded image


1. 7247 2. 665.37

















TABLE 73






1. Ex.


Product
2. m/z


















embedded image


1. 7301 2. 529.29







embedded image


1. 7302 2. 541.3







embedded image


1. 7303 2. 563.13







embedded image


1. 7304 2. 563.31







embedded image


1. 7305 2. 563.31







embedded image


1. 7306 2. 567.31







embedded image


1. 7307 2. 567.31







embedded image


1. 7308 2. 574.32







embedded image


1. 7309 2. 574.32







embedded image


1. 7310 2. 577.32







embedded image


1. 7311 2. 577.32







embedded image


1. 7312 2. 577.32







embedded image


1. 7313 2. 579.32







embedded image


1. 7314 2. 579.32







embedded image


1. 7315 2. 579.32







embedded image


1. 7316 2. 581.32







embedded image


1. 7317 2. 583.32







embedded image


1. 7318 2. 583.32







embedded image


1. 7319 2. 583.32







embedded image


1. 7320 2. 585.32







embedded image


1. 7321 2. 585.32







embedded image


1. 7322 2. 589.32







embedded image


1. 7323 2. 591.33







embedded image


1. 7324 2. 593.33







embedded image


1. 7325 2. 597.33







embedded image


1. 7326 2. 599.33







embedded image


1. 7327 2. 591.33







embedded image


1. 7328







embedded image


1. 7329 2. 613.34







embedded image


1. 7330 2. 617.34







embedded image


1. 7331 2. 599.33







embedded image


1. 7332 2. 591.33







embedded image


1. 7333 2. 609.33







embedded image


1. 7334 2. 613.34







embedded image


1. 7335 2. 617.34







embedded image


1. 7336 2. 617.34







embedded image


1. 7337 2. 617.34







embedded image


1. 7338 2. 617.34







embedded image


1. 7339 2. 625.34







embedded image


1. 7340 2. 631.35







embedded image


1. 7341 2. 635.35







embedded image


1. 7342 2. 639.35







embedded image


1. 7343 2. 639.35

















TABLE 74






1. Ex.


Product
2. m/z









embedded image


1. 7401 2. 515.28







embedded image


1. 7402 2. 529.29







embedded image


1. 7403 2. 541.3







embedded image


1. 7404 2. 563.13







embedded image


1. 7405 2. 563.31







embedded image


1. 7406 2. 563.31







embedded image


1. 7407 2. 563.31







embedded image


1. 7408 2. 567.31







embedded image


1. 7409 2. 567.31







embedded image


1. 7410 2. 574.32







embedded image


1. 7411 2. 574.32







embedded image


1. 7412 2. 577.14







embedded image


1. 7413 2. 577.32







embedded image


1. 7414 2. 577.32







embedded image


1. 7415 2. 577.32







embedded image


1. 7416 2. 579.32







embedded image


1. 7417 2. 579.32







embedded image


1. 7418 2. 579.32







embedded image


1. 7419 2. 581.32







embedded image


1. 7420 2. 583.32







embedded image


1. 7421 2. 583.32







embedded image


1. 7422 2. 585.32







embedded image


1. 7423 2. 585.32







embedded image


1. 7424 2. 589.32







embedded image


1. 7425 2. 591.33







embedded image


1. 7426 2. 593.33







embedded image


1. 7427 2. 597.33







embedded image


1. 7428 2. 591.33







embedded image


1. 7429 2. 609.33







embedded image


1. 7430 2. 613.34







embedded image


1. 7431 2. 617.34







embedded image


1. 7432 2. 617.34







embedded image


1. 7433 2. 617.34







embedded image


1. 7434 2. 627.34







embedded image


1. 7435 2. 631.35







embedded image


1. 7436 2. 639.35







embedded image


1. 7437 2. 639.35







embedded image


1. 7438 2. 651.36

















TABLE 75






1. Ex.


Product
2. m/z









embedded image


1. 7501 2. 481.26







embedded image


1. 7502 2. 495.27







embedded image


1. 7503 2. 495.27







embedded image


1. 7504 2. 507.28







embedded image


1. 7505 2. 529.29







embedded image


1. 7506 2. 529.29







embedded image


1. 7507 2. 529.29







embedded image


1. 7508 2. 529.29







embedded image


1. 7509 2. 533.29







embedded image


1. 7510 2. 533.29







embedded image


1. 7511 2. 540.3







embedded image


1. 7512 2. 540.3







embedded image


1. 7513 2. 543.3







embedded image


1. 7514 2. 543.3







embedded image


1. 7515 2. 543.3







embedded image


1. 7516 2. 543.3







embedded image


1. 7517 2. 545.3







embedded image


1. 7518 2. 545.3







embedded image


1. 7519 2. 545.3







embedded image


1. 7520 2. 547.3







embedded image


1. 7521 2. 549.3







embedded image


1. 7522 2. 549.3







embedded image


1. 7523 2. 549.3







embedded image


1. 7524 2. 551.3







embedded image


1. 7525 2. 551.3







embedded image


1. 7526 2. 555.31







embedded image


1. 7527 2. 557.31







embedded image


1. 7528 2. 559.31







embedded image


1. 7529 2. 560.31







embedded image


1. 7530 2. 573.32







embedded image


1. 7531 2. 579.32







embedded image


1. 7532 2. 583.32







embedded image


1. 7533 2. 583.32







embedded image


1. 7534 2. 583.32







embedded image


1. 7535 2. 583.32







embedded image


1. 7536 2. 583.32







embedded image


1. 7537 2. 591.33







embedded image


1. 7538 2. 583.32







embedded image


1. 7539 2. 597.33







embedded image


1. 7540 2. 601.33







embedded image


1. 7541 2. 605.33







embedded image


1. 7542 2. 605.33







embedded image


1. 7543 2. 593.33

















TABLE 76






1. Ex.


Product
2. m/z









embedded image


1. 7601 2. 453.25







embedded image


1. 7602 2. 467.26







embedded image


1. 7603 2. 467.26







embedded image


1. 7604 2. 479.26







embedded image


1. 7605 2. 501.28







embedded image


1. 7606 2. 501.28







embedded image


1. 7607 2. 501.28







embedded image


1. 7608 2. 501.28







embedded image


1. 7609 2. 505.28







embedded image


1. 7610 2. 505.28







embedded image


1. 7611 2. 512.28







embedded image


1. 7612 2. 512.28







embedded image


1. 7613 2. 515.28







embedded image


1. 7614 2. 515.28







embedded image


1. 7615 2. 515.28







embedded image


1. 7616 2. 515.28







embedded image


1. 7617 2. 517.28







embedded image


1. 7618 2. 517.28







embedded image


1. 7619 2. 517.28







embedded image


1. 7620 2. 519.29







embedded image


1. 7621 2. 521.29







embedded image


1. 7622 2. 521.29







embedded image


1. 7623 2. 521.29







embedded image


1. 7624 2. 523.29







embedded image


1. 7625 2. 523.29







embedded image


1. 7626 2. 527.29







embedded image


1. 7627 2. 529.29







embedded image


1. 7628 2. 541.3







embedded image


1. 7629 2. 545.3







embedded image


1. 7630 2. 547.3







embedded image


1. 7631 2. 551.3







embedded image


1. 7632 2. 555.31







embedded image


1. 7633 2. 555.31







embedded image


1. 7634 2. 555.31







embedded image


1. 7635 2. 555.31







embedded image


1. 7636 2. 555.31







embedded image


1. 7637 2. 563.31







embedded image


1. 7638 2. 565.31







embedded image


1. 7639 2. 569.31







embedded image


1. 7640 2. 573.32







embedded image


1. 7641 2. 577.32







embedded image


1. 7642 2. 577.32

















TABLE 77






1. Ex.


Product
2. m/z









embedded image


1. 7701 2. 481.26







embedded image


1. 7702 2. 495.27







embedded image


1. 7703 2. 495.27







embedded image


1. 7704 2. 507.28







embedded image


1. 7705 2. 529.29







embedded image


1. 7706 2. 529.29







embedded image


1. 7707 2. 529.29







embedded image


1. 7708 2. 529.29







embedded image


1. 7709 2. 533.29







embedded image


1. 7710 2. 533.29

















TABLE 78






1. Ex.


Product
2. m/z









embedded image


1. 7801 2. 507.28







embedded image


1. 7802 2. 521.29







embedded image


1. 7803 2. 521.29







embedded image


1. 7804 2. 533.29







embedded image


1. 7805 2. 555.31







embedded image


1. 7806 2. 555.31







embedded image


1. 7807 2. 555.31







embedded image


1. 7808 2. 555.31







embedded image


1. 7809 2. 559.31







embedded image


1. 7810 2. 559.31







embedded image


1. 7811 2. 566.31







embedded image


1. 7812 2. 566.31







embedded image


1. 7813 2. 569.31







embedded image


1. 7814 2. 569.31







embedded image


1. 7815 2. 569.31







embedded image


1. 7816 2. 569.31







embedded image


1. 7817 2. 571.31







embedded image


1. 7818 2. 571.31







embedded image


1. 7819 2. 571.31







embedded image


1. 7820 2. 573.32







embedded image


1. 7821 2. 575.32







embedded image


1. 7822 2. 575.32







embedded image


1. 7823 2. 575.32







embedded image


1. 7824 2. 577.32







embedded image


1. 7825 2. 577.32







embedded image


1. 7826 2. 581.32







embedded image


1. 7827 2. 583.32







embedded image


1. 7828 2. 585.32







embedded image


1. 7829 2. 585.32







embedded image


1. 7830 2. 589.32







embedded image


1. 7831 2. 591.33







embedded image


1. 7832 2. 599.33







embedded image


1. 7833 2. 601.33







embedded image


1. 7834 2. 605.33







embedded image


1. 7835 2. 609.33







embedded image


1. 7836 2. 609.33







embedded image


1. 7837 2. 609.33







embedded image


1. 7838 2. 609.33







embedded image


1. 7839 2. 609.33







embedded image


1. 7840 2. 617.34







embedded image


1. 7841 2. 619.34







embedded image


1. 7842 2. 623.34







embedded image


1. 7843 2. 519.29







embedded image


1. 7844 2. 627.34







embedded image


1. 7845 2. 631.35







embedded image


1. 7846 2. 631.35







embedded image


1. 7847 2. 643.35

















TABLE 79






1. Ex.


Product
2. m/z









embedded image


1. 7901 2. 477.26







embedded image


1. 7902 2. 485.27







embedded image


1. 7903 2. 485.27







embedded image


1. 7904 2. 486.27







embedded image


1. 7905 2. 495.27







embedded image


1. 7906 2. 504.28







embedded image


1. 7907 2. 505.28







embedded image


1. 7908 2. 507.28







embedded image


1. 7909 2. 509.28







embedded image


1. 7910 2. 509.28







embedded image


1. 7911 2. 509.28







embedded image


1. 7912 2. 513.28







embedded image


1. 7913 2. 515.28







embedded image


1. 7914 2. 519.29







embedded image


1. 7915 2. 523.29







embedded image


1. 7916 2. 523.29







embedded image


1. 7917 2. 525.29







embedded image


1. 7918 2. 529.29







embedded image


1. 7919 2. 529.29







embedded image


1. 7920 2. 530.29







embedded image


1. 7921 2. 530.29







embedded image


1. 7922 2. 535.29







embedded image


1. 7923 2. 537.3







embedded image


1. 7924 2. 547.3







embedded image


1. 7925 2. 547.3







embedded image


1. 7926 2. 547.3







embedded image


1. 7927 2. 547.3







embedded image


1. 7928 2. 547.3







embedded image


1. 7929 2. 549.3







embedded image


1. 7930 2. 549.3







embedded image


1. 7931 2. 555.31







embedded image


1. 7932 2. 555.31







embedded image


1. 7933 2. 557.31







embedded image


1. 7934 2. 557.31







embedded image


1. 7935 2. 557.31







embedded image


1. 7936 2. 567.31







embedded image


1. 7937 2. 567.31







embedded image


1. 7938 2. 569.31







embedded image


1. 7939 2. 571.31







embedded image


1. 7940 2. 571.31







embedded image


1. 7941 2. 608.33







embedded image


1. 7942 2. 621.34







embedded image


1. 7943 2. 443.24







embedded image


1. 7944 2. 457.25







embedded image


1. 7945 2. 471.26







embedded image


1. 7946 2. 471.26







embedded image


1. 7947 2. 473.26







embedded image


1. 7948 2. 483.27







embedded image


1. 7949 2. 485.27







embedded image


1. 7950 2. 489.27







embedded image


1. 7951 2. 499.27







embedded image


1. 7952 2. 513.28







embedded image


1. 7953 2. 514.28







embedded image


1. 7954 2. 525.29







embedded image


1. 7955 2. 525.29







embedded image


1. 7956 2. 536.29







embedded image


1. 7957 2. 539.3







embedded image


1. 7958 2. 541.3







embedded image


1. 7959 2. 547.3







embedded image


1. 7960 2. 572.31

















TABLE 80






1. Ex.


Product
2. m/z









embedded image


1. 8001 2. 459.25







embedded image


1. 8002 2. 459.25







embedded image


1. 8003 2. 469.26







embedded image


1. 8004 2. 469.26







embedded image


1. 8005 2. 473.26







embedded image


1. 8006 2. 477.26







embedded image


1. 8007 2. 485.27







embedded image


1. 8008 2. 485.27







embedded image


1. 8009 2. 485.27







embedded image


1. 8010 2. 486.27







embedded image


1. 8011 2. 493.27







embedded image


1. 8012 2. 495.27







embedded image


1. 8013 2. 495.27







embedded image


1. 8014 2. 495.27







embedded image


1. 8015 2. 495.27







embedded image


1. 8016 2. 495.27







embedded image


1. 8017 2. 495.27







embedded image


1. 8018 2. 502.28







embedded image


1. 8019 2. 502.28







embedded image


1. 8020 2. 502.28







embedded image


1. 8021 2. 505.28







embedded image


1. 8022 2. 505.28







embedded image


1. 8023 2. 507.28







embedded image


1. 8024 2. 507.28







embedded image


1. 8025 2. 507.28







embedded image


1. 8026 2. 509.28







embedded image


1. 8027 2. 509.28







embedded image


1. 8028 2. 513.28







embedded image


1. 8029 2. 513.28







embedded image


1. 8030 2. 513.28







embedded image


1. 8031 2. 515.28







embedded image


1. 8032 2. 519.29







embedded image


1. 8033 2. 521.29







embedded image


1. 8034 2. 523.29







embedded image


1. 8035 2. 523.29







embedded image


1. 8036 2. 523.29







embedded image


1. 8037 2. 525.29







embedded image


1. 8038 2. 529.29







embedded image


1. 8039 2. 529.29







embedded image


1. 8040 2. 530.29







embedded image


1. 8041 2. 530.29







embedded image


1. 8042 2. 535.29







embedded image


1. 8043 2. 537.3







embedded image


1. 8044 2. 547.3







embedded image


1. 8045 2. 547.3







embedded image


1. 8046 2. 547.3







embedded image


1. 8047 2. 544.3







embedded image


1. 8048 2. 547.3







embedded image


1. 8049 2. 547.3







embedded image


1. 8050 2. 547.3







embedded image


1. 8051 2. 548.3







embedded image


1. 8052 2. 548.3







embedded image


1. 8053 2. 547.3







embedded image


1. 8054 2. 555.31







embedded image


1. 8055 2. 553.3







embedded image


1. 8056 2. 569.31







embedded image


1. 8057 2. 569.31







embedded image


1. 8058 2. 571.31







embedded image


1. 8059 2. 608.33







embedded image


1. 8060 2. 621.34







embedded image


1. 8061 2. 443.24







embedded image


1. 8062 2. 457.25







embedded image


1. 8063 2. 471.26







embedded image


1. 8064 2. 471.26







embedded image


1. 8065 2. 469.26







embedded image


1. 8066 2. 473.26







embedded image


1. 8067 2. 483.27







embedded image


1. 8068 2. 485.27







embedded image


1. 8069 2. 483.27







embedded image


1. 8070 2. 499.27







embedded image


1. 8071 2. 505.28







embedded image


1. 8072 2. 537.3







embedded image


1. 8073 2. 537.3







embedded image


1. 8074 2. 547.3

















TABLE 81






1. Ex.


Product
2. m/z









embedded image


1. 8101 2. 510.28







embedded image


1. 8102 2. 518.28







embedded image


1. 8103 2. 518.28







embedded image


1. 8104 2. 519.29







embedded image


1. 8105 2. 526.29







embedded image


1. 8106 2. 528.29







embedded image


1. 8107 2. 537.3







embedded image


1. 8108 2. 538.3







embedded image


1. 8109 2. 540.3







embedded image


1. 8110 2. 540.3







embedded image


1. 8111 2. 542.3







embedded image


1. 8112 2. 542.3







embedded image


1. 8113 2. 548.3







embedded image


1. 8114 2. 552.3







embedded image


1. 8115 2. 554.3







embedded image


1. 8116 2. 556.31







embedded image


1. 8117 2. 558.31







embedded image


1. 8118 2. 562.31







embedded image


1. 8119 2. 580.32







embedded image


1. 8120 2. 580.32







embedded image


1. 8121 2. 580.32







embedded image


1. 8122 2. 580.32







embedded image


1. 8123 2. 580.32







embedded image


1. 8125 2. 580.32







embedded image


1. 8126 2. 588.32







embedded image


1. 8126 2. 588.32







embedded image


1. 8127 2. 590.32







embedded image


1. 8128 2. 590.32







embedded image


 . 8129 2. 604.33







embedded image


1. 8130 2. 612.34







embedded image


1. 8131 2. 654.36







embedded image


1. 8132 2. 476.26







embedded image


1. 8133 2. 580.32







embedded image


1. 8134 2. 580.32

















TABLE 82






1. Ex.


Product
2. m/z









embedded image


1. 8201 2. 488.27







embedded image


1. 8202 2. 496.27







embedded image


1. 8203 2. 504.28







embedded image


1. 8204 2. 504.28







embedded image


1. 8205 2. 505.28







embedded image


1. 8206 2. 512.28







embedded image


1. 8207 2. 514.28







embedded image


1. 8208 2. 523.29







embedded image


1. 8209 2. 524.29







embedded image


1. 8210 2. 526.29







embedded image


1. 8211 2. 526.29







embedded image


1. 8212 2. 528.29







embedded image


1. 8213 2. 528.29







embedded image


1. 8214 2. 528.29







embedded image


1. 8215 2. 532.29







embedded image


1. 8216 2. 534.29







embedded image


1. 8217 2. 537.3







embedded image


1. 8218 2. 538.3







embedded image


1. 8219 2. 542.3







embedded image


1. 8220 2. 542.3







embedded image


1. 8221 2. 544.3







embedded image


1. 8222 2. 544.3







embedded image


1. 8223 2. 548.3







embedded image


1. 8224 2. 548.3







embedded image


1. 8225 2. 551.3







embedded image


1. 8226 2. 551.3







embedded image


1. 8227 2. 554.3







embedded image


1. 8228 2. 556.31







embedded image


1. 8229 2. 566.31







embedded image


1. 8230 2. 566.31







embedded image


1. 8231 2. 566.31







embedded image


1. 8232 2. 566.31







embedded image


1. 8233 2. 566.31







embedded image


1. 8243 2. 566.31







embedded image


1. 8235 2. 566.31







embedded image


1. 8236 2. 568.31







embedded image


1. 8237 2. 574.32







embedded image


1. 8238 2. 574.32







embedded image


1. 8239 2. 576.32







embedded image


1. 8240 2. 576.32







embedded image


1. 8241 2. 576.32







embedded image


1. 8242 2. 586.32







embedded image


1. 8243 2. 586.32







embedded image


1. 8244 2. 588.32







embedded image


1. 8245 2. 590.32







embedded image


1. 8246 2. 590.32







embedded image


1. 8247 2. 598.32







embedded image


1. 8248 2. 627.34







embedded image


1. 8249 2. 640.35







embedded image


1. 8250 2. 462.25







embedded image


1. 8251 2. 476.26







embedded image


1. 8252 2. 490.27







embedded image


1. 8253 2. 492.27







embedded image


1. 8254 2. 492.27







embedded image


1. 8255 2. 502.28







embedded image


1. 8256 2. 504.28







embedded image


1. 8257 2. 504.28







embedded image


1. 8258 2. 508.28







embedded image


1. 8259 2. 530.29







embedded image


1. 8260 2. 533.29







embedded image


1. 8261 2. 544.3







embedded image


1. 8262 2. 546.3







embedded image


1. 8263 2. 546.3







embedded image


1. 8264 2. 558.31







embedded image


1. 8265 2. 558.31







embedded image


1. 8266 2. 560.31







embedded image


1. 8267 2. 566.31







embedded image


1. 8268 2. 591.33







embedded image


1. 8269 2. 595.33







embedded image


1. 8270 2. 555.31

















TABLE 83






1. Ex.


Product
2. m/z









embedded image


1. 8301 2. 465.882







embedded image


1. 8302 2. 465.885







embedded image


1. 8303 2. 475.827







embedded image


1. 8304 2. 479.89







embedded image


1. 8305 2. 483.829







embedded image


1. 8306 2. 491.79







embedded image


1. 8307 2. 491.792







embedded image


1. 8308 2. 492.787







embedded image


1. 8309 2. 499.846







embedded image


1. 8310 2. 501.826







embedded image


1. 8311 2. 501.825







embedded image


1. 8312 2. 501.833







embedded image


1. 8313 2. 510.822







embedded image


1. 8314 2. 510.821







embedded image


1. 8315 2. 511.841







embedded image


1. 8316 2. 513.855







embedded image


1. 8317 2. 515.832







embedded image


1. 8318 2. 515.832







embedded image


1. 8319 2. 515.837







embedded image


1. 8320 2. 519.782







embedded image


1. 8321 2. 519.783







embedded image


1. 8322 2. 519.781







embedded image


1. 8323 2. 525.813







embedded image


1. 8324 2. 529.806







embedded image


1. 8325 2. 529.81







embedded image


1. 8326 2. 531.804







embedded image


1. 8327 2. 531.812







embedded image


1. 8328 2. 535.83







embedded image


1. 8329 2. 535.831







embedded image


1. 8330 2. 541.788







embedded image


1. 8331 2. 543.821







embedded image


1. 8332 2. 553.797







embedded image


1. 8333 2. 553.796







embedded image


1. 8334 2. 553.795







embedded image


1. 8335 2. 554.73







embedded image


1. 8336 2. 554.727







embedded image


1. 8337 2. 554.738







embedded image


1. 8338 2. 554.738







embedded image


1. 8339 2. 554.727







embedded image


1. 8340 2. 561.836







embedded image


1. 8341 2. 561.838







embedded image


1. 8342 2. 564.714







embedded image


1. 8343 2. 564.704







embedded image


1. 8344 2. 564.72







embedded image


1. 8345 2. 573.823







embedded image


1. 8346 2. 573.735







embedded image


1. 8347 2. 575.839







embedded image


1. 8348 2. 577.818







embedded image


1. 8349 2. 577.814







embedded image


1. 9350 2. 585.818







embedded image


1. 8351 2. 529.808







embedded image


1. 8352 2. 614.763







embedded image


1. 8353 2. 628.727







embedded image


1. 8354 2. 449.857







embedded image


1. 8355 2. 463.867







embedded image


1. 8356 2. 479.856







embedded image


1. 8357 2. 511.842







embedded image


1. 8358 2. 520.859







embedded image


1. 8359 2. 533.903







embedded image


1. 8360 2. 545.823







embedded image


1. 8361 2. 547.909







embedded image


1. 8362 2. 510.817







embedded image


1. 8363 2. 542.833







embedded image


1. 8364 2. 573.815







embedded image


1. 8365 2. 547.798

















TABLE 84






1. Ex.


Product
2. m/z









embedded image


1. 8401 2. 491.883







embedded image


1. 8402 2. 491.883







embedded image


1. 8403 2. 501.823







embedded image


1. 8404 2. 501.827







embedded image


1. 8405 2. 505.89







embedded image


1. 8406 2. 509.829







embedded image


1. 8407 2. 517.795







embedded image


1. 8408 2. 517.799







embedded image


1. 8409 2. 518.796







embedded image


1. 8410 2. 525.851







embedded image


1. 8411 2. 527.831







embedded image


1. 8412 2. 527.833







embedded image


1. 8413 2. 536.833







embedded image


1. 8414 2. 536.829







embedded image


1. 8415 2. 537.845







embedded image


1. 8416 2. 539.859







embedded image


1. 8417 2. 541.84







embedded image


1. 8418 2. 541.843







embedded image


1. 8419 2. 541.843







embedded image


1. 8420 2. 546.786







embedded image


1. 8421 2. 546.792







embedded image


1. 8422 2. 546.79







embedded image


1. 8423 2. 547.854







embedded image


1. 8424 2. 551.826







embedded image


1. 8425 2. 555.819





Error! Objects cannot be created from editing field codes.








embedded image


1. 8426 2. 555.817







embedded image


1. 8427 2. 557.81







embedded image


1. 8428 2. 557.813







embedded image


1. 8429 2. 561.839







embedded image


1. 8430 2. 561.833







embedded image


1. 8431 2. 564.841







embedded image


1. 8432 2. 567.795







embedded image


1. 8433 2. 569.823







embedded image


1. 8434 2. 579.797







embedded image


1. 8435 2. 579.796







embedded image


1. 8436 2. 579.794







embedded image


1. 8437 2. 580.738







embedded image


1. 8438 2. 580.732







embedded image


1. 8439 2. 580.733







embedded image


1. 8440 2. 580.734







embedded image


1. 8441 2. 580.726







embedded image


1. 8442 2. 581.805







embedded image


1. 8443 2. 587.844







embedded image


1. 8444 2. 587.835







embedded image


1. 8445 2. 590.723







embedded image


1. 8446 2. 590.726







embedded image


1. 8447 2. 590.724







embedded image


1. 8448 2. 599.834







embedded image


1. 8449 2. 599.749







embedded image


1. 8450 2. 601.854







embedded image


1. 8451 2. 603.831







embedded image


1. 8452 2. 603.83







embedded image


1. 8453 2. 611.83







embedded image


1. 8454 2. 555.824







embedded image


1. 8455 2. 585.817







embedded image


1. 8456 2. 640.779







embedded image


1. 8457 2. 654.746







embedded image


1. 8458 2. 475.871







embedded image


1. 8459 2. 489.879







embedded image


1. 8460 2. 503.885







embedded image


1. 8461 2. 505.866







embedded image


1. 8462 2. 507.828







embedded image


1. 8463 2. 537.859







embedded image


1. 8464 2. 546.877







embedded image


1. 8465 2. 559.921







embedded image


1. 8466 2. 559.919







embedded image


1. 8467 2. 573.925







embedded image


1. 8468 2. 579.876







embedded image


1. 8469 2. 536.831







embedded image


1. 8470 2. 568.843

















TABLE 85






1. Ex.


Product
2. m/z









embedded image


1. 8501 2. 367.2







embedded image


1. 8502 2. 381.2







embedded image


1. 8503 2. 443.2







embedded image


1. 8504 2. 457.3







embedded image


1. 8506 2. 443.1







embedded image


1. 8507 2. 323.1







embedded image


1. 8508 2. 365.2







embedded image


1. 8509 2. 379.21







embedded image


1. 8510 2. 381.21







embedded image


1. 8511 2. 381.21







embedded image


1. 8512 2. 393.22







embedded image


1. 8513 2. 395.22







embedded image


1. 8514 2. 397.22







embedded image


1. 8515 2. 407.22







embedded image


1. 8516 2. 409.22







embedded image


1. 8517 2. 411.23







embedded image


1. 8518 2. 421.23







embedded image


1. 8519 2. 421.23







embedded image


1. 8520 2. 425.23







embedded image


1. 8521 2. 429.24







embedded image


1. 8522 2. 439.24







embedded image


1. 8523 2. 443.24







embedded image


1. 8524 2. 443.24







embedded image


1. 8525 2. 445.24







embedded image


1. 8526 2. 445.24







embedded image


1. 8527 2. 444.24







embedded image


1. 8528 2. 444.24







embedded image


1. 8529 2. 446.25







embedded image


1. 8530 2. 457.25







embedded image


1. 8531 2. 480.26







embedded image


1. 8532 2. 483.27







embedded image


1. 8533 2. 483.27







embedded image


1. 8536 2. 431.24







embedded image


1. 8537 2. 429.24







embedded image


1. 8538 2. 397.22







embedded image


1. 8539 2. 411.23







embedded image


1. 8540 2. 411.23







embedded image


1. 8541 2. 432.24







embedded image


1. 8542 2. 433.24







embedded image


1. 8543 2. 438.24







embedded image


1. 8545 2. 464.26







embedded image


1. 8546 2. 466.26







embedded image


1. 8547 2. 478.26







embedded image


1. 8548 2. 498.27







embedded image


1. 8549 2. 365.1







embedded image


1. 8549 2. 337.1







embedded image


1. 8550 2. 351.1

















TABLE 86






1. Ex.


Product
2. m/z









embedded image


1. 8601 2. 403.22







embedded image


1. 8602 2. 407.22







embedded image


1. 8603 2. 421.23







embedded image


1. 8604 2. 434.24







embedded image


1. 8605 2. 391.22







embedded image


1. 8606 2. 434.24







embedded image


1. 8607 2. 375.21







embedded image


1. 8608 2. 375.21







embedded image


1. 8609 2. 391.22







embedded image


1. 8610 2. 399.22







embedded image


1. 8611 2. 417.23







embedded image


1. 8612 2. 415.23







embedded image


1. 8613 2. 428.24







embedded image


1. 8614 2. 430.24







embedded image


1. 8615 2. 434.24







embedded image


1. 8616 2. 434.24







embedded image


1. 8617 2. 446.25







embedded image


1. 8618 2. 460.25







embedded image


1. 8619 2. 459.25







embedded image


1. 8620 2. 474.26







embedded image


1. 8621 2. 377.21







embedded image


1. 8622 2. 406.22







embedded image


1. 8623 2. 412.23







embedded image


1. 8624 2. 420.23







embedded image


1. 8625 2. 426.23







embedded image


1. 8626 2. 427.23







embedded image


1. 8627 2. 431.24







embedded image


1. 8628 2. 446.25







embedded image


1. 8629 2. 446.25







embedded image


1. 8630 2. 407.2







embedded image


1. 8631 2. 407.2







embedded image


1. 8632 2. 409.2







embedded image


1. 8633 2. 421.2







embedded image


1. 8634 2. 439.2







embedded image


1. 8635 2. 455.3







embedded image


1. 8636 2. 475.3







embedded image


1. 8637 2. 419.2







embedded image


1. 8638 2. 448.2







embedded image


1. 8639 2. 379.2







embedded image


1. 8640 2. 437.2







embedded image


1. 8641 2. 415.23







embedded image


1. 8642 2. 443.24







embedded image


1. 8643 2. 416.23







embedded image


1. 8644 2. 417.23







embedded image


1. 8645 2. 423.23







embedded image


1. 8646 2. 423.23







embedded image


1. 8647 2. 430.24







embedded image


1. 8648 2. 437.24







embedded image


1. 8649 2. 439.24







embedded image


1. 8650 2. 466.26







embedded image


1. 8651 2. 423.23







embedded image


1. 8652 2. 425.23







embedded image


1. 8653 2. 437.24







embedded image


1. 8654 2. 437.24







embedded image


1. 8655 2. 437.24







embedded image


1. 8656 2. 445.24







embedded image


1. 8657 2. 445.24







embedded image


1. 8658 2. 451.25







embedded image


1. 8659 2. 476.26







embedded image


1. 8660 2. 479.26







embedded image


1. 8661 2. 477.26







embedded image


1. 8662 2. 479.26








Claims
  • 1. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a patient in need thereof comprising administering a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt, thereof, to said patient, wherein said compound is selected from the group consisting of the compounds of the formulas:
  • 2. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a mammal in need thereof, comprising administering to said mammal an amount of a first compound, or a pharmaceutically acceptable salt thereof; andan amount of at least one second compound, said second compound being an anti-cancer agent;
  • 3. The method of claim 2, further comprising radiation therapy.
  • 4. The method of claim 2, wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, liposomal doxorubicin, taxotere, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl-]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, tipifarnib, L778,123 (a farnesyl protein transferase inhibitor), BMS 214662 (a farnesyl protein transferase inhibitor), gefitinib, erlotinib, antibodies to EGFR, imatinib, interferon alfa-2b, aramycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, ispinesib, SB-743921, GSK-923295, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestbsterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Trastuzumab, tositumomab, bortezomib, ibritumomab tiuxetan, arsenic trioxide, capecitabine, Vinorelbine, Porfimer, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, cetuximab, satriplatin, Gemtuzumab ozogamicin, bevacizumab, pemetrexed, panitubimab, sunitinib, sorafenib, dastinib, nilotinib, lapatinib and alemtuzamab.
  • 5. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a mammal in need thereof, comprising administering to said mammal an amount of a first compound, or a pharmaceutically acceptable salt, thereof; andan amount of temozolomide;wherein the amounts of the first compound and said temozolomide result in a therapeutic effect, wherein said first compound is selected from the group consisting of the compounds of the formulas:
  • 6. The method of claim 5, further comprising radiation therapy.
  • 7. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a mammal in need thereof, comprising administering to said mammal a composition comprising a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of the compounds of the formulas:
  • 8. The method of claim 7, further comprising administering radiation therapy.
  • 9. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a mammal in need thereof, comprising administering to said mammal a composition comprising (i) a therapeutically effective amount of a first compound, or a pharmaceutically acceptable salt thereof, and (ii) an anti-cancer agent, wherein the amounts of said first compound and anti-cancer agent result in a therapeutic effect, further wherein said first compound is selected from the group consisting of the compounds of the formulas:
  • 10. The method of claim 9, wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, liposomal doxorubicin Caelyx®, Myocet®, Doxil®, taxotere, taxol, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl-]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, tipifarnib, L778,123 (a farnesyl protein transferase inhibitor), BMS 214662 (a farnesyl protein transferase inhibitor), gefitinib, erlotinib, antibodies to EGFR, imatinib, interferon alfa-2b, aramycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, ispinesib, SB-743921, GSK-923295, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Trastuzumab, tositumomab, bortezomib, ibritumomab tiuxetan, arsenic trioxide, Xeloda capecitabine, Vinorelbine, Porfimer, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, cetuximab, satriplatin, Gemtuzumab ozogamicin, bevacizumab, pemetrexed, panitubimab, sunitinib, sorafenib, dastinib, nilotinib, lapatinib and alemtuzamab.
  • 11. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt thereof, to said patient, wherein said compound is selected from the group consisting of the compounds of the formulas:
  • 12. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a patient in need thereof, comprising administering to said patient a composition comprising a therapeutically effective amount of at least one compound, or a pharmaceutically acceptable salt thereof, to said patient, wherein said compound is selected from the group consisting of the compounds of the formulas:
  • 13. The method of claim 12, wherein said composition further comprises an anti-cancer agent.
  • 14. The method of claim 12, further comprising administration of radiation therapy.
  • 15. The method of claim 13, wherein said anti-cancer agent is selected from the group consisting of a cytostatic agent, cisplatin, doxorubicin, liposomal doxorubicin, taxotere, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, 4-[2[-4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl-]1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, tipifarnib, L778,123 (a farnesyl protein transferase inhibitor), BMS 214662 (a farnesyl protein transferase inhibitor), gefitinib, erlotinib, antibodies to EGFR, imatinib, interferon alfa-2b, aramycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, ispinesib, SB-743921, GSK-923295, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, oxaliplatin, leucovirin, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17α-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, Hexamethylmelamine, Trastuzumab, tositumomab, bortezomib, ibritumomab tiuxetan, arsenic trioxide, capecitabine, Vinorelbine, Porfimer, Liposomal, Thiotepa, Altretamine, Melphalan, Trastuzumab, Lerozole, Fulvestrant, Exemestane, Fulvestrant, Ifosfomide, Rituximab, cetuximab, satriplatin, Gemtuzumab ozogamicin, bevacizumab, pemetrexed, panitubimab, sunitinib, sorafenib, dastinib, nilotinib, lapatinib and alemtuzamab.
  • 16. A composition comprising (i) at least one compound selected from the group consisting of satriplatin, Gemtuzumab ozogamicin, bevacizumab, panitubimab, sunitinib, sorafenib, dastinib, nilotinib, lapatinib and (ii) at least one compound, or a pharmaceutically acceptable salt thereof, wherein said at least one compound in (ii) is selected from the group consisting of the compounds of the formulas:
  • 17. A method of inhibiting a cyclin dependent kinase selected from the group consisting of CDK 1, CDK 2, CDK 5, and CDK 9 in a patient in need thereof, comprising administering the composition of claim 16 to said patient.
  • 18. A method of treating a disease in a patient in need thereof with said composition of claim 16, wherein said disease is selected from the group consisting of: Burkett's lymphoma;chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia.
  • 19. A method of treating a disease in a patient in need thereof with a composition, wherein said disease is selected from the group consisting of: chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia, and further wherein said composition comprises a pharmaceutically acceptable carrier and at least one compound, or a pharmaceutically acceptable salt thereof, wherein said at least one compound is selected from the group consisting of the compounds of the formulas:
  • 20. A method of treating a cancer selected from the group consisting of chronic lymphocytic leukemia (CLL), breast cancer, non-small cell lung cancer (NSCLC), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and mantle cell leukemia in a patient in need thereof comprising administering a therapeutically effective amount of a compound of the formula
REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No. 11/710,644 filed Feb. 23, 2007, which is a divisional of application Ser. No. 11/245,401 filed Oct. 6, 2005 (now U.S. Pat. No. 7,196,078), which in turn is a Continuation-in-Part of U.S. patent application Ser. No. 10/776,988, filed Feb. 11, 2004 (now U.S. Pat. No. 7,119,200), which is a Continuation-in-Part of U.S. patent application Ser. No. 10/654,546 filed Sep. 3, 2003 (now U.S. Pat. No. 7,161,003), which claims priority to U.S. provisional patent applications, Ser. Nos. 60/408,027 filed Sep. 4, 2002 and 60/421,959 filed Oct. 29, 2002.

US Referenced Citations (9)
Number Name Date Kind
5571813 Rühter et al. Nov 1996 A
5602136 Rühter et al. Feb 1997 A
5602137 Rühter et al. Feb 1997 A
6107305 Misra et al. Aug 2000 A
6180627 Blagg et al. Jan 2001 B1
6383790 Shokat May 2002 B1
6413974 Dumont et al. Jul 2002 B1
20050222163 Eck et al. Oct 2005 A1
20070027135 Bruncko et al. Feb 2007 A1
Foreign Referenced Citations (19)
Number Date Country
10223917 Dec 2003 DE
0628559 Apr 2002 EP
WO 9118904 Dec 1991 WO
WO 9218504 Oct 1992 WO
WO 9535298 Dec 1995 WO
WO 9910325 Mar 1999 WO
WO 0026210 May 2000 WO
WO 0037473 Jun 2000 WO
WO 0210162 Feb 2002 WO
WO 0222610 Mar 2002 WO
WO 0232893 Apr 2002 WO
WO 0240485 May 2002 WO
WO 0250079 Jun 2002 WO
WO 02064211 Aug 2002 WO
WO 03091256 Nov 2003 WO
WO 03101993 Dec 2003 WO
WO 2006002119 Jan 2006 WO
WO 2007044441 Apr 2007 WO
WO 2007044449 Apr 2007 WO
Non-Patent Literature Citations (37)
Entry
Fischer, P.M.; Gianella-Borrador A.;CDK inhibitors in clinical development for the treatment of cancer, Expert. Opin. Investig. Drugs; 2003; 12(6); 955-970.
Fischer, P.M.; Gianella-Borradori, A.; Recent progress in the discovery and development of cyclin-dependent kinase inhibitors, I Expert. Opin. Investig. Drugs; 2005; 14(4); 457-477. I.
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.
Vippagunta et. al., “Crystalline Solids,” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predicatable?” Acc. Chem. Res., vol. 27, pp. 309-314 (1994).
Anderson et al, “Preparation of Water-Soluble Compounds Through Salt Formation”, The Practice of Medicinal Chemistry, pp. 739-754 (1996).
Berge et al, “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, vol. 66, No. 1, pp. 1-19 (1977).
Bible et al., “Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration”, Cancer Research, vol. 57, pp. 3375-3380 (Aug. 15, 1997).
Bingham et al, “Over One Hundred Solvates of Sulfathiazole”, Chem. Comm., pp. 603-604 (2001).
Caira et al, “Preparation and Crystal Characterization of a Polymorph, a Monohydrate, and an Ethyl Acetate Solvate of the Antifungal Fluconazole”, J. Pharmaceutical Sci., vol. 93, No. 3, pp. 601-611 (2004).
Feng et al, “Discovery of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors Incorporating Aminopyridyl Moieties at the P1 Position”, J. Med. Chem., vol. 40, pp. 3726-3733 (1997).
Gennaro (ed.), “Remington's Pharmaceutical Sciences”, 18th Edition, Mack Publishing Co., Easton, Pennsylvania (1990).
Gould, “Salt Selection for Basic Drugs”, International J. of Pharmaceutics, vol. 33, pp. 201-217 (1986).
Greene et al, Protective Groups in Organic Synthesis, Wiley, New York (1981).
Gudmundsson et al, Synthesis of Novel Imidazo[1,2-a]pyridines with Potent Activity Against Herpesviruses, Organic Letters, vol. 5, No. 8, pp. 1369-1372 (2003).
Gupton et al, An Alternative Preparation of the 2-Dimethylaminomethylene-1,3-bis (dimethylimmonio)propane Salt from Phosphonoacetic Acids and Some Applications in Heterocyclic Synthesis, J. Heterocyclic Chem., vol. 28, pp. 1281-1285 (1991).
Heinisch et al, “Synthesen und Reaktionen von Pyridazinderivaten, 3. Mitt.”, Monatschefte fur Chemie, vol. 104, pp. 1372-1382 (1973).
Higuchi et al, “Pro-Drugs as Novel Delivery Systems”, vol. 14, A.C.S. Symposium Series (1987).
Hosoi et al, “Evidence for cdk5 as a Major Activity Phosphorylating Tau Protein in Porcine Brain Extract”, J. Biochem., vol. 117, pp. 741-749 (1995).
Kim et al, “Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities”, Journal of Medical Chemistry, vol. 45, pp. 3905-3927 (2002).
López-Rodriguez et al, Design, Synthesis and Biological Evaluation of Novel Arachidonic Acid Derivatives as Highly Potent and Selective Endocannabinoid Transporter Inhibitors, J. Med. Chem., vol. 44, pp. 4505-4508 (2001).
Makisumi, “Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5-α]pyrimidines”, Chem. Pharm. Bull., vol. 10, pp. 620-626 (1962).
Meijer et al, “Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5”, Eur. J. Biochem, vol. 243, pp. 527-536 (1997).
Novinson et al, “Synthesis and Antimicrobial Activity of Some Novel Heterocycles. Azolo-αs-triazines1” Journal of Medicinal Chemistry, vol. 19, No. 4, pp. 517-520 (1976).
Novinson et al, “Synthesis and Antifungal Properties of Certain 7-Alkylaminopyrazolo[1,5-α]pyrimidines”, J. Med. Chem., vol. 20, No. 2, pp. 296-299 (1977).
Ongkeko et al, “Inactivation of Cdc2 Increases the Level of Apoptosis Induced by DNA Damage”, J. Cell Sci., vol. 108, p. 2897 (1995).
Ragan et al, “Shock Sensitivity of a Vinamidinium Bis-Perchlorate Reagent and Demonstration of a Lower Energy Alternative”, Synlett, vol. 8, pp. 1172-1174 (2000).
Roche, “Bioreversible Carriers in Drug Design”, American Pharmaceutical Association and Pergamon Press (1987).
Sebolt-Leopold et al, “Mechanisms of Drug Inhibition of Signaling Molecules”, Nature, vol. 441, No. 7092, pp. 457-462 (2006).
Senderowicz et al, “Phase I Trial of Continous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasmns”, Journal of Clinical Oncology, vol. 16, No. 9, pp. 2986-2999 (Sep. 1998).
Shiota et al, “Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo [1,5-α]pyrimidine Derivatives”, Chem. Pharm. Bull., vol. 47, No. 7, pp. 928-938 (1999).
Stahl et al, Camille G. (eds.), “Handbook of Pharmaceutical Salts. Properties, Selection and Use”, Zurich: Wiley-VCH (2002), TOC.
Van Tonder et al, “Preparation and Physicochemical Characterization of 5 Niclosamide Solvates and 1 Hemisolvate”, AAPS PharmSciTech., vol. 1, No. 5, article 12 (2004).
Vesely et al, “Inhibition of Cyclin-Dependent Kinases by Purine Analogues”, Eur. J. Biochem, vol. 224, pp. 771-786 (1994).
The Orange Book (Food & Drug Administration, Washington, DC (http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, May 6, 2010.
International Search Report for related case PCT/US2008/004906, mailed Aug. 25, 2008.
Related Publications (1)
Number Date Country
20070281951 A1 Dec 2007 US
Provisional Applications (2)
Number Date Country
60408027 Sep 2002 US
60421959 Oct 2002 US
Divisions (1)
Number Date Country
Parent 11245401 Oct 2005 US
Child 11710644 US
Continuation in Parts (3)
Number Date Country
Parent 11710644 Feb 2007 US
Child 11788856 US
Parent 10776988 Feb 2004 US
Child 11245401 US
Parent 10654546 Sep 2003 US
Child 10776988 US